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Abstract  
Plasmodium falciparum is responsible for most malaria-related morbidity and 
mortality, mostly affecting young children, non-immune adults and pregnant 
women. A characteristic feature of the pathogenesis of infection caused by P. 
falciparum is the cytoadherence of infected erythrocytes to the endothelial cells 
lining the microvessels of host organs. This phenomenon, termed 
''sequestration'', mainly results from the adhesive interactions between P. 
falciparum erythrocyte membrane protein-1 (PfEMP1) proteins on the surface of 
infected erythrocytes and various host endothelial receptors such intercellular 
adhesion molecule 1 (ICAM-1), which is hypothesised to have a role in cerebral 
malaria. PfEMP1 molecules consist of several Duffy binding-like (DBL) and 
cysteine rich interdomain region (CIDR) domains that have different 
cytoadhesive functions. The second class of DBL domains, DBLβ, has been 
associated with adhesion to ICAM-1 receptors.  
In the present study, we selected four recombinant PfEMP1ICAM-1-DBLβ 
domains for mouse immunisations. Thirteen monoclonal (mAbs) and polyclonal 
antibodies (pAbs) were raised to three recombinant domains (DBL13, DBL31 
and DBL41). All mouse mAbs and pAbs comprised IgM antibodies that 
recognised homologous and heterologous DBLβ domains. Most mAbs and pAbs 
labelled the surface of erythrocytes infected by P. falciparum isolates, with an 
IgM labelling capacity ranging from 10.1% to 67.6% of total IEs. Mouse 
antibodies showed similar patterns of reactivity with ICAM-1-binding and non-
binding isolates, and reacted with a parasite isolate from a different genome 
(3D7). Surprisingly, we detected a remarkable reduction in IE population after 
incubation with mouse mAbs and pAbs, and this was mainly observed with 
antibodies that strongly labelled the surface of IEs. We demonstrated that this 
haemolysis was resulted from an immunological interaction between mouse 
IgMs and a parasite-derived component on the surface of live IEs.  
Antibodies raised to DBL41 were the most effective in all assays. Of these, three 
antibodies (pAb B5, mAb B4, mAb G6) and an anti-DBL31 mAb (E7) 
significantly blocked IE adhesion to purified proteins (ICAM-1 and CD36) 
under static and flow conditions. These antibodies also blocked parasite 
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adhesion to HUVEC under conditions of blood flow. In a separate work, we 
characterised the immune response of eight semi-immune serum samples 
obtained from female adults living in Kilifi County, Kenya. Our results indicated 
that semi-immune sera specifically recognised five recombinant DBLβICAM-1 
domains and a VAR2CSA DBL domain, and recognised the surface of 
erythrocytes infected by diverse parasite isolates with variable levels of 
reactivity. Some sera, particularly JA225 and JA235, significantly inhibited IE 
adhesion to ICAM-1 under both static and flow conditions. To our knowledge, 
this is the first study to examine the use of PfEMP1ICAM-1-DBLβ domains for the 
development of mouse mAbs and pAbs that recognise homologous and 
heterologous parasite isolates and block IE adhesion. However, further work is 
required to identify the surface ligand(s) involved in interaction with mouse IgM 
and to investigate the mechanisms of IgM-mediated IE lysis.  
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Chapter 1: Introduction  
1.1 The burden of malaria disease 
The protozoan parasite Plasmodium falciparum is the causative agent of the 
most virulent forms of malaria disease affecting humans worldwide. Although P. 
vivax, P. ovale, P. malariae and P. knowlesi also cause human infections, P. 
falciparum is responsible for most malaria-related morbidity and mortality, 
mostly affecting young children, non-immune adults and pregnant women and is 
the focus of this study (Beeson and Brown, 2002, Weatherall et al., 2002). 
According to the latest reports, there was an estimated 198 million malaria 
illness episodes and 584 thousands deaths that occurred globally in 2013, with 
about 1.2 billion people at high risk of developing malaria infection. The 
majority of deaths occurred in Africa where an estimated 90% of the total global 
deaths take place and mainly in children under 5 years of life who represent 78% 
of all mortalities (Wold malaria report, WHO, 2014). P. falciparum malaria is 
the leading cause of most deaths in children aged ˂ 5 years among all mortalities 
caused by pathogenic infectious agents, which account for 64% of all child 
mortalities globally and 81% in Africa (Elliott and Beeson, 2008). The 
increasing availability of commercial vaccines for most of the other pathogenic 
causes of child deaths may lead to an increase in the relative contribution of P. 
falciparum to child mortalities, which is considered as the main pathogen for 
which a vaccine is not yet provided (Elliott and Beeson, 2008). There is an 
ongoing need for the development of effective vaccines that help to reduce the 
burden of malaria mortality, especially in light of increasing drug resistance and 
decreasing efficiency of vector control programs (Chan et al., 2012). 
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1.2 The life cycle of P. falciparum 
P. falciparum has a complex life cycle that involves both a mosquito vector and 
a human host (Rowe et al., 2009). The cycle starts when a parasite-infected 
female anopheles mosquito injects P. falciparum parasites in the form of 
sporozoites into subcutaneous tissues and less commonly directly into the blood 
circulation of the human host during a blood meal (Ponnudurai et al., 1991, 
Menard et al., 2013). The sporozoites migrate through the bloodstream and 
invade liver cells (hepatocytes). However, some authors prefer the view that 
sporozoites inoculated into the skin travel to the liver via the lymphatic system 
rather than by blood capillaries to reach hepatocytes (Ponnudurai et al., 1991, 
Vaughan et al., 1999). However, the exact proportions of sporozoites that follow 
each route (blood or lymphatic) is probably influenced by several factors such as 
the vessel density at the inoculation site and the parasite species (Menard et al., 
2013). The main receptor on sporozoites involved in invasion of hepatocytes is 
the circumsporozoite protein (CS), which binds to heparan sulphate 
proteoglycans (HSPG) on hepatocytes upon invasion (Frevert et al., 1993). It has 
been shown that sporozoites traverse several hepatocytes before finally the 
invasion on one hepatocyte takes place followed by parasite development (Mota 
et al., 2001). 
Inside hepatocytes, an ~8- to 12-day incubation period allows the asexual 
multiplication of parasite before it finally generates tens of thousands of 
daughter cells called merozoites, which are released into the bloodstream where 
they rapidly invade multiple red blood cells [RBCs] (Beeson and Brown, 2002, 
Weatherall et al., 2002). The merozoites invade RBCs in a cascade of processes 
including parasite attachment, formation of junctions and entrance. The 
mechanism involved in this invasion is complex and includes proteins on the 
surface of merozoites (Mphande et al., 2008). Inside the infected erythrocyte 
(IE), P. falciparum parasites grow, multiply and divide in a cellular 
compartment known as the parasitophorous vacuole [PV] (Menard et al., 2013). 
Merozoites develop within IEs into ring stage, trophozoite and schizont stage 
parasites. Each P. falciparum asexual intra-erythrocytic cycle takes 48 hours and 
is completed by the production of new merozoites into the bloodstream, which 
re-infect other non-IEs (Rowe et al., 2009). The symptoms of malaria disease 
20 
 
(fever, anaemia, impaired consciousness, chills, etc.) only occur during the 
asexual cycle of parasite development and multiplication within RBCs and most 
existing drugs target this stage of parasite life cycle (Wirth, 2002, Weatherall et 
al., 2002). In addition, the intra-erythrocytic stage of parasite development 
develops chronic infections that can last for over a year within the infected host 
(Smith and Craig, 2005).   
During the asexual cycle, a small proportion of ring-stage parasites develop into 
sexual parasite stages known as male and female gametocytes, which may be 
taken up by the female mosquito during blood meal. The gametocytes are fused 
in the mosquito gut to form a zygote, which further develops into ookinete. The 
latter then crosses the wall of the mosquito gut and forms an oocyst filled with 
sporozoites, which bursts resulting in the release of sprozoites that migrate to the 
mosquito salivary glands, ready to be injected into another human host (Wirth, 
2002). Thus, the life cycle of P. falciparum includes three invading stages steps: 
the ookinete crossing the gut wall in the mosquito, the sporozoites infecting the 
mosquito salivary glands and the host liver cells, and the merozoites invading 
the host RBCs (Figure 1.1). 
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Figure 1.1. The life cycle of P. falciparum. The cycle is complex involving mammal and 
mosquito hosts. The asexual multiplication occurs in the human host, whereas the sexual 
reproduction takes place within the mosquito. Details about the life cycle are found in the text. 
The figure was obtained from (Menard et al., 2013).   
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1.3 Pathophysiology of P. falciparum malaria disease 
The pathogenesis of malaria stems from different parasite and host factors that 
simultaneously contribute to the severity and consequences of the disease. Most 
P. falciparum infection episodes in endemic regions result in mild symptoms 
such as headache, fever, lethargy and malaise which often followed by full 
recovery even without intake of anti-malaria drugs (Beeson and Brown, 2002). 
Adults in these endemic areas encounter asymptomatic malaria infections which 
quickly cleared by the host immune response targeting the parasitized RBCs 
(Storm and Craig, 2014). However, some episodes develop into severe and life-
threatening disease, which characterised by several clinical features including 
severe anaemia, impaired consciousness and respiratory distress (Marsh et al., 
1995). There is an increasing recognition that severe malaria is a multi-system 
disease affecting many tissues and organs, although most marked complications 
may appear to occur in a single organ such as the brain (Miller et al., 2002).  
 
1.3.1 Severe malaria anaemia  
The pathogenesis of severe malaria anaemia is mainly due to two groups of 
contributing factors: increased lysis of infected and non-infected erythrocytes 
(immune mediated lysis, phagocytosis) and decreased production of RBCs 
[dyserythropoiesis, effect of inflammatory cytokines and parasite factors] 
(Ghosh and Ghosh, 2007). Erythrocytes are destroyed with the completion of the 
parasite erythrocytic asexual cycle inside the red cells. Phagocytosis of 
parasitized red cells by macrophages following opsonisation by antibodies 
and/or complement components also contributes to increased destruction of 
RBCs. Other factors involved in the reduction of non-IEs include the overall 
increased number of active macrophages, together with the enhanced signals for 
the detection and clearance of non-IEs during malaria infection leading to 
hypersplenic state characterised by removal of infected and non-infected RBCs 
(Weatherall et al., 2002, Ghosh and Ghosh, 2007). Phagocytosis and 
complement mediated lysis are the primary mechanisms of non-specific immune 
mediated destruction of RBCs in malaria disease (Autino et al., 2012). Chronic 
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malaria anaemia is more common in endemic areas and with other contributory 
factors can lead to severe anaemia (Ghosh and Ghosh, 2007).  
 
1.3.2 Pathogenesis of malaria sequestration  
A characteristic feature of the pathogenesis of infection caused by P. falciparum 
is the cytoadherence of IEs to the endothelial lining of small blood vessels 
[described in detail in the following section] (Miller et al., 2002). This 
phenomenon, termed ''sequestration'', results from the adhesive interactions 
between parasite-derived proteins inserted on the surface of P. falciparum-IEs 
and various host receptors expressed on endothelial cells (ECs), non-infected 
erythrocytes and placenta (Gardner et al., 1996, Turner et al., 1994). Only 
mature forms of the parasite sequester from the circulation to vascular 
endothelium lining various organs (e.g. brain, lung, heart, liver and kidney), the 
placenta and subcutaneous adipose tissues (Miller et al., 2002, Smith et al., 
2013). As a result, only younger developmental forms (i.e. ring stage) of P. 
falciparum parasites are found in the peripheral circulation (Udeinya et al., 1983, 
Smith et al., 1995). Although only mature parasites sequester in vivo, 
cytoadhesion to some EC lines has been observed in vitro in erythrocytes 
infected by P. vivax (Autino et al., 2012). A recent study demonstrated that non-
viable parasites killed by different antimalarial drugs retain the ability to 
cytoadhere for at least 24 hours after fatal dosages of treatment, indicating that 
sequestration is not exclusive to viable parasites (Hughes et al., 2010).  
Sequestration and accumulation of parasitized erythrocytes in host organs and 
tissues are thought to be the pathogenic basis of severe complications of malaria 
disease (Autino et al., 2012). Manifestations following parasite sequestration 
including extensive obstruction of microcirculatory blood flow leading to 
impaired tissue perfusion (Dondorp et al., 2008), endothelial dysfunction at the 
site of sequestration by inducing pro-inflammatory cytokines and coagulation 
pathways (Turner et al., 1994, Moxon et al., 2009), release of parasite toxins, 
stimulation of the host immune response, resulting in vital organ dysfunction 
and death even with intense chemotherapy (Ockenhouse et al., 1991, Autino et 
al., 2012).  
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Sequestration of IEs is associated with organ-specific malaria syndromes from 
IE binding to brain (cerebral malaria [CM]) and placenta (placental malaria 
[PM]). The several ECs lining these organs and syncytiotrophoblasts in the 
placenta express various host receptors at different expression levels (Miller et 
al., 2002). Some of these host receptors have been suggested to be associated 
with organ-specific malaria syndromes such intercellular adhesion molecule 1 
(ICAM-1 or CD54) in CM (Turner et al., 1994, Newbold et al., 1999, Ochola et 
al., 2011) and chondroitin sulphate A (CSA) in PM (Fried and Duffy, 1996, 
Beeson et al., 2000). Pathogenesis of CM, PM and other adhesive phenotypes 
such as rosetting (adherence of IEs to non-IEs) and auto-agglutination 
(adherence of IEs to other IEs) will be discussed in detail later in this chapter.  
 
1.3.3 Other pathological consequences  
Metabolic acidosis, respiratory distress, hypoglycaemia and general induction of 
pro-inflammatory cytokines are other key pathological manifestations of severe 
malaria (Miller et al., 2002). Respiratory distress could be a consequence of 
multiple underlying complications acting individually or in combination (Marsh 
et al., 1995). It may result from fluid retention following malaria infection, and 
was detected in patients with normal or negative fluid balance and with 
metabolic acidosis (Beeson and Brown, 2002). Occurrence of respiratory distress 
in non-immune adults with severe malaria can be life threatening, often leading 
to pulmonary oedema and adult respiratory distress syndrome (Autino et al., 
2012, Marsh et al., 1995). A study conducted on hospitalised Kenyan children 
admitted with malaria symptoms found that children with respiratory distress or 
impaired consciousness were at great risk for death (Marsh et al., 1995).  
The release of merozoites along with large amounts of malaria toxins and 
parasite products in the blood following rupture of schizonts leads to stimulation 
of the innate immune response and release of inflammatory mediators (Autino et 
al., 2012). Antibodies, cytokines such as tumor necrosis factor-α (TNF-α), 
interferon-γ (IFN-γ), interlukin-12 (IL-12) and mediators such nitric oxide (NO) 
have been suggested to protect against the blood-stage parasites (Miller et al., 
2002, Rovira-Vallbona et al., 2012). However, an imbalance between the release 
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of pro- or anti-inflammatory cytokines or mediators may contribute to the 
severity of malaria disease (Rovira-Vallbona et al., 2012, Autino et al., 2012). 
Higher concentrations of TNF-α were observed in plasma samples collected 
from severe malaria than non-malaria patients and have been associated with 
CM (Kwiatkowski et al., 1990). In addition, in vitro studies have demonstrated 
that stimulation of EC lines with proinflammatory cytokines such as TNF-α 
caused an up-regulation of ICAM-1 expression (Dobbie et al., 1999, Gray et al., 
2003), a receptor that was found at significantly higher levels in the brain vessels 
of patients who died from CM (Turner et al., 1994).  
 
1.4 Sequestration of P. falciparum IEs and major 
adhesive phenotypes  
During the 48-hour parasite maturation inside IEs, the parasite causes several 
structural and morphological alterations to the host cell. As a result, the IE 
becomes more rigid, more metabolically active and able to sequester from the 
peripheral circulation and adhere to the endothelium lining vasculature of 
different organs (Hughes et al., 2010). A major parasite-derived modification to 
the host erythrocyte that enables the parasite to sequester is the development of 
several thousands of electron-dense protrusions called ''knobs'' (~100 nm in 
diameter) on the infected cell surface [Figure 1.2] (Kilejian, 1979, Pologe et al., 
1987). These knobs only appear on the IE surface with the development of the 
parasite to trophozoite and schizont stages, but not on cells infected by ring stage 
parasites (Kilejian, 1979, Udeinya et al., 1983). Different proteins synthesised by 
the parasite are associated with the formation and expression of knobs on the 
host cell membrane. Among those, knob-associated histidine rich protein 
(KAHRP) is the major structural component located at the cytoplasmic side of 
the erythrocyte membrane (Kilejian, 1979, Pologe et al., 1987, Horrocks et al., 
2005). Other parasite-derived proteins such as P. falciparum erythrocyte 
membrane protein 3 (PfEMP3) and mature infected erythrocyte surface protein 
(MESA; also called PfEMP2) are also related to establishment of knobs (Biggs 
et al., 1989, Chan et al., 2014). Knob structures act as sites for anchoring the 
putative cytoadherence molecule PfEMP1 on the external surface of IEs (Leech 
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et al., 1984, Horrocks et al., 2005). PfEMP1 protein family have long been 
considered as the major parasite-derived protein exported to the IE surface and 
mediate IE cytoadhesion (Baruch et al., 1995, Su et al., 1995, Smith et al., 1995). 
Both in vitro and in vivo studies demonstrated that knobs play a significant role 
in parasite cytoadhesion. Electron microscopy investigations of post-mortem 
samples have provided morphologic evidence that the adhesion sites of IEs to 
ECs to be the knobs, and laboratory studies have linked the loss of knobs from 
lab-adapted isolates with the loss of ability to mediate cytoadhesion 
(MacPherson et al., 1985, Horrocks et al., 2005). However, a previous study has 
shown that parasites were capable of maintaining the formation of knobs on the 
IE surface under in vitro conditions while losing the capacity to facilitate 
cytoadhesion, and demonstrated that the loss of binding was not due the loss of 
knobs (Udeinya et al., 1983). Another study provided evidence for the presence 
of a knobless parasite isolate capable of facilitating a strong adhesion to C32 
melanoma cells (Biggs et al., 1989). This isolate was incapable of expressing 
KAHRP protein due to deletion of kahrp gene. Although the attachment of 
melanoma cells to the parasite through knobs was observed, adhesion to areas on 
the IE surface where knobs were absent was also observed (Biggs et al., 1989). 
However, a recent study investigated the cytoadhesion properties of knobby and 
knobless parasite isolates and demonstrated that both static and flow adhesion 
were significantly decreased in all knobless isolates, and this correlated with the 
remarkable reduction (~50%) of PfEMP1 expression in isolates with knobs on 
the surface compared to knobless parasites (Horrocks et al., 2005). Therefore, it 
has been suggested that knobs could be essential but not sufficient for 
parasitized cell adhesion to vascular endothelial receptors (Pologe et al., 1987, 
Biggs et al., 1989). These findings indicate that the expression of PfEMP1 
protein, but not the morphologic knobs, is a key essential determinant of parasite 
adhesion. However, the recent findings that RIFIN (Goel et al., 2015) and 
STEVOR (Niang et al., 2014) mediate rosetting highlights the importance of 
investigating the role of other parasite-derived surface antigens in parasite 
cytoadhesion.  
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Figure 1.2. Parasite-mediated modifications to the IE. Scanning (A) and transmission (B) 
electron microscopy showing the electron-dense knob structures on the surface of IEs (arrows) 
[acquired from (Chan et al., 2014)].  
 
 In addition to its role in the parasite virulence, sequestration is believed to play a 
significant role in the survival of P. falciparum parasites within the infected host 
(Udeinya, 1990, Winograd et al., 2004). First, the parasite sequesters in areas 
where oxygen tension is low (venules, venous capillaries), an environment that 
favours the parasite growth (Udeinya et al., 1983, Biggs et al., 1989) as shown in 
in vitro studies (Trager and Jensen, 1976). Parasitized erythrocytes sequester in 
the endothelial lining of microvessels, where the shear stress is low enough to 
facilitate the interaction between the parasite ligands and endothelial receptors 
and allows for the establishment of chronic disease (Winograd et al., 2004, 
Chakravorty and Craig, 2005). Second, the sequestered mass of mature parasites 
are protected from host immune response in the peripheral blood circulation and 
from detection and destruction by the spleen (Udeinya et al., 1983, Biggs et al., 
1989, Pologe et al., 1987), as non-adherent mature parasites are destroyed 
rapidly in the spleen (Miller et al., 2002).  
In general, while the number of parasites circulating in the peripheral circulation 
(parasitaemia) is associated with the clinical severity of malaria infection 
(MacPherson et al., 1985), patients with lower or undetectable parasitaemias 
may suffer from severe and life-threatening disease complications due to 
sequestration and accumulation of mature parasites in the vital organs such as 
the brain (Ockenhouse et al., 1991, Weatherall et al., 2002). On the other hand, 
some patients may present with a higher rates of peripheral circulatory 
parasitaemias but only develop moderate symptoms (Ockenhouse et al., 1991). 
A B 
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Therefore, peripheral parasite count cannot be a sufficient indicator for 
diagnosing severe infections per se (Weatherall et al., 2002) and must be 
supported by other diagnostic tests for determining the severity of the disease. 
For the example, levels of plasma concentrations of P. falciparum histidine rich 
protein 2 (PfHRP2) released by the P. falciparum into the plasma can be used to 
measure the total parasite biomass in P. falciparum malaria infection and can be 
used as a parameter reflecting disease severity and outcome (Dondorp et al., 
2005). 
Three major IE cytoadhesion traits have been recognised (Figure 1.3) and 
described in detail in the following section; these include i) IE cytoadhesion to 
receptors in the brain (CM) and placenta (PM), ii) adhesion of IEs to non-IEs 
(rosetting), and (iii) adherence of parasitized erythrocytes to other IEs (IE 
clumping).  
 
 
Figure 1.3. Cytoadhesion phenotypes of P. falciparum IEs. (a): graphic representation of different adhesion 
traits of IEs to receptors on host cells such as ECs (sequestration), non-IEs (rosetting) and to other IEs in 
the presence of platelets (platelet-mediated clumping). (b): In vitro adhesion of IEs to cultured brain ECs, 
observed under the light microscope after Giemsa staining. (c): Rosetting of IEs observed in vitro under the 
light microscopy of Giemsa-stained P. falciparum culture preparations. (d): Platelet-mediated IE clumps 
formed after incubation with platelets and visualised under the light microscope after Giemsa staining. The 
figure was acquired from (Rowe et al., 2009). 
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1.4.1 Cerebral malaria  
CM is one of the most severe and life-threatening complications of malaria 
disease and remains a major public health concern in Africa and South East Asia 
(Martins and Daniel-Ribeiro, 2013). About 1% of all malaria episodes caused by 
P. falciparum develop into CM; with 90% of the cases occur in children in Sub-
Saharan Africa (Storm and Craig, 2014). Child mortality rate due to CM remains 
very high (10-20%) despite the sufficient antimalarial treatment (Martins and 
Daniel-Ribeiro, 2013). Furthermore, the infection causes long-term neurological 
and cognitive defects such as psychiatric issues, memory impairment and 
learning difficulties in about 10-20% in children who survived an episode of CM 
(Desruisseaux et al., 2010).  
The primary event for the development of CM is not entirely understood in spite 
of the large amount of existing data about the disease (Martins and Daniel-
Ribeiro, 2013). However, sequestration of IEs to the brain post-capillary 
venules, inflammatory responses and endothelial dysfunction may account for 
the majority of mechanisms that govern CM (Berendt et al., 1994, Desruisseaux 
et al., 2010). Sequestration of the IEs results in the mechanical obstruction of the 
capillary blood flow (cerebral vessels, capillaries and small venules) leading to 
reduced perfusion, hypoxia and coma (Berendt et al., 1994). Immediate post-
mortem examination of individuals who died from CM clearly revealed an 
increased number of sequestered trophozoites and schizonts in the brain 
microvessels relative to patients who died from other malaria-related (non-CM) 
complications (MacPherson et al., 1985). The release of parasite toxins in the 
blood and imbalanced inflammatory response leads to brain endothelial 
dysfunction, breakdown of blood brain barrier (BBB), cerebral oedema and 
coma (MacPherson et al., 1985, Martins and Daniel-Ribeiro, 2013). Together 
with the sequestration and inflammation, acute liver failure was recently 
suggested to be necessary for the development of CM (Martins and Daniel-
Ribeiro, 2013).  
Patients with CM typically have P. falciparum parasitaemia and unarousable 
deep coma often with convulsions. CM coma is confirmed after excluding other 
causes of coma such as meningitis, and can be distinguished from impaired 
consciousness in which patients develop Balantyre coma score of four or less 
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(Berendt et al., 1994, Marsh et al., 1995). However, any grade of impaired 
consciousness may indicate the parasite entrance to the brain (Beeson and 
Brown, 2002).  
Sequestration of IEs to the brain vasculature results from specific interaction 
between PfEMP1 on the surface of IEs with adhesion receptors present on the 
endothelial surface of cerebral microvasculature such as ICAM-1 (Dobbie et al., 
1999, Martins and Daniel-Ribeiro, 2013). However, the involvement of ICAM-1 
and other adhesion receptors such as CD36 in the pathogenesis of CM will be 
discussed later in this chapter.  
 
1.4.2 Pregnancy associated malaria  
PM or pregnancy-associated malaria (PAM) is a significant cause of morbidity 
and mortality for both the mother and the child in Sub-Saharan Africa and 
caused by parasites that preferentially sequester in the intervillous space of the 
placenta in pregnant women (Oleinikov et al., 2008). This adhesion phenotype is 
relatively common with P. falciparum, less common with P. vivax (Autino et al., 
2012) and occurs when mature asexual stages of the parasite express specific 
variant surface antigens [VSAs] (Barfod et al., 2006) that selectively adhere to 
CSA expressed on the syncytiotrophoblasts lining the placenta (Fried and Duffy, 
1996), and may also bind to other receptors such as HA and immunoglobulins 
(Igs) (Beeson et al., 2004, Beeson et al., 2000). The major clinical 
manifestations of the infection are maternal anaemia which may lead to death of 
the mother, low birth weight and stillbirth, premature delivery and increased 
mortality of the newborn (Beeson and Brown, 2002, Miller et al., 2002). 
A specific PfEMP1, VAR2CSA, is the most important VSA associated with PM 
(Salanti et al., 2004). VAR2CSA is a large PfEMP1 protein (~350 kDa) encoded 
by var2csa gene and comprised of six distinct Duffy binding-like (DBL) 
domains including those involved in CSA binding such as DBL2x and DBL3x 
(Avril et al., 2006). Var2csa is relatively conserved in sequence and existed a 
single-copy gene in most parasite genomes (Salanti et al., 2003). Transcription 
of var2csa gene is markedly upregulated in placental parasites and parasite lines 
selected for adhesion to CSA in vitro (Salanti et al., 2003), and disruption of the 
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var2csa gene of P. falciparum results in the failure to retain CSA-adhesion 
phenotype (Viebig et al., 2005) suggesting a significant role of var2csa in 
mediating placental binding. Parasites isolated from placentas of infected 
women are phenotypically distinct from other parasite isolates as they 
preferentially bind to placental receptors such as CSA, but fail to bind CD36, a 
common host receptor for parasite adhesion to the microvasculature (Fried and 
Duffy, 1996, Miller et al., 2002). This suggests that a distinct sub-population of 
parasites have been selected to sequester not to the endothelium but to the 
placenta, a site of low immune response, where they can establish maternal 
malaria (Miller et al., 2002). The reason for the lack of ability to bind CD36 is 
due to the absence of the CD36-binding CIDRα2-6 domains in var2csa-encoded 
PfEMP1 proteins (Salanti et al., 2003; Smith et al., 2013).  
While adult individuals living in malaria endemic areas develop immunity 
against malaria, pregnant women become highly susceptible to the disease and 
the risk is highest during their first pregnancy (primigravdae) when mothers lack 
sufficient immunity against PM (Fried et al., 1998, Viebig et al., 2005). 
However, women in these areas acquire protective immunity against PM as a 
function of parity; susceptibility to the infection rapidly reduced with increasing 
parity and age, and the mechanism of protection seems to be development of 
adhesion-inhibitory antibodies that block IE adhesion to the placenta (Fried et 
al., 1998, Beeson et al., 2004). Multigravidae generally have higher amounts of 
Igs that target placental parasites and block adhesion to CSA than primigravidae 
or men, reflecting a higher exposure to malaria infection (Beeson et al., 2004, 
Fried et al., 1998). Higher levels of VAR2CSA-specific IgG are correlated with 
acquired protection against the clinical manifestations of PM such as low birth 
weight (Salanti et al., 2004), suggesting that it could be possible to develop a 
vaccine targeting VAR2CSA to protect pregnant women in PM endemic areas. 
Furthermore, adhesion-inhibitory sera from African women were found to block 
CSA adhesion of parasites from other regions in the world (Fried et al., 1998), 
which propose that the immunogenic targets for PM might be conserved and 
CSA-binding is a common feature globally.  
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1.4.3 Rosetting  
Rosetting, the adhesion of two or more non-IEs to a mature parasitized erythrocyte 
(David et al., 1988), is a property of parasite cytoadherence that is thought to 
contribute to significant microvascular obstruction (Kaul et al., 1991, Carlson and 
Wahlgren, 1992). Most studies that investigated the association between rosetting 
and disease outcome suggested that rosetting parasites occur more frequently in 
patients with severe malaria disease (Newbold et al., 1999), suggesting a significant 
role of this cytoadherence phenotype in the pathogenesis of severe malaria. Parasites 
that cause rosetting can be categorised into two types: parasites that mediate the 
binding of non-immune natural IgM antibodies in the plasma or serum to the IE 
surface and those that do not do so (Ghumra et al., 2012). Binding to non-immune 
IgM was originally proposed to act as 'bridges' between the IE and surrounding 
RBCs (Scholander et al., 1996), but the recent findings that IgM binding site is 
mapped close to the C-terminus of PfEMP1 makes this suggestion uncertain 
(Stevenson et al., 2015). Rather, it appears that the function of Fc-dependent IgM in 
rosetting is strengthening the interaction of multiple domains of PfEMP1 head 
structure with their receptors on the erythrocyte surface (Stevenson et al., 2015). 
Although Barfod et al., 2011 indicated that non-specific IgM binding has a role in 
escaping immunity in the VAR2CSA-type PfEMP1 by masking critical epitopes on 
the IE surface, inhibiting the subsequent binding of specific antibodies and 
protecting the parasite from phagocytosis; the recent findings by Stevenson et al., 
2015 argued against this and found that IgM binding did not inhibit specific IgG 
labelling or masked opsonised IEs from phagocytosis in a rosette-mediating 
PfEMP1.    
P. falciparum, P. vivax and P. ovale are all have the capacity to form rosettes, but 
only P. falciparum-mediated rosettes are correlated with severe malaria especially 
in African children (Autino et al., 2012). In an early Kenyan study, rosette 
formation in 154 fresh parasites isolated from Kenyan children with different 
malaria syndromes was studied and the results showed that the ability to form 
rosettes was correlated with severe malaria disease (Rowe et al., 1995). Another 
field study found a strong association between rosette formation and CM in 
parasites isolated from Gambian children with CM or UCM (Treutiger et al., 1992). 
Furthermore, a study conducted on 209 Malian children showed that rosetting was 
significantly higher in P. falciparum parasites isolated from severe malaria patients 
compared with non-severe and UCM control cases (Doumbo et al., 2009).  
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Several studies have demonstrated that the key parasite ligands that mediate rosette 
formation are PfEMP1 molecules on the surface of IEs (Chen et al., 1998a, Rowe et 
al., 1997), although a very recent work has shown that RIFINs can also mediate 
rosetting (Goel et al., 2015). The functional erythrocyte binding region on PfEMP1 
was identified and found to be the N-terminal DBLα domain (Rowe et al., 1997, 
Russell et al., 2005), which has been associated with binding to host molecules on 
the surface of non-IEs such as complement receptor 1 [CR1] (Rowe et al., 1997), 
heparan sulphate [HS] (Chen et al., 1998a, Chen et al., 2000) and antigens of blood 
groups A and B (Carlson and Wahlgren, 1992, Rowe et al., 2007) for rosette 
formation. Previous work has demonstrated that the ABO blood grouping influences 
the size of rosettes formed but not the general frequency; rosettes with cells from 
blood group-O patients are generally smaller and tend to be easily disrupted 
compared to the larger rosettes formed with cells from group A or B individuals, 
with group-A rosettes likely to be the largest amongst all blood groups (Rowe et al., 
2007, Carlson and Wahlgren, 1992). Therefore, blood group-O may be a protective 
factor against severe disease while non-O blood group individuals may be at a 
greater risk for developing life-threatening malaria due to the mechanism of 
increased rosette formation (Carlson and Wahlgren, 1992, Rowe et al., 2007). 
 
1.4.4 Auto-agglutination and platelet-mediated clumping 
The cytoadhesion of mature IEs with each other to form clumbs is an adhesion 
phenotype that was firstly termed auto-agglutination [Figure 1.4] (Roberts et al., 
1992). This cytoadhesion phenotype was more frequently observed in children 
with severe malaria than those with mild disease, suggesting its role in the 
contribution to severe disease presumably through local disturbance of 
microcirculatory blood flow and/or other significant physiological functions  
(Roberts et al., 2000). IE auto-agglutination is distinct from rosetting, since auto-
agglutinating parasite clones do not form rosettes and rosetting parasites do not 
auto-agglutinate IEs (Roberts et al., 1992). It was demonstrated that auto-
agglutination of P. falciparum-IEs is mediated by platelets and clumping 
requires the surface expression of platelet glycoprotein CD36 (Pain et al., 2001). 
Platelet-mediated clumping is an adhesive phenotype expressed by some CD36-
binding isolates and is common in field isolates such as those in Kenya. This 
cytoadherent phenotype is associated with severe disease probably through local 
obstruction of blood flow (Pain et al., 2001).  
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1.5 Variant surface antigens on the surface of IEs 
Infection of erythrocytes by P. falciparum parasites leads to multiple 
morphological and structural changes that affect cellular membrane rigidity, 
permeability and host cell surface antigens. These changes benefit the parasite 
development within the host cell and contribute to the acquisition of nutrients 
and waste removal, chronicity of infection and establishment of adhesive 
phenotypes (Smith and Craig, 2005, Sanyal et al., 2012). Although parasite-
derived sub-cellular changes are significant for parasite maturation and 
pathogenesis, the major focus of the following section will be VSAs on the 
surface of IEs. 
During the intra-erythrocytic stage of development, several parasite-derived 
antigens are synthesised and exported to the surface of IEs (Leech et al., 1984). 
These VSAs are extremely polymorphic, highly immunogenic in nature and 
induce an immune response that targets IEs for providing protective immunity 
against malaria (Bull et al., 1998, Marsh et al., 1989). VSAs are implicated in 
the cytoadhesion of P. falciparum-IEs in the microvessels of various organs, a 
key pathological feature of severe malaria disease (Berendt et al., 1994). 
Although the phenomenon of parasite sequestration in humans is only observed 
extensively with P. falciparum infections, all malaria species seem to have the 
capacity to alter their host surface by expressing VSAs on the IE membrane 
(Smith et al., 1995).  
To date, several VSAs have been identified including PfEMP1 (Leech et al., 
1984), repetitive interspersed family (RIFIN) proteins (Cheng et al., 1998, 
Fernandez et al., 1999, Kyes et al., 1999), sub-telomeric variable open reading 
frame (STEVOR) proteins (Cheng et al., 1998, Niang et al., 2009), surface-
associated interspersed gene family (SURFIN) proteins (Winter et al., 2005) and 
presumably other proteins such as P. falciparum Maurer's cleft 2 transmembrane 
(PfMC-2TM) proteins (Sam-Yellowe et al., 2004). In addition to parasite-
derived surface antigens, altered host proteins such as modified band 3 have also 
been implicated as immune targets and suggested as surface ligands for 
cytoadhesion (Winograd et al., 2004).  
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1.5.1 PfEMP1 
The most extensively characterised VSA is PfEMP1, a highly polymorphic 
protein that has a significant role in the parasite virulence, survival and 
transmission (Smith, 2014). PfEMP1 proteins are encoded by members of the 
var multigene family, expressed on the surface of IEs and are associated with 
cytoadherence of parasitized erythrocytes to various host receptors on ECs, 
infected and non-IEs, and thus contributing to the pathogenesis of severe malaria 
disease (Baruch et al., 1995, Su et al., 1995, Smith et al., 1995). PfEMP1 was 
first recognised by immunoprecipitation with immune sera collected from Aotus 
monkeys as a highly polymorphic, high molecular weight (MW) protein, 
sensitive to protease digestion on intact IEs and was suggested as a constituent 
of the parasite-derived knobs (Leech et al., 1984). PfEMP1 molecules are 
synthesised and transported to the surface of IEs at ~18 hours post-invasion 
during the intra-erythrocytic asexual stage of parasite development (Kyes et al., 
2000). These proteins are exported to the IE surface with the N-terminal binding 
region localised at the external surface of the cell and the C-terminal on the 
cytoplasmic side (Su et al., 1995, Rask et al., 2010).  
 
1.5.1.1 Structure of PfEMP1 molecules 
Despite the extensive diversity in sequence, size and domain organization of 
PfEMP1 proteins, they have a common structure and can be grouped according 
to sequence similarity (Kraemer et al., 2007). PfEMP1 proteins are 150 – 350 
kDa in size and each protein contains single intracellular (ID) and 
transmembrane (TM) domains, and ~2 to 7 tandemly arranged extracellular 
domains (30-45 kDa per domain) connected with disulphide bonds. From the 
extracellular N-terminal to the cytoplasmic C-terminal, the modular PfEMP1 
consists of an N-terminal segment (NTS), several DBL and CIDR domains, TM 
region and a highly conserved acidic terminal segment [ATS] (Smith et al., 
2000b, Rask et al., 2010). The ATS segment and TM region are thought to 
anchor the PfEMP1 molecule at the knob structure on the surface of IEs (Su et 
al., 1995). Due to the variability of the PfEMP1 domain architecture, DBL 
domains are categorised first by position in the protein and second by type 
36 
 
(Smith et al., 2000b). For instance, the first N-terminal DBL domain for most 
PfEMP1 proteins is DBLα type, and thus it is named ''DBL1α'' which is always 
followed by a CIDR1 domain. The N-terminal DBL-CIDR tandem is the most 
conserved extracellular region and known as the semi-conserved head structure 
(Su et al., 1995, Smith, 2014).  
Rask et al. (2010) re-classified PfEMP1 domains based on analyses of 399 
distinct PfEMP1 sequences from seven parasite genomes (four Asian, two 
African and one South American isolate). Their analyses have confirmed the 
already existed grouping of DBL domains (by Smith et al., 2000b, Gardner et 
al., 2002 and Lavstsen et al., 2003) into six major classes based on sequence 
similarity: DBLα, β, γ, δ, ε and ζ. In addition, five relatively smaller different 
classes were also identified including four N-terminal DBL domains of 
VAR2CSA and DBLα of VAR3. DBLα was further divided into 3 groups 
(DBLα0, DBLα1 and DBLα2) and sequences of these groups have been grouped 
into several subclasses (e.g. DBLα1.3 of VAR3). The CIDR domain has been 
divided into 5 major classes: CIDRα, β, γ, δ and pam, of which CIDRδ was 
firstly identified (Rask et al., 2010). The PfEMP1 C2 domain always follows a 
DBLβ domain and never followed other DBL classes (Smith et al., 2000a). The 
tandem arrangement DBLβC2 was always found as a combination; with C2 
being an essential part of the same DBLβ domain and thus the term (C2) was 
omitted from all DBLβ domains (Rask et al., 2010, Gullingsrud et al., 2013). 
Subsequent work on the classification of PfEMP1 structure has revealed that 
PfEMP1 proteins are characterised by 23 conserved motifs called domain 
cassettes (DCs), defined as two or more tandemly arranged domains belonging 
to a specific sub-class (i.e. combination of DBL and CIDR sub-domains) and 
existing in three or more of the seven sequenced parasite genomes (Rask et al., 
2010). Of particular significance, DC8 and DC13 have been associated with 
specific clinical consequences. Transcription levels of the conserved DC8 and 
DC13 have been demonstrated to be elevated in isolates causing severe malaria 
complications in children than those causing uncomplicated malaria (UCM) 
(Lavstsen et al., 2012, Almelli et al., 2014). In addition, P. falciparum lines 
panned for binding to human brain microvascular endothelial cells (HBEC) 
expressed higher levels of DC8 genes (Claessens et al., 2012, Avril et al., 2012), 
37 
 
although DC8-expressing parasites also bound significantly to primary ECs from 
the heart, dermis and lung (Avril et al., 2012). Despite the potential role of 
ICAM-1 in CM pathogenesis, IEs selected on expression of DC8 and DC13 by 
panning on HBECs do not bind to ICAM-1 or only adhere at significantly lower 
levels (Avril et al., 2012, Claessens et al., 2012). A recent study has identified 
another DC (termed DC4) present in group A var genes from six genetically 
diverse P. falciparum isolates. Parasites containing the three domains of DC4 
adhered preferentially to ICAM-1 receptors (Bengtsson et al., 2013). These data 
suggest that specific PfEMP1 DCs may have a critical role in the development of 
malaria-related pathological outcome.  
 
1.5.1.2 Var genes 
Sequencing of P. falciparum parasite genomes has advanced our understanding 
about the structural and functional properties of var genes. Each parasite genome 
contains ~60 copies of var genes encoding the multidomain PfEMP1 proteins 
(Baruch et al., 1995, Su et al., 1995, Smith et al., 1995, Gardner et al., 2002, 
Kraemer et al., 2007, Lavstsen et al., 2003). The diversity of this gene family is 
extremely high within and between parasite genomes, and even clonal cultures 
are enormously heterogeneous phenotypically (Gardner et al., 1996). In most 
cases, the parasite expresses only one PfEMP1 copy on the surface of IEs at a 
time in a mutually exclusive fashion (Chen et al., 1998b). Although one var gene 
is expressed in each parasite, this can switch at a rate of up to 2% per parasite 
generation (Roberts et al., 1992). However, Horrocks et al. (2004) showed that 
switching rates vary dramatically between different variants, and each var gene 
has its own switching rate (Horrocks et al., 2004). Switches in expression of var 
genes favour the parasite survival through evading the host immune response 
and allows the parasite to sequester in the microvessels of the host organs 
(Kraemer et al., 2007). 
Despite the high diversity of var gene repertoires, most of these genes are 
categorised into three major groups (A, B and C) and two intermediate groups 
(B/A and B/C) on the basis of chromosomal location (central or telomeric), 
conserved upstream promoter sequence (UpsA, UpsB and UpsC) and gene 
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orientation (Gardner et al., 2002, Lavstsen et al., 2003). Groups A and B are 
located in the sub-telomeric regions in the chromosome, whereas group C is 
present in the central chromosomal regions (Gardner et al., 2002). Comparisons 
of parasite genomes have revealed the presence of three additional relatively 
conserved genes at the sequence level: var1csa, var2csa and Type 3 var genes, 
which are found in almost all isolates with ˃ 75% sequence identity among 
multiple domains (Kraemer et al., 2007). Var gene groupings have clinical and 
functional significance and can be linked to certain parasite pathologies. For 
instance, var2csa encodes a PfEMP1 protein that mediates the adhesion to CSA 
receptors and therefore has a crucial rule in the pathogenesis of PM (Salanti et 
al., 2004, Salanti et al., 2003). In addition, expression of group A and to some 
extent group B var genes has been associated with severe malaria, as shown in 
several published studies (e.g. Kaestli et al. 2006, Jensen et al., 2004, Rottmann 
et al., 2006, Kyriacou et al., 2006, Falk et al., 2009).   
 
1.5.1.3 PfEMP1 Adhesive properties  
The multiple domains of the extracellular region of PfEMP1 proteins have 
different binding specificities and can predominantly adhere to various host 
receptors (Smith et al., 2000a, Rowe et al., 1997, Baruch et al., 1997, Chen et al., 
2000, Turner et al., 2013). The effectiveness of a given PfEMP1 to bind to host 
cells mainly depends on the adhesion characteristics of that PfEMP1 variant, 
availability of host ligands with appropriate binding properties and the host 
antibody repertoire to PfEMP1 proteins (Lavstsen et al., 2003).  
The PfEMP1 adhesive domains for a variety of host receptors have been 
identified and mapped to different DBL and CIDR domains (Smith et al., 
2000a). Although several receptors have been identified as ligands for IE 
binding (described in detail later in this chapter), CD36 and ICAM-1 are the best 
understood adhesion candidates. The most common binding specificity of CIDR 
domain in the semi-conserved head structure is adhesion to human CD36 
receptor (Baruch et al., 1997, Chen et al., 2000). This binding property (i.e. 
binding to CD36) is a common adhesive phenotype for numerous PfEMP1 
variants and mainly limited to groups B and C PfEMP1 proteins (Rask et al., 
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2010, Smith, 2014). Subsequent sequence comparisons has led to the sub-
grouping of PfEMP1 domains (e.g. CIDRα1.4) (Rask et al., 2010). Whereas 
CIDRα2-6 sequence types are associated with CD36 binding, CIDRα1 domains 
(subtypes 1.1, 1.4, 1.5 and 1.7) encode binding to endothelial protein C receptors 
[EPCR] (Turner et al., 2013). The DBLα1-CIDRβ/γ/δ head structure is 
associated with rosetting, and CIDRβ/γ/δ domains in this tandem do not bind to 
CD36 or EPCR indicating that different PfEMP1 head structures domains 
mediate distinct binding properties (Rask et al., 2010, Smith, 2014).  
DBL domains are essential in two main processes associated with malaria 
pathogenesis: invasion of erythrocytes and mediating IE adhesion to various host 
receptors (Howell et al., 2008). It has been shown that different DBL domains 
mediate cytoadhesion to particular host receptors depending on the primary 
sequence and class of these domains. For example, DBLα domain has been 
found to bind to host receptors such as CR1 (Rowe et al., 1997), HS molecules 
(Chen et al., 1998a, Chen et al., 2000) and antigens of blood groups A and B 
(Carlson and Wahlgren, 1992, Chen et al., 2000) located on the surface of non-
IEs for rosette formation. The second class of DBL domains, DBLβ, has been 
associated with adhesion to ICAM-1 receptors (Smith et al., 2000a, Oleinikov et 
al., 2009, Howell et al., 2008, Brown et al., 2013). In an analysis of the entire 
DBLβ domains in the IT4 P. falciparum parasite genome (n=25), six domains 
bound to ICAM-1 receptors (Howell et al., 2008). It has been demonstrated that 
PfEMP1-ICAM-1 interaction is mediated fully by single DBLβ domain that 
binds to the N-terminal region of ICAM-1 to form a 1:1 complex (Brown et al., 
2013). Phylogenetic criteria has led to the classification of PfEMP1 domains into 
small (four extracellular domains) and large (5-9 extracellular domains) PfEMP1 
molecules [Figure 1.5] (Smith, 2014). DBLβ type is only found in larger 
PfEMP1 molecules (Smith, 2014) and therefore ICAM-1 binding is mainly 
restricted to large PfEMP1 proteins.  
Although an early study demonstrated that both CIDR1α and DBL2δ domains 
bind to platelet-endothelial cell adhesion molecule-1 [PECAM-1] (Chen et al., 
2000), a recently published work indicated that IE adhesion to PECAM-1 is 
mediated by DC5-containing PfEMP1 variants (Berger et al., 2013, see section 
1.6.5 for more details).  
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Figure 1.4. Structural and adhesive properties of PfEMP1 molecules. Typical arrangement of 
PfEMP1 molecules (blue). The arrow demonstrates how classification of adhesive domains has 
evolved in higher domain organization of PfEMP1 molecules into small and large proteins. The 
graph was acquired from (Smith, 2014).   
 
 
1.5.1.4 Antigenic variation 
PfEMP1 molecules are expressed on the surface of IEs during the second half of 
the intra-erythrocytic cycle of P. falciparum parasite development (Smith et al., 
1995). Each mature IE is thought to select and express only one var gene (out of 
a repertoire of ~60 genes) at a time, such that a single PfEMP1 reaches the 
surface of IEs (Chen et al., 1998b). However, switching of var gene expression 
can occur at each new cycle of erythrocytic invasion, in a phenomenon known as 
''antigenic variation'' (Chen et al., 1998b, Roberts et al., 1992). In vitro studies 
showed that P. falciparum parasites undergo a clonal switching in antigenic 
phenotypes at a rate up to 2% per generation in the absence of immune pressure 
(Roberts et al., 1992). Since several PfEMP1 molecules have distinct receptor-
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binding specificities, clonal switching between expressions of diverse var gene 
variants, in a mutually exclusive fashion, allows the parasite to change its 
antigenic and cytoadhesion properties (Salanti et al., 2010, Smith et al., 1995). 
This higher rate of antigenic switching provides an additional complication for 
laboratory researchers studying parasite cytoadhesion in vitro, and assays that 
require longer periods of parasite cultures must involve regular selection on 
particular adhesion phenotype to maintain the required binding property (Rowe 
et al., 2009).  
As well as changing the adhesion phenotype, switching of var gene expression 
allows the parasite to evade the host immune response and promote chronic 
infection (Chakravorty and Craig, 2005). The acquired antibody response to 
parasite-derived surface antigens demonstrates higher levels of strain-specificity 
(discussed in detail later in this chapter). This is evident from studies showing 
that the predominant agglutinating antibody response in humans to the IE 
surface was principally variant-specific, and cross-reactive antibodies to 
different serotypes were rare (Newbold et al., 1992). Sera collected from 
children in the Gambia (Marsh and Howard, 1986) and Papua New Guinea 
(Forsyth et al., 1989) during convalescence reacted predominantly with 
homologous but not heterologous parasites in agglutination assays. Since the 
response is principally variant-specific, the mechanism of antigenic variation 
allows the development of repeated infections by exploiting gaps in the 
repertoire of strain-specific acquired antibody response (Bull et al., 1998, 
Gamain et al., 2001). Immune evasion is likely occur by distracting the host 
adaptive immune response from the significant cross-reactive antigenic 
determinants and guiding that response to strong, polymorphic epitopes (Gamain 
et al., 2001). These data indicate that the parasite antigenic variation is a key 
factor contributing to the pathogenesis of malaria infection.  
 
1.5.2 RIFIN 
RIFIN proteins are the largest family of clonally variant antigens expressed on 
the surface of P. falciparum-IEs. RIFINs are low MW proteins (30– 45 kDa) 
encoded by the rif (repetitive interspersed family) multigene family which 
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contains 150-200 genes per parasite genome (Winter et al., 2005, Kyes et al., 
1999, Fernandez et al., 1999). They had originally been called ''rosettins'' and 
were proposed to mediate rosetting, before it was clearly demonstrated that 
PfEMP1 is the main rosetting ligand (Kyes et al., 1999). RIFINs co-express with 
PfEMP1 on the surface of parasitized erythrocytes, although transcriptional 
analyses demonstrated that rif genes are expressed after var genes, only for a 
limited time from late ring to early pigmented trophozoite stages of asexual 
blood cycle [~18-23 hours after RBC invasion] (Kyes et al., 1999, Kyes et al., 
2000). This co-expression has prompted assumptions that expression and export 
of RIFIN and PfEMP1 proteins are connected (Craig and Scherf, 2001). In 
contrast to var, rif genes transcribe and express multiple gene copies in a single 
parasite, resulting in the expression of several RIFINs at the surface of IEs 
(Fernandez et al., 1999).  
In contrast to PfEMP1 of which as little as 1 µg/ml of trypsin treatment can 
cleave the protein, RIFIN proteins are almost unaffected with up to 100 µg/ml 
trypsin digestion (Fernandez et al., 1999, Kyes et al., 1999). It has been shown 
that human immune sera agglutinated IEs treated with trypsin at conditions (˃ 
100 µg/ml) such that the highly trypsin-sensitive PfEMP1 proteins are mostly 
removed but RIFINs are detected, which suggests the existence of immunogenic 
epitopes in this family of proteins targeted by agglutinating antibodies 
(Fernandez et al., 1999). Another study revealed that RIFIN recombinant 
proteins were well recognised by a large panel of human immune sera 
suggesting the capacity of these proteins to induce a strong immune response in 
P. falciparum-infected adults in malaria endemic regions (Abdel-Latif et al., 
2002). It has been shown that acquisition of specific anti-RIFIN antibodies was 
associated with protection against P. falciparum malaria (Abdel-Latif et al., 
2003). Although their biological significance and role in natural immunity are 
largely unknown (Rowe et al., 2009, Chan et al., 2012), the higher expression 
level of these genes by P. falciparum parasites, their surface localisation and 
sequence diversity suggest a potential role for these proteins in the parasite 
interaction with host cells (Kyes et al., 1999). Recently, Goel et al. (2015) have 
demonstrated that RIFINs are expressed on the surface of IEs, bind to RBCs 
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(preferentially of blood group A) to form large rosettes and mediate 
microvascular adhesion of IEs.  
 
1.5.3 STEVOR 
STEVOR proteins, encoded by the stevor multigene family (30-40 copies per 
parasite genome), represent the third largest family of clonally-variant parasite-
derived antigens identified in P. falciparum (Cheng et al., 1998). Several stevor 
gene copies were observed in a single parasite, and the peak transcription takes 
place during late trophozoite and early schizont stages of parasite development 
(Niang et al., 2009). Unlike PfEMP1 and RIFIN, data presenting evidence that 
STEVOR proteins are exported to external surface of parasite-infected RBCs are 
inadequate. Niang et al. (2009) have demonstrated that STEVORs are expressed 
on the surface of IEs using a combination of live immunofluorescence assay 
(IFA) and flow cytometry, and that the expression was only located on 
erythrocytes infected by parasites at the schizont stage.  
Similar to RIFINs, the biological function of STEVOR proteins is largely 
unknown (Chan et al., 2014). Both protein families have been suggested to play 
a role in host-parasite interaction and antigenic properties (Beeson et al., 2006, 
Niang et al., 2009, Rowe et al., 2009). A recent study provided evidence that 
STEVOR is a RBC binding protein that mediate rosetting independently of 
PfEMP1 via interation with glycophorin C on the erythrocyte surface and 
STEVOR-mediated rosetting has a protective role for merozoites from invasion-
inhibitory antibodies (Niang et al., 2014). Another study showed that increased 
expression of stevor genes contributes to decreased deformability and increased 
rigidity of IEs, which may has a role in enhancing PfEMP1-mediated parasite 
sequestration (Sanyal et al., 2012). In addition, the clonal diversity of STEVOR 
proteins makes them potential candidates involved in immune evasion alongside 
with RIFIN and PfEMP1 proteins (Chan et al., 2014). 
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1.5.4 SURFIN 
SURFINs are high molecular weight polymorphic proteins (~280-300 kDa) 
encoded by a small family of genes termed surf (surface-associated interspersed 
genes) multigene family, which contains 10 genes per parasite genome (Winter 
et al., 2005). Different surf genes are differentially transcribed depending on the 
developmental stage of intra-erythrocytic parasite cycle; some genes (e.g. surf1.3) 
are transcribed during late trophozoite and schizont stages, while others (e.g. 
surf4.2) are transcribed from early rings to schizont stages. This variation in 
transcriptional profiles may suggest a diversity in the functions of proteins 
transcribed by the corresponding genes (Mphande et al., 2008).  
It has been suggested that SURFIN proteins are present on both IEs and 
merozoites, the two developmental parasite stages that are exposed to the host 
immune system (Winter et al., 2005). Surface localisation of SURFINs on IEs 
was confirmed in two parasite isolates (FCR3 and 3D7), with a member termed 
SURFIN4.2, which was cleaved off the surface by trypsin treatment. In addition, 
immuno-electron microscopy analyses revealed that this family of proteins are 
present in the knob structures, suggesting their co-transportation with PfEMP1 at 
the surface of parasitized erythrocytes (Winter et al., 2005). However, recent 
data showed that another member of the SURFIN family (SURFIN4.1) is present 
in the PV, but not in the erythrocyte cytosol, and on the released merozoites. 
Agglutination and immunofluorescence data suggested that SURFIN4.1 is not 
exposed on the surface of IEs (Mphande et al., 2008). Although the biological 
function of SURFIN is not yet known, some SURFIN members have been 
associated with parasite invasion to the host erythrocytes (Mphande et al., 2008, 
Winter et al., 2005). In addition, relation of SURFINs to the surfaces of different 
parasitic developmental stages may suggest a contribution to parasite survival 
(Winter et al., 2005). 
 
1.5.5 Modified band 3 
One of the earliest identified proteins on the surface of IEs is a parasite-mediated 
modification of an erythrocyte surface protein, band 3 (Winograd and Sherman, 
1989). Band 3 is a protein found abundantly on the surface of RBCs and acts as 
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an anion transporter (Smith and Craig, 2005). Parasite-modified band 3 has been 
suggested as an immune target (Chan et al., 2012) since it is trypsin-resistant, 
located on the surface of IEs (Figure 1.6) and was immunoprecipitated by 
monoclonal antibodies (mAbs) raised to band 3 (Gardner et al., 1996). In 
addition, this highly abundant protein on the IE surface has been suggested as a 
ligand for IE adhesion to thrombospondin (TSP) and CD36 (Winograd et al., 
2004, Chan et al., 2014). Selective chemical alteration of modified band 3 has 
led to a substantial decrease in CD36 adhesion, but not TSP, which supports its 
essential role in CD36 binding (Winograd et al., 2004). In addition, synthetic 
peptides obtained from modified band 3 have been demonstrated to block 
adhesion to CD36 receptors, and antibodies raised against two structural portions 
of the protein were found to inhibit parasite adhesion to melanoma cells 
expressing CD36 (Beeson and Brown, 2002). However, its association to 
PfEMP1-mediated parasite cytoadhesion remains unknown (Chan et al., 2014).  
 
1.5.6 PfMC-2TM 
P. falciparum Maurer's clefts two-transmembrane proteins (PfMC-2TM) are 
encoded by a small gene family called pfmc-2tm (approximately 13 genes) and 
located at Maurer's clefts of IEs (Sam-Yellowe et al., 2004, Chan et al., 2014). 
Almost all pfmc-2tm genes are transcribed during the trophozoite stage of 
parasite development and unlike PfEMP1 proteins, 4 to 10 gene products are 
expressed at a given time (Sam-Yellowe et al., 2004). The biological function of 
PfMC-2TM proteins remains to be identified, and it has not been confirmed 
whether these proteins are related to the IE membrane or exported to outer 
surface of the parasitized erythrocyte (Chan et al., 2014).   
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Figure 1.5. Parasite-derived modifications to P. falciparum-IEs. Invasion of erythrocytes by P. 
falciparum results in dramatic morphologic and structural modifications to the host erythrocytes, 
which include the expression of knob structures and insertion of VSAs on the surface of IEs. The 
graph was acquired from (Chan et al., 2014).  
 
 
 
1.6 Human receptors for P. falciparum-IE adhesion  
A diverse array of human cell receptors have been shown to mediate P. 
falciparum-IE cytoadhesion (reviewed in Rowe et al., 2009) including ICAM-1 
(Berendt et al., 1989), CD36 (Barnwell et al., 1989, Ockenhouse et al., 1989), 
TSP (Roberts et al., 1985), EPCR (Turner et al., 2013), PECAM-1/CD31 
(Treutiger et al., 1997), CSA (Rogerson et al., 1995), E-selectin and vascular cell 
adhesion molecule-1 (VCAM-1) (Ockenhouse et al., 1992b), rosetting receptors 
including CR1 (Rowe et al., 1997), HS (Chen et al., 1998a), blood groups A and 
B antigens (Carlson and Wahlgren, 1992) and serum proteins IgG/IgM, 
fibrinogen and others (Scholander et al., 1996).  
The majority of P. falciparum-IEs bind to CD36 and to some extent to ICAM-1 
receptors which are broadly expressed in the microvasculature (Rogerson et al., 
1999, Newbold et al., 1997, Ochola et al., 2011). An exception for this universal 
binding are IEs isolated from the placenta of malaria-infected women. These 
receptors are either constitutively expressed on the host cells in vivo or up-
regulated after stimulation by inflammatory cytokines (Cooke et al., 1995). A 
single clone of P. falciparum-IEs has been shown to have a multiple binding 
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capacities and bind several endothelial receptors (Ockenhouse et al., 1992b). In 
order to mediate a firm adhesion to the endothelium, P. falciparum-IEs first 
tether, roll before becoming firmly attached to the host endothelial receptors 
(Miller et al., 2002, Autino et al., 2012). This adhesion mechanism is similar to 
cytoadhesion of leukocytes (Miller et al., 2002). The majority of host receptors 
are involved in the tethering and rolling but incapable of mediating firm 
adhesion on their own such as ICAM-1, which may function as a rolling receptor 
for IEs in cerebral vessels (Cooke et al., 1994, Miller et al., 2002). On the other 
hand, only particular receptors such as CD36 and CSA provide stationary and 
stable attachment of parasitized erythrocytes to the endothelium under flow 
pressure (Miller et al., 2002, Cooke et al., 1994). This cooperation between 
capturing and stationary receptors is suggested to promote efficient sequestration 
(Gray et al., 2003; McCormick et al., 1997).  
 
1.6.1 ICAM-1 
ICAM-1 (CD54) is an 80-114 kDa transmembrane glycoprotein that belongs to 
the Ig supergene family (van de Stolpe and van der Saag, 1996). The structure of 
ICAM-1 molecules is composed of five Ig-like extracellular domains (D1-D5) 
and a short cytoplasmic tail (Brown et al., 2013). It is widely distributed in 
various human tissues including vascular endothelium and numerous immune 
cells (Berendt et al., 1992). This receptor is constitutively expressed on ECs at 
basal levels and can be significantly up-regulated both in vivo and in vitro in 
response to several cytokines such as tumour necrosis factor-α (TNF-α), 
interlukin-1 (IL-1) and interferon-γ [IFN-γ] (van de Stolpe and van der Saag, 
1996, Berendt et al., 1992).  
ICAM-1 plays an important role in several biological processes such as 
inflammatory responses, antigen-independent interactions between lymphocytes 
and target molecules and T-cell mediated immune response. On the vascular 
endothelium, ICAM-1 has a significant role in the migration of leukocytes from 
the blood to tissues at the sites of inflammation. Leukocyte interaction with 
ICAM-1 is mediated via leukocyte function-associated antigen (LFA-1) and 
macrophage-1 antigen [Mac-1] (van de Stolpe and van der Saag, 1996, Berendt 
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et al., 1992). ICAM-1 functions as a ligand for other receptors such as CD43, 
hyaluronan and fibrinogen, and mediates binding to pathogens such as human 
rhinoviruses (van de Stolpe and van der Saag, 1996) and P. falciparum IEs 
(Berendt et al., 1989). In vitro, cytokine- and endotoxin-activated ECs bound to 
P. falciparum-IEs at increased levels via ICAM-1 ligands compared to binding 
with non-activated ECs (Berendt et al., 1989), indicating that cytokine-mediated 
ICAM-1 up-regulation increases parasite adhesion. The binding site on ICAM-1 
for P. falciparum IEs has been identified and mapped to the opposite face of 
ICAM-1 binding region for LFA-1 (Figure 1.7). P. falciparum IEs have been 
shown to bind a region on ICAM-1 that is distinct from, but overlaps, the 
binding sites for LFA-1, human major-type rhinovirus and fibrinogen 
(Ockenhouse et al., 1992a, Berendt et al., 1992). Adhesion studies have 
demonstrated that ICAM-1 plays a significant role in capturing parasitized 
erythrocytes from the flowing blood (Gray et al., 2003), and it has been shown 
that ICAM-1 and CD36 synergise to facilitate firm adhesion to the endothelium 
(McCormick et al., 1997).  
 
Figure 1.6. The crystal structure of the N-terminal domain of human ICAM-1 illustrating the 
binding sites for LFA-1 (blue), fibrinogen (red) and P. falciparum-IEs (yellow). The binding site 
for parasitized erythrocytes appears to involve the BED 'side' of the N-terminus of ICAM-1 Ig-
like domains. This binding site was determined using parasite isolates with different ICAM-1 
binding avidities, and different panels of ICAM-1 mutants (e.g. K29). The binding to human 
rhinovirus includes residues distributed along the entire Ig domain [graph acquired from (Tse et 
al., 2004)]. 
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1.6.1.1 Association between ICAM-1 binding and severe malaria 
disease  
Adhesion of parasitized erythrocytes to host receptors on the brain 
microvasculature is essential for the development of a fatal malaria-related 
disease, CM (Smith et al., 2000a). The pathophysiological importance of 
ICAM-1 binding is not completely understood and evidence to support its 
association with severe disease, particularly CM, is inconclusive (Cooke et 
al., 1994, Rowe et al., 2009). However, several lines of evidence have 
implicated ICAM-1 as having a role in the development of CM. First, 
immunohistochemical studies on postmortem tissues of patients who died 
from CM found that ICAM-1 expression was significanly up-regulated in the 
endothelium of cerebral microvasculature, and this higher ICAM-1 
expression co-localised with adhered IEs (Turner et al., 1994). Second, a 
large study conducted in Kenya, using parasite isolates from patients with 
defined clinical syndromes as well as isolates from healthy but parasitized 
community controls, showed an increased, although just missed statistical 
significance, ICAM-1 adhesion in parasites from patients with CM compared to 
those with asymptomatic malaria (Newbold et al., 1997). Another more recent 
large study examined the adhesion patterns of 101 patient isolates from different 
clinical syndromes showed that ICAM-1 adhesion was higher in isolates from 
CM patients, whereas increased CD36 adhesion was associated with 
uncomplicated malaria disease (Ochola et al., 2011). In agreement with these 
findings, Turner et al. (2013) found that adhesion to ICAM-1 was higher in 
isolates causing severe malaria than mild or UCM. However, it should be 
mentioned that a large field study conducted on Malawian children found an 
inverse assoiation between ICAM-1 adhesion and disease severity (Rogerson 
et al., 1999) and no difference was observed in adhesion of IEs to ICAM-1 
between parasites from severe and UCM in another study (Ockenhouse et 
al., 1991).  
Third, a single natural mutation in the ICAM-1 gene designated ICAM-1kilifi 
occurs at higher frequncy within African populations and was associated 
with severe malaria; such that individuals homozyogous for the Kilifi allele 
have increased susceptibility to CM in East Africa (Fernandez-Reyes et al., 
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1997), although a study in West Africa suggested a protective role of ICAM-
1kilifi against severe disease (Kun et al., 1999) and in vitro assays showed that 
adhesion of P. falciparum-IEs to ICAM-1kilifi was reduced compared to 
reference type (Craig et al., 2000). However, another study indicated that 
this polymorphism only protects against non-malarial febrile illnes and does 
not protect against severe malaria in East Africa (Jenkins et al., 2005).  
Despite the potential role of ICAM-1 in CM pathogenesis, IEs selected for 
expression of DC8 and DC13 by panning on HBECs were found not to adhere to 
ICAM-1 (Avril et al., 2012, Claessens et al., 2012). In addition, all but one 
ICAM-1 binding DBL domains belong to DBLβ domains from group B or C 
PfEMP1 variants (Howell et al., 2008, Oleinikov et al., 2009, Janes et al., 2011). 
Recent reports also indicated that the role of CD36 in CM pathogenesis may 
be more important as once thought. Parasite isolates from CM patients have 
been shown to adhere significantly more to CD36 than those from UCM 
(Almelli et al., 2014). Surprisingly, the study showed no difference in the 
binding capacities to ICAM-1 receptors, suggesting a key role of CD36, but 
not ICAM-1, in parasite sequestration during CM (Almelli et al., 2014). 
However, the reduced level of binding to ICAM-1 compared to CD36 may 
occur due to suboptimal binding between IEs and ICAM-1 caused by 
conformational alterations of the protein when attached to a plastic surface. 
In addition, Almelli et al. (2014) used ICAM-1 coating concentrations of 
only 10 µg/ml, which seems to be suboptimal for adhesion assays. Taken 
together, it might be convinceable to suggest that IE cytoadhesion to ICAM-
1 contributes to parasite sequestration and development of severe malaria 
disease, but additional studies are required to further validate this 
contribution.   
 
1.6.2 CD36 
CD36 (also known as platelet glycoprotein IV [GPIV] and GP88) is an 88 kDa 
integral membrane protein found on several cell types including ECs, macrophages, 
platelets and monocytes. This receptor has several biological functions including 
platelet adhesion, TSP-dependent interactions, signal transduction, macrophage 
phagocytosis of senescent neutrophils, immune responses in humans (Greenwalt et 
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al., 1992) and acting a receptor for malaria cytoadhesion (Barnwell et al., 1989, 
Ockenhouse et al., 1989). Direct evidence implicating CD36 as a receptor for P. 
falciparum IEs was provided from in vitro studies showing that parasitized 
erythrocytes were able to bind to plastic-adsorbed CD36 receptors, and this 
adhesion was blocked by anti-CD36 mAbs (Ockenhouse et al., 1989, Barnwell et 
al., 1989).  
The parasite ligand for CD36 adhesion is CIDRα domain of PfEMP1 (Baruch et al., 
1997, Chen et al., 2000) encoded by groups B and C var gene subtypes (Rask et al., 
2010, Smith, 2014). Purified CD36 receptors have the capacity to bind to most wild 
and culture-adapted P. falciparum isolates, although quantitative levels of binding 
are variable (Chilongola et al., 2009, Newbold et al., 1997, Rogerson et al., 1999). 
However, IEs isolated from placentas of infected pregnant women have been shown 
to bind to placental receptors such as CSA, but fail to bind to CD36 receptors (Fried 
and Duffy, 1996). Furthermore, it has been shown that a CIDR domain cloned from 
the expressed var gene of the CSA-binding FCR3 isolate was found not to bind to 
CD36 receptors (Buffet et al., 1999). This is due to the lack of CIDRα2-6 domains, 
the binding sites for CD36, in the var2csa-encoded PfEMP1 domains (Salanti et 
al., 2003; Smith et al., 2013).  
 
1.6.2.1 CD36 adhesion properties and association with disease severity  
Similar to ICAM-1, no definitive association between disease severity and CD36 
adhesion has been established (Cooke et al., 1994, Beeson and Brown, 2002, 
Rowe et al., 2009). In a large field study conducted in Africa (Rogerson et al., 
1999) and another study in Thailand (Ockenhouse et al., 1991), no significant 
difference in CD36 adhesion capacity between parasites from severe and UCM 
has been found, in contrast to findings from a recent study showing that a higher 
number of CM isolates bound more to CD36 compared to UCM patients 
(Almelli et al., 2014). On the other hand, findings from two large studies in 
Africa showed that parasites isolated from individuals with UCM have 
significantly higher levels of binding to CD36 than parasites from those with 
severe malaria, which may suggest a role for this receptor in host control of 
malaria (Newbold et al., 1997, Ochola et al., 2011). In another study, the low 
levels of CD36 expression in cerebral vessels of people who died from severe 
malaria showed no change from controls, in contrast to significantly increased 
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expression of ICAM-1 (Turner et al., 1994). However, the same study showed a 
highly significant correlation between CD36 expression and sequestered IEs in 
the brain endothelium of post-mortem tissues. A recent paper has indicated that 
CD36 deficiency was associated with protection against P. falciparum malaria 
anaemia in African children, suggesting a role for this receptor in malaria 
pathogenesis (Chilongola et al., 2009).  
Although CD36 expression in the brain endothelium is negligible (Beeson and 
Brown, 2002, Chilongola et al., 2009), IE binding to these endothelia can occur 
indirectly as a bridging interaction via platelets which are widely distributed in 
the brain and express higher levels of CD36 (Almelli et al., 2014). Moreover, it 
has been shown that auto-agglutination of P. falciparum IEs is mediated by 
platelets and requires the surface expression of CD36 platelet receptors (Pain et 
al., 2001). Despite the fact that CD36 is a common receptor for adhesion of most 
clinical and laboratory isolates, its implication in severe disease requires further 
elucidation. 
 
1.6.3 EPCR 
EPCR is widely expressed on various arteries and veins throughout the body but 
also expressed at lower levels in particular vascular beds, including the brain 
(Aird et al., 2014). EPCR is a receptor of the serum factor protein C and acts as 
cofactor for its physiological conversion to activated protein C, which also 
requires thromboduiln. On the EC surface, activated protein C plays a significant 
role in various functions including anticoagulant activities and protein C-
mediated cytoprotective pathway by the activation of protease activated receptor 
1 [PAR-1] (Figure 1.8). Cytoprotective effects on ECs include activation of anti-
inflammatory and anti-apoptotic responses, modifications of gene expression 
patterns and protection of endothelial barriers (Aird et al., 2014, Smith, 2014).  
Two recently published studies by Turner et al. (2013) and Moxon et al. (2013) 
have provided significant new understandings about the role of EPCR in P. 
falciparum malaria disease. Turner et al. (2013) have identified EPCR as a new 
receptor mediating IE adhesion to ECs on the brain endothelium, and IE 
adhesion to EPCR was significantly higher among patients with severe malaria 
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than those with mild or UCM. Parasite binding to EPCR was demonstrated to 
involve the interaction between the receptor with CIDRα1 domains of DC8-
containing PfEMP1 molecules (Turner et al., 2013). In addition, they found that 
pre-incubation of DC8-CIDRα1.1 or DC13-CIDRα1.4 with EPCR interfered 
with the binding of EPCR with activated protein C, indicating that PfEMP1 DCs 
and activated protein C compete for the same binding site. The lack of protein C-
EPCR binding complex may lead to endothelial barrier disruption and 
development of pro-inflammatory pathways, which in turn may contribute to 
severe malaria (Turner et al., 2013).  
Moxon et al. (2013) examined autopsies from Malawian children with CM and 
found an increased cerebral fibrin clots and loss of EPCR at sites of sequestered 
IEs in the cerebral microvessels. Using ex vivo endothelial phenotype assays of 
subcutaneous tissues, they demonstrated that both EPCR and its cofactor 
thromboduiln are absent at the sites of IE sequestration of non-fatal CM. 
Changes in EPCR and thromboduiln levels correlated with increased levels of 
soluble EPCR and soluble thromboduiln in the cerebrospinal fluid. It is therefore 
hypothesised that IE adhesion in cerebral vessels of CM patients may further 
down-regulate EPCR and/or thromboduiln expression, which constitutively 
found at lower levels in the brain, and this reduction makes the brain vulnerable 
to fibrin deposition, micro-haemorrhages and organ-specific pathology (Moxon 
et al., 2013).  
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Figure 1.7. Effects of P. falciparum-IE adhesion to EPCR. A: normal functional protein C 
system (described in the text). B: following P. falciparum infection, IEs bind to EPCR leading to 
inhibition of EPCR functions and enhancement of EC activation, which in turn leads to the 
release of cytokines, soluble EPCR (sEPCR) and soluble thromboduiln (sTM) in the blood. APC: 
activated protein C. The graph was acquired from (Aird et al., 2014). 
 
 
1.6.4 CSA  
CSA receptor is expressed on the surface of syncytiotrophoblasts lining the 
intervillous space of the placenta (Fried and Duffy, 1996). P. falciparum-IEs 
have been shown to adhere to CSA (Rogerson et al., 1995), and the latter was 
uniquely implicated in the development of PM through the binding of 
VAR2CSA-expressing P. falciparum isolates (Salanti et al., 2003, Salanti et al., 
2004). Several studies have implicated CSA as a key adhesion receptor for P. 
falciparum IEs in the placenta. For instance, an early study showed that parasites 
isolated from placentas of infected pregnant women typically adhered to CSA, 
and adhesion to placental sections occurred in a CSA-dependent fashion (Fried 
and Duffy, 1996). Although CSA has been detected in the vasculature of the 
brain, no steady correlation was observed between parasite binding to CSA and 
development of severe disease in children or non-pregnant adults (Beeson and 
Brown, 2002).  
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1.6.5 PECAM-1 (CD31) 
PECAM-1/CD31 is a highly glycosylated 130-kDa polypeptide expressed on 
ECs, monocytes, granulocytes and platelets. It belongs to the Ig supergene 
family and contains six extracellular Ig-like domains and a long cytoplasmic tail. 
P. falciparum-IEs have been demonstrated to bind to PECAM-1/CD31 on the 
vascular endothelium, to PECAM-1-transfected cells and directly to recombinant 
PECAM-1/CD31 receptors immobilised on plastic (Treutiger et al., 1997). 
Additionally, soluble PECAM-1 and mAbs raised to the amino-terminal segment 
of PECAM-1 inhibited IE binding. The binding site on PECAM-1/CD31 was 
suggested to be residing in the first four domains of the protein (Treutiger et al., 
1997). On the IE side, binding of PECAM-1/CD31 was mapped to CIDR1α and 
DBL2δ domains of PfEMP1 molecules (Chen et al., 2000). Although about 50% 
of field parasite isolates from Kenya were shown to bind to PECAM-1/CD31 
receptors in some reports, no significant association with severe disease has been 
detected (Rowe et al., 2009).   
Recently, Berger et al. (2013) demonstrated that parasite isolates expressing 
DC5 bind to PECAM-1 receptors. DC5 is a four-domain C-terminal cassette 
found exclusively in group A PfEMP1 proteins (Rask et al., 2010). Antibodies to 
each of the four domains in DC5 react with the native PfEMP1 on the surface of 
IEs. Furthermore, anti-DC5 antibodies blocked adhesion of DC5-expressing 
isolates to transformed human bone marrow ECs that express PECAM-1. Anti-
DC5 antibodies are naturally acquired during the first years of life by individuals 
living in endemic regions, and people who have higher levels of anti-DC5 
antibodies are expected to have less malaria febrile episodes, suggesting a role of 
DC5 as effectors of malaria immunity (Berger et al., 2013).  
 
1.6.6 Thrombospondin   
The adhesive glycoprotein TSP is produced by both melanoma and ECs and 
suggested to be present on the surface of these cells (Roberts et al., 1985). It is 
released in the circulating blood in response to thrombin-mediated platelet 
activation (Rowe et al., 2009) and has been associated with cell-to-cell and cell-
to-matrix adhesion (Rock et al., 1988). TSP is considered as the first identified 
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receptor mediating P. falciparum adhesion and implicated in parasite 
sequestration (Roberts et al., 1985). P. falciparum-IEs bind to purified TSP 
adsorbed onto plastic and TSP-secreting melanoma cells under static conditions 
(Roberts et al., 1985) and to ECs expressing TSP under conditions of blood flow 
(Rock et al., 1988). The IE ligand for binding to TSP is debatable, with PfEMP1, 
the membrane phospholipid ''phosphatidylserine'' derived from RBCs and 
modified band 3 suggested as potential binding ligands. No particular PfEMP1 
domains have been shown to mediate the binding to TSP (Rowe et al., 2009).  
 
1.6.7 VCAM-1 and E-selectin  
VCAM-1 (CD106) is a member of the Ig supergene family and consists of six 
extracellular domains (Rowe et al., 2009, Ockenhouse et al., 1992b). It mediates 
the adhesion of lymphocytes to the endothelium in a distinct mechanism from 
LFA-1 and ICAM-1 (Udomsangpetch et al., 1996). E-selectin (CD62E or 
endothelial leukocyte adhesion molecule-1 [ELAM-1]) is expressed on ECs at 
tissue sites of inflammation (Rowe et al., 2009). It belongs to a family of 
molecules termed selectins; a structurally associated protein similar to the 
mammalian lectins, epidermal growth factor and complement regulatory 
molecules (Ockenhouse et al., 1992b), and has been demonstrated to augment 
the rolling of neutrophils (Udomsangpetch et al., 1996). 
P. falciparum parasites were selected in vitro by consecutive panning on purified 
VCAM-1 and E-selectin proteins and shown to bind to the same proteins in 
recombinant soluble forms (Ockenhouse et al., 1992b). Parasites isolated from 
patients with severe malaria bound to TNF-α-activated human vascular 
endothelial cells (HUVECs) through VCAM-1 and E-selectin receptors 
(Ockenhouse et al., 1992b). However, a large African field study of nearly 200 
isolates demonstrated that only very few patient-derived parasite isolates bound 
to VCAM-1, whereas almost none of the isolates bound to E-selectin (Newbold 
et al., 1997). Another field study conducted on Thai patients showed that the 
percentage of binding of all tested isolates to VCAM-1 and E-selectin was 
negligible (Udomsangpetch et al., 1996).  
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1.7 PfEMP1 vaccine studies  
Despite the significant role of PfEMP1 as target of natural immunity and as a 
key virulence candidate in pathogenesis of severe malaria, the high level of 
diversity of these proteins limits their potential for the development of a malaria 
vaccine (Bull et al., 1999, Bull et al., 2000, Nielsen et al., 2004). However, 
several published studies have provided evidence that the development of a 
PfEMP1-based vaccine could be possible by showing that PfEMP1 recombinant 
proteins can mount a protective immune response in experimental animals 
(Tables 1.1 and 1.2). Immunisation of Aotus monkeys with single CDIR1α 
domains induced a protective immune response against fatal parasite infection 
with homologous parasite isolate, although the response was not sufficient for 
protection against heterologous parasite challenge probably due to the variant-
specificity of the immune response and extensive variability of PfEMP1 variants 
(Baruch et al., 2002). 
In another study, the researchers have immunised rats with phylogenetically 
variant recombinant DBLα domains and the induced antibodies cross-reacted 
with heterologous domains and reduced sequestration of with homologous and 
heterologous isolates in a novel in vivo model for human P. falciparum-IE 
sequestration (Ahuja et al., 2006). This and other published studies (Baruch et 
al., 2003, Gratepanche et al., 2003, Bengtsson et al., 2013, Angeletti et al., 2013, 
Avril et al., 2011, Nielsen et al., 2009, Salanti et al., 2010, Saveria et al., 2013, 
Avril et al., 2008, Oleinikov et al., 2008, Obiakor et al., 2013) have 
demonstrated that induction of cross-reactive animal antibodies recognising 
heterologous domains and parasite isolates is possible (Tables 1.1 and 1.2). In an 
attempt to overcome the variant-specific nature of antibodies raised against 
PfEMP1 variants, some researchers have used various combinations of PfEMP1 
domains to increase the cross-reactivity of the immune response (Gratepanche et 
al., 2003, Baruch et al., 2003, Moll et al., 2007). For instance, immunisation of 
mice with different combinations with CIDRα domains induced antibodies 
capable of agglutinating erythrocytes infected by diverse parasite isolates 
(Gratepanche et al., 2003, Baruch et al., 2003). Epidemiological studies on 
pregnant women in malaria-endemic areas have demonstrated that a vaccine that 
blocks IE binding to CSA and placental sequestration would protect these 
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women against the consequences of PM (Avril et al., 2006). Women in these 
areas acquire protection as they develop antibodies against VAR2CSA during 
consecutive pregnancies (Salanti et al., 2004, Barfod et al., 2006), making 
VAR2CSA a major target for vaccine development. This is supported by 
published studies showing that immunising animals with the full-length (Avril et 
al., 2011, Khunrae et al., 2010) or single domains (Nielsen et al., 2009, Salanti et 
al., 2010, Saveria et al., 2013, Obiakor et al., 2013, Avril et al., 2010) of 
VAR2CSA induced antibodies in animal antisera that reacted with several CSA-
binding parasites and blocked IE adhesion to CSA receptors (Table 1.2). 
For the development of a PfEMP1-based vaccine, two main approaches have 
been used to overcome the major obstacles of antigenic variation. The first 
approach aims to develop a multivalent vaccine comprising several distinct 
PfEMP1 variants for inducing an extensive repertoire of antibodies to cover the 
high level of antigenic diversity in parasite populations. However, identifying 
the number of different candidates involved in such PfEMP1-based vaccine 
remains an obstacle. In addition, the number of distinct variants required would 
be too large based on the sequence analysis data showing the high level of 
PfEMP1 sequence diversity (Beeson et al., 2013). Another challenge of this 
approach is the higher rate of gene recombination (Claessens et al., 2014), which 
allows the parasite to express other antigenically distinct epitopes that are not 
included in the vaccine. 
The second approach aims to direct the immune response to conserved epitopes 
or regions in PfEMP1 such that an effective vaccine would elicit cross-reactive 
antibodies with most if not all PfEMP1 variants in various populations (Gamain 
et al., 2001, Beeson et al., 2013). Defining conserved PfEMP1 epitopes involved 
in the pathogenesis of severe disease and shared between genotypically distinct 
parasites is highly challenging. Despite the high diversity of PfEMP1 proteins, 
some conservations at the structural level must exist to maintain its cytoadhesion 
function (Gamain et al., 2001, Bull et al., 1999). It was proposed that common 
''basic types'' of PfEMP1 proteins are expressed during malaria infection, and 
these types seem to be immunogenic and elicit an immunogenic antibody 
response (Giha et al., 1999). Immune sera from people living in various African 
countries agglutinated erythrocytes infected by isolates from distant areas, 
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suggesting the existence of cross-reactive epitopes expressed by several parasite 
strains (Aguiar et al., 1992). Another study conducted in a village in Sudan 
indicated that although parasites circulating in the area are genetically diverse 
and express distinct PfEMP1 proteins, they also exhibit a significant overlap in 
their PfEMP1 repertoires (Giha et al., 1999). In another study, parasites collected 
from severe malaria patients were frequently agglutinated by antibodies in 
heterologous plasma, indicating that a dominant subset of parasite-derived 
antigens are present on the surface of IEs and recognised by prevalent antibodies 
(Bull et al., 1999). The ability of serum IgG to recognise ''common'' epitopes is 
encouraging since parasites expressing commonly recognised VSA have been 
associated with severe disease (Bull et al., 1999, Bull et al., 2000). This and the 
recent identification of conserved DCs in PfEMP1 molecules and their 
association with severe disease may raise hope that the achievability of a 
PfEMP1-based vaccine may be possible. However, further work is needed to 
characterise the tertiary and quaternary structure of PfEMP1 proteins and 
identify conserved epitopes as well as their potential to elicit a specific 
protective immune response.  
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Immunogen Animal Reference Antibody response 
CIDRα domains Aotus monkeys (Baruch et al., 2002) 
The produced antibodies protected against fatal parasite infection with homologous, but not 
heterologous isolates. 
DNA plasmids expressing 
3 CIDRα domains 
Mice (Baruch et al., 2003) 
The produced antibodies were reactive against corresponding PfEMP1s as shown by ELISA, flow 
cytometry and agglutination of IEs. Some mouse sera showed a limited cross-reactivity with 
heterologous parasite isolates and recognised heterologous domains.   
DNA immunisation 
followed by a protein boost 
of 3 CIDRα domains 
Mice 
(Gratepanche et al., 
2003) 
A broad range of cross-reactivity to heterologous CIDRα domains was observed in mice immunised 
with the three domains simultaneously.  
10 different recombinant 
DBLα domains 
Rats (Oguariri et al., 2003) 
The produced antibodies recognised conserved PfEMP1 synthetic peptides but failed to label the 
surface of trophozoite-IEs and were incapable of recognising the full length PfEMP1 from laboratory 
strains. Antibodies also failed to agglutinate IEs. 
DBL1α, CIDR1α and 
DBL2δ domains 
Mice / rats / rabbits (Chen et al., 2004) 
Immune sera reacted with the surface of live IEs as well as linear recombinant proteins in ELISA and 
immunoblotting. Anti-DBL1α antisera and sera raised against a mixture of all domains disrupted 
rosettes and auto-agglutinates. Anti-DBL1α antisera protected against P. falciparum IE sequestration in 
an in vivo model of severe malaria. 
NTS-DBL1α/x domains of 
3D7-PfEMP1 
Rats (Ahuja et al., 2006) 
The antisera showed a wide range of cross-reactivity to diverse DBL1α/x domains in ELISA. In 
addition, the produced antibodies reduced parasite sequestration in an in vivo model.  
DBLα alone or in 
combination with other 
DBLα domains 
Rats / monkeys (Moll et al., 2007) 
The produced antibodies reacted with the surface of homologous and heterologous parasites. 
Antibodies significantly reduced PfEMP1-mediated sequestration of homologous isolates in 
immunised rats and protected against heterologous parasite sequestration after direct and indirect 
immunisation of rats. Antibodies significantly blocked IE adhesion in immunised monkeys.  
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NTS-DBL1α of varO 
parasites 
Mice 
 
(Vigan-Womas et al., 
2008) 
Anti-NTS-DBL1α antisera produced high antibody titres in ELISA against recombinant NTS-DBL1α 
domains, recognised the surface of varO-IEs and disrupted varO-IE rosettes. 
Three NTS-DBL1α 
domains 
Mice 
(Vigan-Womas et al., 
2011) 
Mouse antibodies produced by each recombinant NTS-DBL1α domain cross-reacted with their allelic 
forms by ELISA but showed a strict variant-specific IE surface reactivity and rosette-disruption. 
DBLα, CIDRα and DBLβ 
domains from DC4-
containing PfEMP1s 
Rats 
(Bengtsson et al., 
2013) 
The produced sera reacted with the surface of erythrocytes infected by heterologous P. falciparum 
isolates expressing DC4-containing PfEMP1 variants. 
DBLα1.5 and DBLα1.8 
domains from group A 
PfEMP1 variants 
Rabbits (Ghumra et al., 2012) 
The produced antibodies labelled the surface of IEs, inhibited rosetting and induced phagocytosis 
against homologous isolates. Furthermore, the antibodies cross-reacted with heterologous rosetting 
isolates, including clinical parasites from Africa.  
Peptide sequences of 
subdomain 2 of DBL1α 
Rats / rabbits 
(Blomqvist et al., 
2013) 
Antisera recognised the recombinant peptides as shown in ELISA and labelled the surface of live IEs. 
50% of tested isolates (laboratory or clinical) were surface reactive as indicated by flow cytometry and 
IFA.  
Three NTS-DBLα domains Rats / goats (Angeletti et al., 2013) 
All recombinant proteins induced high antibody titres and exhibited substantial levels of cross-
reactivity with heterologous NTS-DBLα proteins as shown by ELISA and flow cytometry. All antisera 
labelled the surface of erythrocytes infected by homologous PfEMP1 variants and showed some levels 
of cross-reactivity with heterologous isolates.  
Table 1.1. Vaccine studies based on immunisation of animals with PfEMP1 domains involved in CD36 binding and rosetting.  
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Immunogen Animal Reference Antibody response 
Full-length VAR2CSA / 3 
domain constructs (DBL4-
6) 
Mice / rabbits 
(Avril et al., 
2011) 
Antibodies in animals immunised by either immunogen recognised several VAR2CSA single domains in 
ELISA. Both immunogens elicited cross-reactive antibodies recognising diverse CSA-binding P. falciparum 
isolates. Only rabbit antibodies raised to the full-length VAR2CSA inhibited homologous CSA-binding parasite 
adhesion.   
DNA plasmid of NTS-
DBL2X of VAR2CSA 
Mice / rabbits 
(Bigey et al., 
2011) 
The produced antibodies significantly inhibited IE adhesion to CSA similar to antibodies raised against the full-
length VAR2CSA. 
VAR2CSA single domains, 
sub-domains and multi-
domains  
Rats 
(Nielsen et al., 
2009) 
Antibodies raised against VAR2CSA DBL4 domains were surface reactive and efficiently blocked CSA 
adhesion of several genetically-distinct parasite isolates. Overall, multi-domains elicited higher levels of surface 
reactivity than single domains.  
All VAR2CSA domains 
from 3D7 and HB3 parasites 
Rats 
(Salanti et al., 
2010) 
All 3D7 recombinant proteins except DBL6 elicited cross-reactive IgG antibodies that labelled VAR2CSA on 
the surface of IEs. Only antibodies raised against DBL3-HB3 T1 and DBL1-3D7 almost completely inhibited 
IE adhesion to CSA.  
Individual domains of 3D7 
VAR2CSA variant 
Rats / mice 
(Saveria et al., 
2013) 
Antibodies raised against DBL4ε, DBL5ε, DBL6ε and tandems of DBL4-DBL5 and DBL5-DBL6 all bind to 
placental parasites and laboratory isolates selected for CSA binding. Antisera to DBL5ε and DBL6ε blocked 
placental parasite adhesion to placental tissues and inhibited binding of several field isolates to CSA.  
DBL3 and DBL5 
(VAR2CSA-3D7), DBL5 
(VAR2CSA-FCR3) and  
DBL2 (PFL0008-3D7) 
Rabbits 
(Magistrado et al., 
2008) 
Antibodies raised against recombinant domains of VAR2CSA labelled the surface of P. falciparum parasites 
isolated from infected placentas.  
All VAR2CSA DBL Rabbits (Andersen et al., The produced antibodies reacted with the surface of erythrocytes infected by CSA-binding isolates (3D7 and 
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domains and ID2 domain  2008) FCR3). 
DBL3X and DBL6ε 
domains of VAR2CSA  
Mice 
(Fernandez et al., 
2008) 
Antisera raised against DBL6ε-VAR2CSA-FCR3 domain specifically recognised the surface of CSA-binding P. 
falciparum isolates and partially blocked IE adhesion to CSA receptors. 
DBL1, DBL3, DBL4, DBL5 
and DBL6 of VAR2CSA-
3D7 
Rabbits / mice 
(Oleinikov et al., 
2008) 
Anti-DBL5 antisera cross-reacted with the surface of CSA-binding P. falciparum laboratory isolates (3D7 and 
FCR3) and a clinical PM isolate. Anti-DBL6 antisera only reacted with 3D7-IEs.  
All six domains of 
VAR2CSA-3D7 
Rabbits / mice 
(Barfod et al., 
2006) 
Antisera raised in animals immunised with each of the domains reacted exclusively with the immunising 
domain as shown in ELISA. Some of the antisera reacted with the surface of IEs.  
Full-length VAR2CSA from 
FCR3 isolate 
Rats 
(Khunrae et al., 
2010) 
The produced antibodies completely inhibited recombinant VAR2CSA binding, as well as IE adhesion to 
chondroitin sulphate proteoglycans (CSPG). Of particular significance, anti-DBL4ε inhibited FCR3-IE adhesion 
to CSA by 90%.   
DBL2X, DBL3X, DBL2X-
S3, DBL3X-S3 of FCR3 
line 
Rats / rabbits 
(Obiakor et al., 
2013) 
Purified IgG from antisera raised against all domains recognised the surface of erythrocytes infected by 
homologous and some heterologous isolates. Anti-DBL3X-S3 inhibited IE binding to CSA receptors.  
Individual VAR2CSA DBL 
domains 
Rabbits 
(Avril et al., 
2008) 
Rabbit antisera reacted with homologous FCR3 isolates. Antisera to several DBL domains cross-reacted with 
different P. falciparum isolates.  
Full-length VAR2CSA from 
FCR3 isolate, CSA-binding 
VAR2CSA fragments 
Rats  
(Clausen et al., 
2012) 
Antibodies raised to CSA-binding fragments were efficient at blocking IE binding to CSA. Some sera partially 
cross-inhibited placental isolates. 
VAR2CSA-DBL1 and 
DBL5 domains  
Rabbits  
(Avril et al., 
2010) 
Immunisation with DBL5 domains induced a broadly cross-reactive response that recognised almost all tested 
lab-adapted CSA-binding isolates and clinical parasites from pregnant women from distinct regions. On the 
other hand, immunisation with DBL1 elicited antibodies with a relatively less reactivity with tested parasites.   
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DBL5ε, DBL6ε and 
DBL5ε-DBL6ε 
Mice / goats 
(Fernandez et al., 
2010) 
All recombinant domains induced cross-reactive antibodies that blocked 40 – 96% of IE adhesion to CSA. 
Antibodies raised to DBL5ε from 3 distinct parasite genotypes exhibited strain-specific IE blocking capacity. 
CSA-binding DBL3γ of 
VAR1CSA  
Mice  (Bir et al., 2006) 
The produced antibodies cross-reacted with diverse CSA-binding P. falciparum isolates and blocked their 
adhesion to placental cryosections under flow conditions. Antibodies to DBL3γ domains cross-reacted with 
DBL3X of VAR2CSA.  
Full-length VAR2CSA from 
3D7 isolate 
Rabbits  
(Srivastava et al., 
2011) 
Rabbit antibodies against the full-length VAR2CSA inhibited the interaction between DBL1X-6ε and decorin 
by 72%, and these antibodies predominantly target DBL3X and to some extent DBL5ε single domains.  
Several single and multiple 
VAR2CSA domains 
Rats  
(Dahlback et al., 
2011) 
Purified IgG antibodies from immunised rats reacted with VAR2CSA of homologous FCR3-IEs. The 
multidomains induced higher flow cytometry response than single domains. Antibodies against NTS-DBL4ε 
and NTS-DBL3X efficiently blocked FCR3-IE adhesion to CSPG. Antibodies to the full-length VAR2CSA 
almost completely abolished IE binding.  
5 single or double domain 
constructs of VAR2CSA 
Mice  
(Bordbar et al., 
2012) 
All domains but DBL2X and Id1 induced a high-titre antibody response as measured by ELISA. Sera from mice 
immunised by NTS-DBL1X-Id1 showed a partial blocking capacity, whereas antibodies in antisera raised to 
Id1-DBL2X completely ablated IE binding to CSA. The latter antisera also labelled the surface of erythrocytes 
infected by field isolates from pregnant women, and blocked adhesion of 8 tested isolates.  
Table 1.2. Vaccine studies based on immunisation of animals with VAR2CSA domains involved in PM.  
 
. 
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1.8 Antibodies to malaria disease 
Immunoglobulins or antibodies are classified into five main classes (IgG, IgA, 
IgE, IgD and IgM), which in humans is further divided into nine subclasses 
(IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgE, IgD and IgM), all secreted from B 
cells. Each antibody is visualised as a Y shape and consists of four polypeptides: 
two pairs of heavy (µ, γ1, γ2, γ3, γ4, α1, α2, ε and δ) and light (κ and λ) chains 
both comprising variable domain and constant domains (Pleass and Holder, 
2005, Greenfield, 2014). The heavy and light chains are joined together with 
covalent and non-covalent bonds. The variable domains comprise three hyper-
variable or complementarity determining regions (CDR) which recognise the 
antigen. The main function of antibodies is binding to antigens, and in malaria 
disease they have several functions such as neutralisation of malaria toxins and 
inhibition of parasite invasion. Passive administration of human Igs from sera of 
hyperimmune adults has been shown to be effective in controlling malaria 
disease, indicating that Igs have an essential role in the protection against 
malaria (Cohen et al., 1961). However, direct binding to pathogens can be 
insufficient and antibody-mediated activation of other effector mechanisms is 
often required for the identification and destruction of invading pathogens. 
Activation is achieved through the Fc region of antibodies, which facilitates the 
effector mechanism via binding to Fc receptors (FcR) and/or complement 
(Pleass and Holder, 2005, Greenfield, 2014). There are different FcRs for all 
classes of antibodies (reviewed in Pleass, 2009), which are widely expressed on 
various types of cells of the immune system. Examples of FcRs include 
receptors for IgG (FcγRI, FcγRII, FcγRIII), IgE (FcεRI), IgA (FcαRI, Fcα/µR) 
and IgM (Fcα/µR) (Pleass, 2009). FcRs can activate or block different immune 
effector mechanisms including phagocytosis, antioxidant secretion, antibody-
dependent cellular toxicity and production of cytokines and other inflammatory 
mediators (Pleass and Holder, 2005, Greenfield, 2014).  
 
1.8.1 IgM antibodies  
IgM is the only antibody class expressed by all vertebrates and the first antibody 
to be produced during an immune response. It is extremely effective at 
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neutralising pathogens and activating the classical complement cascade 
(Czajkowsky et al., 2010, Couper et al., 2005). While the heavy chains of most 
Igs contain three constant domains, the µ heavy chains of IgM contain a fourth 
Cµ domain (i.e. Cµ4). The extra two (Cµ2) domains are located in the hinge 
regions and provide extra flexibility of the antigen-binding Fab domains 
(Czajkowsky and Shao, 2009). There are two classes of IgM: immune (or 
antigen-specific) IgM which is secreted in response to foreign pathogens, and 
non-immune (or natural) IgM which has a low affinity and broad reactivity, and 
secreted without previous exposure to any specific antigen (Czajkowsky et al., 
2010). The latter class is produced by B-1 B cells and has a major role to control 
the dissemination of viruses and bacteria as part of the host first line defence 
(Czajkowsky et al., 2010, Ghumra et al., 2008). 
Parasite-specific IgM has been shown to play a significant role in limiting the 
parasite replication in a murine model (Couper et al., 2005). However, its role in 
human malaria remains largely unknown (Ghumra et al., 2008). Similarly, the 
role of non-immune IgM in malaria is not entirely clear, although it has been 
demonstrated that non-immune IgM binds to the surface of P. falciparum-IEs 
through Fc, and this was demonstrated to correlate with rosetting and severe 
malaria in field isolates and laboratory clones (Rowe et al., 2002). An early 
study showed that P. falciparum parasites were unable to form rosettes when 
cultured in serum-free medium, and rosetting was restored after the addition of 
IgM from normal donors, indicating the importance of natural IgM in rosetting 
(Clough et al., 1998). Furthermore, CSA-binding P. falciparum-IEs (implicated 
in PM) are also able to bind non-immune IgM, and VAR2CSA variants involved 
in CSA-adhesion contain IgM-binding domains (Rasti et al., 2006). However, 
binding to non-immune IgM is only restricted to P. falciparum isolates with 
particular virulence-associated binding phenotypes (i.e. rosetting and CSA-
binding), and isolates with other adhesion phenotypes such as ICAM-1 or CD36 
binding do not seem to bind non-immune IgM (Rowe et al., 2002).  
 
 
 
67 
 
1.8.2 Consequences of PfEMP1-IgM binding  
It is not completely understood why P. falciparum parasites have evolved to 
bind IgM molecules through Fc regions. Several potential functional 
consequences of IgM-PfEMP1 interaction that favour the parasite development 
have already been described (reviewed in Czajkowsky et al., 2010) including 
inhibition of the binding of specific antibodies by masking critical PfEMP1 
domains, interference with the binding of IgM with FcµR on B cells and T cells, 
interference with immune functions associated with binding of Fcα/µR 
expressed on follicular dendritic cells (FDCs), enhancement of IE sequestration 
in host microvessels or placenta, or interference with immunological signalling 
pathways and pathogen clearance mechanisms [summarised in Figure 1.9] 
(Czajkowsky et al., 2010). A recent study has demonstrated that P. falciparum 
parasites evade the host specific immune response by masking critical epitopes 
on PfEMP1 by binding non-specific IgM (Barfod et al., 2011). Non-specific IgM 
binding to VAR2CSA-expressing P. falciparum isolates interfered with 
subsequent binding of specific mAbs (IgG isotype) to the critical domains 
DBL3X and DBL5ε, protected the parasite from phagocytosis and did not 
interfere with their ability to bind CSA receptors (Barfod et al., 2011). In the 
case of rosetting phenotype, IgM binding was suggested to act as bridge between 
IEs and non-IEs to stabilise rosettes (Somner et al., 2000).  
Complement activation is one of the earliest markers of immune response to 
malaria (Roestenberg et al., 2007). The polymeric structure of IgM 
predominantly benefits these molecules to efficiently agglutinate and neutralise 
pathogens or pathogen-infected cells. This sole structure makes IgM extremely 
efficient at activating the classical cascade, as a single IgM molecule is capable 
of activating the complement system leading to the lysis of a single RBC 
(Czajkowsky et al., 2010). Upon binding to the surface epitope on IEs, IgM may 
undergo a conformational change favouring the binding of C1q (Czajkowsky 
and Shao, 2009) which facilitates downstream components terminating in the 
assembly of membrane attack complexes (MAC) that lyse the cell. However, 
binding of IgM by PfEMP1 could interfere with complement activation by 
locking out C1q-binding sites on IgM or forcing IgM to be oriented with its 
functional flat site facing the IE surface, thus hiding C1q-binding sites from C1q 
(Czajkowsky et al., 2010). 
68 
 
 
Figure 1.8. Possible functional consequences associated with IgM-PfEMP1 binding. A: 
activation of B cells through interactions with BCR (and CR1/2). A: facilitation immunological 
synapse formation through FcµRs found on T cells. B: activation of B cells through interaction 
with BCR. C: direct interaction between BCR on B cells and PfEMP1 variants. D: activation of 
B cells and FDCs through interaction with Fcα/µRs. E: inhibition of potential antigens on the 
surface of IEs through masking mechanism resulted from IgM binding to PfEMP1. F: activation 
of ECs through interaction with the endothelial receptor CD300LG. G: activation of the classical 
pathway through the binding of the potent activator, C1q. The graph was obtained from 
(Czajkowsky et al., 2010). 
 
1.8.3 IgM-PfEMP1 binding sites  
The parasite ligands that mediate IE binding to IgM have been identified and 
shown to be the PfEMP1 molecules on the surface of IEs. A number of different 
PfEMP1 domains from IgM-binding isolates have been demonstrated to bind 
IgM; these include DBL4β, DBL5ε, DBL6ε, DBL7ε and DBL2-X domains of 
different parasite strains (Ghumra et al., 2008, Semblat et al., 2006, Rasti et al., 
2006). Using interaction studies with domain swapped antibodies, IgM mutants 
and anti-IgM mAbs, the region of polymeric IgM molecule that mediates 
PfEMP1 binding was identified as Cµ4 (Ghumra et al., 2008). This demonstrates 
that PfEMP1 is an Fc-binding protein of P. falciparum isolates that have the 
specificity to binding IgM. This IgM binding region was found to be shared by 
diverse IgM-binding P. falciparum isolates of different adhesion phenotypes, 
suggesting that different parasite isolates expressing diverse PfEMP1 variants all 
bind to the same region on human IgM molecules (Ghumra et al., 2008). 
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1.9 Development of monoclonal antibodies against 
PfEMP1 recombinant proteins  
Strategies aiming to block PfEMP1 domains involved in IE cytoadhesion have 
been hypothesised to decrease the severity of malaria disease by decreasing or 
suppressing the capacity of parasite-infected erythrocytes to sequester to the host 
microvessels (Chattopadhyay et al., 2004). The development of hybrid cells 
(hybridomas) secreting antibodies with monoclonal specificity to defined P. 
falciparum antigens is an early approach that has long been shown to be 
successful. The use of purified malaria antigens can be used for immunising 
animals and studying the immune response (Perrin et al., 1980). MAbs directed 
against diverse adhesive domains of PfEMP1 may have a therapeutic value in 
reducing severe disease. Antibody-mediated adhesion-inhibition and/or reversal 
methods have been demonstrated not only reduce capacity of IEs to cytoadhere, 
but also to play a significant role in the removal of IEs from the peripheral 
circulation by the host spleen and reduce the harmful inflammatory responses in 
vital tissues (Rowe et al., 2009, Salanti et al., 2010). In addition to their 
adhesion-blocking role, these antibodies appear to opsonise IEs and induce 
phagocytosis (Ghumra et al., 2008, Ghumra et al., 2011). However, attempts to 
develop mAbs targeting the conformational VSAs have mostly been 
unsuccessful, and in spite of intensive efforts in several laboratories, only a 
small number of mAbs have been successfully developed (Table 1.3). This 
shortage of success may be due to the large number of immunodominant VSAs 
that have the capacity to elicit a strong immune response in animals, making the 
induction specific mAbs directed to minor or relatively less immunogenic 
antigens or conformational epitopes very difficult (Lekana Douki et al., 2002).  
The majority of mAb studies in anti-adhesive therapies have focussed on the 
relatively-conserved domains: CIDR1-α, DBL-1α and VAR2CSA domains 
involved in IE adhesion to CD36, rosetting-related receptors and CSA, 
respectively (Table 1.3). In one of these studies, mouse mAbs obtained by 
immunisation with CIDRα domains have demonstrated substantial levels of 
surface reactivity with erythrocytes infected by genetically diverse P. falciparum 
isolates. One of these mAbs reacted with 90% of tested isolates, and only failed 
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to react with a non-CD36 binding isolate (Gamain et al., 2001). VAR2CSA 
variant is a vaccine candidate for protection against PM (Chan et al., 2014). 
Mouse mAbs generated against the full-length (Avril et al., 2006) or single 
domains (Costa et al., 2003) of VAR2CSA blocked IE adhesion to CSA 
receptors, suggesting that production of antibodies with in vivo therapeutic 
functions based on VAR2CSA domains may be feasible. Although these 
domains are not completely conserved, it was hoped that their variation is more 
relatively limited unlike the other highly diverse functional candidates such as 
DBLβ domains. Despite the potential role of ICAM-1 receptors in the 
pathogenesis of CM, no studies have been published - to our knowledge - for the 
development of mAbs targeting the ICAM-1-binding parasite ligand DBLβ 
domains. Only some work has been carried out to block the parasite adhesion at 
the ICAM-1 side using inhibitors to the IE-binding determinants on ICAM-1 
(e.g. Tse et al., 2004).  
The presence of numerous VSAs on the surface of IEs makes the significance of 
PfEMP1 relative to other variant antigens difficult to quantify. Most 
immunoassays that use recombinant PfEMP1 domains for antibody production 
cannot highlight the relative importance of antibodies targeting PfEMP1 proteins 
independently of antibody responses directed to other VSAs (Beeson et al., 
2013, Marsh and Kinyanjui, 2006). Nevertheless, a recent novel approach using 
genetically modified P. falciparum lines with suppressed PfEMP1 expression 
has shed some light on the significance of PfEMP1 and other VSAs as targets 
for protective antibody response among serum samples collected from 
individuals living in malaria endemic areas in Eastern Africa (Chan et al., 2012). 
The study showed that binding of IgG to the surface of erythrocytes infected by 
the transgenic line was greatly reduced in comparison with the parental line 
expressing PfEMP1, suggesting that acquired antibody response to the surface of 
parasitized erythrocytes is mainly directed towards PfEMP1, with other VSAs 
playing minor roles as immune targets (Chan et al., 2012). The study also 
revealed that PfMEP1-specific antibodies were correlated with protective 
immunity against symptomatic malaria and mediated opsonic phagocytosis of 
IEs.  
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Immunogen Animal Reference Antibody response (mAbs/pAbs) 
Full-length VAR2CSA of FCR3CSA 
isolate 
Mice (Avril et al., 2006) 
Mouse mAbs blocked 0-60% of P. falciparum adhesion to CSA and immunoprecipitated PfEMP1CSA 
(VAR2CSA). These mAbs also specifically selected CSA-adhering IEs and mediated the purification of 
VAR2CSA from IE.  
6 extracellular domains of rosetting 
PfEMP1-R29 isolate 
Rabbits 
(Ghumra et al., 
2011) 
Antibodies to all PfEMP1 domains reacted with the surface of IEs, and antibodies to all domains except DBL2 
inhibited rosetting, opsonise IEs and induced phagocytosis. Anti-NTS-DBL1α antibodies were most effective in 
all assays.  
Intact IEsCSA or CHO cells 
expressing rDBL-γ3CSA from FCR3 
isolate 
Mice 
(Lekana Douki et 
al., 2002) 
The produced mAbs, of which ~70% were IgMs, recognised the surface of IEsCSA and several of these mAbs 
cross-reacted with P. falciparum isolates from diverse West African areas. 
CIDR1 from PfEMP1 that is 
functionally conserved for CD36 
adhesion 
Mice 
(Gamain et al., 
2001) 
Two mAbs targeting different regions of CIDR1 domains recognised several P. falciparum isolates expressing 
distinct PfEMP1 variants. The mAbs cross-reacted with CIDR1 domains of various CD36-binding parasites. One 
of these mAbs reacted with 90% of tested isolates.  
rDBL-γ3CSA from FCR3 and 3D7 
isolates 
Mice 
(Costa et al., 
2003) 
The produced antibodies recognised homologous and heterologous rDBL-γ3CSA domains. Only one mAb 
inhibited and reversed IECSA adhesion to ECs in vitro.  
Table 1.3. Development of mAbs and pAbs based on immunisation of animals with single or full-length PfEMP1 domains.  
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1.10 Acquired immunity against P. falciparum infection 
1.10.1  Early development of acquired immunity  
Malaria is a significant cause of morbidity, but not every malaria infection 
develops into severe life-threatening disease (Autino et al., 2012). The outcome 
of the disease and development into severe pathology depend on a combination 
of multi-factors that include both the host and the infecting parasite. Such factors 
that affect the progression to clinical infection include the age and immune 
status of the host, and endemicity of the parasite (Miller et al., 2002). The first 
exposure to P. falciparum malaria in individuals without previous experience 
usually leads to febrile illness; but in rare occasions it develops into severe 
disease or even death. In endemic areas where malaria transmission is very high 
and stable, repeated exposure to malaria episodes results in the gradual 
acquisition of a clinical immunity, which limits the risk of severe malaria disease 
(Gupta et al., 1999). Protective immune responses acquired this way are 
primarily mediated by IgG antibodies (Cohen et al., 1961, Piper et al., 1999, 
Yone et al., 2005). The risk of severe and life-threatening disease in these 
malaria-endemic areas is usually highest during the first few years of life, after 
which the frequency and severity of disease rapidly decrease over several years 
despite continuous exposure, as individuals acquire natural protective immunity 
(Bull et al., 1998, Gupta et al., 1999).  
Although the diversity of the parasite population is huge, epidemiological data 
suggests that only one or two malaria infections are required for developing 
substantial immune response against non-CM severe disease that require hospital 
admission (Gupta et al., 1999). From approximately 6 months of age, young 
children may ecounter severe malaria episodes and death. From the age of 5 
years, the frequency of symptomatic malaria disease starts to decline and 
malaria-related mortality becomes very rare, though children may continue to 
harbour higher rates of parasitaemia. From adolescence onwards, severe malaria 
episodes do not occur except under exceptional conditions (Marsh, 1992). Sterile 
protective immunity is very rare or never achieved as adults remain vulnerable 
to asymptomatic disease and harbour low parasitaemia (Marsh and Kinyanjui, 
2006).  
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The mechanisms underlying the slow development of clinical immunity to 
malaria are not completely understood, but at least it is partly due to the 
requirement for the host either to recognise most parasites circulating in the area 
or to mount an extensive cross-reactive antibody response to various isolates 
(Newbold et al., 1992). On the parasite side, slow progression of immunity is 
attributable to the immune evasion mechanisms: antigenic variation (substantial 
inter- and intra-clonal diversity of PfEMP1), presence of cross-reactive antigenic 
determinants, and limited immunogenicity of several surface antigens (Barfod et 
al., 2011, Autino et al., 2012). Although antigenic variation in vivo facilitates 
chronic disease, exposure of the host immune system to distinct parasite variant 
antigens resulted from a higher rate of antigenic switching may allow the host to 
rapidly recognise future heterologous infections (Roberts et al., 1992). This may 
explain why a protective immune response is acquired after few malaria 
episodes (Gupta et al., 1999) despite the extensive number of parasite antigenic 
types.  
Parasites causing severe malaria are hypothesised to express PfEMP1 variants 
that are superior in their capacity to cytoadhere due to their greater binding 
affinities to EC receptors. Such parasites are believed to be responsible for 
earlier infections in younger children when protective immunity against these 
parasites has not yet been developed, and first immune responses are thought to 
be directed to these virulent variants (Bull et al., 2000, Lavstsen et al., 2003). 
This may explain why younger children in areas with high transmission rates 
develop severe and life-threatening disease, whereas adults continue to harbour 
parasites that cause mild or non-complicating malaria diseases (Berger et al., 
2013).  
During infection, the parasite is under two contrasting selection pressures; the 
first preferring expression of antigenic variants with significant cytoadherence 
capacity to host cells (functional selection) and the second preferring expression 
of new antigenic determinants that are not identified by previous antibodies 
(immune selection). In young children, functional selection may be more 
significant than immune selection, taken into account that the previous immunity 
in such individuals is mainly poor. In older individuals, the immune selection 
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may be more important to escape pre-existing antibody responses (Bull et al., 
2000).  
 
1.10.2  Antibodies to VSAs confer protection  
Several studies have provided evidence that VSAs on P. falciparum-IEs are 
important targets of naturally acquired immunity, and antibodies directed against 
these highly immunogenic antigens are associated with protection against 
homologous parasite isolates (Giha et al., 2000, Bull et al., 1998). In some 
situations, development of antibodies to heterologous parasites also occurs and 
this has been postulated as an evidence for the presence of cross-reactive 
antibody responses against antigens on the surface of IEs (Chattopadhyay et al., 
2003). However, it is not completely clear whether such cross-reactive 
heterologous responses or responses directed against less immunogenic 
conserved antigens on the IE surface have a significant role in protection against 
clinical disease (Mackintosh et al., 2008).  
The major target for anti-VSA antibodies is believed to be the highly diverse 
PfEMP1 (Newbold et al., 1992, Baruch et al., 1995, Beeson et al., 2006), and 
antibodies directed against this protein are thought to confer protection against 
malaria disease (Baruch et al., 2002, Giha et al., 1999, Bull et al., 1998, Bull et 
al., 1999, Bull et al., 2000, Gupta et al., 1999). A study was conducted on 
plasma samples collected before and after malaria season in a Sudanese village 
showed that both susceptible (individuals who had malaria) and protected 
(individuals who did not have malaria) persons acquired antibodies to VSAs 
during the malaria season, and pre-existing anti-PfEMP1 antibodies can reduce 
the risk of clinical malaria caused by parasites expressing homologous variant 
antigens (Giha et al., 2000). On the other hand, failure to induce antibodies 
recognising the surface of P. falciparum-IEs in another study was associated 
with increased susceptibility to clinical malaria (Mackintosh et al., 2008).  
The mechanisms by which antibodies to VSAs confer protection are not entirely 
clear. Three main hypotheses have been proposed; (1) anti-VSA antibodies, 
particularly those directed to PfEMP1, may provide protection by interfering 
with one or more of the cytoadhesive properties mediated by different domains 
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of PfEMP1 proteins (Marsh et al., 1989, Fried et al., 1998, Marsh and Howard, 
1986). (2) Antibodies to VSAs may also provide protection by opsonising 
parasitized erythrocytes for subsequent phagocytosis, an essential mechanism of 
parasite elimination (Celada et al., 1982, Marsh and Kinyanjui, 2006). Several 
studies on animal models have demonstrated that existence of antibodies 
opsonising IEs is associated with protection. For instance, immunisation of 
rabbits with extracellular PfEMP1 domains elicited antibodies that opsonised IEs 
and induced phagocytosis (Ghumra et al., 2011). A recent study also showed that 
PfEMP1 is the main target for natural immunity and individuals with higher 
levels of anti-PfEMP1 antibodies have enhanced opsonic phagocytosis and 
acquired protection against malaria (Chan et al., 2012). (3) Antibodies to VSAs 
could promote other anti-parasite effector mechanisms such as complement-
mediated lysis and antibody-dependent cytotoxicity (Marsh et al., 1989).  
 
1.10.3  Acquired immune response is mainly variant-specific  
During the development of clinical immunity, especially during the first few 
years of life, production of strain-specific antibodies to PfEMP1 domains is 
essential for preventing infection with previously challenged isolates (Newbold 
et al., 1992, Marsh and Howard, 1986, Bull et al., 1998, Iqbal et al., 1993). This 
type of immune response is important during and after infections with isolates 
causing severe disease (Miller et al., 2002). Several published studies that 
measured the agglutination responses to P. falciparum isolates have 
demonstrated that children acquired strain-specific anti-VSA antibodies rapidly 
following malaria infection (Bull et al., 1998, Bull et al., 1999). This suggests 
that immune response acquired following an infection comprises antibodies 
targeting erythrocytes infected by the homologous isolate, and supports the 
essential role of strain-specific antibodies in protection against malaria infection 
and severe disease (Bull et al., 1998, Newbold et al., 1992). 
Despite the fact that the dominant immune response following an infection is 
variant-specific (Newbold et al., 1992), evidence for the existence of at least 
some degree of cross-reactive response to distinct parasite isolates has been 
observed in some studies (Marsh and Howard, 1986, Newbold et al., 1992, Giha 
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et al., 1999, Ofori et al., 2002). Antibodies in convalescent sera collected from 
adults agglutinated distinct P. falciparum isolates (Chattopadhyay et al., 2003), 
and immune sera obtained from people living in diverse African countries 
agglutinated parasitized erythrocytes from different geographical areas, 
suggesting the presence of cross-reactive epitopes expressed by different parasite 
isolates (Aguiar et al., 1992).  
Marsh and Howard (1986) investigated parasites isolated from ten Gambian 
children with acute and convalescent sera from each child, and showed that most 
acute sera did not react with homologous isolates whereas each convalescent 
serum was highly reactive with homologous but not heterologous isolates. This 
study suggested that infection by P. falciparum results in a great diversity of 
antigenic phenotypes expressed on the surface of IEs, which was evident from 
the variant-specific nature of antibody response. Moreover, semi-immune sera 
from Gambian adults agglutinated erythrocytes infected by the ten children, 
suggesting that by adulthood most individuals acquire a broader cross-reactive 
response that protects against heterologous isolates (Marsh and Howard, 1986). 
However, it should be noted that the exposure to cross-reactive, conserved 
determinants on the surface of IEs was the key factor for induction of a broadly 
reactive response in adult semi-immune sera in this study but not the breadth of 
response to recognise distinct important targets on the surface of the parasitized 
erythrocyte.  It was suggested that the parasite evades strong immune responses 
directed to conserved sites on PfEMP1, such as sites involved in cytoadhesion, 
by ''drawing the attention'' of the host humoral immune response to extremely 
diverse and at the same time more immunogenic epitopes on the protein (Staalso 
et al., 1998). If the immune response to conserved regions is significant for 
protection and essential for the parasite pathogenesis, such conserved regions 
might useful for vaccine development.  
Bull et al. (1999, 2000) have provided evidence for the presence of rare and 
prevalent parasite isolates, and suggested that isolates causing severe disease 
express a unique subset of VSAs associated with severe disease in younger 
children with relatively lower immunity. This was evident from the findings that 
parasites isolated from children with severe malaria had a significantly higher 
agglutination frequency than those isolated from patients with mild malaria 
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infection (Bull et al., 2000). Consistent with these findings, Nielsen et al. (2002) 
showed that parasites isolated from children with severe malaria were broadly 
and more frequently recognised by VSA-specific antibodies in plasma samples 
of local healthy individuals than parasites isolated from children with non-severe 
disease (Nielsen et al., 2002). Thus, P. falciparum isolates that cause clinical 
disease to semi-immune young children appear to express VSAs that are not 
identified by previously existed strain-specific antibodies, which supports the 
''hole in the antibody repertoire'' hypothesis (Nielsen et al., 2002, Ofori et al., 
2002, Bull et al., 1998). Malaria exposure may increase the levels of specific 
antibodies that recognise VSAs expressed by parasite isolates causing current 
infections (Bull et al., 1998, Giha et al., 1999), and acquisition of VSA-specific 
antibodies after repeated exposure appears to gradually limit VSA variants 
causing severe disease and help to close the ''holes'' in antibody repertoire 
(Nielsen et al., 2002).  
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Aims of study  
The main aim of this thesis was to develop monoclonal and polyclonal 
antibodies in mice against recombinant PfEMP1ICAM-1-DBLβ domains and 
characterise the immune response of these antibodies. One of the existing 
approaches to overcome the polymorphism of PfEMP1 in the development of 
therapeutic interventions is to target PfEMP1 subdomains involved in parasite 
binding (Gratepanche et al., 2003). Recombinant proteins corresponding to 
different PfEMP1 domains have been synthesised and used for the induction of 
specific immune responses in standard immunoassays. A benefit of this 
approach is the ability to direct a specific immune response to anticipated 
regions or epitopes for extending the protective response whilst excluding 
undesirable responses. Another advantage is the production of a response with 
an estensive broad-range of antigen coverage maintained under correct protein 
expression and production (Richards and Beeson, 2009). Individual DBLβ 
domains were used rather than the full-length PfEMP1 protein to map the 
minimal receptor-adhesion parts for ICAM-1 binding parasites and to understand 
the functional requirements for receptor adhesion. The specific aims of the 
different chapters were as follows: 
Chapter 2 
- Study the immune response of serum samples obtained from mice 
immunised with recombinant PfEMP1ICAM-1-DBLβ domains expressed as 
hexahistidine-tagged proteins in Escherichia coli (E. coli). This was crucial 
since seroreactivity is an important indication for the efficiency of 
immunisation. In addition, it reflects the specificity of immune respose 
towards immunising antigens.  
- Develop mouse monoclonal and polyclonal antibodies against these DBL 
domains, and characterise the reactivity of these antibodies against 
corresponding homologous and heterologous domains. MAbs and pAbs 
directed against various PfEMP1 domains have been suggested as valuable 
tools for recognising critical functional sites on PfEMP1 involved in parasite 
adhesion and determining the cross-reactivity with parasite strains from 
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irrelevant regions (Lekana Douki et al., 2002). Development of reactive 
mAbs and pAbs secreted by immortal hybridoma lines is required for the 
production of therapeutic interventions. The limited amount of immune sera 
makes them only available for restricted preliminary screening assays.    
Chapter 3 
- Investigate the capacity of mAbs and pAbs to recognise VSAs on the surface 
of erythrocytes infected by ICAM-1-binding and non-binding P. falciparum 
isolates, and evaluate their cross-reactivity with parasite isolates from 
different genomes. VSAs are implicated in the cytoadhesion of P. 
falciparum-IEs in the microvessels of various organs, a key pathological 
feature of severe malaria disease (Berendt et al., 1994). Several studies have 
provided evidence that these VSAs are important targets of naturally 
acquired immunity, and antibodies directed against these highly 
immunogenic antigens are associated with protection against homologous 
parasite isolates (Giha et al., 2000, Bull et al., 1998). 
- Identify the surface epitope(s) labelled by mouse mAbs and pAbs. 
- Localise the surface labelling of mouse IgM antibodies using 
immunofluorescence assays. 
Chapter 4 
- Evaluate the capacity of mouse mAbs and pAbs to block the adhesion of IEs 
to immobilised receptors (ICAM-1 or CD36) or primary HUVEC under 
static or physiological flow conditions. MAbs directed against varied 
adhesive domains of PfEMP1 may have a therapeutic value in reducing the 
severerity of malaria disease. Antibody-mediated adhesion-blocking have 
been demonstrated not only decrease the capacity of IEs to sequester, but 
also to play an important role in the elimination of IEs from the circulation 
by the host spleen and reduce the damaging inflammatory responses in vital 
organs (Rowe et al., 2009, Salanti et al., 2010). In addition to their adhesion-
inhibition role, these antibodies seem to opsonise IEs and induce 
phagocytosis (Ghumra et al., 2008, Ghumra et al., 2011). 
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Chapter 5 
- Characterise the functional antibody response of eight serum samples 
obtained from adult female donors living in Junju sub-location, Kilifi 
County, Kenya against a panel of DBL domains.  
- Investigate the reactivity of semi-immune sera against the surface of live 
erythrocytes infected by diverse human lab-adapted P. falciparum isolates.  
- Assess the ability of semi-immune sera to inhibit the adhesion of IEs to 
immobilised receptors (ICAM-1 or CD36) or HUVEC under static or 
physiological flow conditions.  
- Investigate the presence of IgG antibodies that have the capacity to 
agglutinate IEs.  
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Chapter 2 
 
Production and characterisation of 
monoclonal and polyclonal antibodies 
raised to PfEMP1ICAM-1-DBLβ domains  
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Chapter 2: Introduction 
During the intra-erythrocytic stage of P. falciparum development, several 
parasite-derived antigens are synthesised and exported to the surface of IEs 
(Leech et al., 1984). These VSAs are extremely polymorphic, highly 
immunogenic in nature and induce an immune response that targets IEs for 
providing protective immunity against malaria (Bull et al., 1998, Marsh et al., 
1989). The most extensively characterised VSA is PfEMP1, a highly 
polymorphic protein associated with cytoadherence of parasitized erythrocytes 
to various host receptors (Baruch et al., 1995, Su et al., 1995, Smith et al., 1995). 
The modular PfEMP1 consists of several DBL and CIDR domains that mediate 
parasite cytoadhesion (Rask et al., 2010). The second class of DBL domains, 
DBLβ, has been associated with adhesion to ICAM-1 receptors (Smith et al., 
2000a, Oleinikov et al., 2009, Howell et al., 2008, Brown et al., 2013). A diverse 
array of human cell receptors have been shown to mediate P. falciparum-IE 
cytoadhesion (reviewed in Rowe et al., 2009) including ICAM-1 (Berendt et al., 
1989), which implicated in the pathogenesis of CM.  
One of the current approaches to overcome the diversity of PfEMP1 domains in 
the development of vaccines and therapeutic interventions is targeting PfEMP1 
subdomains involved in parasite cytoadhesion (Gratepanche et al., 2003). 
Recombinant purified proteins for variable PfEMP1 domains have been 
synthesised and used for the induction of specific antibody responses in standard 
immunoassays. An advantage of this approach is the capacity to direct a specific 
immune response to a desired region or epitope for extending the protective 
response whilst excluding unwanted responses. Another advantage is the 
production of a response with broad-range of antigen coverage maintained under 
correct protein expression and production (Richards and Beeson, 2009). 
However, due to the large size of PfEMP1, expression of the full-length 
recombinant proteins is challenging (Beeson et al., 2013), and therefore only 
single domains or combinations of two or more domains have been mainly 
designed and used for the induction of antibody response. Even the expression of 
several single domains of PfEMP1 is difficult because of their conformational 
nature and/or large size. Some of these domains require particular adjuvants and 
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there is much doubt about choosing the accurate adjuvant-protein combination to 
induce a response with the right fine specificity and constant duration (Richards 
and Beeson, 2009). Recognition of functional domains that have the potential to 
contribute in protection against severe disease, obtainment of the correct folding 
and presentation of recombinant domains, and the likelihood that these domains 
would induce a specific immune response are further challenges for the 
production of specific antibody response against PfEMP1 domains (Richards 
and Beeson, 2009, Beeson et al., 2013).   
In this chapter, we selected four recombinant PfEMP1ICAM-1-DBLβ domains that 
were expressed as hexahistidine-tagged proteins in E. coli for mouse 
immunisations. All domains have been shown to bind ICAM-1 receptors 
(Kraemer et al., 2007, Howell et al., 2008). Individual DBLβ domains were used 
rather than the full-length PfEMP1 protein to map the minimal receptor-binding 
regions for ICAM-1 binding isolates and to understand the functional 
requirements for receptor adhesion. We present evidence that it is possible to 
elicit mAbs and pAbs in mice by immunisation with single recombinant DBLβ 
domains from ICAM-1-binding variants. MAbs and pAbs comprising reactive 
antibodies recognised homologous and heterologous DBLβ domains and 
labelled the surface of erythrocytes infected by P. falciparum isolates. To our 
knowledge, this is the first study to examine the use of PfEMP1ICAM-1-DBLβ 
domains for the development of mAbs and pAbs that recognise homologous and 
heterologous parasite isolates and block IE adhesion.  
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2. Materials and Methods  
2.1 Recombinant Duffy binding-like β (rDBLβ) 
domains 
Recombinant DBL13, DBL27, DBL31 and DBL41 domains used in this work 
were obtained from Matthew Higgins, Oxford. These particular domains have 
been chosen for the present work because they are amongst the limited number 
of expressed DBLβ domains that mediate ICAM-1 binding (see Howell et al., 
2008). Expression and purification of recombinant domains are described in 
detail elsewhere (Brown et al., 2013). DBLβ domains of corresponding PfEMP1 
variants (IT4VAR13, IT4VAR27, IT4VAR31 and IT4VAR41) were cloned into 
modified pET15b vector, and the His-tagged proteins were expressed in E. coli 
Origami B cells. Cells were lysed and the proteins were purified using nickel-
nitrilotriacetic acid-Sepharose (Qiagen) and size-exclusion chromatography.  
 
2.2 SDS-PAGE and Western blotting for 
characterising recombinant DBL domains 
2.2.1 Gel electrophoresis 
Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
was carried out to characterise recombinant PfEMP1ICAM-1-DBLβ proteins 
(rDBL13, rDBL27, rDBL31 and rDBL41) used for mouse immunisations. Each 
protein was adjusted to a concentration of 5µg/20µl PBS and diluted in 
NuPAGE® LDS sample buffer at 1:4 ratio (Novex®, 4×, Cat. No. NP0007) and 
Nuclease Free Water (NFW). Proteins were fully denatured using DL-
dithiothreitol solution (DTT) reducing agent at a ratio of 1:10 relative to total 
sample volume (Thermo Scientific, R0861). 4-12% polyacrylamide NuPAGE® 
Novex® Bis-Tris pre-cast gels (Novex®, Life Technologies, NP0322PK2) were 
washed with distilled water and assembled in electrophoresis chambers 
following manufacturer’s instructions. The chambers were filled with 
1×NuPAGE® MOPS/SDS Running buffer (20×, Novex®, Life Technologies, , 
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NP0001) for resolving medium to large sized proteins (14 kDa to 200 kDa). 
Protein samples were heated on a heating block for ~3 minutes at 90°C and 16 
µl of each sample was loaded into wells of acrylamide gel. A protein ladder of 
known molecular weights (SeeBlue® Plus2 Pre-stained Protein standard, 
Novex®, Life Technologies, LC5925) was also loaded on the gel to recognise 
molecular masses of loaded proteins. The chamber was connected to a power 
supply and an electrical current of 200 volts was run for 45 minutes. Negatively-
charged proteins migrated across the gel from the negative cathode to positive 
anode and separated according to their molecular weights. Following 
electrophoresis, gels were either stained with Coomassie blue stain (PageBlue® 
protein stain, (Thermo Scientific®) or prepared for electrophoretic transfer to 
polyvinylidene difluoride (PVDF) membranes for immunoblotting. 
 
2.2.2 Coomassie blue staining  
Staining of the gel was carried out to visualise all proteins in the sample and to 
evaluate the efficiency of the SDS-PAGE by ensuring that proteins have 
migrated evenly and uniformly. The gel to be stained was thoroughly washed in 
distilled water (×3, 5 minutes each) to remove excess SDS and incubated with 
PageBlue® protein staining solution (Thermo Scientific®, No. 24620) with 
gentle agitation for 30 minutes. The gel can additionally be microwaved for 30-
60 seconds with gentle agitation to accelerate staining with the same equivalent 
sensitivity. PageBlue® contains Coomassie G-250 dye that sensitively stains 
proteins on polyacrylamide gels. The gel was then washed overnight to remove 
excess stain and stained proteins visualised on a light box. Naïve mouse serum 
(NMS) was included as an indicator for correct reduction of proteins; as reduced 
NMS shows  two bands (55 kDa for the heavy chain and 26 kDa for the light 
chain). 
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2.2.3 Immunoblotting of recombinant DBLβ domains with anti-
polyhistidine antibodies  
In Western blotting, electrophoresed proteins are transferred from the gel to a 
membrane to make proteins accessible for immunological identification by 
antibodies. This method provides details about the molecular mass of proteins, 
abundance and heterogeneity. Six pieces of Whatman® filter papers (Sigma-
Aldrich®, diam. 30 mm, product no. Z695033) and three pieces of 0.45 µm 
PVDF membranes (Whatman® Westran®, Sigma-Aldrich®, Z671061) were cut 
to exact size of polyacrylamide gels (75 × 90 mm). The PVDF membranes were 
pre-soaked in 100% methanol for 2 minutes and equilibrated in ×1 working 
solution of NuPAGE® transfer buffer (Novex®, Life Technologies, NP0006-1). 
Filter papers as well as blotting pads were also soaked in transfer buffer. The 
electrotransfer unit was prepared by placing two pre-soaked pads on the 
sandwich cassette, followed by a piece of filter paper and a PVDF membrane. 
The electrophoresed gel was gently removed and placed over the PVDF 
membrane followed by a piece of filter paper and two blotting pads above the 
membrane. All sheets were aligned exactly on top of each other and trapped air 
bubbles squeezed out to ensure that proteins transferred properly. The sandwich 
was placed in an electrotransfer chamber pre-filled with transfer buffer and an 
electrical current of 100 volts was run for 60-65 minutes for transferring proteins 
from the gel to the PVDF membrane. 
After transfer, non-specific binding sites in the membrane were blocked by 
incubating the membrane in 1× PBS containing 0.1% Tween® 20 detergent 
(Sigma-Aldrich®, P1379) and 5% non-fat milk powder (PBSTM). After 2 hours 
of blocking, PVDF membranes were washed three times in 1× PBS containing 
0.1% Tween20 (PBST) and probed with 1:200 diluted HRP-conjugated anti-
polyhistidine monoclonal antibodies (clone HIS-1, Sigma-Aldrich®, A7058) for 
120 minutes with gentle shaking at room temperature. The antibody recognises 
native or denatured proteins tagged with polyhistidine in the sample. It was 
conjugated with HRP and thus was detected without use of a secondary 
detecting antibody. Membranes were then washed three times in PBST and 
bands were resolved by incubating the membranes with developing solution 
including 1× PBS, 0.02% hydrogen peroxide [H2O2] (Sigma, lot number 082 
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K3250) and 0.005% 3,3-Diaminobenzidine HCL substrate [DAB] (Millipore, 
NG16 16211). The substrate reaction proceeded for 5-10 minutes before the 
reaction was blocked by washing membranes with distilled water and the blots 
were dried and analysed. NMS that lacks the polyhistidine tag was included as a 
negative control.  
2.2.4 Immunoblotting of recombinant DBLβ domains with 
mouse antisera   
In this assay, recombinant DBLβ domains were loaded onto 4-12% 
polyacrylamide NuPAGE® gels and transferred to six separate PVDF 
membranes following the same procedure described in the previous section 
(2.2.3). An additional recombinant protein (VAR2CSA-DBL4ε) was included in 
the blots as a negative control. After transferring proteins, PVDV membranes 
were blocked in PBSTM. After 2 hours of blocking, PVDF membranes were 
washed three times in PBST washing buffer and four blots probed with each of 
the mouse antisera (anti-DBL13, anti-DBL27, anti-DBL31 and anti-DBL41), a 
blot probed by HRP-conjugated anti-polyhistidine mAbs (clone HIS-1, Sigma-
Aldrich®, A7058) and the sixth blot was probed with NMS for 120 minutes with 
gentle shaking at room temperature. Immune and control sera were used at 1:250 
dilution (sera: PBST) and anti-polyhistidine antibodies at 1:250 dilution. The 
membranes were then washed three times in PBST and binding of primary 
antibodies in immune or control sera was detected by incubation with goat anti-
mouse IgG (Fc-specific)-HRP conjugated antibodies (Sigma-Aldrich©, product 
No. A2554) at a dilution of 1:500 (antibody: PBST). The membranes were 
incubated for 120 minutes at room temperature with gentle shaking before they 
were washed and developed as described in the previous section (2.2.3).  
 
2.3 Mouse immunisation  
In the present work, two groups of mice were immunised by His-tagged 
recombinant domains (rDBL13, rDBL27, rDBL31 and rDBL41) and stimulation 
of the immune response was carried out using two different adjuvants. 
Immunisation of the first group of animals was carried out at Severn Biotech 
88 
 
Ltd® (Worcestershire, United Kingdom) using Freund's complete/incomplete 
adjuvant (FCA) for immune stimulation. Briefly, a group of eight Balb/c mice 
(two per protein) were injected subcutaneously with 100 µg/ml of each of the 
four recombinant proteins (100 µl) emulsified in an equal volume of FCA. The 
initial injection was followed by three subsequent subcutaneous injections at 
one-week intervals with the same amount of antigens emulsified in Freund's 
incomplete adjuvant for immune boosting. One week after the final booster 
injection, venous blood was collected from mice and immune sera were tested 
for the presence of reactive antibodies by ELISA, immunoblotting and flow 
cytometry. Spleens were gently extracted and preserved in pre-warmed FBS-free 
complete medium (CMNS) for hybridoma production. Two mice were 
immunised and boosted with an emulsion of PBS/FCA following the same 
procedure and their sera were used as negative controls.    
The second immunisation was carried out by Professor Richard Pleass 
(Liverpool School of Tropical Medicine, Liverpool) using Aluminium salts 
(Alum) (Sigma) as an adjuvant following a slightly different protocol. Eight 
Balb/c mice (2 per antigen) were inoculated with 50 µg of recombinant proteins 
emulsified in an equal volume of Alum. The initial immunisation was followed 
by two intermittent subcutaneous injections with 50 µg of recombinant proteins 
in Alum at 2-week intervals for stimulating the immune response. Mouse 
antisera and spleens were collected three days post final injection and used 
immediately for immortalization. Two mice were immunised with PBS/Alum 
and used as controls.  
 
2.4 Characterisation of mouse antisera  
2.4.1 Indirect Enzyme Linked Immunosorbent Assay (ELISA) 
2.4.1.1 Screening mouse antisera by preliminary ELISA 
Recognition of immunising DBL domains by antisera from mice stimulated with 
FCA or Alum adjuvants was assessed by indirect ELSIA. The first assay was 
carried out to screen mouse antisera for the presence of IgG-class antibodies that 
recognise homologous and heterologous domains, as described by Hornbeck et 
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al. (1991) with slight modifications. Briefly, 96-well MaxiSorb microtitre 
polystyrene plates (Nunc®) were coated with 100 µl of recombinant domains 
(rDBL13, rDBL27, rDBL31 and rDBL41) dissolved in 0.1 M carbonate 
bicarbonate buffer at 1 μg/ml and incubated overnight at 4°C. Unbound antigens 
were removed by washing with PBST (×3) and free residual binding sites were 
blocked in PBSTM for 2 hours at room temperature. Plates were washed as 
previous and incubated with mouse immune sera (anti-DBL13, anti-DBL27, 
anti-DBL31 and anti-DBL41) diluted 1:500 in duplicates for 2 hours at room 
temperature with gentle agitation. NMS at 1:500 dilution or mouse mAb BC6 
IgG antibody (20 μg/ml) were also incubated with recombinant antigens and set 
as negative controls. After incubation, wells were washed as previous and 
incubated at room temperature for 1 hour with 100 µl of goat anti-mouse IgG 
(Fc-specific)-HRP conjugated (Sigma-Aldrich©, product No. A2554) diluted 
1:500 in complete medium. Wells were washed again and the reaction was 
developed by adding 100 µl of substrate 3,3´,5´,5´-tetramethylbenzidine 
dihydrochloride (Sigma-Aldrich®, product No. T3405) diluted in phosphate-
citrate buffer with Sodium Perborate (Sigma-Aldrich, product No. P4922) 
according to manufacturer instructions. Plates were incubated for approximately 
10 minutes in the dark at room temperature before the reaction was blocked 
upon colour development by adding 50 µl of 2M H2SO4 to the wells. Optical 
densities (OD) were measured using an ELISA plate reader with a 450-nm 
reference filter. OD values are shown as the average of duplicate wells with 
standard deviation (SD) expressed as error bars. The results were considered 
positive if the mean OD value obtained from immune sera was above the cut-off 
point set at 3 SDs above the mean background absorbance (OD) of NMS. 
Capacity of recognition was set as a grade from + to +++++ as shown in the 
Results section. 
The second indirect ELISA was carried out following the same procedure but 
immune-detection was performed by incubating antisera-antigen complex with 
goat anti-mouse IgM (µ chain specific)-HRP conjugated (Southern Biotech, Cat. 
No. 1021-05) for detecting the presence of IgM reactive antibodies in tested 
immune sera. Developing and blocking were carried out as described above.  
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2.4.1.2 Checkerboard titration ELISA 
Indirect titration ELISAs were carried out to evaluate the antibody titre of mouse 
polyclonal antisera using serial dilutions of immune sera against different 
concentrations of recombinant DBL proteins. The same protocol was followed 
as the previous ELISA (section 2.4.1.1) with some modifications. Briefly, 96-
well polystyrene plates were coated with recombinant domains (DBL13, 
DBL27, DBL31 DBL41 and DBL4ε) at different concentrations (1 µg/ml, 0.5 
µg/ml, 0.1 µg/ml and 0.01 µg/ml) and incubated overnight at 4°C. Plates were 
washed and blocked as described previously, and wells were incubated with 
polyclonal antisera diluted 1:500, 1:1,000, 1:5,000, 1:10,000, 1:50,000 and 
1:100,000 in complete medium and incubated overnight at room temperature 
with gentle shaking. Plates were then washed and incubated with goat anti-
mouse IgG (Fc-specific)-HRP conjugated (Sigma-Aldrich©, product No. 
A2554). Subsequent washing, developing and blocking were carried out as 
described in section 2.4.1.1. Incubation of polyclonal antisera with VAR2CSA-
DBL4ε was included as a negative control. The results were considered positive 
if the mean absorbance (OD) value obtained from a particular immune serum 
was 3 SDs above the mean absorbance value of that antiserum against control 
DBL4ε domain. Capacity of recognition were set as a grade from + to +++++ as 
shown in the Results section.  
 
2.4.2 Analysis of mouse antisera by flow cytometry 
2.4.2.1 Labelling of IEs by antisera 
The ability of mouse polyclonal antisera to recognise the surface of erythrocytes 
infected by homologous and heterologous P. falciparum isolates was assessed by 
flow cytometry. Briefly, P. falciparum parasites (A4, C24, GC503, 2B2, ItG, 
2F6 and outgrown A4) were cultured and maintained following standard 
laboratory conditions. Mature pigmented trophozoites at mid-late stage were 
enriched from stable parasite cultures at 3-8% parasitaemia (i.e. 3-8 parasites per 
100 erythrocytes) and a haematocrit (HCT) of 1-2%, using plasmagel floatation 
(Pasvol et al., 1978). 60-80% of mid-late trophozoites and schizonts were 
resolved from the enrichment, and 3 µl of the enriched pellet was added to 1 ml 
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of PBS with 1% bovine serum albumin (PBS/1%BSA) to prepare IE suspension. 
Aliquots of the suspension (100 µl, 0.8-1 × 106 cells) were washed in 1.5 ml 
microfuge tubes and the pellet was re-suspended with mouse immune or control 
sera at 1:50 dilution and incubated for 60 minutes at 37°C. After incubation, 
cells were washed and bound IgM or IgG antibodies were detected by incubation 
with 1:100 dilution of APC-conjugated goat anti-mouse IgM (µ) secondary 
antibody (Molecular probes®, Cat. No. M31505) or goat anti-mouse IgG (Fc)-
APC conjugated (Thermo Scientific, Product No. 31981), respectively, plus 10 
µg/ml ethidium bromide for staining nuclei of IEs. Cells were incubated in the 
dark for 60 minutes at 37°C. After incubation, cells were washed once, re-
suspended with 400 µl of Cell Wash and analysed using Becton-Dickinson 
FACSCalibur flow cytometer (BD LSRII). All washes and antibody dilutions 
were carried out in PBS/1%BSA. Cells incubated with NMS and stained with 
ethidium bromide and secondary antibodies or those only incubated with 
secondary antibodies and ethidium bromide were included as negative controls. 
Labelling of A4-infected erythrocytes with mAb BC6 (20 µg/ml), which 
recognises an exposed epitope on the native PfEMP1 on A4-IE surface, was 
included as a positive control. Labelling of uninfected cells with mouse IgG or 
IgM antibodies was found at a range of 1-3%, indicating that labelling is specific 
for IEs. Differences in the binding capacity of polyclonal sera against tested 
isolates were further confirmed by repeating experiments. 
 
2.4.2.2 Data analysis   
Data were acquired using FACSCalibur flow cytometer and 50,000 events were 
collected and analysed with FlowJo software (X 10.0, San Carlos, CA, USA). 
Gating on FSC-A vs. SSC-A parameters was carried out to identify RBC 
populations and to exclude cell debris and dead cells, whereas gating on a SSC-
A vs. FITC-A was performed to differentiate infected RBC population (ethidium 
bromide positive) from uninfected erythrocytes. After gating on IEs, APC-
positive cells were gated to show IgM or IgG-labelled IE population. This was 
firstly carried out with a negative control sample (cells incubated with NMS) to 
define APC-positive / APC-negative subsets and to exclude background 
labelling, then the same subset was applied for test antibodies. Thus, specific 
surface staining for IEs was determined in terms of percentage of APC-positive 
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IE population labelled by test antibodies relative to control antibody. A second 
negative control was included for some experiments (cells only incubated with 
secondary antibody plus ethidium bromide) to confirm the lack of reactivity for 
control antibody (NMS). In all assays, a labelling of ˃ 10% of IE population was 
considered positive for surface labelling, whereas ≤ 10% was considered 
negative. Grading of capacity of surface recognition was set as followed: 
+:          if labelled IE population was within a range of 10.1-20% 
++:        if labelled IE population was within a range of 20.1-40% 
+++:      if labelled IE population was within a range of 40.1-60% 
++++:    if labelled IE population was ˃ 60%. 
 
2.5 Production and characterisation of mouse 
monoclonal and polyclonal antibodies  
2.5.1 Hybridoma cell production    
2.5.1.1 SP2/0 myeloma cell line culture     
SP2/0 murine myeloma cell lines were recovered from liquid nitrogen (LiN2) 
storage and cultured 10-15 days in advance prior to fusion with splenocytes and 
maintained in a log phase of growth as described elsewhere (Fuller et al., 
1988a), with minor modifications. SP2/0 cells were cultured and expanded in 
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS), 1% L-glutamine, 1% penicillin/streptomycin and one unit 
of 8-azaguanine (at 20 µg/ml). Myeloma cells were cultured in a medium 
containing 8-azaguanine to ensure their aminopterin sensitivity to Hypoxanthine 
Aminopterin Thymidine (HAT) selection medium following the fusion with 
splenocytes (Fuller et al., 1988a). Cells were cultured in T75 (75 cm2) ventilated 
culture flasks at 37°C in CO2 incubator (9% CO2) and split in a 1/4 ratio every 2-
3 days to maintain a log-phase growth at the appropriate exponential rate and 
avoid decline in cell viability. Prior to fusion with spleen cells, SP2/0 cells were 
checked for viability and maintained at ~106-107 cells/ml. In addition, 
morphology and potential contamination were examined using inverted 
microscope for obtaining a successful fusion. SP2/0 myeloma cells at 
appropriate log-phase growth (~106 cells/ml) were frozen in 10% dimethyl 
sulphoxide in FBS (10%DMSO/FBS) in LiN2 for further use.  
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2.5.1.2 Extraction and preparation of spleen cells   
Spleens from immunised mice were dissected out aseptically and placed in pre-
warmed CMNS within the animal facility. Two spleens obtained from mice 
immunised with the same antigen were placed in a 100-mm sterile Petri dish 
containing 10 ml of pre-warmed CMNS for extracting splenocytes inside a 
sterile hood. Spleens were gently crushed using a sterile syringe plunger and a 
needle into tiny pieces (1 mm in diameter). The suspension was collected in 50-
ml falcon tubes and unwanted debris were allowed to sediment down by gravity 
at room temperature for 3-6 minutes. The upper 95% of suspension containing 
harvested spleen cells was cautiously collected and re-suspended in CMNS. 
Splenocytes were washed three times in CMNS, counted using haemocytometer 
chamber and prepared for fusion.  
 
2.5.1.3 Fusion of splenocytes with SP2/0 myeloma cells    
Freshly extracted spleen cells and SP2/0 myeloma cells were co-pelleted by 
centrifugation and fused using QED Fuse-It® Hybridoma development kit (QED 
Bioscience Inc., product No. K50000) following manufacturer's instructions. 
The fusion protocol was carried out as described elsewhere (Fuller et al., 1988b). 
SP2/0 myeloma cells from stable cultures were detached by agitation and 
centrifuged at 1200 rounds per minute (rpm) for 5 minutes. The pellet was 
washed three times in CMNS to remove serum components and the 
concentration of cells was adjusted to 1 × 106 cells/ml. Splenocytes and SP2/0 
cells were combined at a ratio of 5:1 (splenocytes to SP2/0 cells) in sterile 50-ml 
falcon tube.  
Cells were thoroughly mixed and co-pelleted at 1000 rpm for 5 minutes before 
the supernatant was discarded and the cell mixture was left at a drying state. 
Polyethylene glycol (PEG) fusion reagent was prepared as per manufacturer's 
instructions and 1 ml was added to the cell mixture drop-wise over a 30-second 
period with gentle agitation. This was followed by the addition of 1 ml CMNS at 
a drop-wise manner over 30 seconds to dilute the PEG and further 10 ml of 
CMNS were dropped over a period of 3 minutes. The former dilutions were 
carried out with gentle agitation throughout the procedure. Cells were 
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centrifuged at 1000 rpm for 5 minutes, the supernatant containing traces of PEG 
was extracted and the pellet was re-suspended at a concentration of 1.5 × 106 
cells/ml in cloning medium (DMEM medium supplemented with 10% FBS, 1% 
L-glutamine, 1% penicillin/streptomycin, 10% BriClone hybridoma cloning 
medium (Qed Bioscience Inc., Product No. BRI10000) supplemented with one 
unit of HAT. As the total number of cells resulted from the fusion was 60 × 106 
cells, this was re-suspended in 40 ml cloning medium to yield a concentration of 
1.5 × 106 cells/ml. 200 µl of the cell suspension was aliquoted into 96-well 
plates (~200 wells, 3 × 105 cells/well). Plates were incubated at 37°C in CO2 
incubator for at least 3 days. On the fourth day, wells were inspected for colony 
growth, and 50 µl of fresh cloning medium was added to wells with signs of 
colony growth (Figure 2.1). Wells were checked for the presence of a milky 
cloudy aggregation of cells at the base of each well that indicates hybridoma 
formation. However, cell clumping may also indicate the presence of SP2/0 
aggregates; therefore, hybridomas were inspected under inverted microscope and 
differentiated from SP2/0 aggregates by the size and morphology of cells (Figure 
2.1). Wells were inspected at one-day intervals and growing hybridoma clones at 
10-50% confluence were assayed with ELISA for the production of antigen-
specific antibodies. Hybridoma cell lines were diluted and expanded gradually 
from 96-well plates to 24-well plates, 6-well plates, 25 cm2 and 75 cm2 culture 
flasks containing appropriate volumes of cloning medium.  
 
 
 
 
 
 
Figure 2.1. Growing hybridoma colonies as inspected under inverted microscope. 
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2.5.2 Indirect ELISA for screening hybridoma clones  
Multiple screening ELISAs were carried out to investigate the presence of 
reactive IgG or IgM antibodies in culture supernatants of confluent hybridoma 
cell lines in 96-well plates. Reactivity was checked against recombinant DBL 
domains following the same ELISA protocol described in section 2.4.1.1 with 
some modifications. Briefly, 96-well ELISA plates (Nunc) were coated with 100 
µl of recombinant domains (rDBL13, rDBL27, rDBL31 and rDBL41) dissolved 
in 0.1 M carbonate bicarbonate buffer at 1 μg/ml and incubated overnight at 4°C. 
Washing off unbound antigens and blocking were carried out as described 
section 2.4.1.1. Plates were washed and incubated with 50 µl from the 
supernatant of confluent hybridoma cell line in duplicates for 2 hours at room 
temperature with gentle agitation. After incubation, wells were washed as 
previous and incubated at room temperature for 1 hour with 100 µl of 1:500 
diluted goat anti-mouse IgG (Fc-specific)-HRP conjugated antibody (Sigma-
Aldrich©, product No. A2554) for the detection of reactive IgG or with goat anti-
mouse IgM (µ chain specific)-HRP conjugated (Southern Biotech, Cat. No. 
1021-05) for the detection of reactive IgM antibodies in culture supernatants. 
Following secondary antibody incubation, assays were completed as described 
in section 2.4.1.1. Wells coated with recombinant antigens and incubated with 
complete medium were used as negative controls. Positive hybridomas were 
then either cloned by limiting dilution or expanded and assayed as polyclonal 
antibodies. 
 
2.5.3 Cloning of hybridoma clones by limiting dilution 
Hybridoma cell lines that showed positive reactivity with ELISA were further 
cloned by limiting dilution at 0.8 cells/well to produce monoclonal cell lines that 
secrete monoclonal antibodies, following a protocol described by Fuller et al., 
(1988c). Hybridoma cell lines to be cloned were transferred to 24-well culture 
plates containing 0.5 ml cloning medium and cultured to log-phase of growth 
overnight at 37°C. Each confluent line was counted with a haemocytometer and 
transferred to 6-well plates at 1:100 dilution in 3 ml in the first well, 80 cells/ml 
in the second well and 8 cells/ml in the third well. Then, cells at 80 cells/ml and 
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8 cells/ml were aliquoted in 96-well plates in cloning medium and incubated at 
37°C. Wells containing 0.8 cells/well were inspected for growth and the resulted 
monoclonal colonies were scanned by ELISA for reactivity with recombinant 
domains as described in section 2.4.2. Positive clones were further cultured and 
maintained for further study.  
 
2.5.4 Freezing and recovery of Hybridoma clones  
Confluent hybridoma cell lines at a log-phase growth at ~106 cells/ml were 
resuspended in 10%DMSO/FBS to a final concentration of 5 × 106 
cells/cryovial. Vials were rapidly transferred to a freezing chamber containing 
isopropanol and frozen overnight at -70°C. On the following day, vials were 
transferred to liquid nitrogen, the method of choice for long-term storage of 
hybridoma clones that ensures the endurance of antibody production in frozen 
aliquots (Fuller et al., 1988d). Hybridoma cell lines to be recovered post-
freezing were thawed in 37°C water bath, washed in CMNS to remove traces of 
DMSO, re-suspended in an appropriate volume of cloning medium and 
incubated at 37°C.  
Over-confluent growth of cells in expanded cultures was suspended by the 
addition sodium azide (0.02% w/v). Culture flasks containing dead cells were 
firstly centrifuged at 1200 rpm for 5 minutes, the supernatant was collected and 
filtered through 0.2 µm pore-size filters to ensure the removal of dead cells, and 
recovered culture supernatant containing reactive antibodies was stored at 4°C. 
A total of 300 ml of culture supernatant was collected from each hybridoma cell 
line and preserved for further study. Further ELISAs were carried out at this 
point to confirm positivity for antigen (section 2.4.1.1) following the same 
procedure described in section 2.5.2 but with the addition of 200 µl of 
hybridoma culture supernatants (preserved in 0.02% w/v sodium azide) to wells 
pre-coated with recombinant domains at 5 µg/ml. Although there was no clear 
difference in the capacity of antibody recognition to wells coated with 1 µg/ml 
or 5 µg/ml (data not shown), the latter concentration was used in all subsequent 
ELISA procedures. Mouse polyclonal antisera diluted 1:50 dilution were 
assayed as positive controls, whereas mouse IgM isotype control from murine 
myeloma clone MOPC 104E (Sigma®, M5909, 200μg/ml) was included as a 
negative control (20 µg/ml). 
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2.6 Affinity purification of monoclonal and polyclonal 
antibodies  
A total of thirteen monoclonal and polyclonal hybridoma cell lines that secrete 
reactive murine IgM antibodies were affinity-purified from stable culture 
supernatants using manual gravity flow column affinity chromatography. First, 
the column was packed with 5 ml of goat anti-mouse IgM (µ-chain specific) 
coupled to agarose beads (Sigma-Aldrich®, product No. A4540) and washed 
with 5-6 column volumes of Hank's balanced salt solution (HBSS) (Gibco®, Life 
Technologies, Cat. No. 14175-095). Then, culture supernatants (300 ml) were 
run through the resin of the column at a low flow rate (~0.5-1 ml/min). The 
sample was re-circulated 2-3 times to increase the potential of retaining larger 
amounts of functional antibodies from culture supernatants. The column was 
washed with HBSS as previously to remove contaminants that bind with low 
affinity, before the lower end of the column was capped and captured antibodies 
were eluted from agarose beads by adding 0.1 M glycine pH 2.5 to the 
suspension with gentle agitation for 2-3 minutes. Seven fractions (~2 ml) of 
affinity purified antibodies were then collected in 15 ml falcon tubes containing 
appropriate volume (240-260 µl) of 1 M Tris-HCL pH 9.0 for neutralising the 
pH of the eluted fraction. The pH of eluted fractions was then checked to 
confirm pH of 7.0-8.0. The antibody-depleted flow-through fluid was stored at 
4°C for further study to confirm the absence of antigen-specific antibodies by 
ELISA. Purified antibodies were stored in aliquots (100 µl) at -20°C for further 
study. The column was then washed with 2-3 column volumes of 0.1 M glycine 
pH 2.5, then neutralised with 7-8 column volumes of HBSS and stored at 4°C. 
For long-term storage, the column was filled with 20% ethanol.   
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2.7 Screening eluted fractions by flow cytometry  
All eluted fractions were screened by flow cytometry for the presence of 
antibodies that label the surface of live IEs. This was to identify fraction(s) 
containing the highest amount of reactive antibodies for further study. 
Erythrocytes infected by ItG P. falciparum parasites (IT4var16) were assayed as 
described in section 2.4.2.1 with some modifications. Briefly, aliquots of 
parasite suspension (100 µl, ~µl 0.8-1 × 106 cells) were washed and the pellet 
was re-suspended with 50 µl of each of the eluted fractions and incubated for 60 
minutes at 37°C. The pellet of cells was then washed and incubated with 1:100 
dilution of APC-conjugated goat anti-mouse IgM (µ chain specific) secondary 
antibody (Southern Biotech®, Cat. No. 1020-11L, 0.5mg) plus 10 µg/ml 
ethidium bromide for 60 minutes at 37°C. After incubation, cells were washed 
and analysed as described in section 2.4.2.2. Cells incubated with 20 μg/ml of 
mouse IgM isotype control from murine myeloma clone MOPC 104E (Sigma®, 
M5909, 200 μg/ml) and stained with ethidium bromide and secondary antibodies 
were used to exclude background labelling (1-9% of IE population) and included 
as a negative control. A labelling of ˃ 10% of IE population was considered 
positive. 
 
2.8 ELISA for investigating the efficiency of affinity 
purification   
The recovery of murine IgM from hybridoma culture supernatants by affinity 
purification was assessed by ELISA using either cultures supernatants, purified 
eluted fractions and flow-through medium. A similar procedure was carried out 
as described in section 2.5.2 with some modifications. Briefly, 96-well ELISA 
plates (Nunc) were coated with 100 µl of rDBL31 proteins dissolved in 0.1 M 
carbonate bicarbonate buffer at 5 μg/ml and incubated overnight at 4°C. 
Washing off unbound antigens and blocking were carried out as described 
section 2.4.1.1. Plates were washed and incubated with 200 µl of crude culture 
supernatant, 200 µl of flow-through fluid or 50 µl of purified antibodies in 
duplicates for 2 hours at room temperature with gentle agitation. Purified 
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antibody fraction that showed the highest reactivity in flow cytometry was used 
in this assay. After incubation, wells were washed as previously and incubated at 
room temperature for 1 hour with 1:500 dilution of goat anti-mouse IgM (µ 
chain specific)-HRP conjugated [Southern Biotech, Cat. No. 1021-05] (100 µl). 
Subsequent washing and developing was carried out as described in section 
2.4.1.1. Incubation of 100 μl of complete medium or 100 μl of 20 μg/ml mouse 
IgM isotype control from murine myeloma clone MOPC 104E (Sigma®, M5909, 
200μg/ml) with recombinant proteins were included in the assay as negative 
controls, whereas anti-DBL31 mouse serum (50 μl, 1:10 dilution) was used as a 
positive control. 
 
2.9 Dot blot for estimating the concentration of IgM in 
eluted fractions   
IgM concentration of eluted fractions was estimated semi-quantitatively in 
comparison with mouse IgM control standard spotted down at gradual 
concentrations onto a nitrocellulose membrane. Briefly, 5 μl of each eluted 
fraction was spotted manually onto Whatman® Protran® Nitrocellulose 
membrane (Whatman® GmbH, Germany). Mouse IgM isotype control from 
murine myeloma clone MOPC 104E (Sigma®, M5909, 200 μg/ml) was titrated 
at doubling dilutions from 200 μg/ml down to 0.2 μg/ml in glycine/Trizma-HCL 
pH 7.0 buffer and spotted onto the membrane. Blots were left to dry at room 
temperature for 10-20 minutes, before the membrane was blocked with PBSTM 
at room temperature for 120 minutes with gentle agitation. The membrane was 
washed in distilled water and incubated with HRP-conjugated goat anti-mouse 
IgM (Southern Biotech®, Cat. No. 1021-05, Lot E5406-R690B) at a dilution of 
1:500 overnight at room temperature. On the following day, the membrane was 
washed in distilled water and developed in 1×PBS/1%DAB/0.5%H2O2 solution 
for 10 minutes, before it was thoroughly washed for avoiding excess staining 
and imaged by Gel Doc™ EZ imager (Bio-Rad, Hercules, CA, USA) and 
analysed using Image Lab software version 3.0. 5 µl of complete medium or 
mAb BC6 at 20 µg/ml were spotted onto the membrane and used as negative 
controls.  
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2.10 Double-antibody sandwich ELISA for the 
quantitation of murine IgM 
The concentration of IgM antibodies in purified fractions was quantified using 
double-antibody sandwich ELISA as described elsewhere (Mushens et al., 
1993). Briefly, unlabelled µ-chain specific rat anti-mouse IgM (clone 1B4B1, 
Southern Biotech®, Cat. No. 1140-01, 0.5 mg/ml) was coated onto the plate at 5 
µg/ml in 0.1 M carbonate bicarbonate buffer and incubated overnight at 4°C. 
The plate was washed three times with PBST and blocked in PBSTM for 60 
minutes at room temperature. The plate was washed as previously and 100 µl of 
mAbs/pAbs diluted at 1:100 in complete medium were added to the pre-coated 
wells. Mouse IgM isotype positive control (clone MOPC 104E, Sigma®, M5909, 
200 μg/ml) was titrated from 4000 to 0.12 ng/ml by doubling dilution in 
complete medium and added to the plate (100 µl in duplicate). The plate was 
incubated on the shaker for 120 min at room temperature, before it was 
thoroughly washed and incubated with HRP-conjugated goat anti-mouse IgM 
(Southern Biotech®, Cat. No. 1021-05) at 1:500 dilution for 60 min at RT. Wells 
were washed again and the reaction was developed by adding 100 µl of 
3,3´,5´,5´-tetramethylbenzidine dihydrochloride diluted in phosphate-citrate 
buffer with Sodium Perborate and left for 10 - 15 minutes in the dark at room 
temperature. Finally, 50 µl of 2 M H2SO4 was added to block the reaction and 
the optical densities were measured using an ELISA plate reader with a 450-nm 
reference filter. Incubation of 100 μl of complete medium or 100 μl of 20 μg/ml 
of mAb BC6 with coated antibody were included in the assay as negative 
controls. After generating a standard dilution curve for the mean concentration 
and absorbance values of the mouse IgM standard, the unknown concentration 
of purified mAbs and pAbs was calculated using the excel function =TREND 
(all concentration values of standard, [all absorbance values of standard], 
[absorbance of unknown sample], [constant]). 
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2.11 Parasite culture  
2.11.1  P. falciparum isolates  
Characteristics of parasite isolates used in the present study are indicated in the 
results of Chapter 3 (Table 3.2). All parasites are subject to antigenic switching 
and thus were maintained for 1-3 weeks after selection to minimise the effect of 
mixed populations, since most isolates in continuous cultures lose the capacity to 
bind after a short period (~ 24-43 days), although some continue to bind after 
longer periods (Udeinya et al., 1983). ItG was selected on ICAM-1 and the 
expression of the corresponding var gene (var16) was confirmed in our 
laboratory by PCR. A4 was selected on mAb BC6 (Horrocks et al., 2002) 
followed by FACS analysis of the expressed PfEMP1 with the corresponding 
parasite isolate (A4).  
 
2.11.2  Parasite culture   
Parasites were cultured under standard conditions described elsewhere (Trager 
and Jensen, 1976). Blood-stage parasites were maintained in complete culture 
medium (RPMI 1640 medium supplemented with 37.5 mM HEPES, 7 mM 
glucose, 6 Mm NaOH, 25 mg/ml of gentamicin sulphate, 2 mM L-glutamine and 
10% human serum) at 1-2% HCT in O+ human erythrocytes, pH of 7.2 and in a 
gas mixture of 96% nitrogen, 3% carbon dioxide and 1% oxygen. Cultures were 
checked every 48 hours and maintained at 2 – 10% parasitaemia by dilution in 
washed human RBCs with exchanging culture media and gassing of flasks. 
RBCs were obtained from the British transfusion services (Liverpool, UK) in 
bags lacking anti-coagulant and centrifuged at 3000 rpm for 20 minutes through 
Histopaque (Sigma) to discard plasma and leukocytes. Washed RBCs were 
resuspended in serum-free culture medium to a final HCT of 50% and stored at 
4°C for 7-10 days.  
 
2.11.3  Determination of parasitaemia    
Parasitaemia and stage of growth were determined every alternate day by thin 
blood smears. 300-400 µl of culture was centrifuged in Eppendorf tubes for 30 
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seconds and the pellet was smeared onto a microscope slide, air-dried and fixed 
in 100% methanol for 5 seconds. Fixed smears were rinsed in water and stained 
with 5% Giemsa stain (in phosphate-buffered water, at pH 7.2) for 10-20 
minutes. The slides were rinsed in water, air-dried and inspected under the light 
microscope using 100 × 10 (×1000) magnification under oil immersion objective 
lens. Five hundred (500) RBCs were counted and the number of parasites (rings 
or trophozoites) were counted relative to non-IEs.  
 
2.11.4  Trophozoite enrichment - plasmagel floatation  
This method is based on the capacity of knobby IEs to float on Plasmion, a 
physiological saline solution containing 3% gelatine. The culture to be 
synchronised was transferred to a 50 ml Falcon tube and centrifuged at 1800 rpm 
for 5 minutes. The pellet was resuspended in 1.5-volume of serum-free complete 
medium and 2.5-volume of Plasmion. The suspension was mixed, transferred to 
a 15 ml Falcon tube and allowed to settle for 20 minutes at 37°C. knobby 
trophozoites in the pink top layer were carefully transferred to a clean 15 ml 
Falcon tube, washed in serum-free complete medium (by centrifugation at 1800 
rpm for 5 minutes) and used in assays or added in complete medium for 
continuous cultures. The efficiency of enrichment was assessed by counting the 
parasitaemia in a stained then smear to evaluate the percentage of trophozoites in 
the enriched pellet. Smears taken after this procedure usually showed ~50-80% 
of enriched trophozoites. During microscopic examination of enriched 
trophozoites, spontaneous agglutination was checked and found to be absent at 
higher trophozoite concentrations.  
 
2.11.5  Selection of ItG-IEs on ICAM-1 protein   
ItG-IEs were selected on ICAM-1 to increase the homogeneity of parasites for 
ICAM-1 binding phenotype. 50 µl of Protein A dynabeads (Invitrogen) were 
washed three times in 200 µl PBS/1%BSA using a magnet that recovers the 
beads with every wash, and  resuspended in 200 µl of PBS/1%BSA after the last 
wash. 2.5 µg/ml of purified ICAM-1 protein was mixed with the bead 
suspension on a rotator for 60 minutes at room temperature. ICAM-1-coated 
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dynabeads were purified on the magnet and washed three times in 200 µl of 
PBS/1%BSA. Trophozoites enriched in Plasmion were incubated with ICAM-1-
coated dynabeads and incubated on a rotator for 45 minutes at room temperature. 
Unbound IEs were removed by repeated washing (3×) in PBS/1%BSA. IE-
bound beads were resuspended in fresh complete medium and cultured as 
described above.  
 
2.11.6  Selection of A4-IEs on BC6  
Selection of A4 (IT4var14)-IEs was carried out using mAb BC6, which 
recognises an exposed epitope on PfEMP1 of erythrocytes infected by A4 P. 
falciparum isolate (Roberts et al., 1992, Horrocks et al., 2002). A similar 
protocol to that used in ICAM-1 selection was followed except that Protein G 
dynabeads were used instead of Protein A dynabeads. Following ICAM-1 or 
BC6 selection, batches of selected parasite stabilates were cryopreserved to be 
used in subsequent work.  
 
2.11.7  Cryopreservation of parasites   
Parasites at 5-8% parasitaemia (ring stage) were centrifuged and the pellet was 
cryopreserved in glycerolyte freezing medium at a ratio of 5-volume freezing 
medium to 3-volume pellet. Addition of the cryopreservation medium was 
carried out in two steps. First, one-volume of the medium was added and the 
cells were allowed to stand for 5 minutes before the remaining 4-volumes were 
added slowly. The suspension was gently mixed and transferred to pre-labelled 
cryovials (500 µl per vial). Vials were kept in a polystyrene rack, wrapped with 
tissue papers and allowed to freeze slowly at -80°C overnight before they were 
transferred to liquid nitrogen for long-term storage.  
 
2.11.8  Reconstitution of frozen parasites    
Appropriate volumes of 12% NaCL, 1.8% NaCL, and 0.9% NaCL in 0.2% 
glucose, serum-free complete medium and complete medium were warmed at 
37°C before the thawing starts. Frozen parasite stabilates were carefully 
removed from liquid nitrogen and allowed to thaw at room temperature. As soon 
as the stabilate was thawed, the 500 µl parasite contents was transferred to a 15 
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ml Falcon tube, resuspended in 100 µl of 12% NaCL and allowed to stand for 5 
minutes at room temperature. Then, 5 ml 1.8% NaCL was slowly added over 5 
minutes and the suspension was allowed to stand for 5 minutes. This was 
followed by the addition of 5 ml 0.9% NaCL over 5 minutes and allowed to 
stand for 5 minutes as previous. After that, the suspension was centrifuged at 
1800 rpm for 5 minutes. The pellet was washed in serum-free complete medium, 
before washed parasites were resuspended appropriate volume of complete 
medium (8-10 ml) and cultured as described above.  
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2. Results  
2.1 Analysis of recombinant DBLβ domains by SDS-
PAGE and Western blotting  
The four recombinant DBLβ domains used in this work were obtained from 
Matthew Higgins, Oxford (Brown et al., 2013). All domains, namely rDBL13, 
rDBL27, rDBL31 and rDBL41, were cloned from ICAM-1-binding PfEMP1 
variants from P. falciparum (IT4 genotype) and expressed in E. coli vectors. 
SDS-PAGE was carried out for the separation and recognition of rDBLβ 
domains on 4-12% polyacrylamide gradient gels. Gels were stained with 
PageBlue™ Coomassie brilliant blue protein stain or electrophoretically 
transferred to PVDF membranes and probed with primary monoclonal anti-
polyHistidine HRP-conjugated antibodies. The separation and recognition of 
reduced and non-reduced recombinant proteins are shown in Figures 2.1 and 2.2, 
respectively. Cloned DBLβ domains of different lengths comprised ~391-404 
residues and estimated to have molecular masses of approximately 44.8-46 kDa. 
All rDBLβ migrated in the stained gel and visualised on the blots at molecular 
weights slightly larger than the calculated masses (46-47 kDa), which can be 
explained by presence of vector-specific amino acids and the histidine tag that 
increased the overall size of the protein core. Recombinant DBL41 was observed 
as a relatively faint band at the expected MW range in the stained gel, but the 
band was stronger and specific in the immunoblot at the same MW. The 
calculated and observed MWs of each recombinant protein are summarised in 
Table 2.1.  
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Figure 2.1. SDS-PAGE and Western blotting for the identification of four rDBL domain proteins 
expressed in E. coli. Purified recombinant proteins were adjusted to a concentration of 5 µg in 20 
µl buffer (5 µg of protein was used per well), reduced with NuPAGE® reducing agent and 16 µl 
of each sample was loaded into wells of 4-12% polyacrylamide SDS-PAGE gels. Proteins were 
either stained with PageBlue™ protein stain (A) or transferred to PVDV membrane and probed 
with primary monoclonal anti-polyHistidine HRP-conjugated antibodies at 1:250 dilution (B). 
Blots were developed in a developing solution (1×PBS, 0.02% H2O2 and 0.005% DAB). Naive 
Mouse serum (NMS) was loaded onto the gel (5 µl / 20 µl) and included as an internal control 
for the reduction which showed two bands at 26 kDa (light chain) and 52 kDa (heavy chain) in 
the stained gel, but was not reactive with anti-polyhistidine antibodies since it lacks histidine 
tags. A protein ladder of known MWs (SeeBlue® Plus2 Pre-stained Protein standard) was loaded 
on the gel and indicated in kDa. Lanes 13, 27, 31 and 41 represent rDBL13, rDBL27, rDBL31 
and rDBL41 domains, respectively. 
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Figure 2.2. SDS-PAGE and Western Blotting analysis for the identification of four rDBL domain 
proteins. Purified recombinant proteins were prepared following the same procedure as Figure 
2.1, but under non-reducing conditions. Proteins were either stained with PageBlue™ protein 
stain (A) or transferred to PVDV membrane and probed with primary monoclonal Anti-
polyHistidine HRP-conjugated antibodies (B). A protein ladder of known MWs was loaded on 
the gel and indicated in kDa. Lanes 13, 27, 31 and 41 represent rDBL13, rDBL27, rDBL31 and 
rDBL41 domains, respectively. NMS: Naive Mouse serum. 
 
 
Recombinant 
domains 
Accession 
number 
Length  
(amino acid  
residues) 
Calculated MW 
(kD) 
Observed MW 
(kD) 
DBL13 EF158072.1 391 45.3 ~47 
DBL27 EF158081.1 404 45.8 ~47 
DBL31 AF193424.1 403 46.0 ~47 
DBL41 EF158090.1 393 44.8 ~46 
Table 2.1. Calculated and observed MWs of recombinant DBLβ domains. All recombinant 
proteins were observed at slightly larger MWs than calculated weights.  
 
kDa 
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2.2 Immunisation of mice with recombinant DBLβ 
domains  
In the present work, two groups of mice were immunised with recombinant 
domains and stimulated with different adjuvants. Immunisation of the first group 
was carried out at Severn Biotech Ltd® (Worcestershire, United Kingdom) using 
Freund's complete/incomplete adjuvant (FCA), whereas the second 
immunisation was performed by Professor Richard Pleass, using Alum (Sigma) 
as an adjuvant. After mouse immunisation, sera were collected and analysed for 
reactivity against immunising domains with ELISA and flow cytometry. 
  
2.3 Functional characteristics of mouse antisera  
2.3.1 Analysis of mouse antisera by ELISA 
Indirect ELISAs were carried out to investigate the antibody reactivity of 
polyclonal antisera from mice immunised with various recombinant DBL 
domains using either FCA or Alum for immune stimulation. The assays also 
aimed to determine the immunological class of reactive antibodies present in 
mouse antisera. The results showed that serum samples from mice challenged 
with FCA were devoid of reactive IgG or IgM antibodies that recognise 
homologous and heterologous immunising domains (data not shown). Therefore, 
only analysis of Alum-stimulated mice will be discussed henceforth.  
  
2.3.1.1 Indirect ELISA for investigating the reactivity of mouse antisera 
against recombinant domains 
The first ELISA was carried out to screen antisera from mice stimulated with 
Alum for the presence of IgG class antibodies capable of recognising 
homologous and heterologous antigens (Figure 2.3, Table 2.2). As expected, all 
polyclonal sera showed higher reactivity with their corresponding fusion 
domains compared to the non-immune mouse sera (NMS) negative control, 
except anti-rDBL41 antisera, which recognised their own fusion proteins very 
weakly. However, all polyclonal anti-sera showed variable levels of cross-
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reactivity against other heterologous domains, but had almost no reactivity with 
the rDBL41 protein. A pattern of homologous domain-specificity was observed 
as antisera showed a relatively higher reactivity with their immunising antigens 
compared to other heterologous proteins. For instance, anti-DBL13 antisera 
reacted exclusively with homologous domains, indicating that mice injected with 
rDBL13 antigens elicited specific IgG antibodies that only recognised 
corresponding immunising antigens. 
 
 
 
 
Figure 2.3. Indirect ELISA for investigating the IgG-class reactivity of antisera obtained from 
mice immunised with recombinant domains. 100 µl of rDBL13, rDBL27, rDBL31 and rDBL41 
domains at 1 μg/ml in 0.1 M carbonate bicarbonate buffer were coated onto ELISA plates. Plates 
were blocked and washed as described in Materials and Methods, then incubated with 1:500 
diluted mouse antisera (anti-DBL13, anti-DBL27, anti-DBL31 and anti-DBL41), PBS-injected 
mouse serum (NMS) or mouse monoclonal BC6 IgG antibody (20 μg/ml). Reactive IgG 
antibodies were detected with HRP-conjugated goat anti-mouse IgG antibodies (Sigma) at 1:500 
dilution. Recognition was measured in terms of the magnitude of the response demonstrated as 
optical density (OD) values and shown as the average of duplicate wells with SD values 
expressed as error bars. Incubation of NMS mouse sera or mAb BC6 with recombinant proteins 
was included in the assay as negative control.   
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In the second ELISA, we used a secondary antibody that enables the detection of 
reactive IgM antibodies in mouse polyclonal antisera (Figure 2.4, Table 2.3). 
Mouse immune sera exhibited an overall reduced reactivity with homologous 
and heterologous domains compared to IgG antigen-recognition profile. All 
antisera cross-reacted with heterologous domains, with anti-DBL13 and anti-
DBL27 antisera showing a relatively increased pattern of homologous domain-
specificity. NMS control showed a slightly higher reactivity compared to mAb 
BC6 control, which can be explained by the presence of heterophilic low-affinity 
IgM antibodies in naïve mouse serum capable of recognising some epitopes on 
coated proteins.  
 
 
Figure 2.4. Indirect ELISA for investigating the IgM-class reactivity of antisera obtained from 
mice immunised with recombinant domains. 100 µl of rDBL13, rDBL27, rDBL31 and rDBL41 
domains at 1 μg/ml in 0.1 M carbonate bicarbonate buffer were coated onto ELISA plates. Plates 
were blocked and washed as described in Materials and Methods, then incubated with 1:500 
diluted mouse antisera (anti-DBL13, anti-DBL27, anti-DBL31 and anti-DBL41), PBS-injected 
mouse serum (NMS) or mouse monoclonal BC6 IgG antibody (20 μg/ml). Reactive IgM 
antibodies were detected with HRP-conjugated goat anti-mouse IgM (Southern Biotech) at 1:500 
dilution. Recognition was measured in terms of the magnitude of the response demonstrated as 
OD values and shown as the average of duplicate wells with SD values expressed as error bars. 
Incubation of NMS mouse sera or mAb BC6 with recombinant proteins were included in the 
assay as negative controls.   
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Primary antibodies  
Recombinant DBLβ domains 
DBL13 DBL27 DBL31 DBL41 
Anti-DBL13 antisera +++++ + - - 
Anti-DBL27 antisera +++++ +++++ +++++ ++ 
Anti-DBL31 antisera +++++ +++++ +++++ - 
Anti-DBL41 antisera +++++ +++++ +++++ + 
NMS - - - - 
BC6  - - - - 
 
Table 2.2. Investigating the presence of reactive IgG antibodies in mouse polyclonal antisera 
against recombinant DBLβ domains as measured by indirect ELISA. The results were 
considered positive if the mean absorbance value obtained from immune sera was 3 SDs above 
the mean of NMS absorbance values. Capacity of recognition was as followed: +: ˃ 3 SD values 
above the mean of NMS absorbance value (0.11) to OD value of 0.31, ++: OD values of 0.32 to 
OD values of 0.51, +++: OD values of 0.52 to OD values of 0.71, ++++: OD values of 0.72 to 
OD values of 0.91, +++++: ˃  OD values of 0.91.  
 
 
Primary antibodies  
Recombinant DBLβ domains 
DBL13 DBL27 DBL31 DBL41 
Anti-DBL13 antisera + + - + 
Anti-DBL27 antisera - ++ + - 
Anti-DBL31 antisera + + + + 
Anti-DBL41 antisera - + + - 
NMS - - - - 
BC6  - - - - 
 
Table 2.3. Investigating the presence of reactive IgM antibodies in mouse polyclonal antisera 
against recombinant DBLβ domains as measured by indirect ELISA. The results were considered 
positive if the mean absorbance value obtained from immune sera was 3 SDs above the mean of 
NMS absorbance value. Capacity of recognition was as followed: +: ˃ 3 SD values above the 
mean of NMS absorbance values (0.25) to OD values of 0.45, ++: OD values of 0.46 to OD 
values of 0.65.  
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2.3.1.2 Checkerboard ELISA  
An indirect ELISA was then carried out to screen mouse polyclonal antisera for 
the presence of rDBL-specific antibodies using serial dilutions of immune sera 
against different concentrations of fusion rDBL domains, in order to determine 
the antibody titre of immune antisera (Table 2.4). Figure 2.5 shows the titration 
for anti-DBL31 antisera against different concentrations of homologous and 
heterologous proteins used for mouse immunisation. Only IgG response was 
measured in this assay, as primary screening ELISA showed a relatively weak 
IgM response in mouse antisera (Figure 2.4). The antibody titre was defined as 
the minimum dilution of antisera that shows an OD value above the cut-off point 
set at three SDs above the mean OD value of DBL4ε control. In general, titres 
for most antibodies ranged from 1/1000 and 1/100,000, and an adequate 
antibody response is achieved when antibody titre of test serum was ˃ 1/1000 
(Fuller et al., 1992). 
Overall, titration curves showed that all antisera efficiently recognised their 
corresponding rDBL antigens down to 1:100,000 dilution (Table 2.4). An 
exception was the anti-rDBL41 immune serum, which had not been successful 
in recognising its corresponding protein but cross-reacted with the heterologous 
domains with a titre of 1/1000 with DBL13 and DBL31, and 1:5000 with 
DBL27. Frequencies of recognition were shown to be dependent on the coating 
concentration of proteins as well as the dilution of antisera, i.e. higher 
concentrations of coating protein and lower serum dilution showed the 
maximum reactivity in all assays, and vice versa. All recombinant proteins, 
particularly rDBL31, were recognised well by mouse antisera except DBL41 
which only weekly recognised by anti-DBL13 and anti-DBL27 antisera. In 
addition, all polyclonal sera showed no reactivity with DBL4ε control protein 
indicating that the positive response was specific to recombinant DBLβ domains 
of PfEMP1 from the IT4 parasite genome.   
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Figure 2.5. The reactivity of serial dilutions of anti-DBL31 antisera against different 
concentrations of recombinant DBL domain proteins as measured by indirect ELISA. 96-well 
ELISA plates were coated with rDBL proteins (rDBL13, rDBL27, rDBL31, rDBL41 and 
rDBL4ε control) dissolved in 0.1 M carbonate bicarbonate buffer at 1, 0.5, 0.1 or 0.01 µg/ml. 
Plates were blocked and washed as described in Materials and Methods, then incubated with 
serial dilutions of mouse polyclonal antisera (1:500, 1:1000, 1:5000, 1:10,000, 1:50,000 and 
1:100,000). Reactive IgG antibodies were detected with HRP-conjugated goat anti-mouse IgG 
antibodies (Sigma) at 1:500 dilution. Recognition was measured in terms of the magnitude of the 
response demonstrated as OD values and shown as the average of duplicate wells with SD values 
expressed as error bars. Incubation of NMS mouse sera or mAb BC6 with recombinant proteins 
was included in the assay as negative controls. Recombinant DBL4ε domain was cloned from 
VAR2CSA and used as a negative control in the assay. 
 
 
 
 
 
Concentration of DBL domains Concentration of DBL domains 
Concentration of DBL domains Concentration of DBL domains 
Concentration of DBL domains 
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Immunising DBLβ domains    
DBL4ε (μg/ml) DBL41 (μg/ml) DBL31 (μg/ml) DBL27 (μg/ml) DBL13 (μg/ml) 
Dilution Antisera  
0.01 0.1 0.5 1 0.01 0.1 0.5 1 0.01 0.1 0.5 1 0.01 0.1 0.5 1 0.01 0.1 0.5 1 
- - - - - - + - - + +++ ++++ - - + ++ + + +++ +++++ 1:500  
Anti-
DBL13 
- - - - - - - - - + ++ +++ - + + ++ + + +++ ++++ 1:1000 
- - - - - - - - - + + + + + + ++ - + + ++ 1:5000 
- - - - - - - - - - - + - + + + - - + ++ 1:10000 
- - - - - - - - - - - + - + + + - - + + 1:50000 
- - - - - - - - - - - - - - + + - + + + 1:100000 
- - - - - + + + + +++ +++++ +++++ + ++ ++++ +++++ - - + ++ 1:500  
 
Anti-
DBL27 
- - - - - + + + + +++ +++++ +++++ + + +++ +++++ - - + ++ 1:1000 
- - - - - - - - + ++ ++++ ++++ + + + ++ - - - + 1:5000 
- - - - - - - - + + +++ +++ + + + ++ - - - + 1:10000 
- - - - - - - - + + + ++ - - + + - - - - 1:50000 
- - - - - - - - + + + + - - + + - - - - 1:100000 
- - - - - - - - + +++ +++++ +++++ - + ++++ +++++ - + +++ +++++ 1:500  
 
Anti-
DBL31 
- - - - - - - - + ++ +++++ +++++ - + +++ ++++ - + ++ ++++ 1:1000 
- - - - - - - - - + +++ ++++ - - - ++ - - + ++ 1:5000 
- - - - - - - - - + ++ ++ - - + ++ - - - + 1:10000 
- - - - - - - - - + + + - - + + - - - + 1:50000 
- - - - - - - - - + + + - - - + - - - - 1:100000 
- - - - - - - - - + ++++ +++++ - + ++ ++ - - + ++ 1:500  
 
Anti-
DBL41 
- - - - - - - - - + +++ ++++ - + + ++ - - + ++ 1:1000 
- - - - - - - - - - + + - - + + - - - + 1:5000 
- - - - - - - - - - + + - - - - - - - + 1:10000 
- - - - - - - - - - - - - - - - - - - - 1:50000 
- - - - - - - - - - - - - - - - - - - - 1:100000 
Table 2.4. Summary of the reactivity of serial dilutions of mouse antisera against different concentrations of recombinant DBL domain proteins. The results were 
considered positive if the mean absorbance value obtained from a particular immune serum was 3 SDs above the mean absorbance values of that antisera against 
control DBL4ε domain. Then, capacity of recognition of + to +++++ was determined with an interval of 0.2 OD units. For instance, 3 SD values above the mean 
absorbance of anti-DBL13 antisera against control DBL4ε domain was 0.12. Therefore, all aborbance readings ˃ 0.12 were considered positive. Capacity of 
recognition for anti-DBL13 was as followed: +: ˃ 3 SD values above the mean of control (0.12) to OD values of 0.32, ++: OD values of 0.33 to OD values of 0.52, 
+++: OD values of 0.53 to OD values of 0.72, ++++: OD values of 0.73 to OD values of 0.92. +++++: ˃  OD values of 0.92. Capacity of recogition for the remaining 
sera were not stated for brevity.  
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2.3.2 Analysis of mouse antisera by Western blotting  
To further investigate the immunoreactivity of mouse antisera, recombinant 
DBLβ domains used in mouse immunisation and DBL4ε control domain were 
resolved on SDS-PAGE gels, transferred to PVDF membrane and probed with 
polyclonal immune sera, NMS control serum or primary monoclonal anti-
polyHistidine antibodies (Figure 2.6). All immune sera, except anti-DBL41 
antisera, strongly recognised their corresponding antigens, revealing a major 
band at the expected MW (45 to 46 kDa). Anti-DBL41 antisera exhibited faint 
bands at the range DBL domains MW with DBL27 and DBL31 and a very faint 
band with homologous domain at the same MW (Figure 2.6).   
Recombinant DBL13, DBL27 and DBL31 proteins were recognised not only by 
sera from mice immunised with the homologous proteins, but also by sera 
obtained from heterologous mouse groups. Recombinant DBL31 was similarly 
recognised by homologous sera as well as by anti-DBL13 and anti-DBL27 
antisera. Interestingly, anti-DBL13 mouse sera recognised DBL31 more 
specifically than its corresponding domain, which is inconsistent with the 
previous ELISA (Figure 2.3) that showed a homologous specificity of anti-
DBL13 antisera against corresponding domains. On the other hand, recombinant 
DBL41 only showed a strong band with anti-DBL13 antisera and faint band with 
homologous sera at the MW range of DBL domains. Beside the recognition of 
expressed domains, polyclonal sera also frequently recognised multiple bands of 
variable MWs, particularly a band of ~25 kDa which was recognised by all 
antisera. These bands are most likely breakdown products of recombinant 
proteins and bacterial contaminants and aggregates resulting from expression in 
E. coli.  
Recombinant DBL13, DBL27 and DBL31 proteins were recognised by anti-
polyHistidine antibodies at expected MW sizes of recombinant DBL proteins. 
On the contrary, rDBL41 only showed a very faint band at the same MW. The 
control DBL4ε was identified at a MW of 35-37 kDa with anti-polyhistdine 
antibodies. NMS at the same dilution did not react with recombinant domains. In 
addition, all antisera almost showed no reactivity with VAR2CSA-DBL4ε 
control domain.  
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Figure 2.6. Western Blotting analysis of mouse polyclonal antisera against immunising DBL 
proteins. Recombinant proteins (rDBL13, rDBL27, rDBL31, rDBL41 and rDBL4ε) at 5 µg/20µl 
concentration were reduced with DTT, blotted onto PVDV membrane and probed with 1:250 
dilution of mouse immune sera (anti-DBL13, anti-DBL27, anti-DBL31 and anti-DBL41), NMS 
or with HRP-conjugated anti-polyHistidine antibodies at 1:200 dilution. Primary antibody 
binding in blots A, B, C, D and F was detected by 1:500 diluted HRP-conjugated goat anti-
mouse IgG antibodies (Sigma). Recombinant DBL domains probed with anti-DBL13 mouse 
antisera (A), anti-DBL27 antisera (B), anti-DBL31 antisera (C) and anti-DBL41 anti-sera (D). A 
positive control blot of all proteins was probed with primary monoclonal anti-polyHistidine 
HRP-conjugated antibodies (E). An additional blot was probed with NMS and included as a 
negative control (F). VAR2CSA-DBL4ε recombinant protein was included as an internal 
negative control (lane 40). The molecular weight standard is indicated in kDa. 
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2.3.3 Analysis of mouse antisera by flow cytometry   
The ability of mouse serum IgG or IgM to recognise the surface of IEs was 
tested by flow cytometry using erythrocytes infected with homologous (GC503 
and 2F6) and heterologous P. falciparum strains (Table 2.5). In general, sera 
from mice immunised with rDBL13 domains were the most effective in labelling 
erythrocytes infected with homologous (GC503) and heterologous P. falciparum 
isolates (Figure 2.7, only showing labelling profile of anti-DBL13 antisera). On 
the contrary, there was little or no binding with sera raised to the remaining 
domains. DBL13-induced antibodies, principally of the IgM isotype, highly 
recognised erythrocytes infected with A4, C24, GC503, 2B2 and ItG. Anti-
DBL13 antisera also comprised IgG reactive antibodies; however, the capacity 
of surface recognition for IgG was significantly lower than IgM recognition 
(Figure 2.7).   
Mouse immune sera raised to DBL27 only labelled the surface of 2F6-IEs, a 
parasite isolate expected to express the homologous var27 gene. On the other 
hand, anti-DBL31 and -DBL41 mouse antisera only recognised the surface of 
outgrown A4-IEs, which expected to express a mixture of genes including var31 
variants. Parasite isolates that dominantly express var31 or var41 genes were not 
available for testing, therefore anti-DBL31 and -DBL41 mouse antisera were 
only tested with heterologous isolates. Labelling of non-IEs was observed 
mainly at low frequency, demonstrating the efficacy of the immunisation and 
specificity of reactive antibodies towards parasite-derived proteins on the surface 
of parasitized erythrocytes. NMS had not recognised the surface of IEs, 
indicating the absence of heterophilic antibodies that react with the surface of 
IEs. Taken together, these results indicate that immunised mice elicited 
antibodies, principally of the IgM isotype, capable of staining the surface of 
erythrocytes infected with homologous and heterologous DBL domains.  
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Figure 2.7. Reactivity of anti-DBL13 mouse antisera with the surface of erythrocytes infected by 
different P. falciparum isolates (A4, C24, GC503, 2B2 and ItG) as measured by flow cytometry. 
Labelling was detected using APC-conjugated goat anti-mouse IgM (µ) secondary antibody 
(Molecular probes®) for the detection of reactive IgM antibodies or with goat anti-mouse IgG 
(Fc)-APC conjugated (Thermo Scientific) for the detection of reactive IgG class antibodies. 
Population of IEs labelled with reactive IgM or IgG antibodies are shown in blue. Cells 
incubated with NMS at the same dilution and stained with ethidium bromide and secondary 
antibodies were included as a negative control and shown in red. Labelling of NMS was used to 
exclude background labelling, which was usually found at a range of 1-3% of IE population 
compared to erythrocytes incubated with secondary antibody alone (not shown). A labelling of ˃ 
10% of IE population was considered positive. Positive control includes the labelling of A4-
infected erythrocytes with mAb BC6 (20 µg/ml), which recognises an exposed epitope on 
PfEMP1 of A4-IE surface. Uninfected cells were shown to be negative with labelling IgG or 
IgM antibodies (not shown).  
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  IgM IgG 
Parasites Expected 
var gene 
Anti-
DBL13 
Anti-
DBL27 
Anti-
DBL31 
Anti-
DBL41 
Anti-
DBL13 
Anti-
DBL27 
Anti-
DBL31 
Anti-
DBL41 
A4 var14 +++ - - - + - - - 
C24 ND +++ - - - + - - - 
GC503 var13 +++/++ - - - + - - - 
2B2 var14 +++ - - - - - - - 
ItG var16 +++ -/+ -/+ -/+ + - - + 
2F6 var27 ++ +/++ - - + - - - 
A4 
(outgrown1) 
Mixed 
var genes 
+++ - ++ -/+ + - - - 
Table 2.5. Summary of FACS data for the reactivity of DBLβ domain-specific antisera with 
erythrocytes infected by different P. falciparum isolates. - (labelled IE population ≤ 10%), + 
(labelled IE population 10.1 to 20%), ++ (labelled IE population 20.1 to 40%), +++ (labelled IE 
population 40.1 to 60%). 1 Outgrown A4 was expected to express mixed var genes including 
var31. Results correspond to two experiments. ND: no data.  
 
 
2.4 Development and characterisation of mouse 
monoclonal and polyclonal anti-DBLβ antibodies 
We produced mAbs and pAbs by fusing splenocytes extracted from mice 
immunised with four recombinant DBLβ domains with SP2/0 myeloma cell line. 
Culture supernatants of the resulting hybridoma lines were screened with ELISA 
for reactivity against immunising DBL domains (data not shown). The assays 
also aimed to determine the immunological class of reactive antibodies present 
in culture supernatants. Some hybridoma clones that showed positive reactivity 
by ELISA have been cloned by limiting dilution to produce single clones that 
secrete antibodies with mono-specificity (mAbs), others have been tested in the 
study without limiting dilution (pAbs).  
Following preliminary screening, two ELISAs were carried out to detect IgG or 
IgM reactive antibodies in culture supernatants from hybridomas (Figures 2.8 
and 2.9, respectively). Screening ELISAs demonstrated that out of the initial 
panel of hybridoma clones (n= 17) that showed confluent growth post-fusion, 
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thirteen clones were found to contain reactive antibodies against immunising 
DBL domains (Table 2.6). Interestingly, all positive hybridoma clones only 
secreted reactive IgM antibodies, whereas none of the clones comprised IgG 
antibodies that recognise immunising domains. No pattern of homologous 
domain specificity was observed with hybridoma lines, as all clones exhibited 
variable levels of IgM reactivity with homologous and heterologous DBL 
domains. If a hybridoma clone was reactive with a particular recombinant 
protein, it cross-reacted with the other DBL domains. Table 2.7 summarises all 
hybridoma clones that reacted by ELISA, their specificity and immunising DBL 
domains. These mAbs and pAbs (n= 13) were selected for subsequent 
characterisation in our work.  
 
Figure 2.8. Investigating the presence of reactive IgG antibodies in hybridoma culture supernatants (n= 17) 
against rDBL proteins. 100 µl of rDBL13, rDBL27, rDBL31 and rDBL41 domains at 5 μg/ml in 0.1 M 
carbonate bicarbonate buffer were coated onto ELISA plates. Plates were blocked and washed as described 
in Materials and Methods, then incubated with 200 μl of hybridoma culture supernatants, culture media 
control (CM-CRL) or anti-DBL27 mouse antiserum at 1:500 dilution. Reactive IgG antibodies were 
detected with HRP-conjugated goat anti-mouse IgG antibodies (Sigma) at 1:500 dilution. Recognition was 
measured in terms of the magnitude of the response demonstrated as OD values and shown as the average 
of duplicate wells with SD values expressed as error bars. Incubation of CM-CRL with recombinant 
proteins was included in the assay as negative control, whereas anti-DBL27 mouse antiserum was used as a 
positive control previously shown to give a positive reactivity with all DBL proteins.  
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Figure 2.9. Investigating the presence of reactive IgM antibodies in hybridoma culture 
supernatants (n= 17) against rDBL proteins. 100 µl of rDBL13, rDBL27, rDBL31 and rDBL41 
domains at 5 μg/ml in 0.1 M carbonate bicarbonate buffer were coated onto ELISA plates. Plates 
were blocked and washed as described in Materials and Methods, then incubated with 200 μl of 
hybridoma culture supernatants, CM-CRL or anti-DBL27 mouse antiserum at 1:500 dilution. 
Reactive IgM antibodies were detected with 100 µl HRP-conjugated goat anti-mouse IgM 
(Southern Biotech®) at 1:500 dilution. Recognition was measured in terms of the magnitude of 
the response demonstrated as OD values and shown as the average of duplicate wells with SD 
values expressed as error bars. Incubation of CM-CRL with recombinant proteins was included 
in the assay as negative control, whereas anti-DBL27 mouse antiserum was used as a positive 
control previously shown to give a positive reactivity with all DBL proteins. 
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Hybridoma clone  
Immunising DBLβ domains (5 μg/ml) 
DBL13 DBL27 DBL31 DBL41 
E11 ++++ ++++ ++++ +++ 
B12 ++++ ++++ ++++ ++++ 
A6A ++++ ++++ ++++ ++++ 
H1A - - - - 
A5B - - - - 
A1B - - - - 
2A9 - - - - 
C2 + + + + 
E4 ++++ ++++ ++++ ++++ 
A4 ++++ +++ ++++ +++ 
E7 ++++ ++++ ++++ ++++ 
C9 +++ +++ +++ +++ 
2E10 ++++ +++ ++++ ++++ 
B5 + + + + 
D5 +++ +++ + +++ 
B4 ++ + ++ + 
G6 +++ +++ +++ ++ 
Table 2.6. IgM reactivity of monoclonal and polyclonal hybridoma clones against recombinant 
DBL domains used in mouse immunisations as measured by ELISA. + (OD value ˃ 0.2 above 
negative control), ++ (OD value ˃ 0.4 above negative control), +++ (OD value ˃ 0.6 above 
negative control) and ++++ (OD value ˃ 1.0 above negative control). 
 
 
Hybridoma 
clone 
DBL domain Antibody 
isotype 
Specificity Parent clone 
(if monoclonal) 
E11 DBL13 IgM Polyclonal - 
B12 DBL13 IgM Polyclonal - 
A6A DBL13 IgM Monoclonal C1 
C2 DBL31 IgM Polyclonal - 
E4 DBL31 IgM Polyclonal - 
A4 DBL31 IgM Polyclonal - 
E7 DBL31 IgM Monoclonal E4 
C9 DBL31 IgM Monoclonal E4 
2E10 DBL31 IgM Polyclonal - 
B5 DBL41 IgM Polyclonal - 
D5 DBL41 IgM Polyclonal - 
B4 DBL41 IgM Monoclonal B5 
G6 DBL41 IgM Monoclonal B5 
Table 2.7. Summary of reactive hybridoma clones raised against variant rDBL proteins. 
Hybridomas were generated from the fusion of myeloma cell lines with immunised mice 
splenocytes. Some of the antibody-secreting hybridoma clones have been cloned by limiting 
dilution to single clones (monoclonal specificity); others have been used in the study without 
limiting dilution (polyclonal specificity).  
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2.5 Affinity purification and characterisation of 
purified monoclonal and polyclonal antibodies  
A total of thirteen monoclonal and polyclonal hybridoma cell lines were found 
to secrete reactive IgM antibodies capable of recognising rDBL domains. 
Antibodies were affinity-purified from stable culture supernatants using manual 
gravity flow column chromatography. All eluted fractions resulted from the 
purification were screened by flow cytometry for their ability to recognise the 
surface of erythrocytes infected by ItG parasites, in order to select fraction(s) 
with the highest labelling capacity for further work. Table 2.8 only summarises 
the IgM surface reactivity of all eluted fractions to ItG-IEs, as none of the 
purified mAbs and pAbs comprised surface-reactive IgG antibodies (data not 
shown). Antibody fractions with the highest labelling capacity are shown in 
green and were selected for further analysis. A representative flow cytometry 
profile of surface labelling by pAb B12 eluted fractions is shown in Figure 2.10, 
which clearly demonstrated that fraction 1 comprised all reactive antibodies 
eluted from the purification.  
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Figure 2.10. Reactivity of all eluted fractions of pAb B12 with the surface of erythrocytes 
infected by ItG P. falciparum isolate as measured by flow cytometry. 50 µl of each eluted 
fraction at neat concentrations was incubated with trophozoite-IEs. Labelling was detected using 
APC-conjugated goat anti-mouse IgM secondary antibody (Southern Biotech®) at 1:100 dilution. 
Cells incubated with 20 μg/ml of mouse IgM isotype control from murine myeloma clone 
MOPC 104E (Sigma®) and stained with ethidium bromide and secondary antibodies were used 
to exclude background labelling and included as a negative control. Percentages of IEs labelled 
with reactive IgM antibodies of pAb B12 fractions are shown as APC-A+ subset and were 
obtained relative to a background of control IgM labelling. A labelling of ˃ 10% of IE 
population was considered positive.  
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mAbs/pAbs 
Eluted fractions 
1 2 3 4 5 6 7 
E11 ++ ++ ++ ++ + ++ + 
B12 ++/+ - - - - - - 
A6A - - - - - + ++ 
C2 - - - -  - - - 
E4 ++/+ ++/+ ++/+ - - + + 
A4 - - - - ++ - - 
E7 + ++ ++++ ++++ ++++ ++++ - 
C9 - - - +/- +/- - - 
2E10 - - - +/- +/- +/- - 
B5 - - - + ++ +++ ++ 
D5 + - + ++ + ++ ++ 
B4 - +++ +++ ++ + ++ ++++/+++ 
G6 - ++ ++ ++ +++ ++++ ++++ 
Table 2.8. The reactivity of all eluted fractions of mAbs and pAbs resulted from the affinity purification to 
the surface of ItG-IEs as measured by flow cytometry. Antibody fraction(s) selected for further 
characterisation is/are marked in green. Results of surface reactivity correspond to at least two experiments. 
- (labelled IE population ≤ 10%), + (labelled IE population 10.1 to 20%), ++ (labelled IE population 20.1 to 
40%), +++ (labelled IE population 41 to 60%), ++++ (labelled IE population ˃ 60.1%).  
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Then, an indirect ELISA assay was carried out to assess the efficiency of the 
purification by comparing the level of antibody reactivity for culture 
supernatants prior to purification, purified antibody yield and depleted flow-
through fluid resulted from the purification (Figure 2.11). Recombinant DBL31 
domain was used as a representative coating antigen in this assay. As expected, 
frequencies of recognition of the coated protein for all purified mAbs and pAbs 
were markedly higher than those of pre-purification culture supernatants or 
flow-through media, except purified pAb B12 which almost failed to recognise 
the coated antigen. This was surprising since pAb B12 exhibited positive IgM 
surface labelling with ItG-IEs. This suggests the presence of trivial amounts of 
surface-reactive IgM antibodies resolved from the purification and capable of 
labelling conformational epitopes by flow cytometry but failed to recognise the 
recombinant protein by ELISA. It should be noted that the overall reactivity of 
culture supernatants in this experiment is very low compared to that observed in 
Figure 2.9 and Table 2.6 (e.g. B12), and this inconsistency can be due to the use 
of culture supernatnats preserved for longer periods in sodium azide at 4°C in 
the present experiment, whereas freash supernatants colletced immediately after 
hybridoma culture were used in Figure 2.9.  
Another experiment was carried out to investigate the reactivity of mouse IgM 
antibodies against VAR2CSA-DBL4ε (Figure S1, Appendix). A representative 
pAb (A4) was used and the experiment was carried out following the same 
procedure as in Figure 2.11. The results showed that pAb A4 significantly 
recognised recombinant DBL31 protein but failed to react with DBL4ε.  
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Figure 2.11. Indirect ELISA for investigating the efficiency of affinity purification of mAbs and pAbs. The reactivity of purified antibody yield, culture supernatnat prior to 
purification and the resulted flow-through media were tested against recombinant DBL31 proteins (5 μg/ml). 50 μl purified mAbs/pAbs, 200 μl of hybridoma culture 
supernatants or flow-through fluid resulted from the purification were incubated with coated antigens. Reactive IgM antibodies were detected with 100 µl HRP-conjugated goat 
anti-mouse IgM (Southern Biotech®) at 1:500 dilution. Incubation of CM-CRL or 20 μg/ml of mouse IgM isotype control (Sigma®) with recombinant proteins were included in 
the assay as negative controls, whereas anti-DBL31 mouse serum (50 μl, 1:50 dilution) was used as a positive control. Recognition was measured in terms of the magnitude of 
the response demonstrated as OD values and shown as the average of duplicate wells with SD values expressed as error bars.  
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2.6 Measurement of IgM concentration in purified 
mAbs and pAbs  
A semi-quantitative Dot Blot assay was carried out to estimate the amount of 
IgM in purified mAbs and pAbs (Figure 2.12). IgM concentration in eluted 
fractions was estimated by comparison to a mouse IgM control standard also 
spotted onto nitrocellulose membranes. Immunoblotting analysis confirmed the 
presence of mouse IgM antibodies in purified mAbs and pAbs at a range of 10-
80 μg/ml for most fractions. Fraction 1 of pAb B12 showed a very faint dot 
although it labelled the surface of IEs as shown in Figure 2.10. This can be 
explained by the presence of finite amounts of highly specific IgM antibodies in 
the purified yield that could produce a positive signal for surface labelling but 
failed to be detected in the semi-quantitative Dot Blot.  
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Figure 2.12. Dot Blot assay for estimating the concentration of IgM antibodies in purified mAbs 
and pAbs. 5 μl of all eluted fractions was spotted onto Whatman® Protran® Nitrocellulose 
membrane. Gradual concentrations (200 μg/ml - 0.2 μg/ml) of mouse IgM isotype control 
(Sigma®) were also blotted onto the membrane as a standard for determining the concentration of 
purified antibodies. Control IgM dilutions were carried out in neutralised glycine/Trizma-HCL 
pH 7.0 buffer solution, the same buffer for eluted mouse IgMs. The membrane was blocked and 
washed as described in Materials and Methods. IgM reactivity was detected with HRP-
conjugated goat anti-mouse IgM (Southern Biotech®) at 1:500 dilution. 5 µl of complete medium 
(CM) or mAb BC6 at 20 µg/ml were spotted and used as negative controls.  
 
 
Then, IgM antibodies in affinity-purified yields were quantified using the 
indirect double-antibody sandwich ELISA. In this ELISA, the heavy chain of 
mouse IgM antibodies was captured by unlabelled heavy chain-specific anti-
mouse IgM before the complex was detected with HRP-conjugated goat anti-
CM 
BC6 
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mouse IgM antibodies. The unknown IgM concentration was calculated with 
regard to a standard curve based on known concentration and absorbance values 
derived from the mouse IgM control (Figure 2.13). We found that quantitated 
IgM concentration in purified yields varied from 0.1 to 66.3 µg/ml. Table 2.9 
summarises the concentration of IgM antibodies in all purified mAbs and pAbs 
selected for the study. Quantitation of pAb B12 confirms previous ELISA 
(Figure 2.11) and Dot Blot (Figure 2.12). 
 
 
 
Figure 2.13. Slope of a standard dilution curve generated from gradual concentrations of 
commercially provided mouse IgM control as indicated by double-antibody sandwich ELISA. 
Briefly, unlabelled µ-chain specific rat anti-mouse IgM (Southern Biotech®) at 5 µg/ml in 0.1 M 
carbonate bicarbonate buffer was coated onto the plate. The plate was blocked and washed as 
described previously, before mAbs/pAbs were added at 1:100 dilution. Mouse IgM isotype 
control (Sigma®) was diluted by doubling dilution into gradual concentrations (4000-0.12 ng/ml) 
and added to the plate. Reactive IgM antibodies were detected with 100 µl HRP-conjugated goat 
anti-mouse IgM (Southern Biotech®) at 1:500 dilution. Incubation of CM-CRL or 20 μg/ml of 
BC6 mAb (IgG class antibodies) with coated antibody were included in the assay as negative 
controls. The unknown concentration of IgM in purified mAbs and pAbs was obtained with 
regard to a standard curve of known concentration and absorbance values using the excel 
function =TREND (all concentration values of standard, [all absorbance values of standard], 
[absorbance of unknown concentrtion], [constant]).  
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IgM control (standard) Purified mAbs and pAbs 
Concentration 
(ng/ml) 
Absorbance at 
450 nm (OD 
values) 
Antibody 
Fraction 
Absorbance at 
450 nm (OD 
values)  
Concentration 
(µg/ml) 
4000 1.03965 E11 fr4 0.7558 16.9 
2000 0.9702 B12 fr1 0.09775 0.1 
1000 0.96245 A6A fr7 0.78835 29.5 
500 0.8773 C2 fr4 0.8472 43 
250 0.76905 E4 fr3 0.63935 8 
125 0.7486 A4 fr5 0.88855 56.6 
62.5 0.59785 E7 fr3 0.88925 57 
31.25 0.46765 C9 fr5 0.7158 11.1 
15.6 0.3787 2E10 fr6 0.67825 9.6 
7.8 0.2881 B5 fr6 0.8926 59 
3.9 0.1855 D5 fr7 0.7966 31.4 
1.95 0.1414 B4 fr3 0.78945 29.7 
0.97 0.1073 G6 fr7 0.90512 66.3 
0.49 0.0752 A6A fr6 0.77125 25.5 
0.24 0.06555 C2 fr5 0.80775 33.9 
0.12 0.0686 A4 fr6 0.6626 8.9 
  E7 fr4 0.8771 49.9 
  B5 fr5 0.84735 43.1 
  B4 fr4 0.76615 23.2 
  G6 fr3 0.7527 15 
  Pool 1 0.88 14 
  Pool 2 0.7511 51.6 
  CM 0.05 0.01 
  BC6 0.05 0.01 
Table 2.9. Summary of the final IgM concentration of purified mAbs and as measured by 
double-antibody sandwich ELISA. Pool 1: a pool of pAb E11, pAb B12, mAb A6A and pAb E4 
of equal volumes was prepared and quantitated for further investigations. Pool 2: mAb E7, pAb 
B4, pAb D5 and mAb G6 was prepared for the same purpose. Fr: fraction.  
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2.7 Discussion 
Sequestration of IEs to endothelial cells lining the post-capillary venules of 
various host organs is a distinctive feature in the virulence of P. falciparum 
infection (Cooke et al., 1995, Pasloske and Howard, 1994). Among host 
endothelial ligands that mediate cytoadhesion, ICAM-1 was linked to severe 
forms of malaria diseases, including CM (Newbold et al., 1997, Turner et al., 
1994). PfEMP1 is a major parasite-derived protein ligand exported to the surface 
of IEs and is associated with the adhesion of IEs to host endothelium (Cooke et 
al., 1995). Early studies have revealed that the binding domain of ICAM-1 
receptors on the parasite PfEMP-1 ligand has been mapped and located within 
two domains; DBLβ2 and C2 (Smith et al., 2000a) which termed DBLβ in this 
work as C2 domain is basically a part of the main DBLβ domain (Gullingsrud et 
al., 2013).  
MAbs and pAbs directed against various PfEMP1 domains have been suggested 
as valuable tools for recognising critical functional sites on PfEMP1 involved in 
parasite adhesion and determining the cross-reactivity with parasite strains from 
irrelevant regions (Lekana Douki et al., 2002). However, it remains unknown 
whether DBLβ domains from PfEMP1 of ICAM-1 binding isolates can induce 
functional and cross-reactive antibodies that are effective in blocking parasite 
adhesion to ICAM-1. In the present study, we selected four recombinant 
PfEMP1ICAM-1-DBLβ domains that were expressed as hexahistidine-tagged 
proteins in E. coli and shown to bind ICAM-1 proteins (Kraemer et al., 2007, 
Howell et al., 2008) for mouse immunisations. DBLβ domains were used rather 
than the full-length PfEMP1 protein to map the minimal receptor-binding 
regions for ICAM-1 binding isolates and to understand the functional 
requirements for receptor adhesion. In addition, if we had used the full-length 
PfEMP1 domains we may not be able to recover any relevant anti-DBLβ mAbs. 
We present evidence that it is possible to elicit mAbs and pAbs in mice by 
immunisation with single recombinant DBLβ domains from PfEMP1ICAM-1 
variants of the IT4 genome. MAbs and pAbs comprising reactive antibodies 
recognised homologous and heterologous DBLβ domains and labelled the 
surface of erythrocytes infected by P. falciparum isolates. To our knowledge, 
this is the first study to examine the use of PfEMP1ICAM-1-DBLβ domains for the 
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development of mAbs and pAbs that block parasite adhesion to immobilised 
ICAM-1/CD36 receptors or endothelial cell lines, although the same technique 
was used for several other domains and interactions.  
Stimulation of an efficient humoral immune response in mice is crucial for the 
production of mAbs against specific antigens (Fuller et al., 1992). In our study, 
mice were immunised with recombinant domains complexed with either FCA or 
Alum as adjuvants, to increase the probability of a good response towards the 
immunising antigens and to compare the efficiency of both boosting adjuvants. 
Unfortunately, the former adjuvant failed to elicit reactive mouse antibodies and 
all reactive mAbs and pAbs were generated using Alum adjuvant. The failure of 
FCA to induce a specific immune response was surprising since this adjuvant 
has been proven to elicit antibodies with malarial proteins. For instance, Barfod 
et al. (2006) used both Freund's incomplete/complete adjuvant and aluminium 
hydroxide gel for mice immunisation with recombinant VAR2CSA domains and 
found that both adjuvants induced surface-reactive antibodies and no difference 
was observed in eliciting sera with both adjuvant systems. In addition, 
Fernandez et al. (2010) provided evidence that immunisation of mice with single 
DBL domains from VAR2CSA using alum as an adjuvant has induced an 
antibody response that efficiently blocked parasite adhesion to CSA. Since the 
same immunogens were used in both immunisations, we suggest that the 
response was either lost during immunisation or not induced at all, due to failure 
in antigen delivery to FCA-stimulated mice or suboptimal dose that was 
insufficient for inducing an immune response. Failure in the induction of 
antigen-specific immune response with FCA was observed in previous studies. 
For example, a recent study showed that a previously induced inhibitory 
response in immunised rat sera towards specific DBL domains was not 
reproducible in subsequent immunisations (Salanti et al., 2010). The authors 
suggested that different immunisations with the same antigen did not give the 
same fine specificity in each immunisation, as shown by variation in the 
inhibitory response of induced antibodies.  
After mouse immunisation, sera were screened for the presence of reactive 
antibodies that recognise the recombinant immunising domains by ELISA or the 
surface of live IEs by flow cytometry. Indirect primary and checkerboard 
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ELISAs showed that mouse antisera raised to all recombinant domains, except 
DBL41, had higher IgG titres against corresponding immunising antigens. Anti-
rDBL41 antiserum failed to recognise its own domain but cross-reacted with 
heterologous antigens. Moreover, all antisera exhibited variable degrees of 
cross-reactivity with the other heterologous DBL domains but almost failed to 
recognise rDBL41 antigen. These results are consistent with Western Blotting 
data and suggest that rDBL41 used in our work either has not been correctly 
expressed and purified, or has been degraded during expression or after 
purification. In general, poor success of a given antigen in eliciting an adequate 
immune response can be attributed to several factors including unsuitably 
prepared emulsion when using the adjuvant, site of immunisation, dose of the 
immunogen and frequency of immunisation (Fuller et al., 1992). The ability of 
anti-DBL41 antisera to recognise heterologous but not homologous domains as 
shown by ELISA, together with the cross-reactivity of all immune sera against 
all domains except DBL41, strongly suggest that the immunogen has been 
fragmented after mouse immunisation. Alternatively, these data can also suggest 
that the recombinant protein has been degraded prior to immunisation causing 
the loss of critical and functional epitopes on the native protein or that the mouse 
response was targeting a discontinuous section on a conformational epitope in 
the structure of DBL41. 
Protein expression in E. coli is simple, fast, and cheap with expressed proteins 
comprising up to 50% of the cellular protein composition (Francis and Page, 
2010). In addition, E. coli proteins are not glycosylated similar to the native 
malaria proteins (Oleinikov et al., 2008). These are some of the advantages that 
made E. coli the expression system of choice for malarial proteins in many labs 
with more than 30 P. falciparum proteins in the Protein Data Bank having been 
successfully expressed in E. coli (Mehlin et al., 2006). However, the rapid rate 
of bacterial protein expression often results in issues with protein folding, 
including the production of misfolded or unfolded proteins, especially for 
heterologous proteins that require long periods of time to fold correctly (Francis 
and Page, 2010). In the case of malarial proteins, soluble expression in E. coli is 
a challenging task that may lead to lack of expressed proteins or in expression of 
proteins as insoluble inclusion bodies (Mehlin et al., 2006). These obstacles may 
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explain the existence of multiple bands of variable MWs in the immunoblots, as 
bacterial proteins may have been co-purified with the histidine tagged 
recombinant proteins, which is commonly encountered during expression in E. 
coli (Graslund et al., 2008). 
One of the broadly used methods for detecting the presence of reactive 
antibodies against malaria-derived surface antigens is fluorescence-activated cell 
sorting (FACS) analysis. Our FACS data indicated that mouse immune sera only 
labelled the surface of IEs but mainly not non-IEs, confirming that binding was 
specific for P. falciparum-derived VSAs exported to the surface of live IEs. We 
found that antisera raised to DBL27, DBL31 and DBL41 only comprised IgM 
antibodies that showed variable reactivities with ItG and outgrown A4 isolates, 
but almost none of these sera contained reactive IgGs. This is the opposite to that 
found in ELISA, as mouse antisera comprised more reactive IgG response 
whereas the IgM response was generally weak (Figure 2.4; Table 2.3). This 
could be due to the higher avidity of IgM molecules that comprise multiple 
antigen binding sites binding to VSAs on the surface of IEs compared to only 
two binding sites for IgG antibodies. The latter has higher affinity for binding to 
linear epitopes in ELISA and their interaction could not be disrupted by 
subsequent washing, contrary to the low affinity binding of IgM antibodies. 
Among all mouse sera, DBL13-specific antiserum comprised cross-reactive IgM 
antibodies that labelled the surface of erythrocytes infected by homologous and 
heterologous isolates. These results indicate that immunised mice elicited 
antibodies, principally of the IgM isotype, capable of staining the surface of 
erythrocytes infected with homologous and heterologous parasite isolates. Of 
particular significance, cross-reactivity with heterologous isolates suggest that 
induced antibodies recognised surface-exposed epitopes on the surface of IEs 
that are shared between tested parasite isolates. However, it is unresolved 
whether these sera were cross-reactive to conserved epitopes on the surface of 
IEs or alternatively they contain a mixture of antibodies of multiple specificities. 
Although surface-labelling was only specific for IEs, we could not confirm that 
the surface protein recognised by antisera was DBLβ or another variant epitope 
in the native PfEMP1, since several immunogenic VSAs co-express with 
PfEMP1 on the parasitized cell surface and can act as antibody binding ligands.  
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In the present study, we identified thirteen hybridoma clones that secrete 
reactive IgM antibodies against DBL13, DBL31 and DBL41 domains. MAbs 
and pAbs not only recognised their corresponding antigens, but also efficiently 
cross-reacted with heterologous domains with a similar capacity of recognition. 
Interestingly, mouse IgM antibodies effectively reacted with rDBL41 domains, 
which was weakly recognised by mouse immune sera. Although mouse antisera 
comprised IgG antibodies that showed a significant reactivity with recombinant 
domains over IgM-class antibodies, we believe that only the small subpopulation 
of IgM-secreting cells were selectively expressed and amplified after fusion. 
Failure to produce anti-DBL27 reactive mAbs and pAbs may indicate that 
antibody-secreting spleen cells were lost during fusion. This cannot be attributed 
to failure in antigen delivery during immunisation or protein degradation, since 
anti-DBL27 antisera showed positive reactivity against recombinant domains 
and recognised the surface of erythrocytes infected by homologous isolates.  
The higher level of cross-reactivity observed in ELISA may propose that all 
recombinant domains share conserved immunogenic epitopes, despite their 
lower level of sequence identity (46%), that were easily recognisable and 
accessible to IgM antibodies. This cross-reactivity could also be explained by 
the presence of bacterial contaminants that were co-purified with histidine 
tagged recombinant proteins. These contaminants include multiple histidine 
residues and molecular chaperones that bind to recombinant proteins during 
expression (Graslund et al., 2008) and may be more immunogenic than the 
desired antigen to produce an antibody response at lower specificity (Fuller et 
al., 1992).  
All hybridoma culture supernatants were tested for their ability to recognise the 
surface of P. falciparum-IEs by FACS and none of the clones demonstrated IgG-
specific surface labelling (data not shown). Therefore, only IgM antibodies in 
hybridoma culture supernatants were affinity-purified using high liquid 
performance chromatography (HPLC) to obtain a concentrated yield of pure 
IgMs. However, the reactivity of eluted antibodies yielded from the automated 
system was very low when measured by flow cytometry (data not shown) and 
therefore the purification was repeated using manual gravity flow. All IgM 
antibodies resulting from gravity flow purification, except pAb B12, were highly 
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effecient at recognising immunising domains and labelling the surface of IEs, 
and were therefore used in all subsequent in vitro characterisations. The amount 
of IgM in purified yields was firstly estimated semi-quantitatively by dot blot 
and the precise IgM concentration was measured with indirect double-antibody 
sandwich ELISA. This method is simple, sensitive and reliable for quantification 
of mouse IgM antibodies in purified yields obtained from cell culture 
supernatants by comparison with a standard curve produced by a purified mAb 
of the same class (Mushens et al., 1993). NanoDrop UV spectrophotometer was 
also used for IgM quantitation. However, this method was unreliable due to the 
frequent discrepancies obtained in repeated quantitation most likely due to the 
presence of glycine in the elution buffer.  
All eluted fractions were tested for surface fluorescence with live IEs and the 
most reactive fraction was used to confirm the efficiency of the purification by 
ELISA. Purified IgM antibodies were used in flow cytometry at concentrations 
ranging from 0.1-66.3 µg/ml, as the signal was markedly reduced at 1:2 dilution 
and almost lost at further dilutions (discussed in Chapter 3). The lack of IgG 
reactive antibodies in purified mAbs and pAbs, as indicated by ELISA and flow 
cytometry, was consistent with flow cytometry data showing higher surface 
labelling of IgM-class antibodies for mouse antisera.  
An interesting finding in our study was that all positive hybridoma clones only 
secreted reactive IgM antibodies, and none of the clones comprised reactive IgG 
antibodies despite the higher IgG titre of mouse antisera. This was also 
encountered in several published studies revealing the production of reactive 
mouse mAbs of the IgM isotype. For instance, Lekana Douki et al. (2002) 
elicited mAbs in mice against the DBL-γ3CSA of the FCR3 strain. The produced 
mAbs, of which 70.8% were IgMs, labelled the surface of IEsCSA and cross-
reacted with CSA-binding parasites from different geographic areas. In another 
study, 250 mAbs were produced by immunising mice with var2CSA (FCR3CSA) 
and 240 mAbs (96%) were of the IgM isotype that recognised IECSA (Avril et al., 
2006).   
Adjuvants containing aluminium were first discovered in 1926 and currently are 
the most broadly used in vaccine preparations since they are known to induce a 
robust immune response. Within hours of Alum administration, innate 
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inflammatory cells such as neutrophils, eosinophils, dendritic cells and 
monocytes are recruited at the site of exposure (Marrack et al., 2009). However, 
a recent study provided evidence that ~80% of the induced cells following Alum 
injection are eosinophils (Wang and Weller, 2008). The study showed that 
administration of Alum leads to activation of IL-4-expressing eosinophils that 
prime splenic B cell responses leading to early generation of antigen specific 
IgM (Wang and Weller, 2008). This function of early priming (within the first 
week of administration) of IgM synthesis by Alum may explain why all of the 
reactive mouse antibodies induced in our work were of the IgM class.  
Attempts for developing mouse monoclonal antibodies that target the native and 
conformational epitopes on the surface of IEs have occasionally been successful 
due to the presence of large amounts of immunodominant parasite-derived 
VSAs. These surface antigens can elicit a strong immune response in immunised 
mice leading to difficulties in the induction of a specific response to desired 
antigens with a relatively weaker immunogenicity or conformational surface 
epitopes. Only a few number of mAbs directed against parasite-derived surface 
antigens on the parasitized erythrocytes surface have been published. In 
summary, we showed that the mouse immunisation protocol carried out in this 
work was successful in the production of mAbs and pAbs against recombinant 
PfEMP1ICAM-1-DBLβ domains. These mouse mAbs and pAbs comprised 
reactive IgM antibodies that recognised the corresponding DBL domains and 
cross-reacted with heterologous domains. In addition, most of these IgM 
antibodies labelled the surface of live erythrocytes infected by ItG P. falciparum 
isolate. Further work is required to investigate the capacity of these antibodies to 
recognise the surface of erythrocytes infected by phenotypically and 
genotypically distinct parasite isolates, and to dissect their functional role in 
blocking the adhesion of IEs to immobilised receptors or endothelial cells.   
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2.8 Future work  
The biophysical properties of the interactions between IgM antibodies and 
DBLβ domains can be investigated using Surface Plasmon Resonance (SPR) to 
obtain kinetic parameters for the IgM-DBLβ interaction. In addition, an epitope 
mapping assay can be carried out to assess the differences in the fine specificity 
of IgM binding to an array of different PfEMP1 peptides, compared to binding 
of control IgM antibodies. This can provide additional details about the PfEMP1 
domains, if any, involved in interaction with IgM antibodies. To further 
determine whether the high-molecular weight PfEMP1 proteins are the targets of 
mouse anti-sera and labelling mAbs/pAbs, these antibodies can be assessed for 
their capacity to immunoprecipitate 125I-labelled SDS-stage IE extracts [similar 
assays described by (Buffet et al., 1999, Avril et al., 2006)].  
Many malaria vaccine studies have used rodent models to study the 
immunogenicity of particular malaria antigens. Although this approach has the 
advantages of being easily accessible and reasonably priced, it has significant 
limitations. Malaria isolates that infect humans cannot infect mice and those 
infecting mice lack several critical antigens of P. falciparum strains. In addition, 
there are significant differences between humans and mice in terms on the 
immune and pathogenic response to malaria infection (Richards and Beeson, 
2009). These variations have provided a groundwork for the development of 
alternative approaches for ''humanising'' mouse mAbs and pAbs that can be used 
in humans.  
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Chapter 3 
 
Characterisation of infected erythrocyte-
surface labelling by monoclonal and 
polyclonal antibodies  
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Chapter 3: Introduction 
Antibodies to the polymorphic VSAs on the surface of P. falciparum infected 
erythrocytes, particularly PfEMP1, have been shown to play a crucial role in the 
acquisition of protective immunity against severe malaria (Giha et al., 2000, 
Marsh et al., 1989, Bull et al., 1998). An important step in the development of 
therapeutic interventions based on PfEMP1 is the identification of functional 
critical ligands of PfEMP1 proteins involved in parasite cytoadhesion, and the 
investigation of the level of cross-reactivity of these variants with diverse 
parasite strains. MAbs generated against different domains of PfEMP1 could be 
a tool of choice (Lekana Douki et al., 2002). However, despite the extensive 
work to develop mouse mAbs against the native and conformational parasite-
derived antigens, only few attempts were successful (discussed in Introduction 
chapter). This failure to produce specific mAbs was suggested to be due to the 
large number of parasite-derived immunogenic proteins on the surface of IEs, 
which makes it extremely difficult to elicit specific immune response to weekly 
immunogenic surface molecules or conformational epitopes (Lekana Douki et 
al., 2002). 
In this chapter, we used diverse functional assays to characterise the functional 
properties of mouse mAbs and pAbs. P. falciparum isolates of multiple 
phenotypes expressing variant PfEMP1 molecules were tested for surface 
staining. We aimed to assess the degree of specificity and/or cross-reactivity of 
mAbs and pAbs by evaluating their relative abilities to recognise the surface of 
erythrocytes infected by ICAM-1 binding and non-binding isolates from the IT4 
genome, or with P. falciparum isolates from distinct genomes. This was 
challenging since analysis of the surface phenotypes of P. falciparum IEs is 
difficult due to the rapid expression of antigenic and adhesive heterogeneity, 
even in clonal parasite cultures (Gardner et al. 1996). Our results showed that 
mAbs and pAbs specifically recognised the surface of erythrocytes infected by 
homologous and heterologous parasite isolates. We demonstrated that mouse 
antibodies exhibited extensive cross-reactivity against parasite isolates with 
distinct binding properties and genomes. We also provided evidence that mAbs 
and pAbs may partially bind to PfEMP1 on the surface of IEs.  
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3. Materials and Methods 
3.1 Measurement of mouse IgM labelling to the surface 
P. falciparum-IEs by flow cytometry 
MAbs and pAbs were tested for surface reactivity with erythrocytes infected by 
P. falciparum isolates of distinct phenotypes and genotypes. All assays were 
carried out principally as described in Chapter 2 (sections 2.4.2.1 and 2.7) with 
some adjustments. Briefly, aliquots of parasite suspension (100 µl, ~2.5-3 × 106 
cells) were washed in PBS/1%BSA and the pellet was re-suspended with 50 µl 
of each mAb/pAb at 0.1-66 µg/ml and incubated for 30 minutes at 37°C. 
In a separate assay, cells were incubated with mouse IgM antibodies at gradual 
dilutions (1:2, 1:4 and 1:8) in PBS/1%BSA to determine the least concentration 
required for labelling the surface of IEs. All subsequent washings and secondary 
antibody incubations were carried out as shown in section 2.7. Cells incubated 
with 20 μg/ml of mouse IgM isotype control (Sigma®, M5909, 200 μg/ml) and 
stained with ethidium bromide and secondary antibodies were used to exclude 
background labelling and included in all assays as a negative control. Labelling 
of ˃ 10% of IE population was considered positive. The cut-off value of 10% for 
considering positive labelling was determined after several optimization 
experiments showing that although the background labelling of non-IEs was 
ranged between 1 and 9% for most mAbs/pAbs, higher percentages of 
background labelling were frequently observed. Therefore, we believe it would 
be acceptable to set the positive labelling at ˃ 10% of IE population. Data 
analysis and grading of surface binding were performed as described in section 
2.4.2.2. Differences in the binding capacity of mAbs and pAbs against different 
isolates were confirmed in repeat experiments. 
Due to the high percentage of lysed IEs following mouse mAbs/pAbs 
incubation, assay conditions for testing the surface fluorescence by flow 
cytometry were optimised to retain a number of IEs sufficient for detecting 
surface labelling without diluting the binding signal. The number of trophozoite-
enriched cells for detecting surface binding of non-lysing antibodies was 0.8-1.0 
× 107 cells/ml from which 100 µl was used for the assay (0.8-1.0 × 106 cells). 
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However, the number of cells was increased to 2.5-3 × 106 cells for detecting the 
binding mAbs and pAbs which caused the lysis of many IEs. Incubation time for 
mAbs/pAbs was also reduced to 30 minutes, which had no effect on the signal 
but decreased the amount of lysed cells (data not shown). Despite the remarkable 
decrease in IE count upon IgM incubation, surface fluorescence was not 
significantly affected, since 50,000 events were collected for almost all tested 
antibodies.  
 
3.2 Competition assays 
3.2.1 Competition between mouse IgMs and BC6 for surface 
binding to A4-IEs  
The assay was carried out to investigate the effect of pre-incubating A4-IEs with 
mAb/pAbs on the subsequent binding of the BC6 mAb (20 µg/ml) and vice 
versa. BC6 is a mouse monoclonal IgG antibody that specifically recognises an 
exposed epitope on PfEMP1 of erythrocytes infected by A4 P. falciparum 
isolate (Roberts et al., 1992, Horrocks et al., 2002). Two pools of mouse IgMs 
that showed positive surface labelling were used in the competition assays 
including pool 1 (pAb E11, pAb B12, mAb A6A and pAb E4) and pool 2 (mAb 
E7, pAb B4, pAb D5, mAb G6). For investigating the effect of mouse IgM 
antibodies on BC6 binding, 50 µl of mouse antibodies (pool 1, pool 2) were pre-
incubated with IEs for 30 minutes at 37°C, before the washing twice in 
PBS/1%BSA and incubation with 50 µl of mAb BC6 (20 µg/ml) for 30 minutes 
at 37°C. Cells were washed as above and BC6 labelling detected with 100 µl of 
goat anti-mouse IgG (Fc)-APC conjugated (Thermo Scientific, Product No. 
31981) at 1:100 dilution. Cells were analysed for surface labelling using 
FACSCalibur flow cytometer and data were analysed as described in section 
2.4.2.2. The effect of BC6 on subsequent binding by the mAb/pAb pools was 
assessed following the same procedure, but incubating with mAb BC6 first. 
Cells were then washed and incubated with mouse IgM antibodies and bound 
IgM detected with 100 µl of APC-conjugated goat anti-mouse IgM (µ chain 
specific) secondary antibody (Southern Biotech®, Cat. No. 1020-11L, 0.5mg) 
also at 1:100 dilution. Table 3.1 indicates the order of the first and second 
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antibody incubations, as well as the aim of each experiment and secondary 
antibodies used for detecting surface binding.  
Competition was assessed in terms of differences in surface labelling of 
antibodies before and after incubation with the competitor. The percentage of 
reduction in surface labelling to IEs were quantitated following the formula: 
 
 𝑥 = 100 − [( 
𝑎 
𝑏 
 ) × 100] 
 
Where, x = the percentage of reduction in surface labelling  
a = percentage of labelled IEs after incubation with the competitor 
b = percentage of labelled IEs without incubation with the competitor (positive 
control) 
 
3.2.2 Competition between IgM mAbs and pAbs and HIS for 
surface binding to A4-IEs  
The assay was performed to examine the effect of pre-incubating A4-IEs with 
mouse IgMs on the subsequent binding of Malawian hyper immune serum (HIS) 
and vice versa. The same procedure was carried out as in the previous section 
(3.2.1), except that HIS was used in all incubations at 30 mg/ml (Table 3.1). 
Antibody pools (pool 1 and pool 2) were used as in section 3.2.1. Binding of 
HIS was detected with APC-conjugated mouse anti-human IgG-Fc secondary 
antibody (Southern Biotech®, Cat. No. 9042-11) at 1:100 dilution, whereas 
mouse IgM binding was detected as previously (section 3.2.1). Cells stained 
with 50 µl of non-immune sera from UK adults at 1:10 dilution were included as 
a negative control for HIS.  
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3.2.3 Competition between IgM mAbs and pAbs and rat anti-
DBL16 antisera for surface binding to ItG-IEs  
This assay was carried out to investigate the influence of pre-incubating ItG-IEs 
with mouse IgMs on the subsequent binding of rat anti-DBL16 antisera and vice 
versa. The same procedure was carried out as in section (3.2.1), except that rat 
anti-DBL16 antisera were used in all incubations at 1:10 dilution (Table 3.1). 
Similar to the previous section, only antibody pools (pool 1 and pool 2) were 
used in this assay. Binding of rat antisera was detected with APC-conjugated 
goat anti-rat IgG (H+L) secondary antibody (Life Technologies, Cat. No. 
A10540) at 1:100 dilution, whereas binding of mAbs and pAbs was detected as 
specified previously (section 3.2.1).  
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Assay Aim of the assay First antibody  Second 
antibody  
Secondary detecting antibody  
Competition 
between mouse 
IgMs and BC6 for 
surface binding to 
A4-IEs 
Investigating the effect of BC6 on mouse IgMs binding  BC6   Mouse IgMs Goat anti-mouse IgM-APC + Eth. br 
Investigating the effect of mouse IgMs on BC6 binding  Mouse IgMs BC6   Goat anti-mouse IgG-APC + Eth. br 
BC6 positive control  BC6 - Goat anti-mouse IgG-APC + Eth. br 
Mouse IgMs positive control  Mouse IgMs - Goat anti-mouse IgM-APC + Eth. br 
Negative control for BC6 - - Goat anti-mouse IgG-APC + Eth. br 
Negative control for mouse IgMs Isotype IgM CRL  Goat anti-mouse IgM-APC + Eth. br 
Competition 
between mouse 
IgMs and HIS for 
surface binding to 
A4-IEs 
Investigating the effect of HIS on mouse IgMs binding  HIS   Mouse IgMs Goat anti-mouse IgM-APC + Eth. br 
Investigating the effect of mouse IgMs on HIS binding  Mouse IgMs HIS   Mouse anti-human IgG-APC + Eth. br 
HIS positive control  HIS - Mouse anti-human IgG-APC + Eth. br 
Mouse IgMs positive control  Mouse IgMs - Goat anti-mouse IgM-APC + Eth. br 
Negative control for HIS Non-immune UK sera  - Goat anti-mouse IgG-APC + Eth. br 
Negative control for mouse IgMs Isotype IgM CRL - Goat anti-mouse IgM-APC + Eth. br 
Competition 
between mouse 
IgMs and rat anti-
DBL16 antisera for 
binding to A4-IEs 
Investigating the effect of antisera on mouse IgMs 
binding  
Rat antisera    Mouse IgMs Goat anti-mouse IgM-APC + Eth. br 
Investigating the effect of mouse IgMs on antisera 
binding  
Mouse IgMs Rat antisera  Goat anti-rat IgG-APC + Eth. br 
Rat antisera positive control  Rat antisera  - Goat anti-rat IgG-APC + Eth. br 
Mouse IgMs positive control  Mouse IgMs - Goat anti-mouse IgM-APC + Eth. br 
Negative control for rat antisera  - - Goat anti-rat IgG-APC + Eth. br 
Negative control for mouse IgMs Isotype IgM CRL - Goat anti-mouse IgM-APC + Eth. br 
Table 3.1. Summary of primary and secondary antibody incubations for all competition assays. Eth. Br.: ethidium bromide. CRL: control.   
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3.3 Binding of antibodies to trypsin-treated IEs 
The effect of protease treatment on IE surface binding to mouse IgM was 
investigated to determine if binding epitopes on the surface of IEs are affected 
after trypsin treatment. Mature pigmented trophozoites at mid-late stage were 
enriched from cultures at ~3-8% parasitaemia and a HCT of 1-2%, using 
plasmagel floatation. Enriched cells were washed twice in PBS and incubated 
with 1 mg/ml, 100 µg/ml, 10 µg/ml or 1 µg/ml of tosylamido-2-phenylalanyl 
chloromethyl ketone (TPCK)-trypsin (Sigma®, product No. T1426, 10 mg/ml) in 
PBS for 30 minutes at 37°C. Control, undigested samples were incubated with 
PBS and assayed in parallel with test samples. After incubation, trypsin activity 
was inhibited by incubating cells with an equivalent volume of soybean trypsin 
inhibitor at 1 mg/ml (Sigma®, T6414, Lot No. SLBF3888V) for 15 minutes at 
37°C. An additional tube including trypsin-undigested cells was incubated with 
soybean inhibitor and assayed as a negative control. Cells were thoroughly 
washed (×2) to remove excess trypsin and/or soybean inhibitor and re-suspended 
in PBS. 100 µl of suspended cells (~1.0-2.5 × 106 cells) were then incubated 
with mouse IgMs and binding investigated by flow cytometry as previously 
(section 2.4.2.2). The same procedure was used to investigate the effect of 
trypsin digestion on BC6 (20 µg/ml) or HIS (30 mg/ml) binding with some 
minor modifications including secondary antibodies used for detection (see 
sections 3.2.1 and 3.2.2).  
The effect of trypsin digestion on antibody binding was assessed in terms of 
differences in surface labelling of antibodies to trypsin-treated IEs compared to 
untreated cells. The percentage of reduction in surface labelling to IEs were 
quantitated following the formula: 
 
 𝑥 = 100 − [( 
𝑎 
𝑏 
 ) × 100] 
 
Where, x = the percentage of reduction in surface labelling  
a = percentage of antibody labelling to trypsin-treated IEs  
b = percentage of antibody labelling to trypsin-untreated IEs (incubated with 
PBS) 
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3.4 Binding of trypsin-treated ItG-IEs to ICAM-1 
receptors  
Trypsin sensitivity of ItG-IEs cytoadherence to purified ICAM-1 receptors was 
assessed by static protein assay as previously described (McCormick et al., 
1997). Briefly, binding buffer (RPMI 1640, with 5 mM glucose, pH 7.2) was 
first prepared and incubated at 37°C prior to the assay. Then, a trophozoite-IE 
suspension in pre-warm binding buffer and at parasitaemia of 3% and HCT of 
1% was prepared for the static assay. Cells were incubated with different 
concentrations of TPCK-treated trypsin (1000 µg/ml, 100 µg/ml or 10 µg/ml) 
following the same protocol in section 3.3. After the final wash, trypsin-digested 
cells or control samples (undigested cells incubated with PBS) were added to 
petri dishes pre-coated with purified ICAM-1 protein (50 µg/ml) or PBS, and the 
static protein assay was carried out as described in Chapter 4.  
 
3.5 Localisation of IgM surface labelling using IFA  
Binding of mouse antibodies to the external surface of live IEs was visualised 
and localised using live liquid-phase immunofluorescence assay (L-IFA) as 
described elsewhere (Ghumra et al., 2008) with minor modifications. MAb BC6 
was used as a positive control which specifically recognises an exposed epitope 
on PfEMP1 of A4-IEs, and shows a distinct punctate staining over the IE 
(Hughes et al., 2010). A4 trophozoite-IEs, from stable cultures, at 3-8% 
parasitaemia and a HCT of 1-2%, were enriched using plasmagel floatation. 
After two rounds of washing in PBS/1%BSA, unfixed cells were incubated (200 
µl, 2.5-3 × 107 cells/ml) with 100 µl of mAb BC6 (20 µg/ml in PBS/1%BSA) or 
100 µl of mAb E7 (57 µg/ml), for 30 minutes at 37°C. After incubation, cells 
were washed in PBS/1%BSA and IgM labelling was detected by incubation with 
Alexa Fluor®488 goat anti-mouse IgM (µ chain) secondary antibody (Molecular 
Probes, Life technologies, A21042) diluted 1:100 plus 10 µg/ml of 4',6-
diamidino-2-phenylindole dihydrochloride [DAPI] (Life technologies, Ca. No. 
D1306) at 37°C for 60 minutes in darkness. BC6 was detected by incubating 
cells with Alexa Fluor®488 goat anti-mouse IgG (H+L) secondary antibody 
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(Molecular Probes, Life technologies, A11001) at the same conditions. DAPI 
was used to differentiate IEs from non-IEs, as it only stains nuclei of IEs.  IEs 
were washed as above, mounted on a microscope slide and inspected by Zeiss 
Axioskop 40 fluorescence microscope fitted with AxioCam MRc digital camera. 
Cells incubated with 20 µg/ml mouse IgM isotype control (clone MOPC 104E, 
Sigma-Aldrich®, M5909, 200 µg/ml) and stained with secondary IgM +DAPI or 
those incubated secondary IgG + DAPI were included as negative controls for 
E7 and BC6, respectively. A4 parasite culture was selected for BC6 binding to 
enhance the surface labelling signal. It was established that incubation of BC6 at 
a range of temperatures (4-37°C) did not affect the pattern of fluorescence 
(Horrocks et al., 2005). However, all incubations were carried out at 37°C as 
with flow cytometry.  
 
3.6 IgM-mediated IE lysis 
3.6.1 Quantitation of lysed IEs by flow cytometry 
Percentage of lysed IEs resulted from mouse mAb/pAb incubation was 
calculated for all tested parasite isolates using flow cytometry data. As the 
percentage of IE population was obtained by gating SSC-A vs. FITC-A, 
differences in this percentage between isotype IgM control and test antibodies 
were used to assess the percentage of lysed IEs. This was calculated following 
the formula: 
 
 
 𝑥 = 100 − [( 
𝑎 
𝑏 
 ) × 100] 
 
Where, x = the percentage of lysed IEs  
a = percentage of IE population for test antibodies (mouse IgMs)  
b = percentage of IE population for isotype IgM control 
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Grading of haemolysis based on the percentage of lysed IEs was set as followed: 
-:               lysed IEs ≤ 15% 
+:              lysed IEs 15.1-40.9% 
++:            lysed IEs 41-80.9%  
+++:          lysed IEs ≥ 81% of IEs.  
 
We confirmed that mainly IEs were lysed upon antibody incubation by counting 
50,000 cells without a stopping gate (i.e. 50,000 IEs and non-IEs were counted) 
for both IgM control and test sample. The positive lysis of IEs (i.e. ≥ 15%) was 
set at this percentage since up to ~12% of non-specific IE lysis could be detected 
with control antibodies.  
 
3.6.2 Measurement of lysed IEs by microscopy  
20 ml of mixed-stage ItG-IEs from culture was washed twice in PBS/1%BSA, 
pelleted by centrifugation and 300 µl of this was used to make a thin blood film 
on a microscopic slide. The smear was air-dried and fixed in 100% methanol for 
5-10 seconds, before the film was washed in water and stained with 5% Giemsa 
stain for 20 minutes. The slide was washed and examined under the microscope 
using 100× oil immersion objective. 1000 RBCs were counted and the 
percentage of trophozoites/schizonts was estimated relative to the total number 
of cells. Then, 1 ml of the same suspension was incubated with 100 µl of pool 2, 
pAb C2, or PBS for 5, 15, 30 and 60 minutes at 37°C. The percentage of 
trophozoites/schizonts was quantitated at the end of each time point as described 
above. The percentage of lysed IEs was then quantitated for control or test 
samples in relative to the percentage of trophozoites/schizonts before incubation.  
3.7 Statistical analysis 
Spearman's rho correlation was used for correlations between variables using 
SPSS (version 22) and Spearman's rho correlation coefficient (rs) was used to 
determine the strength of the association. A two-tailed t-test was used for testing 
the significance of the correlation, which was considered as statistically 
significant when P value ˂ 0.05. 
151 
 
3. Results  
3.1 Labelling of mouse mAbs and pAbs to the surface 
of P. falciparum IEs 
As described in Chapter 2, we generated mAbs and pAbs by immunising mice 
with four different rDBLβ domains from PfEMP1ICAM-1 variants. We first carried 
out flow cytometry experiments to identify optimal IgM concentrations of 
mouse mAbs and pAbs for labelling IEs. Purified mAbs and pAbs were titred 
out to compare the relative binding strengths of IgM preparations with the 
surface of live IEs. This was done by incubating trophozoite-rich suspensions 
with dilutions of mAbs and pAbs, starting at their original concentrations after 
purification down to 1:8 dilution. Table 3.1 summarises the binding profile of 
mAbs and pAbs to the surface of erythrocytes infected with ItG P. falciparum 
isolate. The end titre is identified as the lowest antibody concentration that labels 
> 10% of IEs in flow cytometry (Figure 3.1, only showing the titration of mAbs 
E7 and B4 with ItG-IEs). We found that the percentage of IEs recognised by 
mAbs and pAbs depended on the dose of IgM used. Most antibodies were found 
to efficiently label IEs at their original concentration and lost the surface binding 
capacity with increasing dilution except mAbs E7, B4 and G6, which continued 
to recognise the surface of IEs down to 1:4 dilution but with a significant 
decrease in the percentage of labelling (Table 3.1). Due to the reduced signal 
with dilution, all mAbs and pAbs tested in subsequent work were used at 
concentrations yielded after affinity purification (rather than using diluted IgMs 
or un-purified supernatants), unless otherwise stated. 
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Table 3.1. Labelling capacity of mouse mAbs and pAbs to the surface of erythrocytes infected 
with ItG P. falciparum isolate at neat, 1:2, 1:4 and 1:8 dilutions. - (labelled IE population ≤ 
10%), + (labelled IE population 10.1 to 20%), ++ (labelled IE population 20.1 to 40%), +++ 
(labelled IE population 41 to 60%), ++++ (labelled IE population ˃ 60.1%). Control IgM: mouse 
IgM isotype control from murine myeloma clone MOPC 104E (Sigma®). Results are based on at 
least two experiments.  
 
 
 
 
 
 
 
 
mAbs/pAbs 
Concentration 
(µg/ml) 
IgM titration  
Neat  1:2 1:4 1:8 
pAb E11 16.9 ++ - - - 
pAb B12 0.1 + - - - 
mAb A6A 29.5 + - - - 
pAb C2 43 - - - - 
pAb E4 8 + - - - 
pAb A4 56.6 ++ - - - 
mAb E7 57 ++++ ++ + - 
mAb C9 11.1 + - - - 
pAb 2E10 9.6 ++/+ - - - 
pAb B5 59 ++++ +/- - - 
pAb D5 31.4 +++/++ + - - 
mAb B4 29.7 +++ +/++ +/- - 
mAb G6 66.3 +++ +/++ -/+ - 
Control IgM 20 - - - - 
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Figure 3.1. FACS histograms of gated erythrocytes infected by ItG isolate and labelled by mAbs 
E7 and B4 at neat concentrations or at 1:2, 1:4 or 1:8 dilutions. Labelling was detected using 
APC-conjugated goat anti-mouse IgM (µ chain specific) secondary antibody (Southern Biotech) 
at 1:100 dilution. Cells stained with 20 μg/ml of mouse IgM isotype control from murine 
myeloma clone MOPC 104E (Sigma®) were included as a negative control and are shown by the 
red trace. The grey shaded area represents the distribution of IEs labelled by mAbs E7 and B4. 
Percentages of IEs labelled with reactive IgM antibodies are shown as APC-A-positive subset 
and were obtained relative to a background labelling of control IgM antibodies. A labelling of ˃ 
10% of IE population was considered positive. 
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Then, we tested the capacity of mouse mAbs and pAbs to label the surface of 
erythrocytes infected by eight laboratory adapted P. falciparum isolates with 
different genotypes and phenotypes, including isolates from which the 
recombinant proteins were cloned and with which mAbs/pAbs were raised 
(Table 3.3). In addition, geometric mean fluorescent intensity (gMFI) values for 
the labelling of mAbs/pAbs to the surface of erythrocytes infected by eight P. 
falciparum isolates are shown in Table S2 in the Appendix. Values of gMFI and 
percentages of labelling are consistent for almost all mAbs and pAbs, as 
mAbs/pAbs that show higher percentages of surface labelling have the highest 
gMFI values and vice versa.  
The origin, dominant transcribed var genes as well as adhesion characteristics of 
tested P. falciparum isolates are summarised in Table 3.2. The var gene 
transcription profiles of five P. falciparum isolates (ICAM-1-binding lines) are 
shown in Figure S2 in the Appendix. The results show that parasite isolates 
expressed the expected var transcript more than five fold changes. IT4var16 also 
expressed another var transcript, IT4var41, besides its corresponding var 
transcript (IT4var16).  
As described in Chapter 2, antibody fractions that showed the highest 
fluorescence signal in screening assays were selected for all subsequent 
analyses. The binding profiles for mAbs and pAbs to ICAM-1 binding and non-
binding isolates, as well as to parasite isolates of distinct genotypes will be 
discussed in detail later in this chapter.  
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Table 3.2: The origin and properties of nine distinct P. falciparum isolates used in the study. 
References: 1 (Howell et al., 2008); 2 (Kraemer et al., 2007); 3 (Avril et al., 2012); 4 (Gray et al., 
2003); 5 (Janes et al., 2011); 6 (Maier et al., 2007).   ND: no data. 
Isolate Alias Genome 
Dominant 
transcribed var gene  
 
Ups 
Adhesion phenotype 
IT4var01 3G8 (5) IT4 var01 UpsC (3,1) 
ICAM-1 (1, 5) 
CD36 (5) 
Rosetting (2) 
IT4var13 GC503 IT4 var13 UpsB (3) ICAM-1 (1) 
IT4var14 
A4, 
A4var (1, 2) 
IT4 var14 UpsB (3,1) 
ICAM-1 (4, 1, 2),  
CD36 (4, 2) 
IT4var16 
ItG, 
IT-ICAM (2) 
IT4 var16 UpsB (3) 
ICAM-1 (4, 1, 2) 
CD36 (4, 2) 
IT4var27 2F6 IT4 ND UpsB (3,1) 
ICAM-1 (1) 
Rosetting (2) 
IT4var31 P5B6 IT4 var31 UpsB (3,1) 
ICAM-1 (1, 2, 5) 
CD36 (2, 5) 
C24 - IT4 ND ND CD36 (4) 
3D7 NF54 3D7 ND ND ND 
CS2 CS2 var (2) IT4 ND ND 
CSA, (2, 6) 
HA (6) 
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Antibody Domain Specificity 3G8 GC503 A4 ItG P5B6 C24 3D7 CS2 
E11 DBL13 Polyclonal   + ++ + ++ ++ - ++ + 
B12 DBL13 Polyclonal - + + + - - + + 
A6A DBL13 Monoclonal ++++ +  +++ + +++ ++ +++ ++ 
C2 DBL31 Polyclonal - - - - - + - + 
E4 DBL31 Polyclonal ++ - + + + - ++ + 
A4 DBL31 Polyclonal ++ - - ++ +++ ++ - ++ 
E7 DBL31 Monoclonal ++++ +++ ++++ ++++ +++ +++ +++ ++++ 
C9 DBL31 Monoclonal - - - + - - - + 
2E10 DBL31 Polyclonal ++ - - + + + - +++ 
B5 DBL41 Polyclonal ++++ +++ +++ ++++ ++++ +++ +++ + 
D5 DBL41 Polyclonal ND ++ ++ ++ +++ ++ ++ ++ 
B4 DBL41 Monoclonal +++ +++ ++ +++ +++ + ++ + 
G6 DBL41 Monoclonal ++++ ++++ ++++ +++ ++++ +++ ++++ +++ 
Table 3.3. The reactivity of monoclonal and polyclonal anti-DBLβ antibodies to the surface of erythrocytes infected by phenotypically and genotypically 
distinct P. falciparum isolates as measured by flow cytometry. Two experiments were carried out to confirm reactivity. - (labelled IE population ≤ 10%), + 
(labelled IE population 10.1-20%), ++ (labelled IE population 20.1-40%), +++ (labelled IE population 41-60%), ++++ (labelled IE population ˃ 60.1%). ND: 
no data.  
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3.1.1 Measurement of IgM binding to the surface of ICAM-1 
binding P. falciparum-IEs  
Mouse mAbs and pAbs were characterised for their capacity to recognise the 
surface of RBCs infected by five ICAM-1 binding P. falciparum isolates from 
the IT4 genotype (3G8, GC503, A4, ItG and P5B6). All mAbs and pAbs, except 
pAb C2, exhibited variable levels of IgM surface recognition of erythrocytes 
infected by at least one ICAM-1 binding isolate with a labelling capacity ranging 
from 10.1% to 67.6% of total IEs (Table 3.3). All antibodies raised to rDBL41 
(pAbs B5 and D5, and mAbs B4 and G6) and a mAb raised to rDBL31 (E7), 
were the most effective in surface recognition. On the contrary, there was little 
or no binding with pAbs B12, C2, E4, 2E10 and mAb C9 against all tested 
isolates. There was no clear pattern of strain-specific recognition by mAbs and 
pAbs to erythrocytes infected by homologous parasite isolates (GC503 and 
P5B6), as all positive mAbs and pAbs equally recognised homologous and 
heterologous isolates. However, pAb A4 recognised erythrocytes infected by its 
corresponding isolate (P5B6) more specifically than heterologous ICAM-1 
binding strains. A representative flow cytometry surface labelling by mAbs and 
pAbs to erythrocytes infected by the strong ICAM-1 binder ItG isolate is shown 
in Figure 3.2.   
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Figure 3.2. FACS histograms of gated erythrocytes infected by ItG isolate and labelled by mAbs 
and pAbs. 50 µl of mouse IgM antibodies were incubated with plasmagel-enriched trophozoite-
IEs and labelling was detected using APC-conjugated goat anti-mouse IgM (µ chain specific) 
secondary antibody (Southern Biotech® at 1:100 dilution). Shaded histograms show IEs 
populations labelled by mouse mAbs/pAbs. Negative controls including cells stained with 20 
µg/ml mouse IgM isotype control (Sigma) shown in blue and those only stained with ethidium 
bromide and secondary antibodies shown in red. Percentages of IEs labelled with reactive IgM 
antibodies are shown as APC-A-positive subset and were obtained relative to a background 
labelling of control IgM antibodies. A labelling of ˃ 10% of IE population was considered 
positive. 
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3.1.2 Measurement of IgM binding to the surface of non-ICAM-
1 binding P. falciparum IEs  
We next tested whether the surface-reactive antibodies could also recognise the 
surface of erythrocytes infected with the non-ICAM-1 binding C24 P. 
falciparum isolate from the IT4 genome (Figure 3.3). Overall, the labelling 
profile resembled that of ICAM-1 binding P. falciparum isolates and IgMs that 
strongly label ICAM-1 binding IEs also labelled C24-IEs with a similar pattern 
(Table 3.3). The only exception was observed with DBL13-specific pAbs (E11 
and B12), which recognised the surface of erythrocytes infected by ICAM-1-
binding isolates but did not react with those infected with C24 (Fig 3.3). This 
indicates that most mAbs and pAbs lack phenotype specificity and were equally 
cross-reactive with non-ICAM-1 binding isolates despite being raised to ICAM-
1 biding DBLβ variants.   
The next question addressed was whether mAbs and pAbs had the ability to 
recognise erythrocytes infected by 3D7, a genotypically distinct P. falciparum 
isolate, to further characterise the specificity of mouse IgM antibodies against 
heterologous strains (Figure 3.4). We detected IgM surface-fluorescence levels 
with 3D7 strain similar to those observed with IT4 isolates (Table 3.3). These 
results may suggest that P. falciparum isolates of distinct genotypes share 
common surface epitopes that can be recognised by our mAbs and pAbs. It is not 
yet known whether shared epitopes are indeed located on the native PfEMP1, 
however, the fact that mAbs and pAbs only label IEs indicates that labelling is 
specific for surface-exposed parasite-derived antigens. It is noteworthy that 
trophozoite-enrichment of 3D7 strain was not achievable with the plasmagel 
floatation procedure used for all tested isolates, as overgrown 3D7 used in this 
assay may have lost surface knobs. Therefore, trophozoites were enriched over a 
magnetic field and the elution (enriched pellet) contained almost 90-95% of 
trophozoites.  
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Figure 3.3. The reactivity of mouse mAbs and pAbs with parasite-derived proteins on the surface 
of C24-IEs as measured by flow cytometry. 50 µl of mouse IgM antibodies was incubated with 
plasmagel-enriched trophozoite-IEs and labelling was detected using APC-conjugated goat anti-
mouse IgM (µ chain specific) secondary antibody (Southern Biotech®) at 1:100 dilution. Shaded 
histograms show IEs populations labelled by mouse mAbs/pAbs. Negative controls including 
cells stained with 20 µg/ml mouse IgM isotype control (Sigma) shown in blue and those only 
stained with ethidium bromide and secondary antibodies shown in red. Percentages of IEs 
labelled with reactive IgM antibodies are shown as APC-A-positive subset and were obtained 
relative to a background labelling of control IgM antibodies. A labelling of ˃ 10% of IE 
population was considered positive. 
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Figure 3.4. MAbs and pAbs surface reactivity with 3D7 P. falciparum-IEs as measured by flow 
cytometry. Trophozoites were enriched by exposure to strong magnetic field and 50 µl of mouse 
IgM antibodies was incubated with trophozoite-enriched IEs. Labelling was detected using APC-
conjugated goat anti-mouse IgM (µ chain specific) secondary antibody (Southern Biotech®) at 
1:100 dilution. The grey shaded area represents the IE population labelled by mAbs/pAbs. 
Negative controls including cells stained with 20 µg/ml mouse IgM isotype control (Sigma) 
shown in blue and those only stained with ethidium bromide and secondary antibodies shown in 
red. Percentages of IEs labelled with reactive IgM antibodies are shown as APC-A-positive 
subset and were obtained relative to a background labelling of control IgM antibodies. A 
labelling of ˃ 10% of IE population was considered positive. 
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3.1.3 Measurement of IgM binding to the surface of non-IEs 
Mouse IgMs were then investigated for their ability to recognise the surface of 
non-IEs for all P. falciparum isolates used in screening assays (Table 3.4). This 
was carried out to assess whether mAbs and pAbs only recognised parasite-
derived VSAs on the surface of IEs or were cross-reactive with other ligands on 
the RBC surface. In general, the results showed that only some mAbs and pAbs 
that exhibited higher capacity for labelling the surface of IEs also exhibited 
variable degrees of cross-reactivity to non-IEs, whereas antibodies that 
moderately recognised the surface of IEs or non-labelling antibodies were not 
reactive with non-IEs. However, labelling to some P. falciparum isolates (i.e. 
GC503, 3D7 and CS2) was mainly specific to the surface of IEs for all tested 
mouse IgMs, whereas binding to non-IEs was negligible. The capacity of mAbs 
and pAbs to significantly label the surface of erythrocytes infected by GC503, 
3D7 and CS2 isolates, but not non-IE populations, indicates that mouse IgMs 
were specific for a parasite-derived VSA on the surface of IEs, and confirms that 
non-specific labelling was only related to some P. falciparum isolates.  
Labelling to non-IEs was mainly observed with mAb A6A, mAb E7, pAb B5, 
mAb B4 and mAb G6.  These mAbs and pAbs were the most effective in IE 
surface recognition among all mouse antibodies. However, labelling to non-IEs 
for these mAbs and pAbs was not observed with all P. falciparum isolates. For 
instance, mAb E7 only showed a high background labelling of non-IEs with only 
3 out of the 8 tested P. falciparum isolates, and pAb B5 labelled the surface of 
non-IEs for 4 P. falciparum isolates. Taken together, these results indicate that 
mouse mAbs and pAbs are mainly specific for the surface of IEs, and the 
background labelling observed with some mAbs/pAbs may suggest that mouse 
antibodies recognise a protein with the homologous structure present both on IE 
and non-IEs. A protein with such characteristics is parasite-modified band 3. 
Band 3 is a protein found abundantly on the surface of erythrocytes and acts as 
an anion transporter (Smith and Craig, 2005). Parasite-modified band 3 is 
abundantly found on the surface of IEs and has been suggested as an immune 
target and a cytoadhesion ligand for IE binding to TSP and CD36 (Winograd et 
al., 2004). Further studies are required to investigate the capacity of mAbs and 
pAbs to bind to band 3 and its parasite-mediated modified form.   
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Table S3 in the Appendix shows geometric mean fluorescent intensity (gMFI) 
values for the labelling of mAbs/pAbs to the surface of non-IEs for all P. 
falciparum isolates. Values of gMFI in Table S1 and percentages of labelling in 
Table 3.4 are consistent for almost all mAbs and pAbs, as mAbs/pAbs that show 
higher percentages of surface labelling have the highest gMFI values and vice 
versa. 
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Antibody Domain Specificity 
Percentage of labelling to non-IE population 
3G8 GC503 A4 ItG P5B6 C24 3D7 CS2 
E11 DBL13 Polyclonal 2.4 3.71 1.57 7.15 1.88 4.52 7.01 2.22 
B12 DBL13 Polyclonal 1.18 2.47 2.68 3.60 1.29 2.38 3.31 1.55 
A6A DBL13 Monoclonal 22.5 1.5 5.92 6.29 15.6 11.4 11.5 2.59 
C2 DBL31 Polyclonal 0.5 2.08 1.28 4.29 0.36 3.62 4.96 1.90 
E4 DBL31 Polyclonal 2.09 1.21 1.51 4.50 1.56 3.58 5.32 0.9 
A4 DBL31 Polyclonal 6.5 2.3 0.92 11.6 3.5 4.86 7.06 1.68 
E7 DBL31 Monoclonal 22.8 5.92 17.6 11.3 10.5 18.7 9.42 8.70 
C9 DBL31 Monoclonal 1.7 2.26 2.87 4.33 1.56 2.64 9.93 3.14 
2E10 DBL31 Polyclonal 1.1 2.18 1.86 5.35 0.98 1.47 9.19 1.91 
B5 DBL41 Polyclonal 24.2 3.37 10.8 19.0 22.6 17.0 10.5 1.94 
D5 DBL41 Polyclonal 14 3.42 3.54 13.6 12.5 11.3 9.10 5.25 
B4 DBL41 Monoclonal 13.4 4.08 18.7 11.4 22.5 16.7 11.7 6.58 
G6 DBL41 Monoclonal 15.1 7.52 12 13.4 21.8 20.1 8.98 8.3 
Table 3.4. The reactivity of monoclonal and polyclonal anti-DBLβ antibodies to the surface of non-infected erythrocytes. Percentages of labelled RBC population were 
obtained from gated population of non-IEs and percentages of APC-A-positive cells were used in the table.  
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3.1.4 Correlation of IgM surface labelling among P. falciparum 
isolates 
To compare the surface binding profiles of all tested isolates with each other, we 
calculated correlation coefficients between the labelling scores by 13 
mAbs/pAbs for a single isolate with those for the other isolates using Spearman's 
rho (rs) correlation test. This enabled the identification whether surface labelling 
to erythrocytes infected by a particular isolate was correlated with labelling to 
the other tested P. falciparum strains. We found that all tested isolates, except 
CS2 and 3D7, showed a significant positive correlation with each other (rs = 
0.56 – 0.95; P ˂ 0.05; n= 13), i.e. if IgM binding to a particular isolate was 
detected, then IgM to the other isolate was also observed especially when higher 
levels of IgM binding were detected (Table 3.5). Labelling of CS2-IEs showed 
no significant correlation with all tested isolates (P ˃ 0.05) whereas binding to 
3D7-IEs was significantly correlated with all tested isolates except C24 (rs = 
0.52, P = 0.07) and CS2 (rs = 0.297, P = 0.33). Some individual mAbs/pAbs 
exhibited either substantial binding to distinct isolates or significant binding to 
other isolates which explains the variation in correlation results. These results 
indicate each individual mAb or pAb possesses an overlapping cross-reactivity 
with P. falciparum isolates, regardless of their binding phenotype or genotype. 
However, since the numbers used in this correlation analysis and in subsequent 
analyses in this study are not large enough to say much about the presence or 
absence of significant correlations, interpretation of correlations that did not 
reach statistical significance must be carried out with extra caution.  
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 3G8 GC503 A4 ItG P5B6 C24 3D7 CS2 
Spearman's 
rho 
3G8 Correlation Coefficient 1.000 .775** .791** .868** .923** .841** .747** .544 
Sig. (2-tailed) . .002 .001 .000 .000 .000 .003 .055 
N 13 13 13 13 13 13 13 13 
GC503 Correlation Coefficient .775** 1.000 .879** .929** .824** .566* .841** .418 
Sig. (2-tailed) .002 . .000 .000 .001 .044 .000 .156 
N 13 13 13 13 13 13 13 13 
A4 Correlation Coefficient .791** .879** 1.000 .780** .786** .560* .951** .368 
Sig. (2-tailed) .001 .000 . .002 .001 .046 .000 .216 
N 13 13 13 13 13 13 13 13 
ItG Correlation Coefficient .868** .929** .780** 1.000 .923** .742** .753** .434 
Sig. (2-tailed) .000 .000 .002 . .000 .004 .003 .138 
N 13 13 13 13 13 13 13 13 
P5B6 Correlation Coefficient .923** .824** .786** .923** 1.000 .852** .769** .489 
Sig. (2-tailed) .000 .001 .001 .000 . .000 .002 .090 
N 13 13 13 13 13 13 13 13 
C24 Correlation Coefficient .841** .566* .560* .742** .852** 1.000 .516 .522 
Sig. (2-tailed) .000 .044 .046 .004 .000 . .071 .067 
N 13 13 13 13 13 13 13 13 
3D7 Correlation Coefficient .747** .841** .951** .753** .769** .516 1.000 .297 
Sig. (2-tailed) .003 .000 .000 .003 .002 .071 . .325 
N 13 13 13 13 13 13 13 13 
CS2 Correlation Coefficient .544 .418 .368 .434 .489 .522 .297 1.000 
Sig. (2-tailed) .055 .156 .216 .138 .090 .067 .325 . 
N 13 13 13 13 13 13 13 13 
Table 3.5. Spearman's rho correlation of the surface labelling profiles of thirteen mAbs/pAbs to 
erythrocytes infected by eight P. falciparum parasite isolates. Binding of IgM to the surface of 
erythrocytes infected by 3G8, GC503, A4, ItG, P5B6, C24, 3D7 or CS2 was determined using 
flow cytometry and surface labelling was expressed as percentage of IEs labelled by mAbs and 
pAbs relative to control IgM binding. Values of Spearman's rho correlation coefficient (rs): 0 (no 
correlation between variables), 0.1 to 0.3 (weak positive correlation), 0.3 to 0.5 (moderate 
positive correlation), 0.5 to 1.0 (strong positive correlation). Correlation is statistically 
significant when P value ˂ 0.05. *: correlation is significant at the 0.05 level. **: correlation is 
significant at the 0.001 level. 
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3.1.5 Correlation between IgM reactivity to recombinant 
domains and IE surface labelling  
The association between IgM reactivity to recombinant domains in ELISA and 
surface labelling to IEs in flow cytometry was investigated to determine whether 
recognition of recombinant proteins used in immunisations correlated with the 
binding to live infected cells. The analysis revealed a strong positive correlation 
between surface labelling of all tested isolates and the reactivity to recombinant 
DBL31 proteins, indicating that IgM antibodies that showed higher capacity of 
surface labelling to IEs also exhibited higher levels of reactivity to recombinant 
domains (Table 3.6). A statistically-significant correlation was observed with all 
tested isolates (rs ≥ 0.56, P ˂ 0.05) except for GC503 and CS2 isolates, which 
showed rs values ≤ 0.53 (P ˃ 0.05).   
 
 
 P. falciparum isolates 
 3G8 GC503 A4 ItG PFB6 C24 3D7 CS2 
Spearman's 
rho (rs)  
0.78 0.53 0.64 0.593 0.74 0.7 0.56 0.46 
P value 0.002* 0.65 0.019* 0.033* 0.004* 0.007* 0.047* 0.12 
Table 3.6. Correlation between surface labelling of 13 mAbs and pAbs to erythrocytes infected 
by eight P. falciparum isolates and reactivity to rDBL31. Binding of mouse IgM to the surface of 
erythrocytes infected by all isolates was expressed as percentage of labelled IEs, whereas values 
of recognition to recombinant DBL31 domains were expressed as the mean OD values of each 
mAb/pAb subtracted from (OD value of the control + 3 SDs). The strength of correlation was 
determined as described in Table 3.4. Correlation is statistically significant when P value ˂ 0.05. 
*: correlation is significant at the 0.05 level.  
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3.2 Competition assays 
A flow cytometric analysis was carried to investigate the influence of pre-
incubating IEs with mAbs and pAbs on subsequent binding of well-characterised 
surface-labelling antibodies to further characterise the surface epitopes 
recognised by mouse IgM antibodies. Competition was defined as an alteration 
or complete inhibition in the relative ability of BC6, anti-DBL16 rat antisera or 
HIS to bind to the surface of IEs pre-incubated with mouse IgM antibodies and 
vice versa. Two pools of mouse IgMs that showed positive surface labelling 
were mainly used in the competition assays including pool 1 (pAb E11, pAb 
B12, mAb A6A and pAb E4) and pool 2 (mAb E7, pAb D5, mAb B4 and mAb 
G6). Antiobody pools were primarily used at this point of study due to lack of 
materials available to do all experiments with individual antibodies.  
 
3.2.1 The effect of pre-incubation of A4-IEs with mAbs and 
pAbs on BC6 surface binding  
We tested the ability of mouse IgMs to interfere with the interaction between 
mAb BC6 and PfEMP1 on the surface of erythrocytes infected with A4 isolate to 
investigate the specificity of mouse IgMs to bind surface PfEMP1 molecules. 
BC6 is a mouse monoclonal IgG antibody that specifically recognises an 
exposed epitope on PfEMP1 of erythrocytes infected by A4 P. falciparum 
isolate (Roberts et al., 1992, Horrocks et al., 2002). Analysis of BC6 binding to 
A4-IEs by flow cytometry showed that 60% (Adams et al., 2000) and up to 80% 
(Hughes et al., 2010) of IEs are recognised by mAb BC6. We therefore 
hypothesised that inhibition of BC6-PfEMP1 interaction may indicate that 
mouse IgMs fully or partially bind to PfEMP1 on the surface of IEs. In the first 
assay, A4-IEs were pre-incubated with mAb BC6, then washed and co-incubated 
with mouse IgMs and tested by flow cytometry for surface fluorescence (Figure 
3.5). The competition results showed that pre-incubating IEs with BC6 reduced 
the subsequent binding of pool 1 and pool 2 mouse IgM antibodies by 25% and 
20%, respectively. On the other hand, pre-incubating IEs with pool 1 reduced the 
subsequent binding of BC6 by 45%, whereas pool 2 only inhibited 10% of IEs 
labelling (Figure 3.5).  
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Figure 3.5. Flow cytometry analysis of the effect of pre-incubating A4-IEs with mouse mAbs 
and pAbs on the subsequent binding of mAb BC6 (20 µg/ml) and vice versa. Shaded histograms 
represent IE populations labelled by mouse pools or BC6 antibodies. Negative controls for 
mouse pools including cells stained with 20 µg/ml mouse IgM isotype control (Sigma) shown in 
red, or those only stained with ethidium bromide and anti-mouse IgG secondary antibodies 
shown in green (for BC6). A: binding of pool 1 (left), the subsequent binding of pool 1 after pre-
incubation with BC6 (right), binding of pool 2 (bottom left) and the subsequent binding of pool 2 
after pre-incubation with BC6 (bottom right). B: binding of mAb BC6 (left), the subsequent 
binding of BC6 after pre-incubation with pool 1 (middle) or pool 2 (right). Labelling was 
detected using APC-conjugated goat anti-mouse IgM (µ chain specific) secondary antibody 
(Southern Biotech®) for mouse pools or with APC-conjugated goat anti-mouse IgG secondary 
antibody (Thermo Scientific) for mAb BC6. IgG or IgM surface labelling were expressed as 
percentage of APC-positive labelled IEs (grey shades) compared to background labelling (red or 
green). A labelling of ˃ 10% of IE population was considered positive. Pool 1 (14 µg/ml) 
includes pAb E11, pAb B12, mAb A6A and pAb E4 and pool 2 (51.6 µg/ml) includes mAb E7, 
pAb D5, mAb B4 and mAb G6.  
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3.2.2 The effect of pre-incubation of A4-IEs with mAbs and 
pAbs on HIS surface binding  
We next investigated whether mouse IgMs can compete with pooled Malawian 
hyper-immune sera (HIS) for IE surface binding and vice versa. HIS comprises 
IgG class antibodies and demonstrates a high level of cross-reactivity against P. 
falciparum isolates of different phenotypes and genotypes (data not shown). We 
first investigated the surface fluorescence of HIS at different concentrations (5 
mg/ml, 10 mg/ml, 30 mg/ml and 60 mg/ml) and found that surface labelling was 
relatively unaffected by increasing the concentration from 30 to 60 mg/ml 
(Figure 3.6), suggesting saturation of binding by HIS at 30 mg/ml. Although HIS 
at 10 or 30 mg/ml demonstrated similar levels of surface labelling, repeating 
assays confirmed that the latter concentration has a higher capacity for surface 
recognition and therefore 30 mg/ml was used in all subsequent assays. 
We then tested the competition profile between our mAbs/pAbs and HIS and 
found that pre-incubating IEs with pool 1 significantly reduced the subsequent 
binding of HIS by 53%, whereas pool 2 inhibited IE binding by 57% (Figure 
3.7). On the reverse experiment, pre-incubating IEs with HIS has reduced the 
binding of pool 1 and pool 2 by 45% and 37%, respectively. This interference of 
binding between mouse IgMs and HIS suggests that the binding site on the 
surface of IEs is closely related between mouse IgMs and HIS. 
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Figure 3.6. The reactivity of HIS against the surface of A4-IEs as measured by flow cytometry. 
50 µl of HIS at 5 mg/ml, 10 mg/ml, 30 mg/ml or 60 mg/ml was incubated with plasmagel-
enriched trophozoite-IEs and the labelling was detected using APC-conjugated mouse anti-
human IgG-Fc secondary antibody (Southern Biotech) at 1:100 dilution. Shaded histograms 
show IEs populations labelled by IgG antibodies. Negative controls including cells stained with 
50 µl of non-immune UK sera at 1:10 dilution shown in blue and those stained with ethidium 
bromide and secondary antibodies alone shown in red. A labelling of ˃ 10% of IE population 
was considered positive.  
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Figure 3.7. Flow cytometry histograms of the effect of pre-incubating A4-IEs with mouse IgM 
pools on the subsequent binding of HIS (30 mg/ml) and vice versa. Shaded histograms show IE 
populations labelled by IgM pools or HIS. Negative controls including cells stained with 20 
µg/ml mouse IgM isotype control (Sigma) shown in red or those stained with 50 µl of non-
immune UK sera at 1:10 dilution shown in blue. A: binding of pool 1 (left), the subsequent 
binding of pool 1 after pre-incubation with HIS (right), binding of pool 2 (bottom left) and the 
subsequent binding of pool 2 after pre-incubation with HIS (bottom right). B: binding of HIS 
(left), the subsequent binding of HIS after pre-incubation with pool 1 (middle) or pool 2 (right). 
IgG or IgM surface labelling expressed as percentage of APC-positive labelled IEs (grey shades) 
compared to background labelling (red or blue). Labelling was detected using APC-conjugated 
mouse anti-human IgG-Fc secondary antibody (Southern Biotech®) for HIS or with APC-
conjugated goat anti-mouse IgM (µ chain specific) secondary antibody (Southern Biotech®) for 
mouse IgM pools. A labelling of ˃ 10% of IE population was considered positive. Pool 1 (14 
µg/ml) includes pAb E11, pAb B12, mAb A6A and pAb E4 and pool 2 (51.6 µg/ml) includes 
mAb E7, pAb D5, mAb B4 and mAb G6.  
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3.2.3 The effect of pre-incubation of ItG-IEs with mAbs and 
pAbs on surface labelling of rat anti-DBL16 antisera  
Two rats were immunised by recombinant DBL16 domains at Severn Biotech 
Ltd® (Worcestershire, United Kingdom) and anti-DBL16 antisera were tested for 
surface fluorescence with erythrocytes infected by the homologous ItG P. 
falciparum isolate. Preliminary flow cytometry scanning assays indicated that 
anti-DBL16 anti-sera specifically recognised ~70-78% of IE population when 
used at 1:10 dilution. On the other hand, other rat anti-sera raised to different 
domains (DBL13, DBL27, DBL31 and DBL41) showed little if any reactivity 
with ItG-IEs which suggests anti-DBL16 antisera specifically bind to ItG-IEs. 
Then we tested the competition between rat anti-sera and mouse IgMs in terms 
of surface labelling to ItG-IEs. Our results demonstrated that both IgM pools 
(pool 1 and pool 2) reduced subsequent surface labelling of rat anti-DBL16 
antisera by ~20% when pre-incubated with IEs. On the other hand, rat antisera 
significantly interfered with mouse IgM binding with an inhibition percentage of 
55% and 36.2% for pool 1 and pool 2 surface binding, respectively as would be 
expected for polyclonal anti-sera (Figure 3.8).  
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Figure 3.8. Flow cytometry histograms of the effect of pre-incubation of ItG-IEs with mouse 
IgM pools on the subsequent labelling of rat anti-DBL16 antisera at 1:10 dilution and vice versa. 
Shaded histograms show IE populations labelled by mouse pools or anti-DBL16 antisera. 
Negative controls including cells stained with 20 µg/ml mouse IgM isotype control (Sigma) 
shown in red or those stained with 50 µl of rat pre-immune sera at 1:10 dilution shown in green. 
A: binding of pool 1 (left), the subsequent binding of pool 1 after pre-incubation with rat anti-
DBL16 antisera (right), the binding of pool 2 (bottom left) and the subsequent binding of pool 2 
after pre-incubation with rat anti-DBL16 antisera (bottom right). B: the binding of rat anti-
DBL16 antisera (left), the subsequent binding of rat anti-DBL16 antisera after pre-incubation 
with pool 1 (middle) or pool 2 (right). Labelling was detected using APC-conjugated goat anti-
rat IgG secondary antibody for rat anti-DBL16 antisera or with APC-conjugated goat anti-mouse 
IgM (µ chain specific) secondary antibody (Southern Biotech®) for mouse pools. IgG or IgM 
surface labelling expressed as percentage of APC-positive labelled IEs (grey shades) relative to 
background labelling (in red and green). A labelling of ˃ 10% of IE population was considered 
positive. Same pools were used as described in Figures 3.5 and 3.7.  
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3.3 Mouse IgM binding to trypsin-treated IEs 
The effect of protease digestion on IE surface proteins on mouse IgM binding 
was investigated to determine if binding epitopes on the surface of IEs are 
affected after trypsin treatment. In addition, this experiment was carried out to 
assess the contribution of PfEMP1, an extremely trypsin-sensitive protein, in the 
binding of mouse mAbs and pAbs. P. falciparum IEs were incubated with 1 
mg/ml, 100 µg/ml or 10 µg/ml of TPCK-treated trypsin and tested for surface 
fluorescence. Firstly, the effect of trypsin treatment on intact IEs was evaluated 
either with static adhesion assay (for ItG-IEs, Figure 3.9) or flow cytometry (for 
A4-IEs with mAb BC6, Figure 3.10). 
In the static adhesion assay, trypsin treated or untreated ItG-IEs were 
investigated for static adhesion to purified ICAM-1 proteins (50 µg/ml) 
immobilised on plastic dishes. We found that ICAM-1 binding with this parasite 
line is highly sensitive to cleavage by trypsin as ItG-IEs binding to ICAM-1 
receptors was almost completely abolished at all tested concentrations (Figure 
3.9). At a concentration of 10 µg/ml, the mean inhibition of adhesion was 
98.3%, at 100 µg/ml and 1 mg/ml, the mean inhibition was 99%. This indicates 
that lower concentrations of trypsin (down to 10 µg/ml) were effective in 
cleaving all the PfEMP1 ligand involved in ICAM-1 binding.  
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Figure 3.9. Adhesion of trypsin-treated ItG-IEs to immobilised ICAM-1 protein. ItG-IEs were 
pre-treated with 1 mg/ml, 100 µg/ml or 10 µg/ml TPCK-treated trypsin (Sigma) diluted in PBS 
(100 µl) then added to petri dishes pre-coated with spots of ICAM-1 protein (50 µg/ml) or PBS. 
Dishes were washed, fixed and stained as described in Materials and Methods. Bound IEs to 
protein or control spots were visualised and counted under the microscope. Data represent 36 
readings obtained from 6 ICAM-1 spots, from two independent dishes. Values expressed as 
mean number of bound IEs per mm2 ± Std. Dev. No trypsin = IEs incubated with PBS (control). 
 
The effect of trypsin digestion on intact IEs was further evaluated by flow 
cytometry in terms of binding of the well-characterised mAb BC6 to A4-IE 
surface. As noted before, mAb BC6 binds an exposed epitope on PfEMP1 of 
A4-IEs (Roberts et al., 1992, Horrocks et al., 2002) and therefore the least 
trypsin concentration required for inhibiting BC6 binding was indicative for 
cleaving the entire PfEMP1, or at least a functional epitope on this large 
molecule. We found that treating IEs with 1 µg/ml of TPCK-treated trypsin 
caused a comparatively modest reduction in BC6 surface binding by about 39% 
relative to control (Table 3.7, Figure 3.10). However, the binding epitope for 
BC6 on PfEMP1 was almost cleaved at ≥ 10 µg/ml trypsin concentrations (at 10 
µg/ml, 100 µg/ml and  1 mg/ml, percentage of IE labelling was reduced by 
97.9%, 98.9% and 98.6%, respectively). This supports previous findings of 
ICAM-1 adhesion that only 10 µg/ml of trypsin was required for cleaving 
functional binding epitopes on PfEMP1, if not the entire molecule.     
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   Trypsin concentration (µg/ml) 
0 1 10 100 1000 
Percentage of IEs labelled by 
BC6 
67.9% 41.3% 1.37% 0.73% 0.98% 
Percentage of reduction 
relative to positive control 
- 39.2% 97.9% 98.9% 98.6% 
Table 3.7. Labelling of mAb BC6 to trypsin-treated A4-IEs as measured by flow cytometry. IEs 
were treated with 1 mg/ml, 100 µg/ml, 10 µg/ml or 1 µg/ml of TPCK-treated trypsin (Sigma) 
diluted in PBS and tested for binding with mAb BC6 (20 µg/ml). Cells incubated with PBS and 
labelled by BC6 were included as a positive control. Surface labelling was indicated in terms of 
the percentage of IE population labelled by mAb BC6.  
 
 
 
Table 3.10. Flow cytometry histograms of mAb BC6 labelling to trypsin-treated A4-IEs. 
Trophozoite-enriched cultures were pre-treated with 1000 µg/ml, 100 µg/ml, 10 µg/ml or 1 
µg/ml of TPCK-treated trypsin and tested with BC6 mAb (20 µg/ml) for surface labelling. BC6 
labelling was detected using APC-conjugated goat anti-mouse IgG secondary antibody (Thermo 
Scientific) at 1:100 dilution. IEs stained with ethidium bromide and anti-mouse IgG secondary 
antibodies were used to exclude the non-specific background labelling of IEs and shown as 
APC-negative IE population (subset). BC6 surface labelling expressed as percentage of APC-
positive IE population compared to background labelling of the control. Cells incubated with 
PBS and labelled by BC6 were included as a positive control for trypsin digestion. A labelling of 
˃ 10% of IE population was considered positive.  
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We then tested the binding of pAb B5, mAb G6 and pool 1 of mouse IgMs to the 
surface of trypsin-treated ItG-IEs to investigate the effect of trypsin digestion on 
mouse IgM labelling (Table 3.8, Figure 3.11). Malawian HIS was also tested as 
it resembled the mouse IgM antibodies in terms of cross-reactivity with 
heterogeneous P. falciparum isolates. The results indicated that surface labelling 
of mAb G6 to ItG-IEs was relatively more sensitive to trypsin digestion at all 
concentrations compared to pAb B5, and labelling was greatly reduced as the 
concentration of trypsin increased. A similar sensitivity to trypsin digestion, 
albeit to a lower extent, was observed with the HIS and pool 1. On the other 
hand, labelling of pAb B5 was mostly unaffected at 10 µg/ml and 100 µg/ml 
trypsin treatment but significantly reduced with 1 mg/ml trypsin digestion. 
Correlation analyses of the parameters revealed a statistically significant strong 
negative correlation between trypsin concentration and percentage of labelled 
IEs by mAb G6, pool 1 and HIS (rs = -1.0, P ˂ 0.0001). The correlation was 
strong but not significant with pAb B5 (rs = -0.8, P ˃ 0.05).  
 
Table S4 in the Appendix shows geometric mean fluorescent intensity (gMFI) 
values for the labelling of pAb B5, mAb G6, pool 1 and HIS to the surface of 
trypsin-treated and non-treated ItG-IEs. Values of gMFI in Table S4 and 
percentages of labelling in Table 3.8 are consistent for all mAbs/pAbs and HIS, 
as antibodies that show higher percentages of surface labelling have the highest 
gMFI values and vice versa.  
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Figure 3.11. Flow cytometry histograms of mAb G6, pAb B5, pool 1 of mouse IgMs and HIS 
labelling to trypsin-treated ItG-IEs. Trophozoite-enriched cells were pre-treated with 1000 
µg/ml, 100 µg/ml or 10 µg/ml of TPCK-treated trypsin and tested with mAbs/pAbs or HIS for 
surface labelling. Cells incubated with PBS and labelled by IgGs or IgMs were included as a 
positive control for surface labelling. Cells stained with 20 µg/ml mouse IgM isotype control 
(Sigma) shown in red or those only stained with ethidium bromide and secondary antibody 
(green) were included as negative controls for mouse IgM antibodies. IgG or IgM surface 
labelling expressed as percentage of APC-positive labelled IEs (grey shades) relative to 
background labelling (red or green). A labelling of ˃ 10% of IE population was considered 
positive.  
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Table 3.8. Labelling of mAb G6, pAb B5, pool 1 of mouse IgMs and HIS to ItG-IEs treated with 
10 µg/ml, 100 µg/ml or 1000 µg/ml of TPCK-treated trypsin as measured by flow cytometry. 
Percentage of labelling was calculated as shown in Figure 3.12.   
 
 
3.4 Localisation of IgM surface labelling using liquid-
phase immunofluorescence assay (L-IFA)  
Binding of mouse IgM antibodies to the outer surface of live IEs was visualised 
using L-IFA. Flow cytometry is a sensitive method for quantitating the number 
of IEs labelled by particular antibodies, however, the localisation of surface 
binding can only be visualised by imaging techniques including IFA. 
Fluorescent microscopy scanning with the strain-specific mAb BC6 revealed a 
punctate fluorescent pattern distributed across the external surface of A4-IEs 
(Figure 3.12), a characteristic pattern of PfEMP1-specific labelling similar to 
  
Trypsin concentration (µg/ml) 
PBS 1000 100 10 
 
G6 
Percentage of IEs labelled by 
mAb G6 
65.2% 24.5% 30.1% 41.7% 
Percentage of reduction 
compared to IgM control 
- 62.4% 53.8% 36% 
 
B5 
Percentage of IEs labelled by 
pAb B5 
53.8% 24.5% 52.4% 55.3% 
Percentage of reduction 
compared to IgM control 
- 54.5% 2.6% 0 
Pool 1  
Percentage of IEs labelled by 
pool 1 of mAbs 
42.7% 18.3% 29.7% 30.5% 
Percentage of reduction 
compared to IgM control 
- 57.1% 30.4% 28.6% 
 
HIS 
Percentage of IEs labelled by 
HIS 
49.2% 23.7% 28.5% 30.3% 
Percentage of reduction 
compared to control serum 
- 51.8% 42.1% 38.4% 
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that observed in a published work (Hughes et al., 2010). A similar surface 
immunolabelling was observed mAb E7 though with less surface distribution 
and fluorescence intensity (Figure 3.13). The labelling was absent with mouse 
IgM control antibody indicating that the labelling was specific for mouse mAbs. 
The assay was carried out using a representative mouse mAb that showed a 
significant labelling by flow cytometry with all tested isolates (i.e. mAb E7). 
The surface labelling was imaged qualitatively by IFA and the percentage of IEs 
showing positive fluorescence signal by tested antibodies was not quantitated.  
 
 
 
Figure 3.12. L-IFA staining of the surface of live A4-IEs with mAb BC6 (20 µg/ml). A: 
fluorescent images of staining parasite nuclei with 10 µg/ml of DAPI (left), staining of the sides 
of IEs (middle) or the top (right) by mAb BC6 using Alexa Fluor® goat anti-mouse IgG (H+L) 
secondary antibody (Molecular Probes). B: fluorescent images of staining IEs with secondary 
antibody alone (negative control) showing stained parasite nuclei with DAPI (left) and with 
Alexa Fluor® goat anti-mouse IgG (H+L) secondary antibody (right). DAPI staining was carried 
out to differentiate IEs from non-IEs.   
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Figure 3.13. L-IFA for staining the surface of live A4-IEs with mAb E7. A: fluorescent images 
of staining parasite nuclei with 10 µg/ml of DAPI (left), staining of the sides of IEs (middle) or 
the top (right) by mAb E7 (49.9 µg/ml) using Alexa Fluor® goat anti-mouse IgM (µ chain) 
secondary antibody (Molecular Probes). B: fluorescent images of staining IEs with 20 µg/ml of 
mouse IgM isotype control (negative control) showing stained parasite nuclei with DAPI (left) or 
with Alexa Fluor® goat anti-mouse IgM (µ chain) secondary antibody (right). DAPI staining was 
carried out to differentiate IEs from non-IEs.   
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3.5 Mouse IgM-mediated IE lysis 
3.5.1 Quantitation of lysed IEs by flow cytometry   
We showed that mouse mAbs and pAbs recognise the surface of erythrocytes 
infected by distinct P. falciparum isolates. However, during flow cytometry 
analyses we observed a remarkable reduction in counts of IEs upon incubation 
with mAbs and pAbs (Table 3.9), whereas the number of normal RBCs was 
mostly unaffected. 69.2% (n=9) of all mAbs and pAbs showed variable levels of 
haemolysis (ranging from 17.2% to 96.2% of total IEs) with all tested P. 
falciparum isolates. Of these lysing antibodies, six (66.7%) showed positive 
surface labelling with all tested parasite isolates. On the other hand, the ability to 
lyse IEs was less frequent among non-labelling IEs. For instance, pAb C2, the 
least labelling mouse IgM antibody, only caused a little if any lysis among tested 
parasite isolates (Table 3.9). Figure 3.14 represents surface labelling to C24-IEs 
by E11, C2, A4, E7 and G6 showing the percentage of lysed IEs against a 
control IgM mAb. 
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Figure 3.14. IgM-mediated IE lysis caused by binding of mouse mAbs/pAbs to C24-IEs as 
indicated by flow cytometry. Trophozoite-enriched cells were incubated with 50 µl of 
mAbs/pAbs for surface labelling. Cells stained with 20 µg/ml mouse IgM isotype control 
(Sigma) shown in blue or those only stained with ethidium bromide and secondary IgM antibody 
alone (red) were included as negative controls. Population of IEs lysed after mouse IgM 
incubation was obtained from the FITC-positive channel (ethidium bromide labelled cells), and 
the percentage of lysed IEs was calculated relative to the percentage of mouse isotype IgM 
control.  
C
o
u
n
t 
185 
 
Antibody  DBL specificity 3G8 GC503 A4 ItG P5B6 C24 3D7 CS2 
E11 DBL13 Polyclonal  +++ 
(90.9%) 
+++ 
(87.3%) 
+++ 
(91.1%) 
+++ 
(80.5%) 
+++ 
(88.7%) 
++ 
(64.1%) 
+++ 
(81.9%) 
+++ 
(90.2%) 
B12 DBL13 Polyclonal  ++ 
(77.2%) 
++ 
(67.4%) 
++ 
(78.4%) 
++ 
(65.2%) 
++ 
(77.5%) 
++ 
(77.2%) 
+ 
(34.9%) 
+++ 
(91.1%) 
A6A DBL13 Monoclonal  +++ 
(93.4%) 
++ 
(79.9%) 
+++ 
(90.9%) 
+++ 
(83.9%) 
+++ 
(94.7%) 
++ 
(79.2%) 
++ 
(63.9%) 
+++ 
(92%) 
C2 DBL31 Polyclonal  - 
(3.3%) 
+ 
(21.6%) 
- 
(13.6%) 
- 
(11.9%) 
- 
(11.9%) 
+ 
(27.3%) 
- 
(8.9%) 
+ 
(37.1%) 
E4 DBL31 Polyclonal  +++ 
(94.6%) 
++ 
(49.9%) 
+++ 
(92.6%) 
++ 
(79.9%) 
+++ 
(95.3%) 
+++ 
(85.3%) 
++ 
(76.7%) 
+++ 
(96.2%) 
A4 DBL31 Polyclonal  - 
(6.9%) 
++ 
(42.5%) 
+ 
(18.2%) 
++ 
(61.9%) 
- 
(0.7%) 
+ 
(20.2%) 
+ 
(22.6%) 
+++ 
(81.7%) 
E7 DBL31 Monoclonal  ++ 
(78.7%) 
+++ 
(87.1%) 
++ 
(62.3%) 
++ 
(64.6%) 
+++ 
(87.9%) 
++ 
(77.8%) 
++ 
(77.3%) 
+++ 
(88%) 
C9 DBL31 Monoclonal  ++ 
(38.6%) 
- 
(15%) 
- 
(11.3%) 
- 
(6.1%) 
++ 
(40.6%) 
++ 
(71.5%) 
+ 
(23.1%) 
+++ 
(89.2%) 
2E10 DBL31 Polyclonal  - 
(3.8%) 
+ 
(20.3%) 
+ 
(18.2%) 
-/+ 
(17.2%) 
- 
(0%) 
+ 
(18%) 
+ 
(27.5%) 
+ 
(36.3%) 
B5 DBL41 Polyclonal  +++ 
(91.7%) 
+++ 
(83.8%) 
+++ 
(90.3%) 
++ 
(76.7%) 
+++ 
(93.3%) 
+++ 
(85.4%) 
+++ 
(91.6%) 
+++ 
(89.2%) 
D5 DBL41 Polyclonal  +++ 
(94.7%) 
+++ 
(82.9%) 
+++ 
(92.5%) 
+++ 
(82.9%) 
+++ 
(92.3%) 
++ 
(79.7%) 
++ 
(76.2%) 
+++ 
(86.3%) 
B4 DBL41 Monoclonal  +++ 
(85.4%) 
+ 
(40.2%) 
+++ 
(81.3%) 
++ 
(75.8%) 
++ 
(75.5%) 
++ 
(71.8%) 
++ 
(60%) 
+++ 
(87.8%) 
G6 DBL41 Monoclonal  ++ 
(69.1%) 
+++ 
(83.8%) 
+++ 
(89.1%) 
++ 
(76.7%) 
+++ 
(89%) 
++ 
(78.2%) 
+++ 
(90.7%) 
+++ 
(93.5%) 
 
Table 3.9. Summary of IgM-mediated IE lysis caused by binding of thirteen mAbs and pAbs to the surface of erythrocytes infected by eight phenotypically 
and genotypically distinct P. falciparum isolates as measured by flow cytometry. Grading of haemolysis based on the percentage of lysed IEs was determined 
as followed: - (lysed IEs ≤ 15%), + (lysed IEs 15.1-40.9%), ++ (lysed IEs 41-80.9%), +++ (lysed IEs ≥ 81% of IEs).  
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3.5.2 Estimating the parasitaemia after IgM incubation     
To further tackle the haemolysis phenomenon, we estimated the parasitaemia 
level of ItG-IEs pre-incubated with mouse IgMs. The number of mid-late 
trophozoites or schizonts was counted over time (5, 15, 30 and 60 minutes) by 
counting 1000 cells of Giemsa stained suspension with/without IgM incubation 
under the microscope (Figure 3.15, Table 3.10). The results showed that the 
percentage of trophozoites/schizonts in cell suspension pre-incubated with pool 
2 was dramatically decreased over time compared to pAb C2 or antibody-free 
suspensions. At 15, 30 and 60 minutes of incubation, the percentage of 
trophozoites/schizonts incubated with pool 2 was decreased by 27.3%, 77.3% 
and 83.3%, respectively relative to pre-incubation percentage (Figure 3.15, 
Table 3.10). On the other hand, percentage of ItG-trophozoites/schizonts was not 
significantly reduced following pAb C2 incubation compared to control 
suspension. These results indicated that haemolysis was initiated after 15 
minutes of antibody incubation, and confirmed previous findings that IE lysis 
was associated with incubation with mouse IgMs that showed positive surface 
labelling. The antibody-free suspension was included in the assay to exclude 
non-specific IE lysis and confirmed that time-dependent cell destruction 
mediated by irrelevant factors was not observed throughout the assay. The 
absence of significant levels of lysed IEs incubated with pAb C2 indicated that 
cell lysis was not caused by buffer-related factors.  
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Figure 3.15. Estimating the percentage of IE lysis after incubation with mouse IgMs over time. 
A: 1 ml of ItG-IE suspension containing mixed-stage parasites was incubated with pAbs C2 or 
pool 2, or tested without adding pAbs (no IgM). The percentage of trophozoites/schizonts was 
firstly estimated microscopically before adding pAb, and then re-estimated at 5, 15, 30 and 60 
minutes after antibody incubation. B: Corresponding Eppendorf tubes containing the IE 
suspension with/without IgM incubation at 60 minutes, showing signs of haemolysis in IE 
suspension incubated with pool 2.  
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Time (minutes) 
0 5 15 30 60 
No IgM 
Trophozoites (%) 6.6 6.5 6.4 6.1 6.1 
% of reduction 0 1.5 3 7.6 7.6 
PAb C2 
Trophozoites (%) 6.6 6.4 6.3 6.2 6.2 
% of reduction 0 3 4.5 6.1 6.1 
Pool 2 
Trophozoites (%) 6.6 6.4 4.8 1.5 1.1 
% of reduction 0 3 27.3 77.3 83.3 
 
Table 3.10. Estimating the percentage of IE lysis with/without incubation with mouse IgM 
antibodies (C2 or pool 2) at 5, 15, 30 and 60 minutes of incubation. The percentage of 
trophozoites was firstly estimated microscopically before adding antibodies, and then estimated 
at 5, 15, 30 and 60 minutes following IgM incubation. Percentage of trophozoite reduction over 
time was calculated relative to percentage of trophozoites before adding mouse IgMs.  
 
 
3.5.3 Correlation between IE surface labelling and lysis 
We then asked the question whether IgM labelling to erythrocytes infected by a 
particular isolate was significantly correlated with haemolysis to that isolate. We 
determined the association between IgM binding, in terms of percentage of 
surface labelling and percentage of IE lysis using Spearman's rho Correlation 
(Table 3.11). We found that 3G8, A4, ItG and P5B6 parasite isolates showed a 
moderate positive correlation between surface labelling and haemolysis (rs = 
0.37-0.49, P ˃ 0.05), i.e. if IgM surface binding to a particular isolate was 
detected, then IE lysis was also observed in that isolate. A statistically 
significant positive correlation was only observed with GC503 (rs = 0.77, P ˂ 
0.05) and 3D7 (rs = 0.92, P ˂ 0.001). Figure 3.16 represents the correlation 
between IE surface labelling and lysis for 3D7 isolate with a scatter plot 
demonstrating the significant linear relationship between both parameters.  
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Correlations 
 
3D7 surface 
labelling 3D7 lysis 
Spearman's rho 
   
  
3D7 surface 
labelling 
Correlation Coefficient 1.000 .923** 
Sig. (2-tailed) . .000 
N 13 13 
3D7 lysis Correlation Coefficient .923** 1.000 
Sig. (2-tailed) .000 . 
N 13 13 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
 
 
 
 
 
 
Figure 3.16. Output of Spearman's rho correlation between surface labelling and IE lysis for 3D7 
parasite strain as indicated by SPSS (version 22). A: Spearman's rho correlation (rs) showing a 
significant positive correlation between the surface labelling of 13 mAbs/pAbs and IE lysis to 
3D7 isolate. B: Scatter plot showing a positive linear relationship between surface binding of 
3D7-IEs and cell lysis as indicated by the line of best fit. R2: coefficient of determination.  
A 
B 
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 P. falciparum isolates 
 3G8 GC503 A4 ItG PFB6 C24 3D7 CS2 
Spearman's rho 
correlation coefficient (rs)  
0.37 0.77 0.48 0.41 0.49 0.52 0.92 -0.25 
P value 0.21 0.002* 0.098 0.17 0.09 0.067 0.0001** 0.409 
 
Table 3.11. Correlation between surface labelling and IE lysis for eight P. falciparum isolates as 
indicated by SPSS (version 22). Values of Spearman's rho correlation coefficient (rs): 0 (no 
correlation between variables), 0.1 to 0.3 (weak positive correlation), 0.3 to 0.5 (moderate 
positive correlation), 0.5 to 1.0 (strong positive correlation), -0.1 to -0.3 (weak negative 
correlation), -0.3 to -0.5 (moderate negative correlation), -0.5 to -1.0 (strong negative 
correlation). Correlation is statistically significant when P value ˂ 0.05. **: Correlation is 
significant at the 0.001 level, *: correlation is significant at the 0.05 level.  
 
 
3.6.3 Effect of IgM dilution on IE lysis 
We then investigated whether diluting the concentration of IgM affected the 
amount of lysis observed. B4 and G6 mAbs were tested for surface labelling 
with ItG-IEs at neat concentrations or at 1:2, 1:4 or 1:8 dilution (Figure 3.17). 
We found that the percentage of lysed cells was noticeably reduced with 
decreasing concentrations of IgM. When subjected to further analysis, IgM 
concentration and percentage of lysed IEs were significantly correlated, with 
correlation coefficients (rs) of 1.0 (P ˂ 0.0001) for B4 and G6. The percentage of 
haemolysis returned to normal levels (˂ 15%) at 1:4 dilution when the surface 
labelling signal also disappeared. These findings confirm that IE lysis was only 
observed with IgM labelling to the surface of IEs, and cell lysis was not detected 
when the surface binding of the tested IgM was lost.  
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Figure 3.17. Association between IgM concentration and percentage of ItG-IEs lysis by mAbs B4 and G6 
as indicated by flow cytometry. Trophozoite-enriched cells were incubated with 50 µl of mAbs at neat 
concentrations or at 1:2, 1:4 or 1:8 dilutions in PBS/1%BSA for surface labelling. Cells stained with 20 
µg/ml mouse IgM isotype control (Sigma) were included as negative controls for mouse IgM binding and 
shown in red. Population of IEs lysed after mouse IgM incubation was obtained from the FITC-positive 
channel (ethidium bromide labelled cells), and the percentage of lysed IEs (shown in red) was calculated 
relative to the percentage of lysis by mouse isotype IgM control. 
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3.7 Discussion  
With the aim of defining smaller regions from the PfEMP1 protein capable of 
inducing functional antibodies that block the adhesion to ICAM-1 receptors, we 
used recombinant DBLβ domains from four ICAM-1 binding PfEMP1 variants 
for mouse immunisation. Only three domains (DBLβ13, DBLβ31 and DBLβ41) 
elicited functional mAbs and pAbs that recognised the corresponding DBL 
domains and cross-reacted with heterologous domains. In the present chapter, 
we used different immunological methods to further characterise the functional 
properties of these antibodies. In general, our results demonstrated that labelling 
was not limited to homologous ICAM-1 binding strains, as antibodies also 
recognised erythrocytes infected by C24, a non-ICAM-1 binding isolates. This 
indicated that induced antibodies were not phenotypically-specific, since DBL 
domains used in mouse immunisation were obtained from ICAM-1 binding 
PfEMP1 proteins.  
Our results also showed that mAbs and pAbs labelled the surface of 3D7 strain-
infected RBCs, which further extended the level of cross-reactivity to a 
heterologous strain with a distinct genotype. We also demonstrated that mAbs 
and pAbs did not show any increased specific labelling for their homologous 
isolates. There was no clear pattern of variant-specific recognition by mouse 
antibodies raised to DBL13 and DBL31 against erythrocytes infected by their 
corresponding parasite isolates (GC503 and P5B6, respectively), as almost all 
positive mAbs and pAbs equally recognised homologous and heterologous 
isolates. For instance, mAb E7 was raised to DBL31 from IT4VAR31, but gave 
stronger labelling with 3G8 and A4 than the homologous strain (P5B6). 
However, pAb A4 was an exception for this observation as it recognised 
erythrocytes infected by its corresponding isolate (P5B6) more specifically than 
heterologous parasites. In terms of specificity, we found that the strongest 
labelling antibodies were mainly monoclonal antibodies. In fact, all mAbs 
except C9 were comparatively most effective in labelling the surface of all tested 
IEs. On the other hand, antibodies of polyclonal specificity varied in their 
capacities to recognise parasitized cells. Variations in labelling the surface of IEs 
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among monoclonal and polyclonal antibodies indicate that non-reactive clones, 
particularly of polyclonal specificity, could not produce antibodies at the right 
fine specificity to recognise surface proteins. It may also demonstrate that 
immunogenic epitopes are conformational and only accessible to antibodies with 
certain specificities.  
An interesting finding of this study was that mAbs and pAbs raised to DBL41 
were comparatively the most effective in all assays. This was surprising, since 
this protein showed the weakest reactivity with homologous and heterologous 
mouse immune sera in ELISA and Western Blotting. E7 was the only mAb from 
DBL31-specific antibodies that showed significant labelling profiles with all 
tested isolates. Other antibodies raised to the same antigen including C2, C9 and 
2E10 showed the least functional reactivity with the surface of parasitized 
erythrocytes. These results suggest that recombinant DBL41 domains expressed 
in E. coli contained the functional components required to elicit a broadly 
reactive immune response. Therefore, this domain might give rise to novel 
therapeutics and development of cross-reactive malaria vaccine.  
Investigating the pattern of individual mouse IgM binding has led to the 
observation that mAbs and pAbs exhibited similar patterns of IgM surface 
labelling among parasite isolates. All tested parasites, except the CSA-binding 
CS2, showed a significant positive correlation between each other in terms of 
surface labelling to diverse parasites. This suggests that reactive mAbs and pAbs 
comprised a repertoire of cross-reactive IgM antibodies that capable of 
recognising erythrocytes infected by diverse P. falciparum strains. The higher 
level of cross-reactivity strongly suggests the presence, among parasites of 
different genotypes, of conserved epitopes within the PfEMP1 or in another 
parasite-derived protein on the surface of infected erythrocytes that are 
accessible to polymeric IgM antibodies. Cross-reactivity cannot be attributed to 
the presence of a mixture of antibodies with multiple specificities, since most 
reactive antibodies were of monoclonal specificities.  
Production of cross-reactive mAbs or pAbs that recognise RBCs infected by 
distinct P. falciparum isolates has been shown in several published studies. For 
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instance, Lekana Douki et al. (2002) produced mAbs in mice to DBL-γ3CSA of 
the FCR3 strain and the produced mAbs, of which 70.8% were IgMs, labelled 
the surface of IEsCSA and cross-reacted with CSA-binding parasites from distant 
geographic areas. Some of the produced antibodies labelled the surface of other 
parasites with other adhesive phenotypes (i.e. ICAM-1 or CD36 binding). In 
another work, Gamain et al. (2001) raised mAbs to CIDR1 region of PfEMP1 
and found that two mAbs, targeting different regions of CIDR1, reacted with up 
to 90% of tested P. falciparum strains expressing variant PfEMP1s. In addition, 
pre-adsorption of serum samples obtained from semi-immune African adults 
with recombinant DBL-1α domains has resulted in the reduction of total anti-
VSA antibody response, suggesting that conserved domains of PfEMP1 may 
induce cross-reactive antibodies (Abdel-Latif et al., 2004). However, the cross-
reactivity of antibodies raised to VAR2CSA or to the head structure (CIDR1α-
DBL1α) is mainly attributed to the relatively higher degree of sequence 
conservation in these domains, and to our knowledge, no mAbs were raised to 
DBLβ domains similar to those raised in the present study.  
Our data indicated that almost all purified mAbs and pAbs efficiently recognised 
recombinant domains as indicated by ELISA, but not all antibodies recognised 
the surface of live IEs. There was a positive correlation between reactivity of all 
mouse IgMs to rDBL31 and surface labelling to erythrocytes infected by all 
tested isolates. For example, mAb E7 and all anti-DBL41 antibodies showed the 
highest levels of reactivity in ELISA and also recognised the surface of most 
tested parasite strains. On the contrary, pAbs E4 and 2E10 and mAb C9 showed 
a higher reactivity against recombinant proteins in ELISA but exhibited the 
weakest profiles of IE surface fluorescence. In addition, pAb C2 significantly 
recognised the recombinant protein but almost failed to recognise parasite 
isolates. The lack of surface reactivity in some antibodies despite their reactivity 
in ELISA likely suggests the importance of conformational 3D epitopes in 
surface labelling, and that critical epitopes that were exposed and easily 
recognisable in linear recombinant proteins were hidden in the native structure 
and only accessible to specific antibodies. Our findings also indicated that the 
presence of IgM per se in a particular mAb/pAb does not account for surface 
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labelling. Some antibodies (e.g. pAb C2) comprised higher amounts of IgM but 
exhibited weak if any surface binding, which indicates that surface reactivity 
was only dependent on the presence of specific antibodies that can recognise 
target epitopes regardless of IgM abundance in purified yields. This was 
supported by the ability of pAb B12 to recognise IEs although this antibody had 
not efficiently purified and only comprised trivial amounts of IgM in the purified 
yield.  
We assumed that the surface protein recognised by mouse IgM antibodies was 
DBLβ domains of the native PfEMP1, a major immunogen exported to the 
surface of IEs and is responsible for at least some of the adhesive properties of 
IEs (Rowe et al., 2009). However, ICAM-1-binding DBLβ domains only share 
46% sequence identity with the other six domains from the IT4 genome (Brown 
et al., 2013), and this extensive sequence diversity among different PfEMP1 
variants suggests that antibody cross-reactivity between different P. falciparum 
isolates could be explained by the recognition of another conserved, cross-
reactive epitope within different PfEMP1 proteins. Despite the geographic 
variation and enormous diversity between HB3, IT4 and 3D7 parasite genomes, 
some examples of segmental sequence similarity were observed between var 
genes of different isolates. For instance, DBL1α of the head structure DBL1α-
CIDR1α tend to have the most similarity between PfEMP1 of HB3, IT4 and 3D7 
parasite genes, although there are regions of similarity in some CIDRI domains 
(Kraemer et al., 2007). This semi-conserved head structure plays a functional 
role in mediating the cytoadherence to multiple independent host receptors 
(Chen et al., 2000) and may act as a candidate for mouse IgM binding. 
Although surface labelling was mainly specific for IEs, we could not confirm 
that labelling was specific for the native PfEMP1 as other parasite-derived 
proteins exported on the surface of IEs also can act as surface epitopes for 
binding. P. falciparum-induced modifications to the host cell surface might have 
resulted in the expression of a novel antigen containing IgM binding epitopes, 
but that antigen has not yet been identified. For instance, parasite-derived 
surface proteins encoded by the rif or stevor multigene families have been 
suggested to play a role in host-parasite interaction and antigenic properties 
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(Beeson et al., 2006, Niang et al., 2009, Rowe et al., 2009). Although their 
biological significance and role in natural immunity are largely unknown (Chan 
et al., 2012), the higher expressed level of these genes by P. falciparum parasites 
suggests their important role in parasite contact with host cells (Smith and Craig, 
2005). They co-express with PfEMP1 proteins on the surface of IEs, despite the 
transcriptional findings that rif genes expressed after var genes, only for a 
limited time from late rings to early pigmented trophozoites (Kyes et al., 2000). 
In addition, human immune sera agglutinated IEs treated with trypsin at 
conditions (˃ 100 µg/ml) such that the highly trypsin-sensitive PfEMP1 proteins 
are mostly removed but RIFINs detected, suggesting the existence of 
immunogenic epitopes in this family of proteins targeted by agglutinating 
antibodies (Fernandez et al., 1999). Another study showed that RIFIN 
recombinant proteins were well recognised by a large panel of human immune 
sera suggesting the capacity of these proteins to induce a strong immune 
response in P. falciparum infected adults in malaria endemic regions (Abdel-
Latif et al., 2002). Furthermore, it has been demonstrated that acquisition of 
specific anti-RIFIN antibodies was associated with protection against P. 
falciparum malaria (Abdel-Latif et al., 2003). Recently, Goel et al. (2015) have 
demonstrated that RIFINs are expressed on the surface of IEs, bind to RBCs 
(preferentially of blood group A) to form large rosettes and mediate 
microvascular adhesion of IEs. Taken together, these studies highlighted the 
immunogenicity of RIFINs and suggested that these proteins can act as binding 
ligands for our mouse mAbs and pAbs. 
Unlike PfEMP1 and RIFIN, data presenting evidence that that STEVOR proteins 
are exported to external surface of IEs are limited. A recently published study 
demonstrated that STEVOR proteins are expressed on the surface of IEs, using a 
combination of live IFA and flow cytometry, and this expression was only 
localised on erythrocytes infected by schizont parasite stage (Niang et al., 2009). 
Additionally, the similarity between STEVOR and RIFIN in terms of shared 
conserved sequences (Smith and Craig, 2005), and the peak expression of 
STEVOR during late trophozoites or early schizonts (Niang et al., 2009) make 
them potential candidates for surface binding. Modified host proteins such band 
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3 have also been proposed as immune targets since they are trypsin-resistant, 
located on the surface of IEs and were immunoprecipitated by mAbs to band 3 
(Gardner et al., 1996). In addition, these highly abundant proteins on the surface 
of IEs were suggested to be involved in adhesion to various cells through CD36 
receptors (Smith and Craig, 2005). Whether or not mAbs and pAbs bind to any 
of the surface proteins noted above is still unknown, and further characterisation 
analyses are needed for defining the surface molecule(s) incorporated in IgM 
binding.  
In competition assays we investigated whether mouse IgMs out-compete BC6, 
HIS or anti-DBL16 rat antisera for IE surface adhesion and vice versa. BC6 and 
anti-rat antisera specifically recognise erythrocytes infected by their 
corresponding parasite isolates (A4 and ItG, respectively) whereas HIS cross-
reacted with different P. falciparum isolates. Based on the assumption that 
strain-specific antibodies (BC6 and anti-DBL16 antisera) label the native 
PfEMP1, we hypothesised that reduction or complete loss of surface labelling 
competed by mAbs/pAbs may indicate that these mouse IgMs fully or partially 
bind to PfEMP1 on the surface of IEs. Our results demonstrated that mAb BC6 
moderately interfered with the subsequent binding of mouse IgMs, which may 
suggest that mAbs and pAbs partially bind to PfEMP1 on the surface of IEs and 
that binding epitopes were partly masked by BC6. The extent of interference by 
BC6 on mouse IgM subsequent binding is a crucial marker for mapping the 
IgM-binding epitopes, since mAb BC6 is an IgG class antibody that only 
recognise an exposed epitope on surface PfEMP1 of erythrocytes infected by A4 
P. falciparum isolate (Roberts et al., 1992, Horrocks et al., 2002). Failure to 
completely block mouse IgM binding does not necessarily indicates that IgMs 
do not bind PfEMP1, as the binding activity of BC6 may lie distal to the mouse 
IgM binding sites on PfEMP1 protein which explains the diversity between BC6 
and mouse IgMs in labelling trypsin-digested IEs. Our findings also suggested 
that the binding sites for mouse IgMs and rat anti-DBL16 antisera are partially 
overlapped on the surface of IEs, as revealed by the remarkable reduction of 
mouse IgM subsequent binding to IEs pre-incubated with anti-DBL16 rat 
antisera. Although mouse IgMs had a relatively lower effect on rat antisera 
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binding, the results noted above support our suggestions that mAbs and pAbs 
partially bind to the surface PfEMP1 molecules since rat anti-DBL16 antisera 
comprise strain-specific antibodies capable of labelling ItG-PfEMP1 variants.  
An alternative explanation of the observations discussed above is that mouse 
IgMs bind to epitopes different from those of BC6 or anti-rat sera on the surface 
of IEs and the influence of mouse IgMs on BC6 or antisera could be explained 
by the binding of the large polymeric IgM molecules to parasite-derived surface 
proteins. This binding may have unintentionally evolved to partly shield 
functional epitopes involved in BC6 and rat anti-DBL16 antisera on PfEMP1 
upon binding to other surface antigens, which explains the limited ability of 
mAbs and pAbs in disrupting specific BC6 and rat antisera binding. This 
confirms that the surface of parasitized erythrocytes must contain separate 
functional domains that mediate binding to variant antibodies and can have 
antigenically distinct epitopes. 
We found that mAbs and pAbs had a significant role in interference with the 
subsequent binding of the cross-reactive HIS, and the latter also remarkably 
reduced the binding of mouse IgMs. This two-sided inhibitory effect can be 
related to cross-reactivity of mouse IgMs and Malawian HIS to the surface of 
erythrocytes infected by diverse parasite isolates. Mouse IgMs could either mask 
a residue important for HIS binding or alter the conformation of the binding 
epitope in such a way to destabilise HIS interaction. However, the fact that HIS 
has a similar effect on mouse IgM binding suggests that at least part of the 
binding site may be common for the HIS and mouse IgMs. A study showed that 
pre-incubating IEsCSA with a human IgM control antibodies or a pool of sera 
from non-immune adults had not affected on anti-VAR2CSA mouse IgM 
antibodies specific for var2csa-PfEMP1, whereas a decrease in IE recognition 
by 42.8% was observed after pre-incubation with immune sera from 
multigavidae women (Avril et al., 2006). This indicates that the binding region 
of cross-reactive immune sera and specific mAbs may overlap and polyclonal 
IgG antibodies in immune sera can partially interfere with the binding of specific 
IgM antibodies, which is consistent with our findings. To sum up, competition 
between mouse IgMs and tested Abs appears to be inconclusive. The notable 
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influence of mAbs and pAbs on the binding of the cross-reactive HIS compared 
to their relatively moderate interference with the strain specific BC6 or anti-
DBL16 antisera may suggest that mouse IgMs bind to non strain-specific but 
cross-reactive epitopes shared between variant P. falciparum isolates. Further 
studies are needed to investigate the kinetics of IgM binding to surface receptors 
and to determine the functionality of these cross-reactive, broadly expressed 
binding receptors. 
Controlled proteolytic digestion of intact IEs has been widely utilised to explore 
the expression of antigens and determine the potential relationship between of 
VSAs expressed on IEs and adhesion phenotype (Gardner et al., 1996, 
Fernandez et al., 1999). We took advantage of the differential sensitivities of 
parasite-derived VSAs to controlled trypsin treatment for characterising the 
surface candidates involved in the binding of mAbs and pAbs. Unlike other 
surface proteins, the high-molecular-weight PfEMP1 is highly sensitive to low 
concentrations of trypsin and can be cleaved from the surface of intact IEs at ≥ 
10 µg/ml trypsin treatment (Leech et al., 1984). This was consistent with our 
preliminary data demonstrating that treating IEs with trypsin at 10 µg/ml was 
extremely effective in abolishing binding ligands for ICAM-1 and BC6 on 
PfEMP1, though the former epitope was abolished at a lower trypsin 
concentration (1 µg/ml). This was shown by the complete loss of BC6 binding to 
PfEMP1 on A4-IEs or binding of ItG-IEs to immobilised ICAM-1 receptors 
upon trypsin digestion. The binding of mouse IgMs was substantially reduced 
with trypsin treatment, i.e. the higher the concentration of trypsin the lower the 
binding detected. However, the binding was not completely ablated as observed 
with mAb BC6. This may propose that mouse IgMs don’t completely bind to 
PfEMP1 as indicated by the sustained binding to IEs at higher trypsin 
concentrations, and suggests a separate or partially-overlapping binding sites for 
mouse IgMs and BC6. Mouse IgMs responded differently to trypsin digestion. 
For example, binding of mAb G6 was reduced by 36% at 10 µg/ml trypsin 
digestion, the suggested concentration required for cleaving PfEMP1, and the 
binding was dramatically reduced with 1 mg/ml trypsin treatment (62%). This 
sensitivity indicates that G6 partially recognises a trypsin-sensitive surface 
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antigen with the characteristics of PfEMP1, with the majority of binding to a 
trypsin-resistant epitope. On the contrary, the binding regions for pAb B5 were 
more resistant to trypsin cleavage at 10 and 100 µg/ml, suggesting its specificity 
to bind a trypsin-resistant ligand expressed on the cell surface. The binding 
profile for HIS to trypsin digested IEs principally resembled that of mouse IgMs, 
particularly mAb G6. This is consistent with previous suggestions in the present 
work that both mouse IgMs and HIS bind the same surface protein or to a largely 
overlapped epitope. However, the naturally acquired immune response in human 
HIS is predominantly variant specific as evidenced from mixed agglutination 
assays of pooled and individual sera in endemic areas (Newbold et al., 1992). On 
the contrary, the nature of the immune response of mouse mAbs and pAbs 
appears to be cross-reactive rather than variant specific, since antibodies with 
monoclonal specificities (mAbs) recognise all tested P. falciparum isolates, and 
showed no specificity for particular genotypes or phenotypes. Several trypsin-
resistant parasite-derived surface proteins, such as RIFINs and modified band 3, 
can act as binding ligands for mouse IgMs and HIS, but the identity of such 
ligands is not yet identified.  
Despite the higher sensitivity of PfEMP1 to trypsin digestion, protease-resistant 
adhesion to ICAM-1 was observed with some parasite lines from the IT4 line 
(Gardner et al., 1996). This may be explained by the rapid antigenic switching in 
P. falciparum parasite isolates that resulted in the existence of a phenotypically 
heterologous protease-resistant subpopulation of IEs within cultures (Gardner et 
al., 1996). It has been established that not all PfEMP1 proteins exported to outer 
membrane of IEs are digested with trypsin (Waterkeyn et al., 2000). A study 
showed that the ∼300 kDa band of intact PfEMP1 was observed following the 
treatment with trypsin, suggesting that either not all of the PfEMP1 is exposed 
and accessible to trypsin, or only some portions of the protein are sensitive to 
trypsin (Beeson et al., 2006). Although the ICAM-1 binding site in PfEMP1 was 
localised within the trypsin cleavage region in Gardner et al. (1996) model for 
PfEMP1 domain proteases digestion, mAbs and pAbs could partially bind to a 
trypsin-resistant constant region of PfEMP1 located close to the membrane, with 
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the majority of antibody population binding to a trypsin-resistant parasite-
derived surface protein.  
In the present study, we detected a notable reduction in IE population after 
incubation with mouse mAbs and pAbs. We further investigated whether i) this 
lysis was IgM-dependant, ii) there was a correlation between surface labelling 
and IE lysis and iii) whether human serum components in culture contributed to 
the lysis phenomenon. Our findings indicated that haemolysis was resulted from 
an immunological interaction between mouse IgMs and a parasite-derived 
component on the surface of live infected erythrocytes as confirmed by three 
observations. First, mainly IEs were lysed upon mouse IgM incubation, whereas 
non-IEs were largely unaffected. Second, the majority of mouse IgMs that 
caused IE lysis were highly efficient in recognising the surface of erythrocytes 
infected by all tested isolates, whereas haemolysis was less observed or absent 
with non-labelling mAbs and pAbs. We observed a moderate to strong 
correlation between surface labelling in terms of percentage of surface 
recognition and percentage of IE lysis. All antibodies raised to DBL41 domains 
(B5, D5, B4 and G6) and anti-DBL31 mAb E7 that demonstrated that highest 
levels of surface recognition with all tested isolates also lysed most IEs of the 
corresponding parasite lines. Furthermore, the concentration of IgM in purified 
mAbs and pAbs was not a significant factor contributing to IE lysis, since 
antibodies with higher IgM concentrations (e.g. C2 and C9) were comparatively 
ineffective in lysing cells compared other antibodies at lower concentrations (E4 
and B4). Third, diluting the signal of surface labelling was significantly 
correlated with decreasing the amount of lysed IEs, and the percentage of lysed 
cells was almost returned to normal levels with the loss of labelling signal of 
tested antibodies. These findings indicated that IE lysis resulted from an IgM-
mediated binding to a parasite-derived protein on the surface of IEs.  
All mAbs and pAbs were purified and neutralised at the same buffer conditions 
at pH 7.0-8.0, therefore, variations in the capacity to destroy IEs among mAbs 
and pAbs indicated that haemolysis was resulted from factors related to IgM-
binding rather than alteration in the buffer conditions. We further investigated 
the effect of temperature on IE lysis by incubating IEs with mAbs/pAbs on ice 
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or at 4°C rather than 37°C. No significant change was observed in terms of 
surface labelling or IE lysis (data not shown), indicating that temperature 
conditions did not influence cell lysis. Although the definite mechanism of IE 
lysis is not yet understood, IgM-dependent complement mediated lysis could be 
the potential mechanism underlying this phenomenon. Binding of IgM to a 
surface epitope, potentially PfEMP1 may result in the activation of the classical 
complement cascade through C1q binding leading to cell lysis. This is possible 
since mouse IgM antibodies bind human complement component C1 (Boulianne 
et al., 1987). In addition, complement activation is one of the earliest markers of 
immune response to malaria (Roestenberg et al., 2007). The polymeric structure 
of IgM antibodies principally benefits these molecules to efficiently agglutinate 
and neutralise pathogens or pathogen-infected cells (Czajkowsky et al., 2010). 
This sole structure makes IgM extremely efficient at activating the classical 
cascade, as a single IgM molecule is capable of activating the complement 
system leading to the lysis of a single RBC (Czajkowsky et al., 2010). Upon 
binding to the surface epitope on IEs, IgM may undergo a conformational 
change favouring the binding of C1q (Czajkowsky and Shao, 2009) which 
facilitates downstream components terminating in the assembly of membrane 
attack complexes (MAC) that lyse the cell. In order to investigate the 
involvement of serum complement components in IE lysis, we tested surface 
labelling of mouse IgMs with IEs cultured in media supplemented with heat-
inactivated human serum compared to those cultured in normal serum. We 
aimed to eliminate complement components present in traces of human serum in 
parasite cultures by heating the serum at 56°C for 30 minutes. The results 
indicated that IE lysis was also detected in heat-inactivated culture media and 
there was no difference in terms of haemolysis between both parasite cultures 
(data not shown). Moreover, parasites were maintained in culture media devoid 
of human serum (supplemented with albumax) and the same finding was 
observed. If cell lysis was mediated through complement activation, our data 
suggest that complement factors are present on the parasite-infected cells rather 
than circulating in the human serum. Although no published evidence 
confirming that C1q in particular is present on the surface of IEs (Czajkowsky et 
al., 2010), an early study demonstrated that components of complement cascade 
are fixed on the surface of P. falciparum IEs (Wiesner et al., 1997). This study 
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also suggested that the parasite relies solely on the host cell to restrict 
complement activation and cell lysis. Thus, binding of IgM may has resulted in 
the disruption of a parasite-derived regulatory protein that suppresses 
complement activation and contributes to establishment of chronic disease.  
Despite the significant role of PfEMP1-specific antibodies in acquiring 
protection against severe malaria, the extensive diversity of PfEMP1 variants 
limits their potential in the development of a universal vaccine (Bull et al., 1999, 
Nielsen et al., 2004). However, some structural conservations that limit the 
diversity of PfEMP1 must exist to maintain its function as an adhesion protein 
(Bull et al., 1999, Gamain et al., 2001). It was suggested that common ''basic 
types'' of PfEMP1 are expressed during P. falciparum infection. These ''basic 
types'' tend to be immunogenic and induce antibody response (Giha et al., 1999). 
Immune sera collected from people living in different African countries 
agglutinated parasitized erythrocytes from distal regions, suggesting the 
presence of cross-reactive epitopes expressed by several parasite isolates (Aguiar 
et al., 1992). Another study showed that antibodies in plasma collected from 
geographically distant and epidemiologically distinct regions recognised VSAs 
of different parasite isolates independent of the geographical origin of those 
parasites, suggesting that the repertoire of immunologically distinct VSAs are 
restricted and geographically-conserved among diverse populations (Nielsen et 
al., 2004). Another study showed that parasite isolates from individuals with 
severe malaria were agglutinated very frequently by heterologous plasma 
antibodies, which provided evidence for the existence of dominant subset of 
antigens on the surface of IEs recognised by prevalent antibodies (Bull et al., 
1999). Moreover, a study conducted on Kenyan children showed that the 
agglutination frequency among parasite isolates causing severe malaria was 
significantly higher than the agglutination frequency of those causing mild 
disease, suggesting that parasites causing severe disease express a prevalent 
subset of VSAs (Bull et al., 2000). These studies are consistent with earlier 
suggestions that the large repertoire of isolate-specific surface antigens may 
comprise antigenically cross-reactive antigens among diverse geographically 
distant parasites (Aguiar et al., 1992). Indeed, our experimentally induced mouse 
antibodies are similar in function to protective antibodies present in immune 
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adults in that they recognise the surface of diverse parasite isolates, making them 
suitable candidates for universal vaccine development.  
In conclusion, our study demonstrated that single domains of E. coli-expressed 
DBLβ from PfEMP1ICAM-1 could elicit broadly cross-reactive, IE-lysing mouse 
antibodies against different strains of heterologous phenotypes and genotype. 
Such dual activity could be highly beneficial in the development of therapeutic 
antibodies. Indeed, cross-reactivity against diverse parasite population is 
encouraging since polymorphisms of PfEMP1 variants and the ability of P. 
falciparum isolates to switch surface PfEMP1 to other variants with different 
phenotypes make it difficult to develop strain-specific vaccine candidates based 
on targeting single DBL domains. An effective vaccine would elicit broadly 
reactive antibodies that cross-react with most, if not all binding isolates, or 
would contain a mixture of components each recognise a different isolate. 
However, further studies are required to further characterise the binding sites for 
mAbs and pAbs on the surface of IEs and to assess their capacity for blocking 
the adhesion of IEs to immobilised receptors or endothelial cells lines. In 
addition, more work is needed to elucidate the molecular mechanism of 
parasitized erythrocyte lysis by mouse IgMs and blood or antibody factors that 
underlie this phenomenon.  
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3.8 Limitations and Future work 
Several functional assays have not yet been carried out due to limitations of time 
and amount of purified antibodies resulting from IgM purifications. Some of 
these significant assays include the investigation of surface reactivity of mAbs 
and pAbs against PfEMP1-knockout P. falciparum isolates. Whether or nor our 
mAbs and pAbs are capable of labelling these transgenic isolates relative to their 
corresponding parental lines is significant in characterising the surface ligand(s) 
labelled by mouse IgM. Recently, we have successfully cultured a CS2 P. 
falciparum isolate with disrupted P. falciparum skeleton binding protein 1 
(PfSBP1) gene. This gene was shown to be required for the transport of PfEMP1 
to the surface of IEs (Maier et al., 2007). Assessing the capacity of mAbs and 
pAbs to label the surface of this CS2∆SBP1 transgenic line may further identify 
the surface binding epitopes. Since the present work has evaluated the reactivity 
of mouse IgMs against lab-adapted parasite isolates, mAbs and pAbs can be 
investigated for surface reactivity with fresh patient isolates.  
The definite mechanism for IgM-mediated IE lysis is not yet understood. We 
suggested that IgM-dependent complement mediated lysis is a potential 
mechanism underlying this phenomenon. It has been shown that components of 
complement cascade are fixed on the surface of P. falciparum IEs (Wiesner et 
al., 1997). Further assays can be carried out to investigate the presence of C1q or 
other complement components on the surface of IEs, such as the use of different 
detecting mAbs directed to these components.  
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Investigating the capacity of mAbs and 
pAbs to block IE cytoadhesion 
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Chapter 4: Introduction  
Our understanding about the interaction between IEs and host receptors comes 
essentially from in vitro studies. IE Adhesion assays under static conditions or in 
laminar flow systems are amongst the major assays used to study the dynamics 
and kinetics of the binding between IEs and their receptors (Cooke and Nash, 
1995). Several in vitro models have been used to study parasite cytoadhesion 
including those investigating the interaction of IEs with purified proteins 
immobilised on plastic (Roberts et al., 1985, Barnwell et al., 1989, Ockenhouse 
et al., 1989, Ockenhouse et al., 1992b, Tse et al., 2004, Craig et al., 2000, 
Madkhali et al., 2014), cDNA transfected cells such as CHO (Berendt et al., 
1989), amelanotic melanoma cells (Barnwell et al., 1989, Ockenhouse et al., 
1989), human ECs such as HUVEC and human dermal microvascular 
endothelial cells [HDMEC] (Madkhali et al., 2014, Gray et al., 2003, 
McCormick et al., 1997) or human tissues such as placenta cryosections (Avril 
et al., 2006). Parasite cytoadhesion under static conditions measures 
immobilization of IEs on coated proteins, whereas flow assays attempt to mimic 
the in vivo physiological system and assess strength or avidity of parasite 
adhesion under the pressure of blood flow (Cooke and Nash, 1995, Ochola et al., 
2011). Although both the static and flow adhesion systems have provided us 
with valuable information about the interaction between the parasite and its 
ligands, these information should be observed in parallel to advance our 
knowledge about these procedures (Cooke and Nash, 1995). 
The suitability of in vitro models for studying the in vivo sequestration can be 
judged by the following criteria: adherence of IEs to receptors on cells or tissues 
must be specific for erythrocytes infected by trophozoites or schizonts; parasite 
adhesion must occur at any level of parasitaemia; IE adhesion must be mediated 
by the direct interaction between protein ligands on the surface of IEs and the 
target cell or tissue; and IE adhesion must be subjected to inhibition or reversal 
by suitable antibodies (Udeinya, 1990). Therefore, the practicality of a particular 
in vitro model can be determined by the closeness of the observations obtained 
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from that model to the results of in vivo sequestration and follow the above 
criteria (Udeinya, 1990). 
Most studies that investigated the cytoadhesion of P. falciparum parasite isolates 
have been carried out under static conditions. In the present chapter, we 
investigated the capacity of mAbs and pAbs to block parasite binding under both 
static and physiological flow conditions, as results taken individually from either 
assays could give contrasting information about interactions between receptors 
and parasite ligands (Chakravorty and Craig, 2005). We evaluated the capacity 
of mouse mAbs and pAbs to block the adhesion of IEs to immobilised receptors 
(ICAM-1 or CD36) or endothelial cell lines under static or physiological flow 
conditions. Our results provided evidence that mAbs and pAbs produced in this 
work not only cross-reacted with different P. falciparum parasite isolates, but 
also cross-inhibited the adhesion of different parasites to immobilised receptors 
and HUVEC line. However, further work is needed to elucidate the mechanism 
of blockade and to evaluate the capacity of inhibition with a diverse range of 
parasite isolates against different proteins and cell lines.  
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4. Materials and Methods 
4.1 Purified proteins used for static and flow adhesion 
assays 
Recombinant protein chimeras of wild-type ICAM-1, consisting of five 
extracellular domains linked to the Fc portion of human IgG1, were prepared in 
our laboratory by Tadge Szestak (Liverpool School of Tropical Medicine, UK) 
following a protocol described by (Craig et al., 1997). NanoDrop 
spectrophotometer was used to estimate the concentration of soluble purified 
proteins (ranging from 200-700 µg/ml), before proteins were aliquoted and 
stored at -80°C for further use. CD36 proteins were provided commercially as 
soluble recombinant proteins (R&D systems, UK), which was stored at -20°C. 
ICAM-1 and CD36 proteins were used in all assays at 50 µg/ml in Dulbecco's 
phosphate buffer saline (PBS). 
 
4.2 Monoclonal antibodies  
MAbs used in adhesion-blocking assays were anti-ICAM-1 mAb 15.2, 
purchased from AbD serotec® (MCA1615T, mouse anti-human CD54, IgG1), 
and anti-CD36 mAb IVC7 which was kindly provided by Prof. Ellen van der 
Schoot (Sanquin, Amsterdam). All mAbs were incubated with IE suspensions at 
5 µg/ml in inhibition assays. Mouse monoclonal and polyclonal IgM antibodies 
were prepared as described in Chapter 2. 
 
4.3 Cytoadhesion assays under static conditions  
4.3.1 IE adhesion to immobilised protein receptors  
Static protein binding assay was carried out as previously described 
(McCormick et al., 1997) with minor modifications. All P. falciparum isolates 
used in the adhesion assays were obtained from cultures maintained for 1-2 
weeks after selection, since most isolates in continuous cultures lose the capacity 
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to bind after a short period (~ 24-43 days), although some continue to bind after 
longer periods (Udeinya et al., 1983). In addition, the use of parasite isolates 
cultured for longer periods as a model for cytoadherence in vivo could be 
misleading (Biggs et al., 1989).  Briefly, multiple circles (~10 mm in diameter) 
were drawn on the base of 60 × 15 mm Falcon Petri dishes (Cat. No. 08-757-
100B, Fisher Scientific). Two dishes were assayed for each parasite isolate. 
Then, spots (2 µl) of soluble ICAM-1-Fc in PBS (50 µg/ml), CD36 (50 µg/ml) 
or PBS were adsorbed in triplicates onto the circles and incubated in a 
humidified chamber at 37°C for 120 minutes to allow proteins to adsorb onto the 
dishes (Figure 4.1). These concentrations had previously been demonstrated to 
be within the dynamic range for observing variations in receptor-adhesion 
interactions (Gray et al., 2003). Protein spots were aspirated off and uncoated 
sites were subsequently blocked overnight at 4°C in 2 ml of PBS/1%BSA. 
Dishes were incubated for 60 minutes at 37°C prior to adhesion assays. Blocking 
solution was removed prior to adding 1.25 ml of IE suspension in binding buffer 
(RPMI 1640 [Sigma®, R4130] supplemented with 2% glucose at pH 7.2) at a 
parasitaemia of 3% and a HCT of 1% to each dish.  
Plates were incubated at 37°C for 60 minutes with gentle resuspension every 10 
minutes. Unbound IEs and non-IEs were removed by 6-8 gentle washes with 
binding buffer and successful washing was monitored using inverted 
microscope. Bound IEs were fixed onto the dishes by the addition of 1% 
glutaraldehyde in PBS for 20 minutes and then stained with 10% Giemsa for 
another 20 minutes at room temperature. Stained IEs were viewed using high-
power microscope (Eclipse T 200, Nikon) under 20 × 15 (×300) magnification. 
Photos of the remaining adherent cells were then captured using Nikon camera 
equipped to the microscope, analysed using HC Image software (Sewickley, 
USA) and counted using Image-Pro Plus Image analyser software version 7.0 
(Rockville MD, USA).  
Data presented correspond to the mean number of bound IEs of 36 readings (6 
protein spots) from two independent dishes (18 readings from each plate) and 
expressed as the mean percentage of binding of IEs incubated with IgM 
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antibodies relative to binding of IEs incubated in buffer alone (normalised to 
100%).  
 
 
 
 
  
 
 
 
 
 
Figure 4.1. Coating of ICAM-1 and CD36 receptors onto bacteriological petri dishes for static 
adhesion assays. PBS spots were included in all assays as negative controls.  
 
4.3.2 Blockade of IE adhesion under static conditions  
To investigate the capacity of mouse mAbs and pAbs to block IE adhesion to 
ICAM-1 or CD36 receptors, the same adhesion assay was carried out as 
described in the previous section with slight modifications. Briefly, IE 
suspension for two dishes (2.5 ml) was centrifuged for 3 minutes at 1800 rpm, 
before the pellet was incubated separately with 100 µl of each of the mouse IgM 
antibodies (pAb C2, pAb A4, mAb E7, pAb B5, mAb B4 and mAb G6) for 30 
minutes at 37°C. After incubation, cells were re-suspended in 2.5 ml binding 
buffer and 1.25 ml was added to each dish (×2), then the assay was continued as 
described in the previous section. MAbs that block parasite adhesion to ICAM-1 
(mAb 15.2) or CD36 (mAb IVC7) were added to IE suspension at 5 µg/ml prior 
to addition to the protein-coated dishes and the same procedure were followed as 
shown above. Percentage of IE adhesion-blocking was determined by the 
difference in the count of IEs assayed in the presence of IgM or IgG antibodies 
relative to IEs incubated in binding buffer alone. The results were expressed as 
percentage of binding of test samples relative to control, normalised as 100%.   
ICAM-1 
(50 µg/ml) 
 
CD36 
(50 µg/ml) 
 
PBS 
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4.4 Cytoadhesion assays under physiological flow 
conditions  
4.4.1 IE adhesion to immobilised receptors  
4.4.1.1 Adhesion to ICAM-1 under flow conditions  
Flow-based protein adhesion assays were carried out using a modified laminar 
flow system as described elsewhere (Gray et al., 2003) with minor 
modifications. P. falciparum IE adhesion to ICAM-1 was determined using 3-
aminopropyl triethoxysilane (APES)-treated Vena8 Fluoro+TM biochips (cat no. 
V8CF-400-100-02, Cellix Ltd, Dublin, Ireland) shown in Figure 4.2. Channels 
were coated with ICAM-1 (50 µg/ml) and incubated in a humidified chamber at 
37°C for 120 minutes before they were blocked with 1%BSA/PBS and incubated 
overnight at 4°C. Micro-slides were connected to tubing system on a 
microscopic stage enclosed within a plastic chamber that maintains the 
temperature at 37°C. IEs were adjusted to 3% parasitaemia and 2% HCT in 500 
µl binding buffer and flowed through the micro-slides using the VenaFlux 
Platform (Cellix) for 5 minutes at a flow rate yielding a wall shear stress of 0.05 
Pa (0.186 ml/min) calculated based on the formula described by Cooke et al. 
(1994). The wall shear stress was calculated to mimic the wall stress in the 
microvessels and temperature of the system was adjusted to 37°C throughout the 
assay. Binding buffer was then perfused for 2 minutes to remove unbound cells. 
The number of stationary adherent IEs was immediately counted in six random 
fields of view on the micro-slide under 20 × 15 (×300) magnification while the 
buffer is still running. Values were then normalised to the number of bound cells 
per square millimetre. Results expressed as the mean percentage of binding of 
IEs incubated with IgM antibodies relative binding of IEs incubated buffer alone 
(normalised to 100%). The assay was run in duplicate per single experiment to 
assess the consistency of the results. Bound IEs were removed from the slides by 
flowing binding buffer at a high level of shear stress over the slides, and removal 
was confirmed by examining the slides under the microscope. Micro-slides were 
washed with water then with binding buffer and stored at 4°C to be re-used in 
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future experiments. Each slide can be used up to six times and a positive control 
was carried out to ensure the validity of the slides.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Vena8 Fluoro+TM biochips (Cellix Ltd, Dublin, Ireland). 
 
 
4.4.1.2 Blockade of IE adhesion to ICAM-1 under flow conditions  
In assays that assess the ability of mouse mAbs and pAbs to inhibit parasite 
binding to immobilised ICAM-1 receptors, the same procedure was followed as 
shown above with some modifications. IE suspension (500 µl) designated for 
each antibody was firstly centrifuged for 3 minutes at 1800 rpm, before the 
pellet was incubated with 100 µl of mAbs or pAbs for 30 minutes at 37°C. After 
incubation, cells were pelleted and re-suspended in 500 µl of binding buffer, and 
then the assay was continued as shown in the previous section. To block specific 
adhesion to ICAM-1, mAb 15.2 was added to the suspension at 5 µg/ml prior to 
start of the assay. To minimise variations that effect the concentration of coated 
proteins during the assay, the same slide was used for cultures with or without 
antibodies. Percentage of IE adhesion blocking was determined by the difference 
in the count of IEs assayed in the presence of IgM antibodies to IEs incubated in 
binding buffer alone. The results were expressed as percentage of binding of test 
samples relative to control, normalised as 100%.  
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4.4.2 IE adhesion to HUVEC  
4.4.2.1 HUVEC culture    
HUVEC was purchased from PromoCell (C-12200, 500,000 cryopreserved 
cells) and cultured in endothelial cell growth medium (PromoCell, C-22120) 
supplemented with endothelial cell growth medium supplement Mix 
(PromoCell, C-39215) following standard conditions. Cells were allowed to 
attach to the internal surface of gelatine-treated ventilated T25 culture flasks 
containing 5 ml warm culture media for 2-3 hours at 37°C in CO2 incubator. 
Then, the media was discarded and replaced by the same volume of warm media 
before the flask was incubated for 48 hours at 37°C in CO2 incubator. Cells were 
checked for growth and confluence every alternate day and fresh culture medium 
was added.  
Confluent cultures were split by trypsinisation using PromoCell detach kit (C-
41220). The kit contains HEPES balanced salt medium (HEPES-BSS), trypsin / 
EDTA solution (0.04%/0.03%) and trypsin neutralising solution (TNS). Sub-
culturing of cells was carried out as followed: culture medium was firstly 
removed from the flasks, then 1.5 ml of HEPES-BSS was added to wash off 
remaining media before HEPES-BSS was removed and trypsin / EDTA solution 
was added to detach adherent cells from plastic surfaces and detachment of cells 
was confirmed by inverted microscope. This was immediately followed by the 
addition of TNS to stop trypsin digestion. The suspension was centrifuged at 300 
× g for 3 minutes before the pellet of cells was re-suspended in fresh warm 
media. Culture medium was changed every alternate day, and stage of 
confluence was monitored using inverted microscope. HUVECs were cultured to 
confluence (6th-7th passage) 24 hours prior to experimentation. On the day of the 
assay, Accutase® (Sigma-Aldrich®, A6964) was used to detach cells rather than 
trypsin.  
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4.4.2.2 Analysis of receptor expression on HUVEC by flow cytometry  
Surface expression of ICAM-1 or CD31 receptors on monolayers of HUVEC 
line was investigated by flow cytometry. Briefly, HUVECs from stable cultures 
were assayed with or without activation by 10 ng/ml of TNF-α at 18-24 hours 
prior to flow cytometry analysis. After activation, ECs were detached by 
treatment with Accutase® (Sigma-Aldrich®, A6964) and neutralised with culture 
medium. Cells were centrifuged at 300× g for 3 minutes, re-suspended with 100 
µl of PBS at 1 × 106 cells/ml and incubated with APC-conjugated mouse anti-
human CD54 (ICAM-1) IgG antibodies (BD biosciences, Ltd.) for ICAM-1 or 
with FITC-conjugated mouse anti-human CD31 IgG antibodies (BD biosciences, 
Ltd) for CD31, at 1:100 dilution for 60 minutes at 37°C. Cells incubated with 
APC-conjugated human IgG isotype control were included as a negative control 
for ICAM-1 expression and used to exclude the background signal, whereas 
cells incubated with FITC-conjugated human IgG isotype control were included 
as a negative control for CD31 expression.  
After incubation, cells were washed in PBS, re-suspended in 400 µl Cell Wash 
and analysed using Becton-Dickinson FACSCalibur flow cytometer (BD 
LSR11). 10,000 events were collected and analysed using FlowJo software 
(10.0, San Carlos, CA, USA). Gating on FSC-A vs. APC-A was carried out to 
recognise HUVEC population expressing ICAM-1 receptors whereas gating on 
FSC-A vs. FITC-A was used to identify CD31-positive cells. Data were 
presented as histograms showing the percentage of ICAM-1- or CD31-positive 
populations relative to corresponding negative controls. Corrected mean 
fluorescence intensity (MFI) of ICAM-1 expression for resting and activated 
HUVEC was calculated by subtracting the MFI values of the isotype control 
from that of positive samples and expressed as clustered columns.    
 
4.4.2.3 IE adhesion to HUVEC under flow conditions   
Flow cell adhesion was designed to mimic the conditions of blood flow through 
microvasculature by allowing IEs to flow through micro-slides coated with ECs 
at a flow rate of 0.24 ml/min (0.05 Pa) using the Cellix system. The assay was 
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carried out as described by Gray et al. (2003) with some modifications. 
Adhesion of A4-IEs was assessed on HUVECs which constitutively express 
ICAM-1 receptors as indicated by flow cytometry (Figure 4.5 in the Results 
section). VenaECTM biochips (8-channels, Cellix, Dublin, Ireland) were coated 
with 100 µg/ml fibronectin (12 µl) to promote adhesion of cells to the chips and 
incubated in a humidified chamber overnight at 4°C. HUVECs were allowed to 
reach confluence (6th-7th passage) and activated with 10 ng/ml of TNF-α 18-24 
hours prior to performing the adhesion assay. After activation, ECs were 
detached by treatment with Accutase® (Sigma-Aldrich®, A6964) and neutralised 
with culture medium. Cells were centrifuged at 300× g for 3 minutes and re-
suspended with appropriate volume of culture medium to obtain 1.5 × 106 
cells/ml. Cells (5 µl) were seeded onto pre-warmed VenaECTM micro-slides and 
incubated in CO2 incubator at 37°C. HUVECs were allowed to adhere to the 
micro-slides and fed every 30 minutes with HUVEC culture medium until 
reaching confluence (~2-3 hours). IE suspension was prepared essentially as for 
flow protein assay, and suspensions were perfused through confluent micro-
slides following the same protocol of VenaFlux Platform (Cellix). The number 
of stationary adherent IEs was then counted in 6 random fields on the micro-
slide under 20 × 15 (×300) magnification and expressed as the number of bound 
cells per square millimetre. Results expressed as the mean percentage of binding 
of IEs incubated with IgM antibodies relative binding of IEs incubated buffer 
alone (normalised to 100%). The assay was run in duplicate in single 
experiments to assess the consistency of the results.  
 
4.4.2.4 Blockade of IE adhesion to HUVEC under flow conditions  
Antibody incubations and washing for assays that investigate the capacity of 
IgM antibodies to block parasite adhesion to HUVEC were carried following the 
same procedure described in section 4.4.1.2.  
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4.5 IE adhesion reversal to immobilised protein 
receptors under static conditions  
Reversal of IE adhesion to ICAM-1 receptors by mAbs and pAbs or anti-ICAM-
1 mAb 15.2 was investigated. Briefly, ItG-IEs were allowed to bind to 
immobilised ICAM-1 (50 µg/ml) on 35 × 10 mm bacteriological Petri dishes 
(Falcon 1058, Becton Dickinson). Adhesion to purified receptors was carried out 
following the same static protein binding assay. Prior to fixation, plates were 
incubated in the absence or presence of 800 µl of pAb C2, mAb E7, pAb G6 or 
anti-ICAM-1 mAb 15.2 (5 µg/ml) for 30 minutes at 37°C, with gentle 
resuspension every 10 minutes. Control dishes where only binding buffer was 
added were assayed in parallel throughout the reversal assay. Antibody 
suspension was aspirated, non-adherent cells were removed by repeated washing 
with binding buffer and the remaining bound IEs were fixed with 1% 
glutaraldehyde and stained with 10% Giemsa stain. Stained IEs were viewed and 
counted as described in static protein assay. Data presented represent the mean 
number of bound IEs of 30 readings from two independent dishes (3 spots each) 
and expressed as the number of IEs bound per mm2 (per square millimetre). 
Percentage of adhesion reversal was determined by comparing the number of 
adherent IEs in presence of mouse IgM Abs relative to number of those 
incubated in the absence of antibodies.  
 
4.6 Statistical analysis 
Spearman's rho correlation was used for indicating the correlation between 
variables using SPSS and Spearman's rho correlation coefficient (rs) was used to 
determine the strength of the correlation. Two-tailed t-test was used for 
indicating the significance of the correlation, which was considered as 
statistically significant when P value ˂ 0.05. One-way ANOVA test with 
Daunett t-test (two-sided) were used to measure the difference in IE adhesion. 
The difference was considered significant when P value ˂ 0.05. All statistical 
analyses were carried out using SPSS version 22.  
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4. Results 
4.1 Adhesion blocking of ItG-IEs to ICAM-1 and CD36 
receptors under static conditions 
4.1.1 Blocking ItG-IE binding to ICAM-1 by mAbs and pAbs 
ItG P. falciparum isolate maintained in laboratory culture was tested for 
adhesion to immobilised ICAM-1 receptors after incubation with mouse IgMs 
that strongly label the surface of live ItG-IEs (e.g. pAb B5, mAbs E7, B4 and G6 
– see chapter 3). We hypothesised that cross-reactive mAbs/pAbs would block 
PfEMP1 regions involved in ICAM-1 binding. A non-labelling mouse antibody 
(pAb C2, raised against rDBL31) was included in the assays as a negative 
control and to investigate the association between surface labelling and adhesion 
blocking. To confirm the specificity of ItG-IE adhesion to ICAM-1, we tested 
the anti-ICAM-1 mAb 15.2 for its ability to inhibit the interaction (control). 
MAb 15.2 maps to ICAM-1 domain 1 and completely abrogates ItG-IE 
interaction with ICAM-1 (Berendt et al., 1992, Cooke et al., 1994, Adams et al., 
2000). Thus, it was used as a positive control for adhesion-inhibition in the 
assays. We also compared the level of binding between IEs incubated in binding 
buffer alone and those incubated with an irrelevant IgM isotype control from 
murine myeloma clone MOPC 104E (Sigma®), and no significant difference was 
observed between both IE suspensions (data not shown). Therefore, cells 
incubated in buffer alone were assayed as positive controls for adhesion in all 
assays.  
We took into considerations the lysis of substantial amounts of IEs following 
incubation with mouse mAbs and pAbs during adhesion blocking assays. First, 
we optimised the incubation time for mAbs/pAbs with IEs such that the least 
amounts of IEs are lysed while not affecting mouse IgM binding, and we found 
that an incubation of 30 minutes is appropriate for IgM binding with a relatively 
less destructive effect on IEs (data not shown). In a separate assay, we evaluated 
the blocking capacity of mAbs after incubation with IEs for a short period (~2-5 
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minutes). Although no lysis of IEs was observed when incubated for this period, 
no blocking effect was observed indicating that the incubation was not sufficient 
for IgM binding (data not shown). 
Similar to previous studies (Ockenhouse et al., 1991, Gray et al., 2003), our 
results showed that ItG-IEs bound strongly to purified immobilised ICAM-1 
receptors (Figure 4.1), and this adhesion was almost completely inhibited by 
pAb B5 and mAbs E7, B4 and G6 (97.8% - 99.9% of inhibition compared to 
binding of IEs incubated with binding buffer alone, P ˂ 0.001). This was 
comparable to IE adhesion blocking by anti-ICAM-1 mAb 15.2, which blocked 
98.9% of IE adhesion to ICAM-1 (P ˂ 0.001). Pre-incubation of IEs with pAb 
A4 inhibited 56.9% of their adhesion to ICAM-1 compared to control (P ˂ 
0.001), whereas pAb C2 did not significantly affect the IE adhesion to ICAM-1 
receptors (P ˃ 0.05). 
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Figure 4.1. Adhesion inhibition of ItG-IEs to purified ICAM-1 receptors under static conditions. 
Binding of IEs (3% parasitaemia, 1% HCT) to ICAM-1 receptors (50 µg/ml) was observed after 
pre-incubating IEs with pAb A4 (56.6 µg/ml), mAb E7 (49.9 µg/ml), pAb B5 (59 µg/ml), mAb 
B4 (29.7 µg/ml), mAb G6 (66.3 µg/ml), pAb C2 (43 µg/ml) or with anti-ICAM-1 mAb 15.2 (5 
µg/ml). The graphs represent the mean percentage of binding to ICAM-1 relative to the binding 
of ItG-IEs incubated in buffer alone (normalised to 100%). Error bars represent SDs of two 
independent dishes (6 spots, 36 readings). Control experiments include binding of ItG-IEs to 
PBS spots immobilised onto the same plates, which showed no binding (data not shown). The 
difference in binding was considered significant if P ˂ 0.05, calculated by One-way ANOVA 
with Daunett t-test (two-sided). Statistically significant adhesion inhibitory capacity compared to 
binding without mouse IgM incubation is represented by two asterisks (P ˂ 0.001). The results 
correspond to one experiment. 
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4.1.2 Blocking ItG-IEs binding to CD36 by mAbs and pAbs 
To further characterise the adhesion blocking of mouse mAbs and pAbs, ItG-IEs 
were tested for binding to immobilised CD36 receptors with or without mouse 
IgM incubation (Figure 4.2). Essentially, similar adhesion-blocking patterns 
were observed with CD36 compared to ICAM-1 receptors. For instance, pre-
incubating ItG-IEs with the four antibodies that blocked ICAM-1 binding (pAb 
B5 and mAbs E7, B4 and G6) significantly inhibited ≥ 98.9% of IE stationary 
binding to CD36 compared to control (P ˂ 0.001). IEs bound to CD36 at ~15% 
of control levels after incubation with pAb A4 (P ˂ 0.001), indicating that 
adhesion-blocking activity of pAb A4 was more specific against CD36 
compared to ICAM-1 receptors. No significant difference in binding to CD36 
was observed after incubating IEs with pAb C2 or anti-ICAM-1 15.2 (P ˃ 0.05). 
This is consistent with ICAM-1 adhesion-blocking findings that non-labelling 
IgM antibodies (pAb C2) had no effect on IE adhesion to immobilised receptors 
under static conditions, and also consistent with pAb C2 not lysing IEs. Failure 
to block the adhesion by the anti-ICAM-1 mAb 15.2 indicated its selective 
specificity for ICAM-1 purified receptors. 
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Figure 4.2. Adhesion inhibition of ItG-IEs to purified CD36 receptors under static conditions. 
Binding of IEs to CD36 receptors (50 µg/ml) was observed after pre-incubating IEs with mouse 
IgMs at the same conditions described in Figure 4.1. The graphs represent the mean percentage 
of binding to CD36 relative to the binding of ItG-IEs incubated in the absence of antibodies 
(normalised to 100%). Error bars are SDs of two independent dishes (6 spots, 36 readings). 
Control experiments include binding of ItG-IEs to PBS spots immobilised onto the same plates, 
which showed no binding (data not shown). The difference in binding was considered significant 
if P ˂ 0.05, calculated by One-way ANOVA test with Daunett t-test (two-sided). Statistically 
significant adhesion inhibitory capacity compared to binding without IgM incubation is 
represented by two asterisks (P ˂ 0.001 One-way ANOVA). The results correspond to one 
experiment. 
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4.2 Adhesion blocking of C24-IEs to CD36 receptors 
under static conditions 
Adhesion of P. falciparum C24-IEs to CD36 purified receptors under static 
conditions was assayed following incubation with mouse IgM antibodies, to 
further investigate the cross-inhibitory effect of mAbs and pAbs (Figure 4.3). 
C24 P. falciparum is an IT4 isolate that strongly binds to CD36 receptors, but 
not ICAM-1 (Roberts et al., 1992, Gray et al., 2003). MAb IVC7 was included 
in the assay as a control for adhesion-inhibition, which significantly blocks IEs 
adhesion to CD36 (Berendt et al., 1989, Cooke et al., 1994). Our results 
demonstrated that mAbs E7, B4, G6 and pAbs A4 and B5 significantly blocked 
C24-IEs binding to CD36 with percent inhibition of 91.5, 91, 93.7, 94.6 and 
95.2%, respectively, compared to binding of control (P ˂ 0.001). Mouse IgMs 
were more efficient at blocking the adhesion to CD36 than anti-CD36 mAb 
IVC7, which inhibited 76.3% of IE adhesion (P ˂ 0.001). Although C24-IEs 
adhesion was only reduced by 29% after incubation with pAb C2, the inhibition 
was considered statistically significant (P ˂ 0.001). This blockade can be 
attributed to the ability of pAb C2 to label the surface of C24-IEs (27.3% of 
surface recognition). Profiles of adhesion blocking to CD36 receptors were 
similar for both ItG- and C24-IEs; if a particular IgM blocked the binding of one 
isolate it also inhibited the adhesion of the other isolate. This may suggest that 
mAbs/pAbs block an essential region of PfEMP1 involved in CD36 binding, i.e. 
CIDRα domains, in both parasite isolates.  
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Figure 4.3. Adhesion inhibition of C24-IEs to CD36 receptors under static conditions. Binding of 
IEs to CD36 receptors (50 µg/ml) was observed after pre-incubating IEs with mouse IgMs at the 
same conditions described in Figure 4.1. Graphs shown represent the mean percentage of binding 
to CD36 relative to the binding of C24-IEs incubated in the absence of antibodies (normalised to 
100%). Error bars are SDs of two independent dishes (6 spots, 36 readings). The difference in 
binding was considered significant if P ˂ 0.05, calculated by One-way ANOVA test with 
Daunett t-test (two-sided). Statistically significant adhesion inhibitory capacity compared to 
binding without IgM incubation is represented by two asterisks (P ˂ 0.001, One-way ANOVA). 
The results correspond to one experiment. 
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4.3 Adhesion blocking of ItG-IEs to ICAM-1 receptors 
under physiological flow conditions 
Next we investigated the ability of mouse IgMs to inhibit adhesion of 
erythrocytes infected by ItG under flow conditions to determine whether 
changing the static conditions of IE binding had any effect on the capacity of 
mouse antibodies to block parasite adhesion. ItG-IEs have been shown to bind 
preferentially to ICAM-1 receptors under flow conditions at physiologically 
relevant wall shear stress of 0.05 Pa (Cooke et al., 1994, Adams et al., 2000). In 
the present work, we only counted the number of IEs that formed stationary 
attachment to immobilised receptors or ECs, whereas IEs that formed rolling 
adhesion were neglected.  
Overall, similar trends of flow-based adhesion blocking were observed but at 
slightly lower levels to those seen under static conditions. Percentages of 
inhibition when compared to control ItG were 91.1, 96.6, 98.4 and 93.3% for 
mAb E7, pAb B5, mAb B4 and mAb G6, respectively (P ˂ 0.001) [Figure 4.4]. 
These inhibition levels were relatively similar to blocking obtained with the anti-
ICAM-1 mAb 15.2 (98.7% of blocking, P ˂ 0.001). Pre-incubating IEs with pAb 
A4 produced a statistically significant reduction in adhesion to ICAM-1 by 
63.3% (P ˂ 0.001), which is comparatively similar to its effect on ICAM-1 
adhesion under static conditions. Although ItG-IEs bound to ICAM-1 at 75% of 
control levels after incubation with pAb C2, the difference in adhesion level was 
significant (P ˂ 0.001) indicating that pAb C2 was more efficient at blocking 
ItG-IE adhesion to ICAM-1 under flow than static conditions. Comparison of 
percentages of static-based blockade to ICAM-1 with those under flow 
conditions revealed a statistically significant positive correlation (rs = 0.94, P ˂ 
0.05, n = 6), indicating that mouse IgMs have the capacity to block parasite 
adhesion regardless of the state of binding.  
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Figure 4.4. Effect of antibody blockade on ICAM-1-mediated ItG-IEs adhesion at an inflow 
shear stress of 0.05 Pa. IE suspension (3% parasitaemia, 2% HCT) was perfused over ICAM-1-
coated (50 µg/ml) micro-slides after pre-incubation with pAb A4 (56.6 µg/ml), mAb E7 (49.9 
µg/ml), pAb B5 (59 µg/ml), mAb B4 (29.7 µg/ml), mAb G6 (66.3 µg/ml), pAb C2 (43 µg/ml) or 
with anti-ICAM-1 mAb 15.2 (5 µg/ml). The graphs represent the mean percentage of binding to 
ICAM-1 relative to the binding of ItG-IEs incubated in the absence of antibodies (normalised to 
100%). Error bars are SDs of the means of six readings from random fields. Blocking capacity 
was confirmed with repeating assay on another micro-slide. The difference in binding was 
considered significant if P ˂ 0.05, calculated by One-way ANOVA test with Daunett t-test (two-
sided). Statistically significant adhesion inhibitory capacity compared to binding without IgM 
incubation is represented by two asterisks (P ˂ 0.001). The results correspond to one experiment. 
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4.4 Adhesion blocking of A4-IEs to HUVEC under 
physiological flow conditions 
To substantiate the in vivo relevance of static assay findings, we used the 
HUVEC to assess the ability of mAbs and pAbs to inhibit A4-IEs cytoadhesion 
under flow conditions. A4-IEs bind to HUVEC via ICAM-1 ligands since these 
ECs express ICAM-1 receptors, but not CD36, upon stimulation with cytokines 
such as TNF-α (Dobbie et al., 1999, Gray et al., 2003). Confluent HUVEC 
monolayers were firstly investigated by flow cytometry for expression of surface 
receptors (ICAM-1 and CD31) at resting state or at 18-24 hours after activation 
with TNF-α (Figure 4.5). As expected, surface expression of ICAM-1 was 
highly upregulated after TNF-α activation (74% of total ECs), although non-
activated HUVECs also expressed ICAM-1 on 50.2% of cells. MFI data 
demonstrated that ICAM-1 expression was upregulated ~10-fold higher after 
TNF-α activation, similar to previous findings showing a 9-fold up-regulation of 
ICAM-1 expression in TNF-α stimulated cells (Dobbie et al., 1999). CD31 is a 
surface marker that constitutively expressed on the surface of ECs (McCormick 
et al., 1997, Gray et al., 2003) and showed positive surface expression levels of 
71.7% and 54.1% for activated and non-activated HUVECs, respectively. 
Adhesion blocking of mAbs and pAbs was only assessed with TNF-α stimulated 
HUVECs, since cytokine-mediated ICAM-1 expression was shown to 
significantly correlate with increased adhesion to ICAM-1 receptors (Gray et al., 
2003). Our findings demonstrated that binding of A4-IEs to activated HUVECs 
was almost completely abrogated by pAb B5 and mAb G6 (93.6% and 94.5%, 
respectively) under physiological flow conditions (Figure 4.6). MAbs E7 and B4 
were comparatively less efficient at blocking IE adhesion, as they reduced IE 
binding to ~25% and 35% of control levels, respectively (P ˂ 0.001). 
Surprisingly, pAb C2, a non-labelling IgM, significantly inhibited 54.9% of IE 
adhesion (P ˂ 0.001). Furthermore, pre-incubation with pAb A4 significantly 
affected binding to stimulated HUVECs (P ˂ 0.05).  
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Figure 4.5. Representative flow cytometry analysis of the expression of ICAM-1 and CD31 surface receptors on monolayers of HUVEC 
with or without activation by 10 ng/ml TNF-α at 18-24 hours prior to the assay. A: expression of CD31 surface marker on non-activated 
(left panel) or activated HUVECs (right panel). B: expression of ICAM-1 receptors on non-activated (left panel) or activated HUVECs 
(right panel). C: the corrected MFI calculated by subtracting the MFI values of the negative control from that of positive samples. Shaded 
histograms represent the percentage of cells expressing the corresponding receptors relative to isotype control signal shown in blue trace 
for CD31 and red trace for ICAM1. Expression of ICAM-1 was detected using APC-conjugated mouse anti-human CD54 (ICAM-1) IgG 
antibodies (BD biosciences, Ltd.), whereas CD31 expression was detected with FITC-conjugated mouse anti-human CD31 IgG antibodies 
(BD biosciences, Ltd) at 1:100 dilution. Cells incubated with APC-conjugated IgG isotype control were included as a negative control for 
ICAM-1 expression (red trace) and used to exclude the background negative signal, and cells incubated with FITC-conjugated IgG isotype 
control were included as a negative control for CD31 expression (blue trace). The results correspond to one experiment.  
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Figure 4.6. Effect of antibody blockade on A4-IEs adhesion to TNF-α stimulated HUVEC under 
flow conditions at a wall shear stress of 0.05 Pa. Confluent HUVEC monolayers on flow micro-
slides were stimulated 18-24 hours prior to the assay with 5 ng/ml TNF-α. Then, IEs (3% 
parasitaemia, 2% HCT) were perfused over the micro-slides after pre-incubation with pAb A4 
(56.6 µg/ml), mAb E7 (49.9 µg/ml), pAb B5 (59 µg/ml), mAb B4 (29.7 µg/ml), mAb G6 (66.3 
µg/ml) or pAb C2 (43 µg/ml). Graphs shown represent the mean percentage of binding to 
HUVEC relative to the binding of A4-IEs incubated in the absence of antibodies (normalised to 
100%). Error bars are SDs of the means of six readings from random fields. Blocking capacity 
was confirmed with repeating assay on another HUVEC-coated channel. The difference in 
binding was considered significant if P ˂ 0.05, calculated by One-way ANOVA test with 
Daunett t-test (two-sided). Statistically significant adhesion inhibitory capacity compared to 
binding without IgM incubation is represented by one asterisk (P ˂ 0.05) or two asterisks (P ˂ 
0.001, One-way ANOVA test). The results correspond to one experiment. 
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4.5 Adhesion blocking of ItG-IEs to ICAM-1 receptors 
after incubation with different concentrations of mAb 
G6 
We next investigated whether adhesion blocking to immobilised receptors was 
dependent on the concentration of tested antibodies. MAb G6, which 
significantly blocked the adhesion of ItG-IEs to ICAM-1 receptors, was used in 
the assay at concentrations yielded on elution from affinity columns (neat) or at 
1:2 or 1:10 dilution (Figure 4.7). The results indicated that mAb G6 inhibited 
ItG-IE adhesion to ICAM-1 in a dose-dependent manner with almost complete 
blocking of IE observed at 66.3 μg/ml (98.8%), inhibited by 45% at 1:2 dilution 
(33.2 μg/ml) and almost unaffected at 1:10 dilution (6.6 μg/ml). A statistically 
significant reduction in the total number of bound IEs was only observed after 
incubation with 66.6 or 33.2 μg/ml IgM concentrations (P ˂ 0.001), whereas no 
significant difference was detected between 6.6 μg/ml (1:10 dilution) and control 
(P ˃ 0.05). In addition, there was a strong negative correlation between antibody 
concentration and number of bound IEs (rs = - 1.0, P ˂ 0.001, n=3). These 
results indicate that the maximal effect of adhesion blocking was observed at 
original antibody concentrations yielded from the purification and consistent 
with previous findings demonstrating that the highest levels of surface labelling 
were observed with antibodies tested at these concentrations.  
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Figure 4.7. Adhesion blocking of ItG-IEs to ICAM-1 receptors under static conditions. The same 
procedure described in the legend of Figure 4.1 was carried out except that G6 was incubated 
with IEs at neat concentration (66.3 µg/ml), or at 1:2 dilution (33.2 µg/ml) or 1:10 dilution (6.6 
µg/ml). The difference in binding was considered significant if P ˂ 0.05, calculated by One-way 
ANOVA test with Daunett t-test (two-sided). Statistically significant adhesion blocking 
compared to binding without IgM incubation is represented by two asterisks (P ˂ 0.001, One-
way ANOVA test). The results correspond to one experiment.  
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4.6 Adhesion reversal of ItG-IEs to ICAM-1 receptors 
under static conditions  
The capacity of mouse mAbs and pAbs to outcompete bound IEs to ICAM-1 
receptors was investigated. ItG-IEs were allowed to bind to immobilised ICAM-
1 receptors under static conditions before mouse IgMs were added in an attempt 
to reverse parasitized erythrocyte adhesion (Figure 4.8). The results show that 
mAbs E7 and G6 could significantly reverse (55.2% and 52.2% respectively) 
binding of IEs to ICAM-1 (P ˂ 0.001). These levels were comparable to 
adhesion reversal obtained with the anti-ICAM-1 mAb 15.2 (55.3%, P ˂ 0.001). 
Although pAb C2 only reversed 19.5% of parasite binding, this reversal was 
considered significant (P ˂ 0.001).  
The ability of antibodies to inhibit almost all IE adhesion to immobilised ICAM-
1 receptors while only reversing ~50% of bound parasites confirms the high-
avidity interaction between ICAM-1 and ItG-IEs with a low off-rate. This is 
consistent with the ability of 15.2 to only reverse 55% of bound IEs despite its 
higher capacity to mask IE-binding sites on ICAM-1. Although ICAM-1 is 
considered as a rolling receptor in interactions that occur under flow conditions, 
the adhesion of this receptor to IEs has been shown to be an avid one, and once 
bound; IEs remained in contact with ICAM-1 receptors even under high wall 
shear stress (Cooke et al., 1994). Taken together, our data indicate that mAbs 
can efficiently block IE binding sites when pre-incubated before the firm 
interaction between ICAM-1 and IEs takes place, while only possessing a 
limited ability for outcompeting bound IEs after that interaction occurs. 
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Figure 4.8. Reversal of ItG-IEs binding to purified ICAM-1 receptors with mouse mAbs under 
static conditions. ItG-IEs (3% parasitaemia, 1% HCT) were allowed to bind to ICAM-1 receptors 
(50 µg/ml), then unbound cells were washed in binding buffer and plates were incubated in the 
presence or absence of mAb E7 (19 µg/ml), mAb G6 (22 µg/ml), pAb C2 (14.3 µg/ml) or anti-
ICAM-1 mAb 15.2 (5 µg/ml). Graphs shown represent the mean percentage of binding to 
ICAM-1 relative to the binding of ItG-IEs incubated in buffer alone (normalised to 100%). Error 
bars represent SDs of 30 readings from independent protein spots. Control experiments include 
binding of ItG-IEs to PBS spots immobilised onto the same plates, which showed no binding 
(data not shown). The difference in binding was considered significant if P ˂ 0.05, calculated by 
One-way ANOVA test with Daunett t-test (two-sided). Statistically significant adhesion reversal 
is represented by two asterisk (P ˂ 0.001). The results correspond to one experiment. 
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4.7 Correlation between surface reactivity, IE lysis and 
adhesion blocking 
We next investigated the statistical correlation between adhesion blocking under 
static or flow conditions with IgM surface labelling in terms of the percentage of 
labelled IEs or with percentages of lysed IEs for all tested mAbs and pAbs 
(n=6). At the first analysis, correlation coefficients (rs) were calculated for the 
association between the percentage of blocking of ItG-IE binding to ICAM-1 or 
CD36 receptors under static or flow conditions with ItG-IE lysis or surface 
labelling mediated by the six mAbs and pAbs. The analyses revealed a strong 
positive correlation, though not significant, between ItG-IE surface labelling and 
adhesion blocking to ICAM-1 under static conditions (rs = 0.77, P ˃ 0.05), to 
ICAM-1 under flow conditions (rs = 0.6, P ˃ 0.05) or to CD36 under static 
conditions (rs = 0.66, P ˃ 0.05). This indicates that the higher the percentage of 
labelled IEs by a particular antibody, the higher the percentage of blocked IEs by 
that antibody and vice versa (Table 4.1). A strong positive correlation was also 
observed between percentages of lysed IEs and adhesion blocking to ICAM-1 
and CD36 receptors under static or flow conditions (rs ranging from 0.67 to 
0.899). The correlation was statistically significant for ItG-IE lysis with 
adhesion blocking to ICAM-1 under static or flow conditions P ≤ 0.05).  
Another correlation analysis was carried out to determine the association 
between surface labelling to C24-IEs, percentage of lysed cells and blocking of 
IE adhesion to CD36 receptors under static conditions (Table 4.1). There was a 
moderate positive correlation between percentage of blocking and C24-IE lysis 
by the six mAbs and pAbs (rs = 0.43, P ˃ 0.05). The correlation was stronger 
and statistically significant between C24-IE lysis and surface labelling (rs = 0.83, 
P ˂ 0.05). The last analysis measured the correlation coefficient for the 
relationship between A4-IEs surface labelling or haemolysis with percentages of 
blocked IEs from binding to HUVEC under flow conditions (Table 4.1). We 
detected a statistically significant positive association between A4-IE lysis and 
adhesion blocking (rs = 0.83, P ˂ 0.05) and between surface labelling and 
adhesion blocking to HUVEC (rs = 0.83, P ˂ 0.05).  
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Correlations 
 
ItG 
lysis 
ItG 
labelling ItG ICAM-1 static 
ItG CD36 
static ItG ICAM-1 flow 
Spearman's rho ItG lysis Correlation 
Coefficient 
1.000 .783 .899* .667 .812* 
Sig. (2-tailed) . .066 .015 .148 .050 
N 6 6 6 6 6 
ItG labelling Correlation 
Coefficient .783 1.000 .771 .657 .600 
Sig. (2-tailed) .066 . .072 .156 .208 
N 6 6 6 6 6 
ItG ICAM-
1static 
Correlation 
Coefficient .899
* .771 1.000 .886* .943** 
Sig. (2-tailed) .015 .072 . .019 .005 
N 6 6 6 6 6 
ItG CD36 static Correlation 
Coefficient .667 .657 .886
* 1.000 .943** 
Sig. (2-tailed) .148 .156 .019 . .005 
N 6 6 6 6 6 
ItG ICAM-1 
flow 
Correlation 
Coefficient .812
* .600 .943** .943** 1.000 
Sig. (2-tailed) .050 .208 .005 .005 . 
N 6 6 6 6 6 
 
 
 
 
 
 
C24 CD36 
static 
C24 surface 
labelling 
C24 IE 
lysis 
Spearman's rho 
C24 CD36 static Correlation  1.000 .829* .429 
Sig. (2-tailed) . .042 .397 
N 6 6 6 
C24 surface labelling Correlation  .829* 1.000 .829* 
Sig. (2-tailed) .042 . .042 
N 6 6 6 
C24 IE lysis Correlation  .429 .829* 1.000 
Sig. (2-tailed) .397 .042 . 
N 6 6 6 
 
 
 
 A4lysis A4 surface labelling A4 HUVEC 
Spearman's rho A4 lysis Correlation Coefficient 1.000 .543 .829* 
Sig. (2-tailed) . .266 .042 
N 6 6 6 
A4 surface labelling Correlation Coefficient .543 1.000 .829* 
Sig. (2-tailed) .266 . .042 
N 6 6 6 
A4 binding to HUVEC Correlation Coefficient .829* .829* 1.000 
Sig. (2-tailed) .042 .042 . 
N 6 6 6 
 
Table 4.1. Output of Spearman's rho correlation between surface labelling, IE lysis and adhesion blocking for ItG, 
C24 and A4 parasite isolates. A: Spearman's correlation coefficients (rs) for the association between surface 
labelling of six mAbs/pAbs to ItG-IEs, IgM-mediated lysis and adhesion-blocking of ItG-IEs to ICAM-1 or CD36 
receptors under static or flow conditions. B: Correlation between surface labelling to C24-IEs, IgM-mediated lysis 
and adhesion blocking of C24-IEs to CD36 receptors under static conditions. C: Correlation between surface 
labelling to A4-IEs, IgM-mediated lysis and adhesion blocking of A4-IEs to HUVEC under flow conditions.  **: 
Correlation is significant at the 0.01 level, *: correlation is significant at the 0.05 level.  
A 
B 
C 
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4.8 Discussion 
Sequestration of parasitized erythrocytes to ECs lining the microvasculature of a 
variety of host organs is thought to be the pathogenic basis of severe malaria 
disease (Miller et al., 2002, Autino et al., 2012). The main parasite-derived 
ligand that mediates IE cytoadhesion is the antigenic variant PfEMP1 protein 
expressed on the surface of parasitized erythrocytes (Baruch et al., 1995, Su et 
al., 1995; Smith et al., 1995), which facilitates parasite adhesion to various 
endothelial receptors such as ICAM-1 (Berendt et al., 1989) and CD36 
(Ockenhouse et al., 1989). Strategies aiming to block PfEMP1 domains 
responsible for cytoadhesion have been hypothesised to reduce the severity of P. 
falciparum malaria by reducing or suppressing the ability of IEs to sequester to 
the host microvasculature (Chattopadhyay et al., 2004). The development of 
mAbs that target different adhesive domains of PfEMP1 is an intervention of 
intense interest. Antibody-mediated adhesion-blocking/reversal methods were 
shown not only to reduce ability of IEs to sequester, but also to have a role in the 
clearance of parasitized erythrocytes from the circulation by the host spleen 
(Pasloske and Howard, 1994, Rowe et al., 2009). In the case of CM, inhibition 
of PfEMP1 interaction with ICAM-1 receptors in the brain micro-vessels may 
contribute to prevention of IE sequestration and hence preventing the severe 
consequences of cerebral disease.  
In the present chapter, we evaluated the capacity of anti-PfEMP1DBLβ mAbs and 
pAbs to block the adhesion of parasitized RBCs to immobilised receptors 
(ICAM-1 or CD36) or endothelial cell lines under static or physiological flow 
conditions. We aimed to investigate whether the cross-reactive, surface-exposed 
VSAs recognised by mAbs and pAbs are critical to molecular function and have 
a role in IE cytoadhesion. This was essential to elucidate since cross-reactive 
IgM antibodies may predominantly recognise epitopes on the surface of IEs that 
are not involved in receptor adhesion. We found that IgM antibodies that 
demonstrated higher levels of cross-reactivity with different parasite isolates 
were able to abrogate binding of erythrocytes infected by different parasite 
isolates to immobilised receptors or ECs, indicating their specificity to target 
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receptor-binding molecules on the surface of IEs. Our data indicated that mAbs 
and pAbs might have a potential therapeutic role through the development of 
anti-adhesion drugs. 
Parasite adhesion is specific for the trophozoite or schizont stage of parasite 
development, as ring-stage parasites do not bind receptors such as CD36 
(Ockenhouse et al., 1991). As discussed in the previous chapter, significant 
percentages of trophozoites/schizonts in parasite suspensions were lysed 
following incubation with mouse IgMs and this lysis varied among different IgM 
antibodies and different parasite isolates. Since most mAbs and pAbs used in 
adhesion blocking assays cause IE lysis, we took into consideration that this 
lysis may largely contribute to blockade of IE adhesion to immobilised receptors 
or ECs. Correlation analyses between surface labelling, IgM-mediated lysis and 
adhesion blocking generally indicated that inhibition of parasite binding to 
immobilised receptors or ECs under flow or static conditions was directly 
associated with the ability of antibodies to recognise the surface of IEs, and also 
correlated with the amount of lysed cells. Antibodies raised to DBL41 domains 
(pAb B5, mAb B4 and mAb G6) and anti-DBL31 mAb E7, which exhibited the 
highest capacities for surface recognition, also demonstrated higher specificities 
in blocking the adhesion of IEs. Surprisingly, pAb C2 that showed low if any 
surface-labelling activity also demonstrated also blocked IE adhesion to 
immobilised receptors under static or flow conditions, though at relatively lower 
capacity compared to mAb E7, pAb B5, mAb B4 and mAb G6. Blockade of 
adhesion also correlated with IgM-dependent IE lysis; as antibodies that caused 
lysis of significant amounts of IEs were highly effective in blocking the 
adhesion of erythrocytes infected with the same parasite isolate.  
In spite of the relatively higher amounts of lysed IEs upon antibody incubation, a 
significant proportion of parasitized cells are not lysed. For instance, incubation 
of ItG-IEs with mAb E7 resulted in an average IE lysis of 64.6%, and adhesion 
inhibition assays demonstrated that mAb E7 inhibits 97.8% and 91.1% of ItG-IE 
binding to ICAM-1 receptors under conditions of static and flow, respectively, 
and 99.1% of static-based binding to CD36. This indicates that 33.2% and 
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26.5% of ItG-IEs were not-lysed but were prevented from binding to ICAM-1 
receptors under static and flow conditions, respectively, whereas 34.5% of IE 
binding to CD36 receptors were inhibited after incubation with mAb E7. In 
another example, pAb A4 only caused lysis of 20.2% of C24-IEs and 
significantly inhibited 94.6% of C24-IEs from binding to CD36 receptors under 
static conditions. This indicates that pAb A4 has the capacity to block ~74% of 
non-lysed C24-IEs. However, this argument should be interpreted with caution 
since correlation data argued against it and indicated that lysis is associated with 
blockade of adhesion. The C24 data are more convincing but weird in that we 
would not expect CD36 blocking. Taken together, these data may indicate that 
mAbs and pAbs have the capacity to block IE binding through a dual effect of 
masking receptor-adhesion surface ligands and interfering with parasite survival 
through destruction of parasite-invaded RBCs.  
Our results showed that mAbs and pAbs specifically inhibited parasite adhesion 
to both ICAM-1 and CD36 receptors. Blocking of ItG-IE binding to ICAM-1 
was significantly correlated with adhesion-inhibition to CD36 receptors (rs = 
0.89, P ˂ 0.05). In addition, mouse IgM antibodies that significantly blocked 
CD36 binding for ItG-IEs also blocked C24 binding, with a comparatively less 
capacity of inhibition. The ICAM-1 binding sites are mapped to DBLβ domains, 
which are clearly distinct from the CIDR domains involved in CD36 binding. 
Therefore, we were surprised that mouse IgMs that blocked ICAM-1 binding 
equally well inhibited CD36 binding. Two suggestions can be attributed to this 
cross-inhibition phenomenon. First, despite the fact that mouse IgMs were raised 
to ICAM-1 binding DBLβ domains, the large polymeric IgM molecules may 
have fully or partially masked critical PfEMP1 epitopes also involved in CD36 
binding. Possible steric hindrance generated after binding of IgM molecules to 
PfEMP1 or adjacent ligands may has blocked the interaction between receptors 
and PfEMP1 domains involved in adhesion. Second, IgM binding may has 
resulted in destabilisation of the basic structure of PfEMP1 leading to loss of 
adhesion capacity of functional domains. These findings suggest that binding 
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regions for mouse IgMs overlap, or localised at close proximity to those for 
ICAM-1 and CD36 binding on the native PfEMP1 protein. 
Most studies that investigated the cytoadhesion of clinical parasite isolates have 
been carried out under static conditions. In this work we tested the capacity of 
mouse antibodies to inhibit parasite binding under both static and physiological 
flow conditions, as results taken individually from either assays could give 
disparate information about interactions between receptors and parasite ligands 
(Chakravorty and Craig, 2005) such as the disparity between ItG and A4 parasite 
isolates in terms of binding to HUVEC under flow conditions (Gray et al., 
2003). In addition, results acquired from static assays alone can be deceptive 
when interpreted on interactions that take place in the blood circulation under 
flow conditions (Adams et al., 2000). Flow-based assays can be useful in 
demonstrating variations in the characteristics and kinetics of ligand-receptor 
interactions that are influenced by the shear pressure induced by flowing blood 
(Cooke et al., 1995, Adams et al., 2000). Comparison of mouse IgM-mediated 
adhesion blocking to plastic-adsorbed ICAM-1 under static conditions with 
inhibition under physiological flow conditions revealed a coefficient of 
correlation of 0.94, indicating that blocking under static and flow conditions was 
positively correlated. These findings indicate that blocking of IgM antibodies 
was not influenced by state of binding (flow or static) although blockade was 
relatively greater under static condition to plastic-adsorbed ICAM-1 receptors 
than inhibition under flow conditions.  
A variety of primary EC lines from different tissues can be used as models for 
studying cytoadhesion such as human dermal microvascular endothelial cells 
(HDMEC) and HUVEC (Gray et al., 2003, Phiri et al., 2009). HUVEC can be 
studied as a model for investigating brain microvascular endothelium as both 
cell lines constitutively express ICAM-1 receptors, but not CD36, when 
stimulated with proinflammatory cytokines such as TNF-α (Dobbie et al., 1999, 
Gray et al., 2003). Previous work has demonstrated that binding of some parasite 
isolates to HUVEC is primarily dependent on ICAM-1 receptors under static 
(Berendt et al., 1989) and flow conditions (Cooke et al., 1994). Based on these 
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characteristics, we hypothesised that blockade of parasite binding to HUVEC 
after incubation with mouse IgMs can be related to their blockade to ICAM-1 
receptors under similar flow conditions. Our findings indicated that mAbs and 
pAbs that blocked parasite adhesion to immobilised ICAM-1 receptors under 
flow conditions also inhibited binding of A4-IEs to activated monolayers of 
HUVECs but at relatively reduced capacity of blocking. An exception for this 
observation was the inhibition profile for pAbs C2 and A4, as the former 
strongly inhibited IE binding whereas pAb A4 did not significantly affect 
parasite adhesion. Although pAb C2 neither labelled the surface of A4-IEs nor 
lysed infected cells, we suggest that a small population of pAb C2 antibodies 
had the required specificity to block binding ligands to HUVEC despite the 
failure of that population to produce a recognisable surface labelling signal. 
Alternatively, HUVECs may express surface receptors that act as ligands for 
mouse IgM binding, and binding of mAbs/pAbs to these receptors may interfere 
with the interaction between IEs with HUVECs. Previous work has shown that 
human IgM binds to HUVEC (Mold and Morris, 2001), but whether mouse IgM 
binds to these cells or not is still unknown.  
The comparatively reduced capacity for IE blocking to HUVEC compared to 
inhibition of binding to immobilised ICAM-1 receptors under flow could be due 
to differences in the length of PfEMP1 molecules expressed by A4 and ItG 
parasite isolates. PfEMP1 proteins expressed by A4 parasites tend to be 
relatively longer than those expressed by ItG isolates (Gray et al., 2003), which 
makes it more difficult for mAbs to access and mask critical epitopes involved in 
cytoadhesion under flow conditions. Although IEs primarily bind to HUVEC 
through ICAM-1, other surface receptors expressed at lower levels such as 
CD36 may support the adhesion of parasitized erythrocytes to HUVEC surface 
(McCormick et al., 1997). Furthermore, other factors such as receptor mobility 
within the surface of HUVEC may has enhanced binding under flow conditions, 
compared to binding to immobilised ICAM-1 receptors. These data suggest that 
the specificity of mouse IgMs to block binding sites on A4-PfEMP1 is relatively 
lower than for ItG, or level of receptor expression on HUVEC and binding 
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avidity of this cell line to A4-IEs may have influenced binding of IgM-coated 
IEs.  
A significant milestone in the development of PfEMP1-based drugs is through 
the production of adhesion-blocking antibodies. Such antibodies would inhibit 
the sequestration of parasitized erythrocytes and consequently lead to clearance 
of parasitized RBCs from peripheral circulation by the spleen (Rowe et al., 
2009). The majority of work in anti-adhesive therapies was carried out on 
placental malaria and CD36-mediated cytoadherence, in which binding regions 
have been characterised and antibodies to soluble proteins based on these 
domains have been shown to be successful in blocking parasite adhesion (Tse et 
al., 2004). To our knowledge, no studies for the development of antibodies 
targeting ICAM-1-binding DBL domains have been published despite the 
potential role of ICAM-1 binding in cerebral malaria. In this work, we presented 
evidence that anti-DBLβ mAbs and pAbs not only cross-reacted with diverse P. 
falciparum parasite isolates but also cross-inhibited binding of IEs to 
immobilised receptors and EC lines. Although we provided evidence that 
blocking can also be mediated by surface labelling, the fact there is no specific 
inhibition to a particular receptor or a parasite isolate, as blocking mAbs and 
pAbs inhibited IE adhesion to all receptors tested, makes it convincible to 
believe that inhibition of IE adhesion is mainly due to IgM-mediated lysis. Since 
a large proportion of IEs are lysed upon mouse IgM incubation, and the effect of 
IgM on non-lysed cells is not yet known nor the reasons why not all IEs are 
lysed, are additional factors that may support the role of lysis in adhesion 
inhibition. Furthermore, the number of samples in the correlation experiments is 
not large enough and interpretation of any positive correlation, such as the 
correlation of surface labelling and inhibition, must be carried out with extra 
caution especially for those that did not reach statistical significance.  
From a therapeutic development point of view, it is promising that cross-reactive 
antibodies possess anti-adhesive properties, regardless of the mechanism of 
inhibition. In fact, effective anti-adhesive antibodies should target all receptor-
binding sites or at least multiple sites at the same time to interfere with parasite 
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adhesion. Therefore, we suggest that mouse IgM antibodies may have 
therapeutic values and could play a significant role in protection against severe 
malaria through blockade of sequestration and lysis of parasite-invaded 
erythrocytes. Identification of the mechanism of IE lysis as well as binding sites 
for mAbs and pAbs on the surface of IEs remains an important subject of 
research, particularly due to the possibility that IgM binding regions would seem 
to be of a significant interest in the quest to develop PfEMP1-based therapies.   
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4.9 Limitations and future work  
Due to limitations of the amount of IgM antibodies yielded from the purification, 
we could not repeat the adhesion-blocking experiments for several times to 
confirm preliminary results. Although most assays were repeated using mAb G6 
and the results were consistent with preliminary findings (data not shown), it is 
recommended that the amount of antibodies in future work be expanded to 
higher volumes for obtaining the required confidence of data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
244 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
Characterisation of semi-immune sera 
collected form female adults living in 
Kenya  
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Chapter 5: Introduction  
In endemic areas where malaria transmission is usually high and stable, repeated 
exposure to malaria infections results in the gradual development of a clinical 
immunity, which limits the parasite-related health consequences (Gupta et al., 
1999). Protective immunity acquired this way is primarily mediated by IgG 
antibodies (Nielsen et al., 2004). The risk of severe and life-threatening disease 
in these areas is usually highest during early childhood, after which the 
occurrence and severity of the disease rapidly decrease over several years, as 
individuals acquire natural protective immunity (Bull et al. 1998, Gupta et al. 
1999).  
Several studies have provided evidence that VSAs on P. falciparum-IEs are 
important targets of naturally acquired immunity, and antibodies directed against 
these highly immunogenic antigens are associated with protection against 
homologous parasite isolates (Giha et al., 2000, Marsh et al., 1989, Bull et al., 
1998). Immunological profiling of sera for the existence of reactive antibodies 
against VSAs is a widely utilised method for evaluating acquired immunity and 
recognising potential candidates for vaccine development (Oleinikov et al., 
2009). Agglutination has been used in several studies for studying immune 
responses and antigenic variation of PfEMP1 molecules, as switches in the 
agglutination phenotype are associated with switches in expression of var genes 
or PfEMP1 molecules (Smith et al., 1995, Chan et al., 2014). Because this 
technique is time-consuming, only provides semi-quantitative results and 
rosettes can be counted by mistake as agglutinates in some conditions, most of 
studies now use other quantitative methods such as flow cytometry for studying 
the antibody response against antigens on the surface of IEs to overcome these 
limitations (Staalose et al., 1999, Giha et al., 2000). Flow cytometry provides 
efficient, precise and quantitative measurement of different combinations of 
parasite strains and serum samples (Ofori et al., 2002). In addition, this 
technique has an important advantage over agglutination assay including the 
ability to measure antibody reactivity to parasite isolates that do not agglutinate 
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IEs (Giha et al., 1999, Ofori et al., 2002). However, in some situations such as 
studying the adhesion blocking capacity of semi-immune sera, the use of both 
agglutination and flow cytometry is important to elucidate the mechanism of 
inhibition.  
In this chapter, we describe the use of several functional assays for 
characterizing the functional antibody response of eight serum samples obtained 
from adult female donors living in Junju sub-location, Kilifi County, Kenya. We 
aimed to evaluate the reactivity of these sera against recombinant PfEMP1 
domains using ELISA and investigate the ability of IgG to recognise the surface 
of erythrocytes infected by diverse P. falciparum isolates of differing genomes 
and PfEMP1 phenotypes. In addition, we investigated the presence of IgG 
antibodies that have the capacity to agglutinate IEs and block the adhesion of IEs 
to immobilised receptors and HUVECs. Our findings demonstrated that semi-
immune sera recognised all tested recombinant domains and exhibited variable 
levels of surface reactivity against tested parasite isolates. In addition, some sera 
exhibited higher capacity at blocking parasite adhesion to immobilised ICAM-
1/CD36 receptors and HUVEC and comprised agglutinating antibodies. These 
findings suggest that some of the semi-immune sera can have therapeutic 
implications and used for further vaccine development research.  
There is no direct relation between the present and previous chapters. However, 
since all assays carried out in this chapter are the same as those in previous 
chapters and the general aims of investigating the immune response towards the 
surface of IEs and assessing the capacity of adhesion blocking are similar to 
those in previous chapters, we decided that this chapter is added to the present 
thesis.   
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5. Materials and Methods 
5.1 Serum samples  
Human serum samples used in the present study were kindly provided by Dr. 
Britta Urban, LSTM. The samples were originally collected from eight female 
adults living in Junju sub-location, Kilifi County, Kenya who were between 31 
and 52 years old (median age, 34.5 ± 6.5 years [Table 5.1]). The definition of 
semi-immune individual is an adult living in an area of malaria endemicity and 
does not have the symptoms at the time of sample collection even if he/she was 
previously infected with P. falciparum malaria (Oguariri et al., 2001). All 
samples were kept at 4°C throughout the period of the study.  
 
 
Table 5.1. Characteristics of semi-immune serum samples used in the present study. Sera were 
collected from female adults living in Kilifi County, Kenya. Blood samples from each donor 
were firstly screened microscopically for presence of parasites (parasitaemia) and malaria 
pigments. Samples were also screened using polymerase chain reaction (PCR) for the molecular 
detection of malaria.  
 
 
 
 
Sample ID Age  Sex Malaria Pigment  Slide results  PCR  
JA221 35 female False  False  Negative  
JA225 35 female False  False  Negative  
JA235 34 female False  False  Negative  
JA238 31 female False  False  Negative  
JA239 33 female False  False  Negative  
JA242 52 female False  False  Negative  
JA249 37 female False  False  Negative  
JA254 34 female False  False  Negative  
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5.2 Indirect ELISA for screening semi-immune sera 
against recombinant DBL domains 
The same ELISA assay was carried out following the procedure described in 
Chapter 2 (section 2.4.1.1) with minor modifications. Briefly, 96-well microtitre 
plates (Nunc®) were coated with 100 µl of recombinant domains (rDBL13, 
rDBL16, rDBL27, rDBL31, rDBL41 and rDBL4ε) dissolved in 0.1 M carbonate 
bicarbonate buffer at 5 μg/ml and incubated overnight at 4°C. Subsequent 
blocking and washing steps were performed as described. After washing, plates 
were incubated with human semi-immune sera (JA221 – JA254) diluted 1:50 in 
complete medium for 2 hours at room temperature with gentle shaking. 
Malawian HIS at 1:50 dilution was used as a positive control. Complete medium 
was included in the assay as a negative control. After incubation, wells were 
washed and incubated at room temperature for 1 hour with 100 µl of HRP-
conjugated goat anti-human IgG antibodies (Sigma) at 1:500 dilution in 
complete medium. Subsequent washing, developing and reading were carried 
out as described in section 2.4.1.1. Recognition was assessed in terms of the 
response indicated as OD values and shown as the average of triplicate readings 
with SD values expressed as error bars. The results were considered positive if 
the mean absorbance value obtained from the semi-immune sera was more than 
the cut-off value described as 3 SDs above the mean of control absorbance 
values.  
 
5.3 Analysis of semi-immune sera by flow cytometry 
The capacity of human semi-immune sera to recognise the surface of 
erythrocytes infected by diverse lab-adapted P. falciparum isolates was assessed 
by flow cytometry following the same protocol described in Chapter 2 (section 
2.4.2) with some modifications. Briefly, mature pigmented trophozoites at mid-
late stage were enriched as described, and 3 µl of the enriched pellet was added 
to 1 ml of PBS/1%BSA to prepare IE suspension. Aliquots of the suspension 
(100 µl, 0.8-1 × 106 cells) were washed in 1.5 ml Eppendorf tubes and the pellet 
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was re-suspended with semi-immune sera or non-immune sera from UK adults 
at 1:25 dilution in PBS/1%BSA and incubated for 60 minutes at 37°C. After 
incubation, cells were washed and bound IgG antibodies were detected by 
incubation with 1:100 dilution of APC-conjugated mouse anti-human IgG-Fc 
secondary antibody (Southern Biotech) plus 10 µg/ml ethidium bromide. Cells 
were incubated in the dark for 60 minutes at 37°C. After incubation, cells were 
washed twice, re-suspended with 400 µl of Cell Wash and analysed using 
Becton-Dickinson FACSCalibur flow cytometer (BD LSR11). All washes and 
antibody dilutions were carried out in PBS/1%BSA. Cells incubated with non-
immune sera from UK adults and stained with ethidium bromide and secondary 
antibodies or those only incubated with secondary antibodies and ethidium 
bromide were included as negative controls. Labelling of uninfected cells with 
human IgG antibodies was found at a very low range. Differences in the binding 
capacity of semi-immune sera against tested isolates were further confirmed by 
repeating experiments (n=2). 
Data were acquired using FACSCalibur flow cytometer and 50,000 events were 
collected and analysed with FlowJo software. Specific surface staining for IEs 
was determined in terms of percentage of APC-positive IE population labelled 
by test antibodies relative to control antibody. In all assays, a labelling of ≥ 10% 
of IE population was considered positive for surface labelling, whereas ≤ 10% 
was considered negative. Grading of capacity of surface recognition was set as 
followed: 
+:          if labelled IE population was within a range of 10.1 - 20% 
++:        if labelled IE population was within a range of 20.1 - 40% 
+++:      if labelled IE population was within a range of 40.1 - 60% 
++++:    if labelled IE population was ˃ 60.1%. 
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5.4 Adhesion-blocking of IEs to ICAM-1 or CD36 
receptors under static conditions 
Blockade of adhesion under static conditions was carried out as described in 
chapter 4 (section 4.3) with some differences. Briefly, IE suspension for each 
dish (1.25 ml) was centrifuged, before the pellet was incubated separately with 
100 µl of semi-immune female sera at 1:25 dilution for 60 minutes at 37°C. 
After incubation, cells were re-suspended in 1.25 ml binding buffer and added to 
each dish (2×), and then the assay was continued as described in section 4.3. 
Previously characterised control mAbs that block IE adhesion to ICAM-1 (mAb 
15.2) or CD36 (mAb IVC7) were added to IE suspension at 5 µg/ml prior to 
addition to the protein-coated dishes and the same procedure were followed as 
shown above. Percentage of IE adhesion-inhibition was determined by the 
difference in the count of IEs assayed in the presence of semi-immune sera 
relative to IEs incubated with UK control sera. The results were expressed as 
percentage of binding of test samples relative to control, normalised as 100%.   
 
5.5 Adhesion-blocking of IEs to ICAM-1 receptors 
under physiological flow conditions 
In assays that assess the ability of human semi-immune sera to block parasite 
binding to immobilised ICAM-1 receptors under flow conditions, the same 
procedure was followed as described in chapter 4 (section 4.4.1) with minor 
modifications. Briefly, IE suspension (500 µl) designated for each serum sample 
was firstly centrifuged, before the pellet was incubated with 100 µl of semi-
immune sera at 1:25 dilution for 60 minutes at 37°C. After incubation, cells were 
centrifuged and re-suspended in 500 µl of binding buffer, and then the assay was 
continued as described in section 4.4.1. To block IE binding to ICAM-1, mAb 
15.2 was added to the suspension at 5 µg/ml prior to beginning of the assay. 
Percentage of IE adhesion blocking was determined by the difference in the 
count of IEs assayed in the presence of semi-immune sera to IEs incubated with 
UK control serum. The results were expressed as percentage of binding of test 
samples relative to control, normalised as 100%.   
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5.6 Adhesion-blocking of IEs to HUVEC under 
physiological flow conditions 
HUVEC culture and investigation of IE adhesion to these cells under conditions 
of physiological blood flow were carried out as described in chapter 4 (Section 
4.4.2). For assessing the capacity of semi-immune sera to block parasite 
adhesion to HUVEC, the same protocol was followed as described in the 
previous section.  
 
5.7 Agglutination assay 
Semi-immune sera were tested in agglutination assay using trophozoite-IEs 
(parasitaemia of 1-5% and haematocrit of 5%) as described by Bull et al., 1999 
with some modifications. Cells were washed in serum-free RPMI 1640, and non-
infected washed RBCs were added, if necessary, to adjust HCT and parasitaemia 
levels. After washing, cells were re-suspended in serum-free RPMI 1640 and 
ethidium bromide was added to a final concentration of 10 µg/ml to label IEs. A 
25 µl reaction volume was prepared for test or control sera at a final dilution of 
1:25 (1 µl of sera added to 24 µl of stained suspension) and added to U-
bottomed 96-wells plate. Then, the plate was sealed using an adhesive film and 
incubated at room temperature on a rotating wheel for 60 minutes in darkness. 
The 25 µl reaction volume was split into two, gently spread onto two pre-
labelled slides and covered with 22 mm coverslips. Slides were examined using 
light and fluorescent microscopes for the presence of agglutinates at 300× (20 × 
15) magnification. 10 fields were examined, and samples were scored positive 
on the basis of the observation of 15 or more agglutinates within all scanned 
fields. Agglutinating scores (based on the size of agglutinates) were also counted 
to provide additional measurements. Five scores based on the number of IEs in 
each agglutinate were included: 3-9, 10-20, 21-40, 41-60 and ≥ 61. To confirm 
that agglutinates were clumps of IEs and not rosettes of non-IEs, all agglutinates 
were stained with ethidium bromide as described above and examined under 
fluorescent microscope.  
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5.8 Statistical analysis 
Spearman's rho correlation was used for assessing the correlation between 
variables using SPSS and Spearman's rho correlation coefficient (rs) was used to 
determine the strength of the correlation. Two-tailed t-test was used for 
determining the significance of the correlation, which was considered as 
statistically significant when P value ˂ 0.05. One-way ANOVA test with 
Daunett t-test (two-sided) was used to measure the difference in IE adhesion. 
The difference was considered significant when P value ˂ 0.05. All statistical 
analyses were carried out using SPSS version 22.  
 
5.9 Ethics approval 
This study was carried out under protocol No. 1131: Integrated studies for the 
development of natural immunity to malaria in children in Kilifi district, Kenya. 
The above protocol was discussed during the 136th Meeting of the 
KEMRI/National Ethical Review Committee held on the 22nd of August, 2006, 
and an approval was granted for the protocol. A copy of the revised protocol is 
provided in the Appendix, together with a copy of the approval granted by 
Oxford Tropical Research Ethics Committee (OXTREC) on the 4th of October 
2006 for studies under the same protocol.  
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5. Results  
5.1 Indirect ELISA for investigating the reactivity of 
semi-immune sera against recombinant DBL 
domains 
Serum samples used in the present study were collected from eight female adults 
living in Junju sub-location, Kilifi County, Kenya. In order to investigate the 
natural human response to malaria antigens, semi-immune sera were tested for 
reactivity with a panel of five recombinant DBLβ domains from PfEMP1ICAM-1 
variants of the IT4 genotype (rDBL13, rDBL16, rDBL27, rDBL31 and rDBL41) 
or with VAR2CSA-DBL4ε domain using indirect ELISA. The reactivity against 
recombinant proteins with serum IgG or IgM were analysed, and frequencies of 
IgG recognition of recombinant proteins with all sera are shown in Figure 5.1 
and Table 5.1. Since no reactivity of serum IgM was observed (data not shown), 
all results will discuss IgG reactivity henceforth. All sera exhibited a broad range 
of immune responses against DBL proteins above the calculated cut-off values, 
with rDBL41 showing the highest levels of reactivity. On the other hand, the 
immune response towards DBL4ε was comparatively weaker for all tested sera. 
It is noteworthy that serum JA249 demonstrated the highest response with 
almost all coated proteins. Thus, each adult is likely to have a repertoire of 
antibodies to different DBL antigens, probably due to repeated exposure to 
malaria infection.   
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Figure 5.1. The reactivity of serum samples collected from eight female adults living in Kilifi, 
Kenya against recombinant DBL domains as measured by indirect ELISA. Plates were coated 
with 100 µl of rDBL proteins (rDBL13, rDBL16, rDBL27, rDBL31, rDBL41 and rDBL4ε) 
dissolved in 0.1 M carbonate bicarbonate buffer at 5 µg/ml and incubated overnight at 4ºC. 
Plates were washed, blocked and incubated with 1:50 dilution of adult sera (JA221 - JA254) or 
CM alone and incubated for 2 hours at room temperature with gentle shaking. Malawian HIS at 
1:50 dilution was used as a positive control. CM was included in the assay as a negative control. 
Reactive IgG antibodies were detected with HRP-conjugated goat anti-human IgG antibodies 
(Sigma) at 1:500 dilution. Recognition was assessed in terms of the response indicated as OD 
values and shown as the average of triplicate readings with SD values expressed as error bars.  
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Semi-immune 
sera 
Recombinant DBL domains 
DBL13 DBL16 DBL27 DBL31 DBL41 DBL4ε 
JA221 ++ +++ ++++ ++++ ++++ +++ 
JA225 +++ +++ ++ ++++ ++++ ++ 
JA235 +++ +++ ++ +++ ++++ ++ 
JA238 +++++ ++++ +++ ++++ +++++ +++ 
JA239 ++++ ++++ +++ +++ ++++ +++ 
JA242 +++ ++++ +++ +++ ++++ ++ 
JA249 ++++ +++++ ++++ +++++ +++++ ++++ 
JA254 ++++ +++++ +++ ++++ ++++ +++ 
HIS ++++ +++ ++++ +++ ++++ +++ 
 
Table 5.1. Investigating the presence of reactive IgG antibodies in serum samples collected from 
eigth frmale adults living in Kilifi, Kenya against recombinant DBL domains as measured by 
indirect ELISA. The results were considered positive if the mean absorbance value for the semi-
immune sera was more than the cut-off value described as 3 SDs above the mean of control 
absorbance values. Capacity of recognition was as followed: +: ˃ 3 SD values above the mean of 
control absorbance value (i.e. 0.19) to OD value of 0.29, ++: OD values of 0.30 to OD values of 
0.39, +++: OD values of 0.40 to OD values of 0.49, ++++: OD values of 0.50 to OD values of 
0.59, +++++: ˃  OD values of of 0.60.  
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5.2 Measurement of IgG binding to the surface of P. 
falciparum-IEs  
Semi-immune sera were then used for comparisons of IgG binding to the surface 
of live erythrocytes infected by A4, ItG, C24, 3D7 and CS2 P. falciparum 
isolates using flow cytometry (Table 5.2). Parasite isolates used in the screening 
were phenotypically distinct; including isolates that bind ICAM-1 and CD36 
from the IT4 genotype (A4 and ItG), non-ICAM-1 binding isolate from the same 
genome (C24), CSA-binding isolate from the IT4 genome (CS2) and strain 
NF54 from the distinct 3D7 genotype. Representative flow cytometry binding 
profiles for semi-immune sera with erythrocytes infected by ItG and 3D7 
isolates are shown in Figures 5.2 and 5.3, respectively. ItG was the most 
specifically recognised P. falciparum isolate by all semi-immune sera followed 
by 3D7, whereas A4 was relatively the least recognised parasite. Overall, the 
variation seen with the reactivity against live IEs was greater than the reactivity 
with recombinant proteins. IgG of most sera bound to the surface of IEs at 
variable levels among all samples (range of the percentage of IE recognition was 
14.2 - 79.5%). Sera JA235, JA239, JA249 and JA254 recognised the surface of 
erythrocytes infected by all tested parasite isolates, whereas JA221 only 
recognised 50% (n=3) of parasite lines. No pattern of strong surface labelling 
was detected for a particular serum although JA235 demonstrated an overall 
higher capacity of recognition with all isolates compared to the other semi-
immune sera. In order to establish appropriate parameter values for the surface 
labelling with flow cytometry and adhesion blocking assays, we first examined 
the binding at different dilutions of semi-immune sera (1:25 or 1:50). We found 
that 1:25 dilution was optimal for surface recognition (data not shown). 
Therefore, it was used in all subsequent surface labelling experiments and 
adhesion blocking assays.  
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Figure 5.2. FACS analysis of ItG-IE surface reactivity with semi-immune sera from female 
adults living in Kilifi, Kenya. 50 µl of each test serum at 1:25 dilution was incubated with 
trophozoite-enriched IEs and labelling was detected using APC-conjugated mouse anti-human 
IgG-Fc secondary antibody (Southern Biotech) at 1:100 dilution. Grey shaded histograms 
represent IE populations labelled by IgG antibodies. Negative controls including cells stained 
with 50 µl of non-immune sera from UK adults at 1:25 dilution shown in blue and those only 
stained with ethidium bromide and secondary antibodies shown in red. Percentages of labelling 
were calculated relative to non-immune UK serum control. A labelling of ˃ 10% of IE 
population was considered positive. Uninfected cells were shown to be negative for labelling 
with semi-immune sera (data not shown).   
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Figure 5.3. FACS analysis of 3D7-IE surface reactivity with semi-immune sera collected from 
female adults living in Kilifi, Kenya. The same assay was carried out as described in Figure 5.2.  
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Serum 
P. falciparum isolates 
A4 ItG C24 3D7 CS2 
JA221 + ++ - ++ - 
JA225 - ++ + + ++ 
JA235 ++ ++++ +++ ++ ++ 
JA238 ++ +++ ++ ++ - 
JA239 + ++ + ++ + 
JA242 - ++ + ++ + 
JA249 ++ ++ + ++ ++ 
JA254 + ++ + ++ ++++ 
UK control - - - - - 
Table 5.2. The reactivity of semi-immune serum samples collected from female adults living in 
Kilifi, Kenya with the surface of erythrocytes infected by phenotypically and genotypically 
distinct P. falciparum isolates as indicated by flow cytometry. - (labelled IE population ≤ 10%), 
+ (labelled IE population 10.1 - 20%), ++ (labelled IE population 20.1 - 40%), +++ (labelled IE 
population 41 - 60%), ++++ (labelled IE population ˃ 60%).  
 
 
5.3 Correlation of IgG surface labelling between P. 
falciparum parasite isolates   
The eight semi-immune serum samples obtained from Kenyan female adults 
were used for comparisons in terms of IgG binding to the surface of A4, ItG,  
C24, 3D7 and CS2-IEs using Spearman's rho correlation test (Table 5.3). This 
was to investigate whether surface labelling by a particular serum to erythrocytes 
infected by a given isolate was correlated with labelling to the other tested 
isolates. For the same serum samples, IgG binding was only significantly 
correlated between ItG and A4 (rs = 0.85, P ˂ 0.05), and between ItG and C24 
parasite isolates (rs = 0.79, P ˂ 0.05) indicating that serum samples labelling the 
surface of ItG-IEs also recognised A4- and C24-IEs particularly when higher 
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IgG response binding were detected. It also suggests that antibody repertoires 
with similar labelling properties were acquired in semi-immune individuals after 
exposure to P. falciparum infection. The comparison also revealed a strong 
positive correlation, although not statistically significant, between A4 and C24 
(rs = 0.62, P ˃ 0.05) and between 3D7 and CS2 (rs = 0.595, P ˃ 0.05). The strong 
significant correlation between parasite isolates expressing different PfEMP1 
variants indicate that semi-immune serum samples are broadly cross-reactive, as 
indicated by the significant association between an ICAM-1 binder (ItG) and a 
non-binding isolate (C24), and between two isolates from different genomes 
(CS2 and 3D7). 
 
 
Correlations 
 ItG A4 C24 3D7 CS2 
Spearman's rho ItG        Correlation Coefficient 1.000 .850** .786* .405 .190 
Sig. (2-tailed) . .007 .021 .320 .651 
N 8 8 8 8 8 
A4 Correlation Coefficient .850** 1.000 .623 .395 -.036 
Sig. (2-tailed) .007 . .099 .333 .933 
N 8 8 8 8 8 
C24 Correlation Coefficient .786* .623 1.000 .310 .452 
Sig. (2-tailed) .021 .099 . .456 .260 
N 8 8 8 8 8 
3D7 Correlation Coefficient .405 .395 .310 1.000 .595 
Sig. (2-tailed) .320 .333 .456 . .120 
N 8 8 8 8 8 
CS2 Correlation Coefficient .190 -.036 .452 .595 1.000 
Sig. (2-tailed) .651 .933 .260 .120 . 
N 8 8 8 8 8 
 
 
 Table 5.3. Spearman's rho correlation of surface labelling profiles of eight semi-immune serum 
samples obtained from Kenyan adult females to erythrocytes infected by five P. falciparum 
parasite isolates. Binding of IgG to the surface of erythrocytes infected by A4, ItG, C24, 3D7 or 
CS2 was determined using flow cytometry and surface labelling was expressed as percentage of 
IEs labelled by semi-immune sera relative to binding of control serum. Values of Spearman's rho 
correlation coefficient (rs): 0 (no correlation between variables), 0.1 to 0.3 (weak positive 
correlation), 0.3 to 0.5 (moderate positive correlation), 0.5 to 1.0 (strong positive correlation). 
Correlation is statistically significant when P value ˂ 0.05. **: correlation is significant at the 
0.01 level. *: correlation is significant at the 0.05 level. 
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5.4 Adhesion blocking studies with semi-immune sera  
5.4.1 Blockade of ItG-IE adhesion to ICAM-1 receptors under 
static conditions 
Semi-immune sera that showed high levels of cross-reactivity with variant 
recombinant DBLβ proteins and recognised the surface of erythrocytes infected 
by diverse parasite lines were tested for their capacity to inhibit IE adhesion to 
immobilised receptors under static or flow conditions. Adhesion assays were 
essentially carried out following the same methods described in Chapter 4 with 
some modifications. Serum samples obtained from non-immune UK adults were 
included in all assays and as negative controls. The first assay was performed to 
assess the capacity of semi-immune Kenyan sera to block ItG-IE binding to 
purified ICAM-1 under static conditions (Figure 5.4). Out of 8 tested sera, only 
two (JA225 and JA235) strongly blocked binding to ICAM-1 by 90.4% and 
93.9%, respectively compared to UK non-immune adult serum (P ˂ 0.001). On 
the other and, JA238 and JA254 moderately inhibited IE adhesion by 30.2% and 
17%, respectively (P ˂ 0.001). With regard to JA221, JA239, JA242 and JA249 
sera, no appreciable anti-adhesive effect was observed.  
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Figure 5.4. Adhesion blocking of ItG-IEs to purified ICAM-1 receptors under static conditions. 
Binding of IEs (3% parasitaemia, 1% HCT) to ICAM-1 receptors (50 µg/ml) was observed after 
incubating IEs with semi-immune sera collected from female adults living in Kilifi, Kenya at 
1:25 dilution (100 µl). Graphs shown represent the mean percentage of binding to ICAM-1 
relative to the binding of ItG-IEs incubated with UK control sera at 1:25 dilution (normalised to 
100%). Error bars represent SDs of two independent dishes (6 spots, 36 readings). Control assays 
include binding of ItG-IEs to PBS spots immobilised onto the same plates, which showed no 
binding (data not shown). The difference in binding was considered significant if P ˂ 0.05, 
calculated by One-way ANOVA test with Daunett t-test (two-sided). Statistically significant 
adhesion inhibitory capacity compared to binding with UK non-immune sera is represented by 
one asterisk (P ˂ 0.05) or two asterisks (P ˂ 0.001). 
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5.4.2 Blockade of C24-IE adhesion to CD36 receptors under 
static conditions 
Semi-immune sera were then tested for inhibition of C24-IEs to immobilised 
CD36 receptors under static conditions (Figure 5.5). C24 P. falciparum-IEs 
strongly bind to CD36 receptors, but not ICAM-1 (Roberts et al., 1992, Gray et 
al., 2003). Contrary to the results observed with ICAM-1, stationary binding to 
CD36 was not greatly affected after incubation with all semi-immune sera 
except JA254 which only blocked 23% of C24-IE binding (P ˂ 0.001). Although 
JA249 caused a reduction of adhesion by ~13%, this effect was no statistically 
significant (P ˃ 0.05). These results suggest that naturally acquired antibodies in 
semi-immune sera lack the capacity to effectively block PfEMP1 domains 
involved in parasite binding to CD36 receptors. This is interesting since binding 
to CD36 is a common adhesion phenotype and most wild and culture-adapted P. 
falciparum isolates have the capacity to bind purified CD36 receptors 
(Chilongola et al., 2009, Newbold et al., 1997, Rogerson et al., 1999). Thus, 
exposure of individuals in endemic areas to this binding phenotype is huge yet 
they did not develop blocking antibodies. However, we should evaluate the 
blocking capacity of sera against different CD36-binding isolates to support 
these results.  
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Figure 5.5. C24-IE adhesion blocking to CD36 receptors with semi-immune sera under static 
conditions. C24-IEs were pre-incubated with semi-immune sera or UK non-immune sera at 1:25 
dilution then allowed to bind with CD36 immobilised on plastic dishes at 50 µg/ml. Graphs 
shown represent the mean percentage of binding to CD36 relative to the binding of C24-IEs 
incubated with UK control sera (normalised to 100%). Error bars indicate SDs of 36 readings 
collected from two independent dishes (6 spots). Control assays include binding of C24-IEs to 
PBS spots immobilised onto the same plates, which showed no binding (data not shown). The 
difference in binding was considered significant if P ˂ 0.05, calculated by One-way ANOVA 
test with Daunett t-test (two-sided). Statistically significant adhesion inhibitory capacity 
compared to binding with UK non-immune sera is represented by one asterisk (P ˂ 0.05) or two 
asterisks (P ˂ 0.001). 
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5.4.3 Blockade of ItG-IE adhesion to ICAM-1 receptors under 
physiological flow conditions 
To validate the in vivo relevance of static-based findings, we tested whether pre-
incubating ItG-IEs with adult pre-immune sera affected their adhesion to ICAM-
1 receptors under physiological flow conditions (Figure 5.6). Similar to blockade 
of ItG-IE adhesion under static conditions, JA225 and JA235 were the most 
effective in inhibiting parasitized erythrocyte binding to ICAM-1 under flow 
conditions, with inhibition percentages of 68% and 46%, for JA225 and JA235 
sera respectively compared to inhibition of UK control serum (P ˂ 0.001). 
Although JA242, JA249 and JA254 sera only inhibited ~18% of ItG-IE 
adhesion, their blockade was considered significant (P ˂ 0. 05).  
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Figure 5.6. Blockade of ItG-IE adhesion to ICAM-1 at an inflow shear stress of 0.05 Pa. IE 
suspension (3% parasitaemia, 2% HCT) was flowed over ICAM-1-coated (50 µg/ml) micro-
slides after incubation with semi-immune sera or UK control serum at 1:25 dilution. Graphs 
shown represent the mean percentage of binding to ICAM-1 relative to the binding of UK 
control sera (normalised to 100%). Error bars represent SDs of the means of 6 readings from 
randomly selected fields. Blocking capacity was confirmed with repeating assay on another 
micro-slide. The difference in binding was considered significant if P ˂ 0.05, calculated by One-
way ANOVA test with Daunett t-test (two-sided). Statistically significant adhesion inhibitory 
capacity compared to binding of UK control sera is represented by one asterisk (P ˂ 0.05) or two 
asterisks (P ˂ 0.001). 
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5.4.4 Blockade of A4-IE adhesion to HUVEC under 
physiological flow conditions 
We then tested the capacity of semi-immune sera to inhibit parasite binding to 
HUVEC under flow conditions at a physiologically relevant shear stress (0.05 
Pa). As stated previously, A4-IEs adhere preferentially to HUVEC via ICAM-1 
ligands, as these ECs express ICAM-1, but not CD36, upon TNF-α activation 
(Dobbie et al., 1999, Gray et al., 2003). A4-IEs were firstly incubated with semi-
immune or control sera at 1:25 dilution, before they were tested for adhesion to 
confluent monolayers of TNF-α-stimulated HUVEC (Figure 5.7). Surprisingly, 
all semi-immune sera have significantly reduced IE adhesion to HUVEC (P ˂ 
0.001), with JA225 and JA235 demonstrating the highest capacity of inhibition 
(~86%) followed by JA238 which blocked ~80% of IE binding (P ˂ 0.001). 
JA221, JA239, JA249 and JA254 exhibited similar levels of blocking (~70%) 
whereas JA242 had the least blocking capacity compared to the other sera, with 
an inhibition percentage of 60% relative to UK control serum (P ˂ 0.001).  
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Figure 5.7. Blockade of A4-IE adhesion by semi-immune sera to TNF-α-stimulated HUVEC 
under flow conditions at a wall shear stress of 0.05 Pa. Confluent HUVEC monolayers on flow 
micro-slides were stimulated 18-24 hours prior to the assay with 5 ng/ml TNF-α. Then, IEs (3% 
parasitaemia, 2% HCT) were flowed over the micro-slides after incubation with semi-immune 
sera or UK non-immune sera at 1:25 dilution. Graphs shown represent the mean percentage of 
binding to HUVEC relative to the binding of UK control sera (normalised to 100%). Error bars 
are SDs of the means of six readings from randomly selected fields. Inhibition capacities were 
confirmed by flowing IE suspensions through another HUVEC-coated channel. The difference in 
binding was considered significant if P ˂ 0.05, calculated by One-way ANOVA test with 
Daunett t-test (two-sided). Statistically significant adhesion inhibitory capacity compared to 
binding of UK control sera is represented by two asterisks (P ˂ 0.001). 
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5.5 Correlation between surface labelling and adhesion 
blocking 
IE labelling by semi-immune sera was tested for correlation with adhesion-
blocking to immobilised receptors or HUVEC (Table 5.4). At the first analysis, 
correlation coefficients (rs) were calculated for the association between blocking 
percentages of ItG-IEs to ICAM-1 receptors under static or flow conditions with 
ItG-IE surface labelling for all semi-immune sera. The analysis revealed a strong 
positive correlation, though not significant, between adhesion-inhibition of ItG-
IEs under static and flow conditions (rs = 0.59, P ˃ 0.05), indicating that semi-
immune sera which strongly blocked parasite adhesion under static conditions 
also blocked the binding under flow. There was a moderate to strong positive 
correlation between ItG-IE surface labelling and adhesion blocking to ICAM-1 
under static conditions (rs = 0.551, P ˃ 0.05), i.e. the higher the percentage of 
labelled IEs by a particular individual serum, the higher the percentage of 
blocked erythrocytes by that serum and vice versa. On the other hand, there was 
no correlation between surface recognition and adhesion blocking under flow 
conditions (Table 5.4).  
Analysis of the association between surface labelling to C24-IEs by semi-
immune sera and blockade of static-based binding to CD36 revealed a moderate, 
not-significant positive correlation between both variables (rs = 0.36, P ˃ 0.05), 
whereas no correlation was detected between surface recognition of A4-IEs and 
adhesion blocking (rs = 0.11, P ˃ 0.05). 
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Correlations 
 
A4 surface 
Labelling 
A4 blocking 
HUVEC 
Spearman's rho A4 surface Labelling Correlation Coefficient 1.000 .114 
Sig. (2-tailed) . .787 
N 8 8 
A4 blocking HUVEC Correlation Coefficient .114 1.000 
Sig. (2-tailed) .787 . 
N 8 8 
 
Table 5.4. Output of Spearman's rho correlation between surface labelling and adhesion blocking for ItG, C24 and A4 
isolates. A: Spearman's rho correlation coefficients (rs) for the association between surface labelling of eight semi-
immune sera to ItG-IEs and adhesion blocking of ItG-IEs to ICAM-1 receptors under static or flow conditions. B: 
Correlation between surface labelling to C24-IEs adhesion blocking of C24-IEs to CD36 receptors under static 
conditions. C: Correlation between surface labelling to A4-IEs and adhesion blocking of A4-IEs to HUVEC under flow 
conditions. Values of Spearman's rho correlation coefficient (r): 0 (no correlation between variables), 0.1 to 0.3 (weak 
positive correlation), 0.3 to 0.5 (moderate positive correlation), 0.5 to 1.0 (strong positive correlation). Correlation is 
statistically significant when P value ˂ 0.05.  
 
Correlations 
 ItG Labelling ItG blocking static ItG blocking flow 
Spearman's rho ItG Labelling Correlation Coefficient 1.000 .479 -.071 
Sig. (2-tailed) . .230 .867 
N 8 8 8 
ItG blocking static Correlation Coefficient .479 1.000 .587 
Sig. (2-tailed) .230 . .126 
N 8 8 8 
ItG blocking flow Correlation Coefficient -.071 .587 1.000 
Sig. (2-tailed) .867 .126 . 
N 8 8 8 
Correlations 
 
C24 surface 
Labelling C24blockingCD36 
Spearman's rho C24 surface 
Labelling 
Correlation 
Coefficient 
1.000 .355 
Sig. (2-tailed) . .388 
N 8 8 
C24 blocking CD36 Correlation 
Coefficient 
.355 1.000 
Sig. (2-tailed) .388 . 
N 8 8 
A 
B 
C    
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5.6 Agglutination assay 
We calculated the agglutination score and frequency of A4- and ItG-IEs 
incubated with each of the semi-immune Kenyan serum to determine whether 
blockade of parasite adhesion was indirectly associated with IE agglutination 
(Tables 5.5 and 5.6). Agglutination score was determined by counting the 
number of IEs in each agglutinate and categorised into five groups based on the 
size of agglutinates, whereas agglutination frequency was estimated by 
quantitating the number agglutinates in 10 random fields under 300× (20 × 15) 
magnification. Despite being sampled from adult females of a similar age and 
living in the same area, the agglutination reactivity of the sera used in this work 
was highly variable. However, all sera that agglutinate A4-IEs also comprised 
agglutinating antibodies to ItG-IEs, but the frequency of agglutinates was 
noticeably higher with A4 than ItG. Out of all tested sera, five samples (JA225, 
JA235, JA238, JA249 and JA254) comprised antibodies that agglutinated A4- 
and ItG-IEs. For A4-IEs, Agglutinates containing 10-20 IEs were the most 
frequent among positive samples, whereas agglutinates that comprised ≥ 61 cells 
were the least observed. On the other hand, the most frequently detected 
agglutinates with ItG-IEs were those containing 3-9 IEs, whereas agglutinates 
containing 41-60 IEs were the least counted. 
Serum samples obtained from non-immune UK donors were included as 
negative controls and showed no signs of IE agglutination. This indicated that 
parasite isolates used in this assay did not form non-specific IE agglutinates. To 
establish that agglutinates only comprised IEs and were not rosettes resulting 
from the binding of two or more non-IEs to one IE, parasite suspensions were 
stained with ethidium bromide and visualised under fluorescent microscope 
(Figure 5.8). We found that all agglutinates were positive for staining with the 
fluorescent dye, which confirms that observed clumps comprised IEs alone.  
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Agglutination score 
(proportion of IEs per agglutinate) 
Frequency of 
agglutinates 
Agglutination 
Sera 3-9 10-20 21-40 41-60 ≥ 61 Total*  
JA221 - 1 - - - 1 Negative 
JA225 2 31 22 2 - 57 Positive 
JA235 14 39 4 - 1 58 Positive 
JA238 25 42 4 - - 71 Positive 
JA239 2 - - - - 2 Negative 
JA242 1 1 - - - 2 Negative 
JA249 7 40 9 3 3 62 Positive 
JA254 10 28 15 1 - 54 Positive 
HS CRL - - - - - 0 Negative 
Table 5.5. Agglutination score and frequency for A4-IEs after incubation with eight semi-
immune Kenyan sera or UK control serum. * Total number of IE agglutinates per 10 fields under 
300× (20 × 15) magnification. Samples were scored positive on the basis of observing ≥ 15 
agglutinates in all scanned fields. HS CRL: control serum from UK donors. 
 
 
 
Agglutination score 
(proportion of IEs per agglutinate) 
Frequency of 
agglutinates 
Agglutination 
Sera 3-9 10-20 21-40 41-60 ≥ 61 Total*  
JA221 - - - - - 0 Negative 
JA225 12 11 2 1 3 29 Positive 
JA235 7 3 2 - 3 15 Positive 
JA238 14 2 - - - 16 Positive 
JA239 - - - - - 0 Negative 
JA242 - - - - - 0 Negative 
JA249 5 4 4 2 3 18 Positive 
JA254 11 7 2 - 1 21 Positive 
HS CRL - - - - - 0 Negative 
Table 5.6. Agglutination score and frequency for ItG-IEs after incubation with eight semi-
immune Kenyan sera or UK control serum. * Total number of IE agglutinates per 10 fields under 
300× (20 × 15) magnification. Samples were scored positive on the basis of observing ≥ 15 
agglutinates in all scanned fields. HS CRL: control serum from UK donors. 
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Figure 5.8. A4-IE agglutination mediated by semi-immune adult sera. IE agglutinates (red 
arrows) were visualised under light microscopy (A, B and C) or fluorescent microscope (D and 
E). Representative A4-IE clumps formed after incubation with JA235 (A) or JA249 (B) semi-
immune sera are indicated by red arrows. A4-IEs did not form clumps after incubation with UK 
non-immune serum control (C). Aggregates of IEs were visualised under fluorescent microscope 
after staining with 10 µg/ml ethidium bromide (D and E) and clumps with non-IEs (rosettes) 
were not observed.   
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5.7 Correlation between adhesion blocking and 
agglutination 
We then tested the statistical correlation between adhesion inhibition under static 
or flow conditions with IE agglutination for all tested sera (n=8). At the first 
analysis, correlation coefficients (rs) were calculated for the association between 
inhibition percentages of A4-IE binding to HUVEC under flow conditions with 
agglutination of the same parasite isolate after incubation with semi-immune 
sera (Table 5.7). The analysis revealed a moderate positive correlation between 
blockade of A4-IE adhesion to HUVEC and agglutination scores (rs = 0.34, P ˃ 
0.05). However, this correlation was not significant since all semi-immune sera 
blocked A4-IEs adhesion to HUVEC whereas only five (JA225, JA235, JA238, 
JA249 and JA254) comprised agglutinating antibodies.  
The association between ItG-IE agglutination following incubation with all 
semi-immune sera and blockade of adhesion to ICAM-1 under static or flow 
conditions was then investigated. There was a strong correlation between 
agglutination and adhesion blocking under static conditions (rs = 0.66, P = 0.07) 
and under flow conditions (rs = 0.51, P ˃ 0.05). This strong correlation, 
particularly for blocking under static conditions, may suggest that adhesion 
blocking was mostly mediated by agglutination, as agglutinates can clearly 
affect IE binding.  
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Correlations 
 Agglutination A4 
A4 blocking 
HUVEC 
Spearman's rho Agglutination A4 Correlation Coefficient 1.000 .337 
Sig. (2-tailed) . .414 
N 8 8 
A4 blocking HUVEC Correlation Coefficient .337 1.000 
Sig. (2-tailed) .414 . 
N 8 8 
 
 
 
Correlations 
 
ItG 
agglutination 
ItG blocking 
flow 
ItG blocking 
static 
Spearman's 
rho 
ItG agglutination Correlation 
Coefficient 
1.000 .512 .663 
Sig. (2-tailed) . .194 .073 
N 8 8 8 
ItG blocking flow Correlation 
Coefficient 
.512 1.000 .587 
Sig. (2-tailed) .194 . .126 
N 8 8 8 
ItG blocking 
static 
Correlation 
Coefficient 
.663 .587 1.000 
Sig. (2-tailed) .073 .126 . 
N 8 8 8 
 
 
Table 5.7. Output of Spearman's rho correlation between adhesion blocking and agglutination for 
A4 and ItG parasite isolates. A: Spearman's rho correlation coefficients (rs) for the association 
between adhesion blocking of A4-IEs to HUVEC under flow conditions and agglutination of A4-
IEs mediated by eight semi-immune sera. B: Spearman's rho correlation coefficients (rs) for the 
association between adhesion blocking of ItG-IEs to ICAM-1 receptors under static or flow 
conditions and agglutination of ItG-IEs. 
 
 
 
 
 
 
 
 
A 
B 
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5.8 Discussion  
Several published studies have provided evidence supporting the significance of 
antibodies directed to the surface of IEs in protection against severe malaria 
disease (Bull et al., 1998, Giha et al., 2000). Immunological profiling of sera for 
the existence of reactive antibodies against VSAs is a widely utilised method for 
evaluating acquired immunity and recognising potential candidates for vaccine 
development (Oleinikov et al., 2009). In this chapter, we describe the use of 
different functional assays including ELISA, flow cytometry, adhesion blocking 
and agglutination for characterizing the functional antibody response of eight 
serum samples obtained from adult female donors living in Junju sub-location, 
Kilifi County, Kenya. We aimed to assess the reactivity of the semi-immune sera 
to bacterially synthesised PfEMP1 domains using ELISA and investigate the 
capacity of IgG to recognise diverse P. falciparum isolates of differing genomes 
and PfEMP1 phenotypes. The capacity of serum IgG to block IE adhesion to 
immobilised receptors and ECs was also assessed, as well as investigating the 
presence of agglutinating antibodies in semi-immune sera. Our results 
demonstrated that semi-immune sera recognised all tested recombinant domains 
and exhibited variable degrees of surface reactivity against tested parasite 
isolates. In addition, some sera exhibited higher efficiency at blocking parasite 
adhesion to immobilised ICAM-1 receptors and HUVEC and comprised 
agglutinating antibodies. These findings suggest that some of the semi-immune 
sera can be used for the development of antibody-based therapeutic implications. 
For instance, antibody-based fragments produced by manipulating the variable 
regions of the antibody genes can be generated and used to design Igs with 
defined class and specificity, directed against functional epitopes on the surface 
of IEs. The Ig variable domain of reactive IgGs could be cloned and engrafted 
onto human constant region genes, for expression in mammalian cells. 
The results obtained from this work clearly demonstrate that all recombinant 
domain proteins were specifically recognised by semi-immune sera with inter-
variable levels of recognition. This may suggest the presence of cross-reactive 
epitopes in the linear domains that were easily recognised by serum IgG 
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antibodies. The pattern of seroreactivity with all recombinant domains can also 
be explained by the presence, in all tested sera, of IgG populations with different 
specificities capable of recognising distinct regions of the recombinant proteins. 
This was supported by the capacity of serum IgG to recognise the distinct 
VAR2CSA DBL4ε domain. In a relatively similar study, semi-immune sera 
obtained from Gabonese individuals were tested against nine DBL-α domains. 
The study revealed that most recombinant domains were recognised by 50 to 
80% of sera from semi-immune individuals, and found that the majority of the 
antibody response was directed to variable regions of DBL-α domains with a 
minor population of antibodies targeting conserved epitopes (Oguariri et al., 
2001). However, the cross-reactive immune response of Gabonese sera was 
expected to some extent since the reactivity was evaluated against the relatively 
conserved DBL-α domains, whereas the response of Kenyan sera in our study 
was assessed against the comparatively diverse DBLβ domains. It is not known 
whether VAR2CSA DBL4ε or PfEMP1ICAM-1 DBLβ domains in this work were 
expressed by a parasite isolate that previously infected the Kenyan female 
adults, but the very strong reactivity of serum IgG indeed suggests a previous 
and possibly frequent exposure of individuals to these domains. 
Two previously described methods were broadly used for the detection of 
antibodies to parasite-derived surface antigens; these include flow cytometry and 
IE agglutination (Oguariri et al., 2001, Newbold et al., 1992, Piper et al., 1999). 
Flow cytometry provides efficient, precise and quantitative measurement of 
different combinations of parasite strains and serum samples (Ofori et al., 2002). 
In addition, this technique has an important advantage over agglutination assay 
including the ability to measure antibody reactivity to parasite isolates that do 
not agglutinate IEs (Ofori et al., 2002, Giha et al., 1999). We used standard flow 
cytometry assay to test semi-immune sera for IgG reactivity against the surface 
of erythrocytes infected by diverse P. falciparum isolates from the IT4 and 3D7 
genomes. Sera were investigated at 1:25 dilution throughout the assays as 
increasing the dilution resulted in substantial reduction in IgG reactivity (data 
not shown). The selective labelling of IgG antibodies to IEs, but not non-IEs, 
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indicates that antibodies recognise PfEMP1 or other parasite-derived protein 
exported to the surface of IEs. All of the eight adult sera that we tested were 
classified as positive for IgG surface binding to at least 80% of the parasite 
isolates used in the assay except JA221 which only showed positive labelling 
with 3 out of the 5 tested parasite lines (60%). We found that JA235, JA239, 
JA249 and JA254 sera had antibodies to all tested parasites, suggesting that they 
may had been previously exposed to related parasite variants.  
The possible explanations for the higher proportion of cross-reactivity with all 
tested isolates are: (a) that individual serum samples comprised populations of 
IgG antibodies of multiple specificities, in accordance with previous conclusions 
(Newbold et al., 1992, Gamain et al., 2001), or (b) that antibodies in the sera 
recognised cross-reactive, probably conserved epitopes on PfEMP1 or other 
VSAs consistent with previous suggestions that antibodies recognising 
conserved regions in VSAs (Marsh and Howard, 1986) or in PfEMP1 (Staalso et 
al., 1998) are induced upon exposure to malaria. An early study conducted in a 
Sudanese village demonstrated that although parasite isolates circulating in the 
region were genetically varied and express distinct PfEMP1 variants, they also 
possessed a significant overlap in their PfEMP1 repertoires (Giha et al., 1999).  
The capacity of serum IgG to recognise ''common'' regions is promising since 
parasites expressing commonly recognised VSA have been associated with 
severe disease (Bull et al., 1999, Bull et al., 2000). Such antibodies with a 
broader specificity range would be acquired after multiple exposures to P. 
falciparum parasites, probably including isolates with similar determinants to 
those used in this study. The weaker or absent reactivity of some semi-immune 
sera to particular parasite isolates while demonstrating higher response to other 
isolates is in agreement with the '' hole in the anti-VSA antibody repertoire'' 
hypothesis (Ofori et al., 2002, Nielsen et al., 2002, Bull et al., 1998). Although 
these ''holes'' would be expected in plasma of younger children due to lower 
exposure to infection (Ofori et al., 2002), adult individuals showing low or 
absent reactivity in the present study may have not been infected with the same 
or antigenically-related P. falciparum isolates to that they fail to recognise. This 
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is consistent with previous findings that serum samples obtained from immune 
Gambian adults failed to agglutinate a significant number of serotypes, 
suggesting that multiple exposure to infection does not necessarily leads to 
production of protective immune response (Newbold et al., 1992).  
In the present study, we found that some semi-immune sera were efficient at 
blocking the adhesion of parasitized erythrocytes to immobilised receptors or 
primary cell lines. This capacity of inhibition can be attributed to two 
contributors; a) surface masking of the adhesion ligands of PfEMP1 proteins by 
specific IgG antibodies in the sera or b) agglutination of infected cells which 
leads to massive reduction in the overall capacity of erythrocyte binding. IgG-
mediated IE lysis was not observed with Kenyan serum samples as detected with 
mouse IgM antibodies in the previous chapters, and therefore was not considered 
as a factor contributing in adhesion blocking.  
The higher capacity of JA225 and JA235 sera, and the relatively moderate 
efficacy of JA238 to block IE adhesion to ICAM-1 under static conditions while 
failing to inhibit the binding to CD36 under the same conditions suggests that 
these sera comprise a population of antibodies capable of masking residues on 
PfEMP1 involved in ICAM-1 binding, i.e. DBLβ domains, or alter the 
conformation of the native PfEMP1 protein leading to disruption of ICAM-1 
binding domains while leaving CD36 binding sites unaffected. The strength of 
reactivity with recombinant IT4VAR16 DBLβ domains as indicated by ELISA 
was not related to adhesion blocking, since JA225 and JA235 sera which 
strongly blocked ICAM-1 binding to ItG-IEs were the least reactive sera 
compared to the other semi-immune sera. On the other hand, some individual 
sera that showed higher reactivity levels with recombinant domains failed to 
block IE adhesion to ICAM-1 receptors. This lack of association is expected 
since recombinant domains will have non-physiological epitopes not seen on the 
IE. However, the surface recognition for JA225 and JA235 sera to ItG-IEs was 
considerably high, particularly for JA235 which exhibited the highest magnitude 
of surface labelling with live IEs. These data indicated that recognition of the 
linear recombinant domains involved in ICAM-1 binding does not necessarily 
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correlate with blockade of parasite adhesion to the same receptors, and suggest 
that ICAM-1 binding ligands on PfEMP1 molecules are conformational with 
critical binding sites being only accessible to a sub-population of specific 
antibodies. On the other hand, serum obtained from JA225 donor had a 
significant, though moderate blocking capacity to ICAM-1 receptors, suggesting 
that a proportion of antibodies partially shielded receptor adhesion ligands on 
PfEMP1 proteins.  
Our findings demonstrated that all semi-immune sera have significantly reduced 
IE adhesion to HUVEC (P ˂ 0.001), with JA225 and JA235 demonstrating the 
highest magnitude of inhibition followed by JA238 serum. A4-IEs bind to 
activated HUVEC through ICAM-1 ligands, since this cell line expresses ICAM-
1 but not CD36 upon TNF-α activation (Dobbie et al., 1999, Gray et al., 2003). 
We found that the results of adhesion blocking to HUVEC are in agreement 
blocking to ICAM-1 receptors under static conditions, which revealed a similar 
higher magnitude of adhesion blocking by JA225 and JA235 sera.  
There was a moderate positive correlation between surface recognition of A4-
IEs and adhesion blocking to HUVEC under flow conditions (r = 0.34, P ˃ 
0.05). The lack of significance may has resulted from the fact that some semi-
immune sera (i.e. JA225 and JA242) significantly blocked the A4-HUVEC 
adhesion but failed to label the surface of IEs. This can be explained by the 
presence of low levels of highly specific antibodies in the semi-immune sera that 
blocked IE adhesion, similar to an observation in a previously published study 
(Beeson et al., 2004). Total antibodies to the parasite-derived VSAs may 
primarily bind to distinct epitopes on the surface of IEs, rather than adhesion 
blocking antibodies that bind more specifically to sites on PfEMP1 involved in 
receptor adhesion (Beeson et al., 2004). Therefore, our findings provide 
evidence that a limited subset of antibody population that failed to produce a 
signal of surface fluorescence can block the adhesion of IEs to cell lines, 
suggesting that adhesion blocking depends on the quality, and not just the 
quantity of antibodies. This is consistent with previous findings suggesting that 
adhesion inhibitory antibodies and those recognising VSAs on the surface of IEs 
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have distinct and overlapping epitopes, possibly were acquired independently 
during infection and have various roles for protection (Beeson et al., 2004). 
Another possible explanation for the overall reduced binding of A4-IEs to 
HUVEC is the ability of serum IgG to bind receptors expressed on activated 
HUVEC, such as ICAM-1, leading to reduced or blocked interaction between 
PfEMP1 and HUVEC receptors.  
Agglutination and flow cytometry assays seem to principally investigate the 
same set of antibodies, with flow cytometry mostly being more sensitive (Ofori 
et al., 2002, Giha et al., 1999). Using the agglutination assay, we addressed the 
question of whether IE clumping mediated by semi-immune sera would give an 
indication of the extent of the contribution of agglutination to the capacity of IE 
adhesion blocking. In addition, we aimed to investigate the general associations 
or differences between measures of antibodies that agglutinate IEs with those 
which block the parasite adhesion or label the surface of IEs, since it has been 
established that samples showing strong reactivity by flow cytometry and 
agglutination inhibited parasite adhesion more efficiently than samples with no 
noticeable reactivity (Beeson et al., 2004). The results of adhesion blocking of 
A4-IEs to HUVEC demonstrated that all semi-immune serum samples 
comprised antibodies that significantly blocked 60-86% of A4-HUVEC 
adhesion under flow conditions. This was not significantly correlated with 
agglutination profiles for all semi-immune sera with A4-IEs since only five sera 
agglutinated A4-IEs (rs = 0.34, P ˃ 0.05). In addition, some semi-immune sera 
such as JA221 and JA239 were efficient at blocking A4-IE adhesion and 
labelled the surface of the same parasite isolate but did not contain agglutinating 
antibodies. This provided evidence that blockade of parasite binding to HUVEC 
was not entirely attributed to IgG-mediated IE agglutination, and other factors 
such as surface labelling may have contributed in blockade of adhesion. This 
also indirectly suggests that the parasite-derived protein on the surface of IEs 
recognised by semi-immune sera is PfEMP1, as it an essential candidate 
involved in parasite adhesion to protein receptors or EC lines.  
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Comparison of the IgG response to the surface of A4-IEs with the agglutination 
profiles of erythrocytes infected by the same isolate revealed a strong positive 
correlation between the two antibody measures. This is in line with previous 
suggestions that antibodies recognising the surface of live IEs in flow cytometry 
were the same nature as agglutinating antibodies (Ofori et al., 2002, Giha et al., 
1999). Several published studies were consistent with this suggestion and 
indicated that the recognised proteins by immune sera using surface labelling or 
agglutination were PfEMP1 proteins (e.g. Chattopadhyay et al., 2003).  
In a recent study, a novel approach was developed using genetically modified P. 
falciparum isolates with suppressed PfEMP1 expression to elucidate the 
importance of PfEMP1 and other VSAs as targets for protective antibody 
response among serum samples collected from residents in malaria endemic area 
in Eastern Africa (Chan et al., 2012). The study revealed that binding of IgG 
antibodies to the surface of erythrocytes infected by the transgenic line was 
significantly reduced compared to wild type isolate that expresses PfEMP1, 
suggesting that acquired antibody response to the surface of IEs mainly targets 
PfEMP1 molecules. However, a proportion of antibody response to transgenic P. 
falciparum isolates was observed suggesting the role of other VSAs as antibody 
targets (Chan et al., 2012). In fact, some published studies suggested that other 
parasite-derived VSAs such as RIFINs and STEVORs might play a significant 
role in immunity against malaria. For instance, a study revealed that human 
immune sera agglutinated IEs treated with trypsin at conditions such that 
PfEMP1 proteins are mostly cleaved off the surface of IEs, indicating that 
RIFINs can be targeted by agglutinating antibodies (Fernandez et al., 1999). 
Another study carried out in an endemic area with intense malaria transmission 
rate in Gabon showed that the majority of adult serum population exhibited a 
higher antibody response to recombinant RIFIN proteins, suggesting that this 
family of proteins is naturally immunogenic (Abdel-Latif et al., 2002). The 
higher levels of anti-RIFIN antibodies in serum samples obtained from 60 
children living in the same hyperendemic area in Gabon significantly correlated 
with parasite clearance from the circulation, suggesting that these antibodies 
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may have a protective role against progression of malaria disease (Abdel-Latif et 
al., 2003). Furthermore, pre-adsorption of antibodies from semi-immune adult 
plasma from the same area in Gabon to recombinant RIFIN proteins resulted in 
the reduction of the level of IgG reactivity with VSAs on the surface of 
erythrocytes infected with different of P. falciparum isolates as measured by 
flow cytometry (Abdel-Latif et al., 2004). The influence of pre-adsorption to 
RIFIN proteins was even higher than for recombinant DBL-1α on the overall 
IgG subsequent binding to VSAs (Abdel-Latif et al., 2004). A cross-sectional 
study of immune adults living in malaria endemic region in Ghana demonstrated 
higher levels of serum IgG antibodies to recombinant STEVOR antibodies. 
Although conclusions regarding the role of anti-STEVOR antibodies in 
protection against severe disease have not been drawn from this study, the 
results indicated that STEVOR proteins could act as targets for antibody-
mediated immunity (Schreiber et al., 2008). We conclude that semi-immune sera 
may comprise antibodies that predominantly bind different VSAs, with the 
majority of the immune response directed to PfEMP1 protein family.   
In the present study, semi-immune sera were tested against a panel of 
genotypically and phenotypically variant lab-adapted P. falciparum isolates to 
extend the diversity rate of expressed var genes and to mimic parasites isolates 
in areas with high malaria endemicity, which have high sequence diversity. The 
higher prevalence of cross-reactive antibodies among semi-immune sera to 
diverse parasite populations (e.g. ItG and 3D7) suggests that different P. 
falciparum isolates share restricted antigenic determinants recognised by IgG 
antibodies in serum pools. Based on the assumption that the target of the 
agglutinating antibodies is PfEMP1 (Baruch et al., 1995), the ability of most sera 
in our study to agglutinate A4- and ItG-IEs would suggest the existence of a 
considerable overlap between PfEMP1 repertoires in variant parasite lines, in 
agreement with previous propositions (Giha et al., 1999). 
In summary, our findings indicate that semi-immune female sera comprise 
antibodies that cross-reacted with diverse P. falciparum isolates and blocked IE 
adhesion to protein receptors and primary ECs. We suggest that the antibody 
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repertoire predominantly bind different VSAs, with the majority of the immune 
response directed to PfEMP1 protein family. Our results may help to guide 
future work required to identify the role of cross-reactive and cross-inhibitory 
antibodies in protection from severe diseases and possible development of 
preventive of therapeutic interventions. Understanding the targets of the 
naturally acquired immune response in individuals living in endemic areas is 
significant for advancing the development of malaria vaccines. However, there 
are key important gaps in our knowledge about other VSAs and their 
significance in protective immunity against severe disease, and more studies 
using multiple approaches are therefore required to elucidate the importance of 
these antigens in immunity. 
 
5.9 Limitations and future work  
The present dataset is limited and it would be premature to make decisive 
conclusions. Because of the limited amount of the serum samples available in 
this work, there were frequently insufficient quantities for repeating assays of 
adhesion blocking and surface reactivity to validate preliminary data. With an 
expanded dataset, we can correlate functional antibody responses with parasite 
samples collected from patients with severe malaria or with a larger panel of 
laboratory-adapted isolates. We can also test the adhesion blocking capacity of 
semi-immune sera to different protein receptors (e.g. CSA) or cell lines (e.g. 
HDMEC and HBEC). Future work will also include investigation of the 
reactivity against other PfEMP1 recombinant proteins including the conserved 
CIDR1α-DBL1α head structure.  
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Chapter 6: General conclusions 
Sequestration of IEs to ECs lining the post-capillary venules of different host 
organs is a characteristic feature in the virulence of P. falciparum infection 
(Cooke et al., 1995, Pasloske and Howard, 1994). Among host endothelial 
ligands that mediate cytoadhesion, ICAM-1 was linked to severe forms of 
malaria diseases, including CM (Newbold et al., 1997, Turner et al., 1994). 
PfEMP1 is a key parasite-derived protein ligand exported to the surface of IEs 
and is associated with the adhesion of IEs to host endothelium (Cooke et al., 
1995). The binding domains of ICAM-1 on PfEMP-1 have been identified as 
DBLβ domains (Smith et al., 2000a, Oleinikov et al., 2009, Howell et al., 2008, 
Brown et al., 2013). In the present work, we selected four recombinant 
PfEMP1ICAM-1-DBLβ domains for mouse immunisations. Sera were collected 
from immunised mice and screened for reactivity against recombinant domains 
and live IEs. We found that antisera raised to all recombinant domains, except 
DBL41, had higher IgG titres against corresponding immunising antigens. Anti-
rDBL41 antiserum failed to recognise its own domain but cross-reacted with 
heterologous antigens. Moreover, all antisera exhibited variable degrees of 
cross-reactivity with the other heterologous DBL domains but almost failed to 
recognise rDBL41 antigen. These results are consistent with Western Blotting 
data and suggest that rDBL41 protein used in the present work either has not 
been correctly expressed and purified, or has been degraded during expression or 
after purification.  
Our FACS data showed that antisera raised to DBL27, DBL31 and DBL41 
comprised IgM antibodies that showed variable reactivities with the surface of 
erythrocytes infected by ItG and outgrown A4 isolates, but almost none of these 
sera contained reactive IgGs. On the other hand, DBL13-specific antiserum 
comprised cross-reactive IgM antibodies that labelled the surface of erythrocytes 
infected by homologous and heterologous isolates. However, it is uncertain 
whether these sera were cross-reactive to conserved epitopes on the surface of 
IEs or alternatively they comprised a mixture of antibodies of multiple 
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specificities. Although surface-labelling was only specific for IEs, we could not 
confirm that the surface protein recognised by antisera was DBLβ or another 
variant epitope in the native PfEMP1, since several immunogenic VSAs co-
express with PfEMP1 on the IE surface and can act as binding ligands.  
Further work has resulted in the production of thirteen hybridoma clones that 
secrete reactive IgM antibodies against DBL13, DBL31 and DBL41 domains. 
The induced mAbs and pAbs elicited not only recognised their corresponding 
antigens, but also efficiently cross-reacted with heterologous domains with a 
similar capacity of recognition. The higher level of cross-reactivity observed in 
ELISA may propose that all recombinant domains share conserved 
immunogenic epitopes, despite their lower level of sequence identity (46%), that 
were easily recognisable and accessible to IgM antibodies. It was surprising that 
all positive hybridoma clones only secreted reactive IgM antibodies, and none of 
the clones comprised reactive IgG antibodies despite the higher IgG titre of 
mouse antisera. The definitive reason for this is not completely understood. We 
suggest that the adjuvant system used for driving the immune response (i.e. 
Alum) may has contributed in priming of IgM synthesis.  
Further FACS analyses demonstrated that labelling of mAbs and pAbs was not 
limited to homologous ICAM-1-binding strains or isolates from the 
corresponding genome, as antibodies also recognised erythrocytes infected by 
C24, a non-ICAM-1 binding isolates, and a genotypically-distinct strain (3D7). 
This indicated that induced antibodies were not specific for a particular binding 
phenotype or genotype, although DBL domains used in mouse immunisation 
were obtained from ICAM-1-binding PfEMP1 variants from the IT4 genome. In 
terms of specificity, we found that the strongest labelling antibodies were mainly 
mAbs, and those raised to DBL41 showed the highest capacity of surface 
binding in all assays in addition to one mAb raised to DBL31 (E7). This was 
surprising, since DBL41 showed the weakest reactivity with homologous and 
heterologous mouse immune sera in ELISA and Western Blotting. These results 
suggest that recombinant DBL41 domains expressed in E. coli contained the 
functional components required to elicit a broadly reactive immune response. 
287 
 
 
 
 
Therefore, this domain can give rise to novel therapeutics and development of 
cross-reactive malaria vaccine.  
Investigating the pattern of individual IgM labelling has led to the finding that 
mAbs and pAbs exhibited similar patterns of IgM surface recognition among 
parasite isolates. The higher level of cross-reactivity strongly suggests the 
presence, among parasites of different genotypes, of conserved epitopes within 
the PfEMP1 or in another parasite-derived protein on the surface of IEs that are 
accessible to polymeric IgM antibodies. Our findings also indicated that the 
presence of IgM per se in a particular mAb/pAb does not account for surface 
labelling, since some antibodies (e.g. pAb C2) comprised higher amounts of IgM 
but exhibited weak if any surface binding. This indicates that surface reactivity 
was only dependent on the presence of specific antibodies that can recognise 
target epitopes regardless of IgM abundance in purified yields. Although surface 
labelling was mainly specific for IEs, we could not confirm that labelling was 
specific for the native PfEMP1 as other parasite-derived proteins exported on the 
surface of IEs also can act as surface epitopes for binding. For instance, RIFINs, 
STEVORs and modified band 3 could act as binding ligands for our mouse 
mAbs and pAbs. 
In competition assays we investigated whether mouse IgMs out-compete BC6, 
HIS or anti-DBL16 rat antisera for IE surface adhesion and vice versa. We 
provided evidence that mAb BC6 moderately interfered with the subsequent 
binding of mouse IgMs, which may suggest that mAbs and pAbs partially bind 
to PfEMP1 on the surface of IEs and that binding epitopes were partly masked 
by BC6. Our findings also suggested that the binding sites for mouse IgMs and 
rat anti-DBL16 antisera are partially overlapped on the surface of IEs, as 
revealed by the remarkable reduction of mouse IgM subsequent binding to IEs 
pre-incubated with anti-DBL16 rat antisera. Alternatively, mouse IgMs may 
bind to surface ligands distinct from those of BC6 or anti-rat sera on the surface 
of IEs and the influence of mouse IgMs on BC6 or antisera could be explained 
by the binding of the large polymeric IgM molecules to parasite-derived surface 
proteins. This binding may have evolved to partly mask functional epitopes 
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involved in BC6 and rat anti-DBL16 antisera on PfEMP1 upon binding to other 
surface antigens, which explains the limited ability of mAbs and pAbs in 
disrupting specific BC6 and rat antisera binding. With regard to HIS, we found 
that mAbs and pAbs had a significant role in interference with the subsequent 
binding of the HIS, and the latter also remarkably reduced the binding of mouse 
IgMs. This two-sided inhibitory effect can be related to cross-reactivity of 
mouse IgMs and HIS to the surface of erythrocytes infected by diverse parasite 
isolates. Mouse IgMs could either mask a residue important for HIS binding or 
alter the conformation of the binding epitope in such a way to destabilise HIS 
interaction. Further studies are required to investigate the kinetics of IgM 
binding to surface receptors and to determine the functionality of these cross-
reactive binding epitopes. 
In our study, we took advantage of the differential sensitivities of parasite-
derived VSAs to controlled trypsin digestion for characterising the surface 
candidates involved in the binding of mAbs and pAbs. Consistent with existing 
data, we demonstrated that PfEMP1 is sensitive to trypsin digestion down to 10 
µg/ml, a concentration that was extremely effective in abolishing binding 
ligands for ICAM-1 and BC6 on PfEMP1. The binding of mouse IgMs (mAb 
G6, mAb B5, pool 1) was substantially reduced with trypsin treatment, i.e. the 
higher the concentration of trypsin the lower the binding detected. However, the 
binding was not completely ablated as observed with mAb BC6. This may 
propose that mouse IgMs partially recognise a trypsin-sensitive surface antigen 
with the characteristics of PfEMP1. However, the sustained binding to IEs at 
higher trypsin concentrations may suggest that a repertoire of mouse IgM 
antibodies bind trypsin-resistant epitopes on the IE surface. Several trypsin-
resistant parasite-derived surface proteins, such as RIFINs and modified band 3, 
can act as binding ligands for mouse IgMs, but the identity of such ligands is not 
yet identified.  
Analysis of surface labelling following incubation with mAbs and pAbs has 
revealed a unique phenomenon associated IgM binding, lysis of IEs. We 
provided evidence that haemolysis was resulted from an immunological 
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interaction between mouse IgMs and a parasite-derived component on the 
surface of live IEs. Only IEs were lysed upon mouse IgM incubation, whereas 
non-IEs were largely unaffected. In addition, the majority of mouse IgMs that 
caused IE lysis were highly effective in recognising the surface of erythrocytes 
infected by all tested isolates, whereas haemolysis was less observed or absent 
with non-labelling mAbs and pAbs. The concentration of IgM in mAbs and 
pAbs was not a significant factor contributing to IE lysis, since antibodies with 
higher IgM concentrations (e.g. C2 and C9) were comparatively ineffective in 
lysing cells compared other antibodies at lower concentrations (E4 and B4). 
These findings indicated that IE lysis resulted from an IgM-mediated binding to 
a parasite-derived protein on the surface of IEs. Although we investigated the 
effect of possible factors such as temperature and serum complement 
components in culture media, the definite mechanism(s) of IE lysis and key 
factors contributing to this phenomenon are not yet understood.  
The capacity of mAbs and pAbs to block the adhesion of IEs to immobilised 
receptors (ICAM-1 or CD36) or EC lines under static or physiological flow 
conditions was investigated. We showed that mAbs and pAbs induced in our 
work not only cross-reacted with diverse P. falciparum isolates but also cross-
inhibited binding of IEs to immobilised receptors and EC lines. Since most 
mAbs and pAbs used in adhesion blocking assays cause IE lysis, we took into 
consideration that this lysis may largely contribute to blockade of IE adhesion to 
immobilised receptors or ECs. Our analyses revealed that blockade of adhesion 
correlated with IgM-dependent IE lysis; as antibodies that caused lysis of 
significant amounts of IEs were highly effective in blocking the adhesion of 
erythrocytes infected with the same parasite isolate. However, despite the 
relatively higher amounts of lysed IEs upon antibody incubation, a significant 
proportion of parasitized cells are not lysed following incubation with mAbs and 
pAbs. We provided evidence that some mAbs and pAbs, such as pAb A4, 
prevented a significant proportion of non-lysed IEs to CD36 receptors under 
static conditions. This may suggest that blockade of adhesion is not entirely 
290 
 
 
 
 
attributed to IE lysis, and other factors such as masking epitopes involved in 
parasite adhesion may contribute in adhesion blocking.  
The ICAM-1 binding sites are mapped to DBLβ domains, which are obviously 
distinct from the CIDR domains involved in CD36 binding. Therefore, we were 
astonished that mouse IgMs that blocked ICAM-1 binding equally well blocked 
CD36 binding. We suggest that the large polymeric IgM molecules may have 
fully or partially masked important PfEMP1 epitopes involved in CD36 binding. 
Possible steric hindrance generated after binding of IgM molecules to PfEMP1 
or adjacent ligands may has blocked the interaction between receptors and 
PfEMP1 domains involved in adhesion. Alternatively, IgM binding may has 
resulted in destabilisation of the basic structure of PfEMP1 leading to loss of 
binding capacity of adhesion domains. These results suggest that binding regions 
for mouse IgMs overlap, or localised at close proximity to those for ICAM-1 and 
CD36 binding on the native PfEMP1 protein. 
In the last experimental chapter, we described the use of different functional 
assays to characterise the immunological response of eight serum samples 
collected from adult female donors living in Junju sub-location, Kilifi County, 
Kenya. Our findings indicated that all recombinant domain proteins used for 
reactive IgG screening were specifically recognised by semi-immune sera with 
variable levels of recognition. Standard FACS assays showed that all adult sera 
comprised reactive IgG antibodies that labelled the surface of at least 80% of 
tested parasite isolates except JA221, which only showed positive labelling with 
60% parasite strains. The higher level of cross-reactivity with all tested isolates 
suggests that individual serum samples comprised sub-populations of IgG 
antibodies of multiple specificities, or that antibodies in the sera recognised 
cross-reactive, probably conserved epitopes on PfEMP1 or other VSAs. 
In the present study, we found that some semi-immune sera were efficient at 
blocking the adhesion of parasitized erythrocytes to immobilised receptors or 
primary cell lines. Of particular significance, two serum samples (JA225 and 
JA235) significantly blocked IE adhesion to ICAM-1 under both static and flow 
conditions. However, all sera except JA254 failed to significantly block parasite 
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adhesion to CD36 receptors. This suggests that blocking sera comprise a 
population of antibodies capable of masking residues on PfEMP1 involved in 
ICAM-1 binding, i.e. DBLβ domains, or alter the conformation of the native 
PfEMP1 protein leading to disruption of ICAM-1 binding domains while leaving 
CD36 binding sites unaffected. This is intriguing since binding to CD36 is a 
common adhesion phenotype and most field and culture-adapted P. falciparum 
isolates bind CD36 receptors (Chilongola et al., 2009, Newbold et al., 1997, 
Rogerson et al., 1999). Thus, exposure of individuals in endemic areas to this 
binding phenotype is huge yet they did not develop blocking antibodies. 
However, we should evaluate the blocking capacity of sera against different 
CD36-binding isolates to support these findings.  
Using the agglutination assay, we addressed the question of whether IE 
agglutination mediated by semi-immune sera contributes to the capacity of IE 
adhesion blocking. Our data have demonstrated that IE agglutination did not 
exclusively contributed in adhesion blocking, since some sera were efficient at 
blocking A4-IE adhesion and labelled the surface of the same parasite isolate but 
did not contain agglutinating antibodies. Thus, other mechanisms such as IgG-
mediated surface labelling and blocking of critical binding epitopes may have 
contributed in the inhibition of IE binding. This may indirectly suggest that the 
labelled protein on the on the surface of IEs by semi-immune sera is PfEMP1.   
Advances in technical approaches highlighted the possibility for synthesising 
antibodies targeting essential malaria antigens and could be used in therapeutic 
interventions. These antibodies could be designed to act as drugs and kill the 
parasite or could have a protective role from infections (Pleass and Holder, 
2005). In addition, antibodies can be used to identify the structure and function 
of critical antigens, and recognise epitopes that could be used for the 
development of vaccines. Due to the lack of good animal models for P. 
falciparum malaria, antibodies can provide an unlimited source of measures to 
provide in vitro associates for development of vaccines (Pleass and Holder, 
2005). Most of the work on human malaria has been focused on antibodies 
purified from immune sera. However, sera comprise a mixture of antibodies with 
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different classes and specificities, and can contain antibody classes that may 
trigger unwanted immune responses (Pleass and Holder, 2005). Therefore, the 
use of antibodies with monoclonal specificities directed to desired antigens 
could be ideal for therapeutic interventions.  
In the present work, we generated mouse mAbs and pAbs that have the capacity 
to recognise the surface of erythrocytes infected by diverse parasite isolates, 
block IE adhesion to different receptors and cell lines and selectively destroy IEs 
while leaving non-IEs largely unaffected. Such multiple activity could be highly 
beneficial in the development of therapeutic antibodies against malaria disease. 
However, passive administration of these mouse IgM antibodies to human hosts 
might not be appropriate for many significant reasons (reviewed in Pleass and 
Holder, 2005). Therefore, genetic engineering approaches could be used in the 
future to provide a ''humanised'' form of our mAbs and pAbs to be used for 
targeting functional parasitic epitopes in human hosts. Antibody-based 
fragments produced by manipulating the variable regions of the antibody genes 
can be generated and used to design Igs with defined class and specificity, 
directed against functional epitopes on the surface of IEs (Pleass et al., 2003). 
This approach can be used to circumvent the problems of using whole 
antibodies, especially for the large IgM molecules. The Ig variable domain from 
a mouse IgM can be cloned and engrafted onto human constant region genes, for 
expression in mammalian cells. This approach can also be applied on reactive 
semi-immune sera (e.g. JA235) by cloning variable domains from an antibody 
repertoire phage library generated from semi-immune sera and linking them to 
constant domains in appropriate expression vectors (reviewed in Pleass and 
Holder, 2005).  
In summary, our work is the first to demonstrate that single domains of E. coli-
expressed DBLβ from PfEMP1ICAM-1 could elicit broadly cross-reactive, IE 
lysing and adhesion blocking mouse antibodies against different strains of 
heterologous phenotypes and genotypes. Indeed, cross-reactivity against diverse 
parasite populations is important since polymorphisms of PfEMP1 variants and 
the ability of P. falciparum isolates to switch surface PfEMP1 to other variants 
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with different phenotypes makes it difficult to develop strain-specific therapeutic 
candidates based on targeting single DBL domains. Therapeutic antibodies 
should be broadly reactive and cross-react with most, if not all isolates, or would 
contain a mixture of components each recognise a different isolate. It is 
significant that cross-reactive antibodies possess anti-adhesive properties, 
regardless of the mechanism of inhibition. In fact, effective anti-adhesive 
antibodies should target all receptor-binding sites or at least multiple sites at the 
same time to interfere with parasite adhesion. Therefore, we suggest that mouse 
IgM antibodies may have therapeutic values and could play a significant role in 
protection against severe malaria. However, further studies are required to 
further characterise the binding sites for mAbs and pAbs on the surface of IEs 
and to assess their capacity for blocking the adhesion of IEs to other receptors or 
EC lines. In addition, more work is needed to elucidate the molecular 
mechanism of IE lysis by mouse IgMs and blood or antibody factors that 
underlie this phenomenon.  
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Appendix 
 
 
Figure S1. Indirect ELISA for investigating the efficiency of affinity purification of mAbs and pAbs against 
different coating antigens. The reactivity of purified antibody yield, culture supernatnat prior to purification 
and the resulted flow-through media of pAb A4 were tested against recombinant DBL31 or VAR2CSA-
DBL4ε (5 μg/ml). 50 μl purified mAbs/pAbs, 200 μl of hybridoma culture supernatants before purification 
or flow-through fluid resulted from the purification were incubated with coated antigens. Reactive IgM 
antibodies were detected with 100 µl HRP-conjugated goat anti-mouse IgM (Southern Biotech®) at 1:500 
dilution. Incubation of Culture medium (CM) or  mouse IgM isotype control with recombinant proteins 
were included in the assay as negative controls, whereas anti-DBL31 mouse serum (50 μl, 1:50 dilution) 
was used as a positive control. Recognition was measured in terms of the magnitude of the response 
demonstrated as OD values and shown as the average of duplicate wells with SD values expressed as error 
bars.  
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Figure S2: var gene transcription profiles of five P. falciparum isolates used in the present study. 
For each parasite isolate, RNA was harvested from ring-stage parasites and expression profiles 
of dominant var genes was determined by RT-qPCR using primers for six var transcripts (var01, 
var13, var14, var16, var31 and var41). The results show that isolates expressed the expected var 
transcript more than five fold changes. IT4var16 also expressed another var transcript, IT4var41, 
besides its corresponding var transcript (IT4var16). IT4var01= 3G8; IT4var13= GC503; 
IT4var14= A4; IT4var16= ItG; IT4var31= P5B6.  
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Antibody Domain Specificity 
gMFI values for the labelling of IEs  
3G8 GC503 A4 ItG P5B6 C24 3D7 CS2 
E11 DBL13 Polyclonal 65 315 103 189 97.4 112 135 127 
B12 DBL13 Polyclonal 49.8 158 93.6 123 50.7 81 70.3 93 
A6A DBL13 Monoclonal 485 72.3 477 50.2 303 213 312 221 
C2 DBL31 Polyclonal 80.9 84.7 81.3 96.7 73.9 150 79.4 159 
E4 DBL31 Polyclonal 88.8 96.3 97.4 116 85.1 101 124 171 
A4 DBL31 Polyclonal 774 181 70.4 221 737 269 75.6 170 
E7 DBL31 Monoclonal 2312 601 2410 436 298 548 528 1269 
C9 DBL31 Monoclonal 74.8 32.5 111 123 57.5 130 95 133 
2E10 DBL31 Polyclonal 282 114 103 127 252 176 86.8 375 
B5 DBL41 Polyclonal 801 502 869 751 1010 1234 407 147 
D5 DBL41 Polyclonal 384 348 381 386 441 76.1 288 301 
B4 DBL41 Monoclonal 424 726 260 338 354 135 156 143 
G6 DBL41 Monoclonal 2727 2550 1349 1305 1848 554 844 983 
IgM   72.2 62 57.6 64.1 73.5 57.3 45.3 54.9 
Table S2. Geometric mean fluorescent intensity (gMFI) values for IEs upon incubation with mAbs and pAbs. RBC population was firstly gated to exclude debris, and then 
IEs (Ethidium bromide positive cells) were carefully obtained by a closer gating from the FITC channel (FITC positive cells). gMFI values for IEs in the APC channel were 
then obtained and added in the table.  
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Antibody Domain Specificity 
gMFI values for the labelling of non-IEs  
3G8 GC503 A4 ItG P5B6 C24 3D7 CS2 
E11 DBL13 Polyclonal 42.8 37.4 44.1 59.8 42 42.8 43.1 46.2 
B12 DBL13 Polyclonal 43.1 40.6 47.6 47.3 36.7 31.7 45.6 38.2 
A6A DBL13 Monoclonal 216 10.4 115 12.2 96.6 65.9 79.1 41.6 
C2 DBL31 Polyclonal 41.6 38.1 39.9 57.7 38.3 46.4 56.4 43.6 
E4 DBL31 Polyclonal 51.9 34.4 39.9 53.3 37.9 35 47.5 34.5 
A4 DBL31 Polyclonal 63 41.5 37.4 93.1 39.6 50.1 58.2 41.2 
E7 DBL31 Monoclonal 664 49.7 314 111 141 168 66.4 198 
C9 DBL31 Monoclonal 51.8 114 46.8 53.8 41.5 39.3 84.8 44.5 
2E10 DBL31 Polyclonal 55.2 45.8 46.9 68.8 43 35.5 59.7 71.8 
B5 DBL41 Polyclonal 488 44.9 265 194 293 166 70.5 32.2 
D5 DBL41 Polyclonal 179 25.8 76.1 25.4 65.1 391 47.4 31.4 
B4 DBL41 Monoclonal 293 108 160 103 207 79 80.8 50.9 
G6 DBL41 Monoclonal 446 59.3 346 198 313 163 92.4 138 
IgM   40.4 37.8 36.4 44.9 38.2 33.5 33.8 34 
Table S3. Geometric mean fluorescent intensity (gMFI) values for non-IEs. RBC population was firstly gated to exclude debris, and then non-IEs (Ethidium bromide negative 
cells) were carefully obtained by a closer gating from the FITC channel (FITC negative cells). gMFI values for non-IEs in the APC channel were then obtained and added in 
the table.
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Table S4. Labelling of mAb G6, pAb B5, pool 1 of mouse IgMs and HIS to ItG-IEs treated with 
10 µg/ml, 100 µg/ml or 1000 µg/ml of TPCK-treated trypsin as measured by flow cytometry. 
Geometric mean fluorescent intensity (gMFI) values for IEs upon incubation with mAbs and 
pAbs are shown in the table. RBC population was firstly gated to exclude debris, and then IEs 
(Ethidium bromide positive cells) were carefully obtained by a closer gating from the FITC 
channel (FITC positive cells). gMFI values for IEs in the APC channel were then acquired and 
added in the table.  
  
Trypsin concentration (µg/ml) 
PBS 1000 100 10 
 
G6 
gMFI 764 156 175 410 
 
B5 
gMFI 438 220 447 428 
Pool 1  gMFI 1194 636 847 856 
 
HIS 
gMFI 510 412 507 515 
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